Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date:
Art Unit: _____ Phone Number 30_____ Serial Number: _____
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

****

STAFF USE ONLY

Searcher: D Schreiber
Searcher Phone #: 272-2526
Searcher Location: Remsen 601 A61
Date Searcher Picked Up: _____
Date Completed: 6/28
Searcher Prep & Review Time: 16
Clerical Prep Time: _____
Online Time: 93

Type of Search

NA Sequence (#) 15
AA Sequence (#) _____
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN _____
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems Comp Pages
WWW/Internet _____
Other (specify) _____

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 125827

TO: Terra Gibbs **Location: rem/2d10/2c18** **Art Unit: 1635** **Monday, June 28, 2004** **Case Serial Number: 10/069079**	**From: David Schreiber** **Location: Biotech-Chem Library** **Remsen E01A61** **Phone: 272-2526** **david.schreiber@uspto.gov**

Search Notes

Schreiber, David 125827

From: Gibbs, Terra
Sent: Wednesday, June 23, 2004 11:59 AM
To: Schreiber, David
Subject: Seqeunce search request...

Hi David,
I have another request for a score over length search:
I need a length limited nucleotide sequence search of nucleobases 1-1000 of SEQ ID NO:1 in USSN 10/069,079, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 80 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched if possible.

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
571-272-0758

STIC SEARCH RESULT FEEDBACK FORM

USPTO

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
571-272-2507 Remsen E01 D86

Voluntary Results Feedback

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art* ***found****, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

  Types of relevant prior art found:
  - ☐ Foreign Patent(s)
  - ☐ Non-Patent Literature
    (journal articles, conference proceedings, new product announcements etc.)
- *Relevant prior art* ***not found****:*
  - ☐ Results verified the lack of relevant prior art (helped determine patentability)
  - ☐ Results were not useful in determining patentability or understanding the invention

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library Remsen Bldg.

Search and Information Resources Administration

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 28, 2004, 08:01:38 ; Search time 2 Seconds
(without alignments)
3.083 Million cell updates/sec

Title: US-10-069-079-1
Perfect score: 1000
Sequence: 1 ccgagccctgaggcaggcgg.....ctgcagctgtgcacatggaa 1000

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 172 seqs, 3083 residues

Total number of hits satisfying chosen parameters: 344

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 174 summaries

Database : rge1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	26	2.6	26	1	AR123060	ACCESSION:AR123060
	2	23	2.3	23	1	AR123058	ACCESSION:AR123058
c	3	21	2.1	21	1	AR123059	ACCESSION:AR123059
	4	20.4	2.0	23	1	AX665280	ACCESSION:AX665280
c	5	20	2.0	20	1	AR123064	ACCESSION:AR123064
c	6	20	2.0	20	1	AR123065	ACCESSION:AR123065
c	7	20	2.0	20	1	AR123066	ACCESSION:AR123066
c	8	20	2.0	20	1	AR123067	ACCESSION:AR123067
c	9	20	2.0	20	1	AR123068	ACCESSION:AR123068
c	10	20	2.0	20	1	AR123069	ACCESSION:AR123069
c	11	20	2.0	20	1	AR123070	ACCESSION:AR123070
	12	17.8	1.8	21	1	AR177580	ACCESSION:AR177580
	13	16.4	1.6	20	1	I62739	ACCESSION:I62739
c	14	16.2	1.6	21	1	AX060430	ACCESSION:AX060430
c	15	16	1.6	18	1	AR086070	ACCESSION:AR086070
c	16	16	1.6	18	1	AR140424	ACCESSION:AR140424
c	17	16	1.6	18	1	AR146905	ACCESSION:AR146905
c	18	16	1.6	18	1	AR216777	ACCESSION:AR216777
c	19	16	1.6	18	1	BD081901	ACCESSION:BD081901
	20	15.8	1.6	19	1	AR037410	ACCESSION:AR037410
	21	15.8	1.6	19	1	I57438	ACCESSION:I57438
	22	15.8	1.6	19	1	AR293541	ACCESSION:AR293541
	23	15.8	1.6	20	1	AR052628	ACCESSION:AR052628
	24	15.8	1.6	20	1	AR130110	ACCESSION:AR130110
	25	15.8	1.6	20	1	AR149436	ACCESSION:AR149436
	26	15.8	1.6	20	1	AR149441	ACCESSION:AR149441
	27	15.8	1.6	20	1	E49408	ACCESSION:E49408
	28	15.8	1.6	20	1	E49413	ACCESSION:E49413
	29	15.8	1.6	20	1	AR182885	ACCESSION:AR182885
c	30	15.8	1.6	20	1	AR298141	ACCESSION:AR298141
	31	15.8	1.6	20	1	AX104051	ACCESSION:AX104051
	32	15.8	1.6	20	1	AX355382	ACCESSION:AX355382
	33	15.8	1.6	20	1	AX547104	ACCESSION:AX547104
	34	15.8	1.6	20	1	BD069976	ACCESSION:BD069976
c	35	15.8	1.6	21	1	AR084563	ACCESSION:AR084563
c	36	15.8	1.6	21	1	AR084566	ACCESSION:AR084566
	37	15.8	1.6	21	1	AR084567	ACCESSION:AR084567
c	38	15.8	1.6	21	1	AR084578	ACCESSION:AR084578
	39	15.8	1.6	21	1	AR084579	ACCESSION:AR084579
	40	15.8	1.6	21	1	AR084582	ACCESSION:AR084582
	41	15.8	1.6	21	1	AR093142	ACCESSION:AR093142
	42	15.4	1.5	17	1	AX215323	ACCESSION:AX215323
	43	15.4	1.5	17	1	AX216895	ACCESSION:AX216895
	44	15.4	1.5	17	1	AX216896	ACCESSION:AX216896
	45	15.2	1.5	20	1	AR124487	ACCESSION:AR124487
c	46	15.2	1.5	20	1	E43717	ACCESSION:E43717
c	47	15.2	1.5	20	1	AR294598	ACCESSION:AR294598
	48	15.2	1.5	20	1	AX019252	ACCESSION:AX019252
c	49	15.2	1.5	20	1	AX224990	ACCESSION:AX224990
	50	15	1.5	17	1	AX216347	ACCESSION:AX216347
c	51	15	1.5	18	1	AR052029	ACCESSION:AR052029
c	52	15	1.5	18	1	AR063606	ACCESSION:AR063606
c	53	15	1.5	18	1	AR093858	ACCESSION:AR093858
	54	14.8	1.5	18	1	A65727	ACCESSION:A65727
	55	14.8	1.5	18	1	AR039651	ACCESSION:AR039651
c	56	14.8	1.5	18	1	AR105620	ACCESSION:AR105620
c	57	14.8	1.5	19	1	AX129119	ACCESSION:AX129119
c	58	14.8	1.5	19	1	AX129120	ACCESSION:AX129120
c	59	14.4	1.4	17	1	AR164080	ACCESSION:AR164080
c	60	14.4	1.4	17	1	AR164081	ACCESSION:AR164081
c	61	14.4	1.4	17	1	AX214998	ACCESSION:AX214998
	62	14.4	1.4	17	1	AX216348	ACCESSION:AX216348
	63	14.4	1.4	17	1	AX216349	ACCESSION:AX216349
c	64	14.4	1.4	17	1	AX545239	ACCESSION:AX545239
c	65	14.4	1.4	17	1	AX545240	ACCESSION:AX545240
c	66	14.4	1.4	17	1	AX672270	ACCESSION:AX672270
	67	14.4	1.4	17	1	AX693197	ACCESSION:AX693197
	68	14.4	1.4	17	1	AX693198	ACCESSION:AX693198
	69	14.4	1.4	17	1	AX727182	ACCESSION:AX727182
c	70	14.4	1.4	17	1	AX733886	ACCESSION:AX733886
c	71	14.4	1.4	17	1	AX733944	ACCESSION:AX733944
	72	14.4	1.4	17	1	AX734657	ACCESSION:AX734657
c	73	14.4	1.4	17	1	AX738881	ACCESSION:AX738881
c	74	14.4	1.4	17	1	AX760672	ACCESSION:AX760672
c	75	14.4	1.4	17	1	AX761200	ACCESSION:AX761200
c	76	14.4	1.4	17	1	BD058091	ACCESSION:BD058091
c	77	14.4	1.4	17	1	BD058092	ACCESSION:BD058092
	78	14.4	1.4	18	1	A67601	ACCESSION:A67601
	79	14.4	1.4	18	1	AR089739	ACCESSION:AR089739
	80	14.4	1.4	18	1	AR098790	ACCESSION:AR098790
c	81	14.4	1.4	18	1	AR292475	ACCESSION:AR292475
	82	14.4	1.4	18	1	AR392128	ACCESSION:AR392128
	83	14	1.4	17	1	AX041067	ACCESSION:AX041067
	84	14	1.4	17	1	AX578428	ACCESSION:AX578428
	85	14	1.4	17	1	AX579016	ACCESSION:AX579016
	86	14	1.4	17	1	AX579350	ACCESSION:AX579350
	87	14	1.4	17	1	AX579351	ACCESSION:AX579351
	88	14	1.4	17	1	AX579523	ACCESSION:AX579523
	89	14	1.4	17	1	AX579896	ACCESSION:AX579896
c	90	14	1.4	18	1	AR181637	ACCESSION:AR181637
	91	14	1.4	18	1	AX041066	ACCESSION:AX041066
c	92	14	1.4	18	1	BD088360	ACCESSION:BD088360
c	93	14	1.4	18	1	AB067907	ACCESSION:AB067907
c	94	13.8	1.4	17	1	BD254815	ACCESSION:BD254815
	95	13.8	1.4	17	1	BD259457	ACCESSION:BD259457
	96	13.8	1.4	17	1	AR188820	ACCESSION:AR188820
	97	13.8	1.4	17	1	AR196336	ACCESSION:AR196336
c	98	13.8	1.4	17	1	AR286193	ACCESSION:AR286193
	99	13.8	1.4	17	1	AR286209	ACCESSION:AR286209
	100	13.8	1.4	17	1	AR324673	ACCESSION:AR324673
c	101	13.8	1.4	17	1	AR398183	ACCESSION:AR398183
	102	13.8	1.4	17	1	AR398199	ACCESSION:AR398199
	103	13.8	1.4	17	1	AX215373	ACCESSION:AX215373
	104	13.8	1.4	17	1	AX474943	ACCESSION:AX474943
	105	13.8	1.4	17	1	AX474944	ACCESSION:AX474944
	106	13.8	1.4	17	1	AX474945	ACCESSION:AX474945

c 107	13.8	1.4	17	1	AX531299	ACCESSION:AX531299
c 108	13.8	1.4	17	1	AX531300	ACCESSION:AX531300
109	13.8	1.4	17	1	AX674185	ACCESSION:AX674185
110	13.8	1.4	17	1	AX759410	ACCESSION:AX759410
111	13.8	1.4	17	1	AX781951	ACCESSION:AX781951
112	13.8	1.4	17	1	AX783270	ACCESSION:AX783270
c 113	13.8	1.4	17	1	AX783521	ACCESSION:AX783521
c 114	13.8	1.4	17	1	ATH524392	ACCESSION:AJ524392
115	13.8	1.4	18	1	A67594	ACCESSION:A67594
c 116	13.8	1.4	18	1	AR039657	ACCESSION:AR039657
117	13.8	1.4	18	1	AR059531	ACCESSION:AR059531
118	13.8	1.4	18	1	AR089732	ACCESSION:AR089732
119	13.8	1.4	18	1	AR092795	ACCESSION:AR092795
120	13.8	1.4	18	1	AR098789	ACCESSION:AR098789
121	13.8	1.4	18	1	AR098791	ACCESSION:AR098791
c 122	13.8	1.4	18	1	AR123678	ACCESSION:AR123678
c 123	13.8	1.4	18	1	BD237949	ACCESSION:BD237949
124	13.8	1.4	18	1	AR242175	ACCESSION:AR242175
c 125	13.8	1.4	18	1	AR242759	ACCESSION:AR242759
126	13.8	1.4	18	1	AX014687	ACCESSION:AX014687
c 127	13.8	1.4	18	1	BD065054	ACCESSION:BD065054
c 128	13.8	1.4	18	1	BD190829	ACCESSION:BD190829
129	13.8	1.4	20	1	AR123065	ACCESSION:AR123065
130	13.4	1.3	15	1	AR033555	ACCESSION:AR033555
131	13.4	1.3	15	1	AR084532	ACCESSION:AR084532
132	13.4	1.3	15	1	AR113377	ACCESSION:AR113377
133	13.4	1.3	15	1	I57784	ACCESSION:I57784
134	13.4	1.3	15	1	AR278935	ACCESSION:AR278935
135	13.4	1.3	15	1	BD207288	ACCESSION:BD207288
136	13.4	1.3	16	1	AR105105	ACCESSION:AR105105
c 137	13.4	1.3	16	1	AX431337	ACCESSION:AX431337
138	13.4	1.3	16	1	BD090038	ACCESSION:BD090038
139	13.4	1.3	16	1	BD225504	ACCESSION:BD225504
c 140	13.4	1.3	17	1	AR074598	ACCESSION:AR074598
141	13.4	1.3	17	1	AR074600	ACCESSION:AR074600
c 142	13.4	1.3	17	1	BD241683	ACCESSION:BD241683
143	13.4	1.3	17	1	BD241714	ACCESSION:BD241714
c 144	13.4	1.3	17	1	BD258290	ACCESSION:BD258290
c 145	13.4	1.3	17	1	AR285940	ACCESSION:AR285940
c 146	13.4	1.3	17	1	AR328101	ACCESSION:AR328101
c 147	13.4	1.3	17	1	AR397930	ACCESSION:AR397930
c 148	13.4	1.3	17	1	AX214999	ACCESSION:AX214999
149	13.4	1.3	17	1	AX216346	ACCESSION:AX216346
c 150	13.4	1.3	17	1	AX216806	ACCESSION:AX216806
c 151	13.4	1.3	17	1	AX545238	ACCESSION:AX545238
c 152	13.4	1.3	17	1	AX545241	ACCESSION:AX545241
153	13.4	1.3	17	1	AX672762	ACCESSION:AX672762
c 154	13.4	1.3	17	1	AX676092	ACCESSION:AX676092
155	13.4	1.3	17	1	AX693196	ACCESSION:AX693196
156	13.4	1.3	17	1	AX693199	ACCESSION:AX693199
157	13.4	1.3	17	1	AX726974	ACCESSION:AX726974
158	13.4	1.3	17	1	AX781949	ACCESSION:AX781949
159	13.4	1.3	17	1	AX781950	ACCESSION:AX781950
160	13.4	1.3	17	1	BD104660	ACCESSION:BD104660
161	13	1.3	15	1	BD208459	ACCESSION:BD208459
162	13	1.3	15	1	BD208460	ACCESSION:BD208460
163	13	1.3	16	1	AX328241	ACCESSION:AX328241
c 164	13	1.3	17	1	BD254226	ACCESSION:BD254226
165	13	1.3	17	1	BD266292	ACCESSION:BD266292
166	13	1.3	17	1	AX579452	ACCESSION:AX579452
167	13	1.3	17	1	AX579772	ACCESSION:AX579772
168	13	1.3	17	1	AX580186	ACCESSION:AX580186
169	13	1.3	17	1	AX722809	ACCESSION:AX722809
170	13	1.3	17	1	AX732611	ACCESSION:AX732611
c 171	13	1.3	17	1	AX732819	ACCESSION:AX732819
c 172	13	1.3	17	1	AX735020	ACCESSION:AX735020
c 173	13	1.3	17	1	AX757003	ACCESSION:AX757003
174	12.8	1.3	17	1	AX531299	ACCESSION:AX531299

ALIGNMENTS

```
RESULT 1
AR123060
LOCUS       AR123060                 26 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 4 from patent US 6168950.
ACCESSION   AR123060
VERSION     AR123060.1  GI:14108026
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 26)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 4 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .26
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.5;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 CGTCCAGAGGAACGAATGATCAGGGA 503
              ||||||||||||||||||||||||||
Db          1 CGTCCAGAGGAACGAATGATCAGGGA 26


RESULT 2
AR123058
LOCUS       AR123058                 23 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2 from patent US 6168950.
ACCESSION   AR123058
VERSION     AR123058.1  GI:14108024
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 2 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 3.6;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 GAAACTCTCAAAGGGTTGCACAA 467
              |||||||||||||||||||||||
Db          1 GAAACTCTCAAAGGGTTGCACAA 23


RESULT 3
AR123059/c
LOCUS       AR123059                 21 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 3 from patent US 6168950.
ACCESSION   AR123059
VERSION     AR123059.1  GI:14108025
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 3 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
```

```
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        509 TGAAGGCAACCTGTATGCCAG 529
              |||||||||||||||||||||
Db         21 TGAAGGCAACCTGTATGCCAG 1


RESULT 4
AX665280
LOCUS       AX665280                 23 bp    DNA     linear   PAT 26-MAR-2003
DEFINITION  Sequence 38 from Patent WO03002765.
ACCESSION   AX665280
VERSION     AX665280.1  GI:29290405
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Sellar,G.C. and Gabra,H.
  TITLE     Cancer
  JOURNAL   Patent: WO 03002765-A 38 09-JAN-2003;
            Cancer Research Technology Limited (GB)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 20.4;  DB 1;  Length 23;
  Best Local Similarity   95.5%;  Pred. No. 11;
  Matches   21;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         98 GCGAGCGGGCGGACTGGCGGCG 119
              ||||||||||||  |||||||||
Db          2 GCGAGCGGGCGGGCTGGCGGCG 23


RESULT 5
AR123064/c
LOCUS       AR123064                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 8 from patent US 6168950.
ACCESSION   AR123064
VERSION     AR123064.1  GI:14108030
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 8 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGGAGGAGC 32
              ||||||||||||||||||||
Db         20 GCAGGCGGCGGCGGAGGAGC 1


RESULT 6
AR123065/c
LOCUS       AR123065                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 9 from patent US 6168950.
ACCESSION   AR123065
VERSION     AR123065.1  GI:14108031
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 9 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         44 GCAGCGCGCGCGCGGCTGCC 63
              ||||||||||||||||||||
Db         20 GCAGCGCGCGCGCGGCTGCC 1


RESULT 7
AR123066/c
LOCUS       AR123066                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 10 from patent US 6168950.
ACCESSION   AR123066
VERSION     AR123066.1  GI:14108032
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 10 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         94 GGCCGCGAGCGGGCGGACTG 113
              ||||||||||||||||||||
Db         20 GGCCGCGAGCGGGCGGACTG 1


RESULT 8
AR123067/c
LOCUS       AR123067                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 11 from patent US 6168950.
ACCESSION   AR123067
VERSION     AR123067.1  GI:14108033
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 11 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        148 GAGCTGGACCAGCTGCCTGA 167
              ||||||||||||||||||||
Db         20 GAGCTGGACCAGCTGCCTGA 1


RESULT 9
AR123068/c
LOCUS       AR123068                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 12 from patent US 6168950.
ACCESSION   AR123068
VERSION     AR123068.1  GI:14108034
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 12 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        230 CGGACGCAGCGGGGAGTGGG 249
              ||||||||||||||||||||
Db         20 CGGACGCAGCGGGGAGTGGG 1


RESULT 10
AR123069/c
LOCUS       AR123069                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 13 from patent US 6168950.
ACCESSION   AR123069
VERSION     AR123069.1  GI:14108035
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 13 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        309 CCACCTTACCGAGTCGGTGG 328
              ||||||||||||||||||||
Db         20 CCACCTTACCGAGTCGGTGG 1


RESULT 11
AR123070/c
LOCUS       AR123070                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 14 from patent US 6168950.
ACCESSION   AR123070
VERSION     AR123070.1  GI:14108036
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 14 02-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.5;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGGGTTGC 463
              ||||||||||||||||||||
Db         20 AGAAACTCTCAAAGGGTTGC 1


RESULT 12
AR177580
LOCUS       AR177580                  21 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 20 from patent US 6312934.
ACCESSION   AR177580
VERSION     AR177580.1  GI:17919935
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Johnson,G.L.
  TITLE     Human MEKK proteins, corresponding nucleic acid molecules, and uses
            therefor
  JOURNAL   Patent: US 6312934-A 20 06-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.8%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 23;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        527 CAGCCTGGAAGCACGAATGGT 547
              | |||||||||||||| ||||
Db          1 CGGCCTGGAAGCACGAGTGGT 21


RESULT 13
I62739
LOCUS       I62739                    20 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 2 from patent US 5660982.
ACCESSION   I62739
VERSION     I62739.1  GI:2480447
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tryggvason,K., Kallunki,P. and Pyke,C.
  TITLE     Laminin chains: diagnostic uses
  JOURNAL   Patent: US 5660982-A 2 26-AUG-1997;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 36;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              |||||||| |||||||||
```

```
Db          1 GAATCACTGAGCAGCTGA 18

RESULT 14
AX060430/c
LOCUS       AX060430                21 bp    DNA     linear   PAT 22-JAN-2001
DEFINITION  Sequence 50 from Patent WO0100841.
ACCESSION   AX060430
VERSION     AX060430.1  GI:12405907
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Griffin,J., Carlile,A.J., Cayley,P.J., Mackay,E.A., Warner,S.A.,
            Vincent,J.L. and Lee,M.D.
  TITLE     Insecticidal proteins from paecilomyces and synergistic
            combinations thereof
  JOURNAL   Patent: WO 0100841-A 50 04-JAN-2001;
            ZENECA LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primers"

  Query Match             1.6%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 44;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        171 GCCGCTCTTCCTTGCCGCCTC 191
              || |||||||||||| ||| |
Db         21 GCGGCTCTTCCTTGCTGCCCC 1


RESULT 15
AR086070/c
LOCUS       AR086070                18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 54 from patent US 5985552.
ACCESSION   AR086070
VERSION     AR086070.1  GI:10012836
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Howell,M.D., Brostoff,S.W. and Carlo,D.J.
  TITLE     Vaccination and methods against diseases resulting from pathogenic
            responses by specific T cell populations
  JOURNAL   Patent: US 5985552-A 54 16-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 16
AR140424/c
LOCUS       AR140424                18 bp    DNA     linear   PAT 16-JUN-2001
DEFINITION  Sequence 54 from patent US 6207645.
ACCESSION   AR140424
VERSION     AR140424.1  GI:14482920
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Howell,M.D., Brostoff,S.W. and Carlo,D.J.
  TITLE     Vaccination and methods against diseases resulting from pathogenic
            responses by specific T cell populations
  JOURNAL   Patent: US 6207645-A 54 27-MAR-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 17
AR146905/c
LOCUS       AR146905                18 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 54 from patent US 6221352.
ACCESSION   AR146905
VERSION     AR146905.1  GI:15110708
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Howell,M.D., Brostoff,S.W. and Carlo,D.J.
  TITLE     Method of preventing the proliferation of V.beta.14 or
            V.beta.17-Expressing T cells
  JOURNAL   Patent: US 6221352-A 54 24-APR-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 18
AR216777/c
LOCUS       AR216777                18 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 4 from patent US 6413516.
ACCESSION   AR216777
VERSION     AR216777.1  GI:23315710
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Chang,J.C.C., Brostoff,S.W. and Carlo,D.J.
  TITLE     Peptides and methods against psoriasis
  JOURNAL   Patent: US 6413516-A 4 02-JUL-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 19
BD081901/c
LOCUS       BD081901                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Peptide and method against psoriasis.
ACCESSION   BD081901
VERSION     BD081901.1  GI:22627511
KEYWORDS    JP 2001288108-A/1.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Chang,J.C.C., Brostoff,S.W. and Carlo,D.J.
  TITLE     Peptide and method against psoriasis
  JOURNAL   Patent: JP 2001288108-A 1 16-OCT-2001;
            THE IMMUNE RESPONSE CORP
COMMENT     OS   Artificial Sequence
            PN   JP 2001288108-A/1
            PD   16-OCT-2001
            PF   28-FEB-2001 JP 2001055930
            PR   14-JAN-1994 US    08/182967
            PI   JENNIE C C CHANG,STEVEN W BROSTOFF,DENNIS J CARLO PC
            A61K38/00,A61P17/06,A61P37/02//C07K14/725,A61K37/02 CC   primer
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 20
AR037410
LOCUS       AR037410                  19 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2 from patent US 5801158.
ACCESSION   AR037410
VERSION     AR037410.1  GI:5955266
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Thompson,J.D. and Draper,K.G.
  TITLE     Enzymatic RNA with activity to RAS
  JOURNAL   Patent: US 5801158-A 2 01-SEP-1998;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||  ||||||  |||
Db          1 GGCGGCGGAGGCAGCAGCG 19


RESULT 21
I57438
LOCUS       I57438                    19 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 2 from patent US 5610052.
ACCESSION   I57438
VERSION     I57438.1  GI:2482502
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Thompson,J.D. and Draper,K.G.
  TITLE     Enzymatic RNA with activity to ras
  JOURNAL   Patent: US 5610052-A 2 11-MAR-1997;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||  ||||||  |||
Db          1 GGCGGCGGAGGCAGCAGCG 19


RESULT 22
AR293541
LOCUS       AR293541                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5276 from patent US 6537751.
ACCESSION   AR293541
VERSION     AR293541.1  GI:31680825
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5276 25-MAR-2003;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        745 GGAGTAAGGAGAAAAAGAG 763
              |||  ||||||||||||||
Db          1 GGAACAAGGAGAAAAAGAG 19


RESULT 23
AR052628
LOCUS       AR052628                  20 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 28 from patent US 5831066.
ACCESSION   AR052628
VERSION     AR052628.1  GI:5975992
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Reed,J.C.
  TITLE     Regulation of bcl-2 gene expression
  JOURNAL   Patent: US 5831066-A 28 03-NOV-1998;
FEATURES              Location/Qualifiers
     source           1. .20
```

```
                /organism="unknown"
                /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 24
AR130110
LOCUS       AR130110                 20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 13 from patent US 6187587.
ACCESSION   AR130110
VERSION     AR130110.1  GI:14118007
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Popoff,I., Brown-Driver,V.L. and Cowsert,L.M.
  TITLE     Antisense inhibition of e2f transcription factor 1 expression
  JOURNAL   Patent: US 6187587-A 13 13-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 CAGGCGGCGGCGGAGGAGC 32
              |||||||||||||| || ||
Db          1 CAGGCGGCGGCGGCGGCGC 19


RESULT 25
AR149436
LOCUS       AR149436                 20 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 7 from patent US 6228592.
ACCESSION   AR149436
VERSION     AR149436.1  GI:15114027
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.
  TITLE     Nucleic acid detection in cytoplasm
  JOURNAL   Patent: US 6228592-A 7 08-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 26
AR149441
LOCUS       AR149441                 20 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 12 from patent US 6228592.
ACCESSION   AR149441
VERSION     AR149441.1  GI:15114032
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.
  TITLE     Nucleic acid detection in cytoplasm
  JOURNAL   Patent: US 6228592-A 12 08-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 27
E49408
LOCUS       E49408                   20 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Method for detecting cytoplasmic target nucleic acid in living
            cell.
ACCESSION   E49408
VERSION     E49408.1  GI:18629307
KEYWORDS    JP 2001025400-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.
  TITLE     Method for detecting cytoplasmic target nucleic acid in living cell
  JOURNAL   Patent: JP 2001025400-A 7 30-JAN-2001;
            BUNSHI BIO HOTONIKUSU KENKYUSHO
COMMENT     OS   Artificial Sequence
            PN   JP 2001025400-A/7
            PD   30-JAN-2001
            PF   28-DEC-1999 JP 1999373904
            PR
            PI   AKIHIKO TSUJI,MASAHIKO HIRANO,HIROYUKI KOSHIMOTO, PI   KANAME
            ISHIBASHI
            PC   C12Q1/68,C12N15/09//G01N21/78,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 28
E49413
LOCUS       E49413                   20 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Method for detecting cytoplasmic target nucleic acid in living
            cell.
ACCESSION   E49413
VERSION     E49413.1  GI:18629312
```

```
KEYWORDS    JP 2001025400-A/12.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tsuji,A., Hirano,M., Koshimoto,H. and Ishibashi,K.
  TITLE     Method for detecting cytoplasmic target nucleic acid in living cell
  JOURNAL   Patent: JP 2001025400-A 12 30-JAN-2001;
            BUNSHI BIO HOTONIKUSU KENKYUSHO
COMMENT     OS   Artificial Sequence
            PN   JP 2001025400-A/12
            PD   30-JAN-2001
            PF   28-DEC-1999 JP 1999373904
            PR
            PI   AKIHIKO TSUJI,MASAHIKO HIRANO,HIROYUKI KOSHIMOTO, PI   KANAME
            ISHIBASHI
            PC   C12Q1/68,C12N15/09//G01N21/78,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 29
AR182885
LOCUS       AR182885                 20 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 57 from patent US 6339068.
ACCESSION   AR182885
VERSION     AR182885.1  GI:20226092
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Krieg,A.M., Davis,H.L., Wu,T. and Schorr,J.
  TITLE     Vectors and methods for immunization or therapeutic protocols
  JOURNAL   Patent: US 6339068-A 57 15-JAN-2002;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 30
AR298141/c
LOCUS       AR298141                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9876 from patent US 6537751.
ACCESSION   AR298141
VERSION     AR298141.1  GI:31685425
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9876 25-MAR-2003;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        428 GTGAGATGGAGAATAAAGA 446
              |||||||||| | ||||||
Db         20 GTGAGATGGAAAGTAAAGA 2


RESULT 31
AX104051
LOCUS       AX104051                 20 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 243 from Patent WO0122972.
ACCESSION   AX104051
VERSION     AX104051.1  GI:13920248
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 243 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 32
AX355382
LOCUS       AX355382                 20 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 410 from Patent WO0197843.
ACCESSION   AX355382
VERSION     AX355382.1  GI:18620050
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
  JOURNAL   Patent: WO 0197843-A 410 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Synthetic oligonucleotide-phosphodiester backbone"
```

```
  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 33
AX547104
LOCUS       AX547104                  20 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 243 from Patent WO02053141.
ACCESSION   AX547104
VERSION     AX547104.1  GI:25812248
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 243 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 34
BD069976
LOCUS       BD069976                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Use of nucleic acids containing unmethylated CPG dinucleotide in
            the treatment of LPS-associated disorders.
ACCESSION   BD069976
VERSION     BD069976.1  GI:22615579
KEYWORDS    JP 2001513776-A/65.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Schwartz,D.A. and Krieg,A.M.
  TITLE     Use of nucleic acids containing unmethylated CPG dinucleotide in
            the treatment of LPS-associated disorders
  JOURNAL   Patent: JP 2001513776-A 65 04-SEP-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION
COMMENT     OS   Artificial Sequence
            PN   JP 2001513776-A/65
            PD   04-SEP-2001
            PF   25-FEB-1998 JP 1998537810
            PR   28-FEB-1997 US    60/039405
            PI   DAVID A SCHWARTZ,ARTHUR M KRIEG
            PC   A61K49/00,C07H21/02,C07H21/04,A01N43/04
            CC   synthetic oligonucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 45;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 35
AR084563/c
LOCUS       AR084563                  21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 52 from patent US 5981185.
ACCESSION   AR084563
VERSION     AR084563.1  GI:10011334
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 52 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db         20 GGCGGCGGCGGCGGCGGCG 2


RESULT 36
AR084566/c
LOCUS       AR084566                  21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 55 from patent US 5981185.
ACCESSION   AR084566
VERSION     AR084566.1  GI:10011337
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 55 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db         19 GGCGGCGGCGGCGGCGGCG 1


RESULT 37
AR084567
LOCUS       AR084567                  21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 56 from patent US 5981185.
ACCESSION   AR084567
VERSION     AR084567.1  GI:10011338
```

```
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 56 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          2 GGCGGCGGCGGCGGCGGCG 20


RESULT 38
AR084578/c
LOCUS       AR084578                 21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 67 from patent US 5981185.
ACCESSION   AR084578
VERSION     AR084578.1  GI:10011349
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 67 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db         21 GGCGGCGGCGGCGGCGGCG 3


RESULT 39
AR084579
LOCUS       AR084579                 21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 68 from patent US 5981185.
ACCESSION   AR084579
VERSION     AR084579.1  GI:10011350
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 68 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          3 GGCGGCGGCGGCGGCGGCG 21


RESULT 40
AR084582
LOCUS       AR084582                 21 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 71 from patent US 5981185.
ACCESSION   AR084582
VERSION     AR084582.1  GI:10011353
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 71 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 41
AR093142
LOCUS       AR093142                 21 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 11 from patent US 5998596.
ACCESSION   AR093142
VERSION     AR093142.1  GI:10019894
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Bergan,R. and Neckers,L.
  TITLE     Inhibition of protein kinase activity by aptameric action of
            oligonucleotides
  JOURNAL   Patent: US 5998596-A 11 07-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 42
AX215323
LOCUS       AX215323                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 765 from Patent WO0159103.
ACCESSION   AX215323
VERSION     AX215323.1  GI:15525366
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
```

```
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 765 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 35;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||| ||||||||
Db          1 GCGGCGGCAGCAGGTGC 17


RESULT 43
AX216895
LOCUS       AX216895                17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2337 from Patent WO0159103.
ACCESSION   AX216895
VERSION     AX216895.1  GI:15526956
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2337 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 35;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCAGC 127
              | ||||||||||||||||
Db          1 CCGGCGGCGGCGGCAGC 17


RESULT 44
AX216896
LOCUS       AX216896                17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2338 from Patent WO0159103.
ACCESSION   AX216896
VERSION     AX216896.1  GI:15526957
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2338 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 35;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||||| ||
Db          1 GCGGCGGCGGCAGCAGC 17


RESULT 45
AR124487
LOCUS       AR124487                20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 56 from patent US 6171860.
ACCESSION   AR124487
VERSION     AR124487.1  GI:14109848
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of rank expression
  JOURNAL   Patent: US 6171860-A 56 09-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 56;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        294 CAGCCGGCGCGGCGCCCACC 313
              |||||| ||| |||||| ||
Db          1 CAGCCGCCGCCGCGCCCTCC 20


RESULT 46
E43717/c
LOCUS       E43717                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for detecting abnormality in IRF-1 gene.
ACCESSION   E43717
VERSION     E43717.1  GI:22554626
KEYWORDS    JP 2001136973-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Takami,S., Kinoshita,S., Tada,S. and Saito,H.
  TITLE     Method for detecting abnormality in IRF-1 gene
  JOURNAL   Patent: JP 2001136973-A 4 22-MAY-2001;
            OTSUKA PHARMACEUT CO LTD
COMMENT     PN   JP 2001136973-A/4
            PD   22-MAY-2001
            PF   16-NOV-1999 JP 1999324975
            PI   SATOSHI TAKAMI,SHIGETOSHI KINOSHITA,SHINICHIRO TADA,HIDETSUGU
            PI   SAITO
            PC   C12N15/09,C12Q1/68,C12Q1/68,G01N33/50,C12N15/00 CC   IRF-1
            RFLP R primer
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
```

```
  Best Local Similarity   85.0%;  Pred. No. 56;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        203 CCTCGACTTCCCCGTCGCCG 222
              |||  |||||||| ||||||
Db         20 CCTGTACTTCCCCTTCGCCG 1


RESULT 47
AR294598/c
LOCUS       AR294598                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6333 from patent US 6537751.
ACCESSION   AR294598
VERSION     AR294598.1  GI:31681882
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 6333 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 56;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        550 GAAAGGAGAAATAGGCGAGG 569
              |||| ||||||||||  |||
Db         20 GAAATGAGAAATAGGAAAGG 1


RESULT 48
AX019252
LOCUS       AX019252                 20 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 6 from Patent WO9941380.
ACCESSION   AX019252
VERSION     AX019252.1  GI:10043277
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Vercelli,D. and Agresti,A.
  TITLE     The regulatory sequence of gamma -4 germline (gl) transcript and
            its applications
  JOURNAL   Patent: WO 9941380-A 6 19-AUG-1999;
            VERCELLI DONATA (IT); AGRESTI ALESSANDRA (IT)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 56;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        367 GAGCCCGGGGAGAAGCGGGC 386
              ||| | |||||||.||||||
Db          1 GAGGCTGGGGAGACGCGGGC 20


RESULT 49
AX224990/c
LOCUS       AX224990                 20 bp    DNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 144 from Patent WO0161030.
ACCESSION   AX224990
VERSION     AX224990.1  GI:15555063
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gray,D.M. and Bollon,A.P.
  TITLE     Libraries of optimum subsequence regions of mrna and genomic dna
            for control of gene expression
  JOURNAL   Patent: WO 0161030-A 144 23-AUG-2001;
            Cytoclonal Pharmaceutics, Inc. (US) ; University of Texas at
            Dallas, Dept. of Molecular and Cell Biology (US); Lab. of
            Experimental Carcinogenesis, National Cancer Institute/NIH (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 56;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        299 GGCGCGGCGCCCACCTTACC 318
              |||||||||||||| |  ||
Db         20 GGCGCGGCGCCCACATCTCC 1


RESULT 50
AX216347
LOCUS       AX216347                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1789 from Patent WO0159103.
ACCESSION   AX216347
VERSION     AX216347.1  GI:15526408
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1789 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.5%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              |||||||||||||||
Db          2 GGCGGCGGCGGCAGC 16


RESULT 51
AR052029/c
LOCUS       AR052029                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 15 from patent US 5830756.
ACCESSION   AR052029
VERSION     AR052029.1  GI:5975393
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
```

```
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Haskill,J.Stephen., Baldwin,A.S. Jr. and Ralph,P.
  TITLE     DNA and expression vector encoding I.kappa.B Protein
  JOURNAL   Patent: US 5830756-A 15 03-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1


RESULT 52
AR063606/c
LOCUS       AR063606                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 15 from patent US 5846714.
ACCESSION   AR063606
VERSION     AR063606.1  GI:5992914
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Haskill,J.Stephen., Baldwin,A.S. Jr. and Ralph,P.
  TITLE     Method of identifying a chemical that alters dissociation of an
            NF-KB/IKB complex
  JOURNAL   Patent: US 5846714-A 15 08-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1


RESULT 53
AR093858/c
LOCUS       AR093858                 18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 15 from patent US 6001582.
ACCESSION   AR093858
VERSION     AR093858.1  GI:10020604
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Haskill,J.Stephen., Baldwin,A.S. Jr. and Ralph,P.
  TITLE     Inhibitor of NF-.kappa.B transcriptional activator and uses thereof
  JOURNAL   Patent: US 6001582-A 15 14-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1


RESULT 54
A65727
LOCUS       A65727                   18 bp    DNA     linear   PAT 29-MAR-1999
DEFINITION  Sequence 8 from Patent WO9735973.
ACCESSION   A65727
VERSION     A65727.1  GI:4531346
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Lenzen,G., Pietri-Rouxel,F., Drumare, Marie-Francoise and
            Strosberg,A.D.
  TITLE     CANINE beta 2- AND beta 3-ADRENERGIC RECEPTORS AND USE THEREOF
  JOURNAL   Patent: WO 9735973-A 8 02-OCT-1997;
            VETIGEN (FR)
COMMENT     Other publication FR 2746813 19971003.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match           1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        390 CGCCGCCGAGCCGTCTCC 407
              |||||| ||| |||||||
Db          1 CGCCGCAGAGACGTCTCC 18


RESULT 55
AR039651
LOCUS       AR039651                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 499 from patent US 5807743.
ACCESSION   AR039651
VERSION     AR039651.1  GI:5959014
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 499 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 TCCTGCAGCGGCCCCCGC 422
              ||||||||| ||||| ||
Db          1 TCCTGCAGCTGCCCCTGC 18


RESULT 56
AR105620/c
LOCUS       AR105620                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 95 from patent US 6096722.
ACCESSION   AR105620
VERSION     AR105620.1  GI:12819217
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
```

```
  AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
  TITLE     Antisense modulation of cell adhesion molecule expression and
            treatment of cell adhesion molecule-associated diseases
  JOURNAL   Patent: US 6096722-A 95 01-AUG-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 50;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         27 AGGAGCCCTCAAGGCGAG 44
              |||||| ||||||| |||
Db         18 AGGAGCACTCAAGGGGAG 1


RESULT 57
AX129119/c
LOCUS       AX129119                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 337 from Patent WO0130362.
ACCESSION   AX129119
VERSION     AX129119.1  GI:14135424
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 337 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cdk3 ribozyme binding site"

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 58;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        783 GAGTGGCAGAATCACACC 800
              |||||||||||| | ||||
Db         19 GAGTGGCAGAAACTCACC 2


RESULT 58
AX129120/c
LOCUS       AX129120                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 338 from Patent WO0130362.
ACCESSION   AX129120
VERSION     AX129120.1  GI:14135425
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 338 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cdk3 ribozyme binding site"

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 58;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        783 GAGTGGCAGAATCACACC 800
              |||||||||||| | ||||
Db         18 GAGTGGCAGAAACTCACC 1


RESULT 59
AR164080/c
LOCUS       AR164080                 17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 3 from patent US 6271210.
ACCESSION   AR164080
VERSION     AR164080.1  GI:16235018
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sivaraman,V.S., Wang,H.-y. and Malbon,C.C.
  TITLE     Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for cancer
  JOURNAL   Patent: US 6271210-A 3 07-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              |||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 60
AR164081/c
LOCUS       AR164081                 17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 4 from patent US 6271210.
ACCESSION   AR164081
VERSION     AR164081.1  GI:16235020
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sivaraman,V.S., Wang,H.-y. and Malbon,C.C.
  TITLE     Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for cancer
  JOURNAL   Patent: US 6271210-A 4 07-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              |||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 61
AX214998/c
LOCUS       AX214998                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 440 from Patent WO0159103.
```

```
ACCESSION   AX214998
VERSION     AX214998.1  GI:15525041
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 440 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAAA 616
              ||||||| ||||||||
Db         16 GGAGATGAATCTGAAA 1


RESULT 62
AX216348
LOCUS       AX216348                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1790 from Patent WO0159103.
ACCESSION   AX216348
VERSION     AX216348.1  GI:15526409
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1790 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGC 130
              |||||||||||||| ||
Db          1 CGGCGGCGGCAGCAGC 16


RESULT 63
AX216349
LOCUS       AX216349                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1791 from Patent WO0159103.
ACCESSION   AX216349
VERSION     AX216349.1  GI:15526410
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1791 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGC 130
              ||||||| ||||||||
Db          1 CGGCGGCAGCAGCTGC 16


RESULT 64
AX545239/c
LOCUS       AX545239                  17 bp    DNA     linear   PAT 26-NOV-2002
DEFINITION  Sequence 752 from Patent EP1243660.
ACCESSION   AX545239
VERSION     AX545239.1  GI:25810450
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J., Gu,Y. and Nguyen,C.T.
  TITLE     Human udp-galnac:polypeptide n-acetylgalatosaminyltransferase 10
  JOURNAL   Patent: EP 1243660-A 752 25-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              ||||||||| ||||||
Db         17 AGCCCTCAATGCGAGC 2


RESULT 65
AX545240/c
LOCUS       AX545240                  17 bp    DNA     linear   PAT 26-NOV-2002
DEFINITION  Sequence 753 from Patent EP1243660.
ACCESSION   AX545240
VERSION     AX545240.1  GI:25810451
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J., Gu,Y. and Nguyen,C.T.
  TITLE     Human udp-galnac:polypeptide n-acetylgalatosaminyltransferase 10
  JOURNAL   Patent: EP 1243660-A 753 25-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

```
                    /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              ||||||||| ||||||
Db         16 AGCCCTCAATGCGAGC 1


RESULT 66
AX672270/c
LOCUS       AX672270                  17 bp    DNA     linear   PAT 29-MAR-2003
DEFINITION  Sequence 715 from Patent WO03004526.
ACCESSION   AX672270
VERSION     AX672270.1  GI:29330618
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 715 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 67
AX693197
LOCUS       AX693197                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 5929 from Patent EP1281758.
ACCESSION   AX693197
VERSION     AX693197.1  GI:29416161
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 5929 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCAG 654
              |||||||||||| ||||
Db          2 TCCAGGAGAGGGCCAG 17


RESULT 68
AX693198
LOCUS       AX693198                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 5930 from Patent EP1281758.
ACCESSION   AX693198
VERSION     AX693198.1  GI:29416162
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 5930 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCAG 654
              |||||||||||| ||||
Db          1 TCCAGGAGAGGGCCAG 16


RESULT 69
AX727182
LOCUS       AX727182                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4869 from Patent WO03025176.
ACCESSION   AX727182
VERSION     AX727182.1  GI:30506525
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4869 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCA 623
              ||||||||||||| ||
Db          1 GATCTGAAATGAACCA 16


RESULT 70
AX733886/c
LOCUS       AX733886                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5520 from Patent WO03025175.
ACCESSION   AX733886
```

```
VERSION     AX733886.1  GI:30513229
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5520 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 71
AX733944/c
LOCUS       AX733944                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5578 from Patent WO03025175.
ACCESSION   AX733944
VERSION     AX733944.1  GI:30513287
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5578 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 72
AX734657
LOCUS       AX734657                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 247 from Patent WO03025177.
ACCESSION   AX734657
VERSION     AX734657.1  GI:30513934
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 247 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCA 623
              |||||||||||||| |
Db          1 GATCTGAAATGAATGA 16


RESULT 73
AX738881/c
LOCUS       AX738881                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4471 from Patent WO03025177.
ACCESSION   AX738881
VERSION     AX738881.1  GI:30518171
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4471 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        914 CTAACTCTTTCCTGAT 929
              |||||| |||||||||
Db         17 CTAACTTTTTCCTGAT 2


RESULT 74
AX760672/c
LOCUS       AX760672                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 3993 from Patent WO03040369.
ACCESSION   AX760672
VERSION     AX760672.1  GI:32255288
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3993 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
```

```
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 75
AX761200/c
LOCUS       AX761200                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4521 from Patent WO03040369.
ACCESSION   AX761200
VERSION     AX761200.1  GI:32255816
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4521 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 76
BD058091/c
LOCUS       BD058091                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for breast cancer.
ACCESSION   BD058091
VERSION     BD058091.1  GI:22603697
KEYWORDS    JP 2001518881-A/3.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sivaraman,V.S., Wang,H.Y. and Malbon,C.C.
  TITLE     Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for breast cancer
  JOURNAL   Patent: JP 2001518881-A 3 16-OCT-2001;
            THE RESEARCH FOUNDATION OF STATE UNIV OF NEW YORK
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001518881-A/3
            PD   16-OCT-2001
            PF   19-MAR-1998 JP 1998541700
            PI   VIMALA S SIVARAMAN,HSIEN YU WANG,CRAIG C MALBON PC
            C12N15/11,A61K31/70,C12Q1/68//A61K48/00
            CC   The molecular type is mRNA which is antisense. FH   Key
                 Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              |||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 77
BD058092/c
LOCUS       BD058092                 17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for breast cancer.
ACCESSION   BD058092
VERSION     BD058092.1  GI:22603698
KEYWORDS    JP 2001518881-A/4.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Sivaraman,V.S., Wang,H.Y. and Malbon,C.C.
  TITLE     Antisense oligonucleotides for mitogen-activated protein kinases as
            therapy for breast cancer
  JOURNAL   Patent: JP 2001518881-A 4 16-OCT-2001;
            THE RESEARCH FOUNDATION OF STATE UNIV OF NEW YORK
COMMENT     OS   Homo sapiens (human)
            PN   JP 2001518881-A/4
            PD   16-OCT-2001
            PF   19-MAR-1998 JP 1998541700
            PI   VIMALA S SIVARAMAN,HSIEN YU WANG,CRAIG C MALBON PC
            C12N15/11,A61K31/70,C12Q1/68//A61K48/00
            CC   The molecular type is cDNA which is antisense. FH   Key
                 Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 51;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              |||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 78
A67601
LOCUS       A67601                   18 bp    DNA     linear   PAT 05-MAY-1999
DEFINITION  Sequence 21 from Patent WO9744485.
ACCESSION   A67601
VERSION     A67601.1  GI:4756464
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Goodfellow,P.N.
  TITLE     METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
  JOURNAL   Patent: WO 9744485-A 21 27-NOV-1997;
            HEXAGEN TECHNOLOGY LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .18
```

```
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
               ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 79
AR089739
LOCUS       AR089739                 18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 21 from patent US 5994075.
ACCESSION   AR089739
VERSION     AR089739.1  GI:10016494
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Goodfellow,P.N.
  TITLE     Methods for identifying a mutation in a gene of interest without a
            phenotypic guide
  JOURNAL   Patent: US 5994075-A 21 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
               ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 80
AR098790
LOCUS       AR098790                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 45 from patent US 6077672.
ACCESSION   AR098790
VERSION     AR098790.1  GI:12808556
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of TRADD expression
  JOURNAL   Patent: US 6077672-A 45 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          3 TGGCGGCGGCGGCGGC 18


RESULT 81
AR292475/c
LOCUS       AR292475                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4210 from patent US 6537751.
ACCESSION   AR292475
VERSION     AR292475.1  GI:31679759
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4210 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        549 GGAAAGGAGAAATAGG 564
              ||||||||||||||| |
Db         17 GGAAAGGAGAAATATG 2


RESULT 82
AR392128
LOCUS       AR392128                 18 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 43 from patent US 6613567.
ACCESSION   AR392128
VERSION     AR392128.1  GI:40116018
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of Her-2 expression
  JOURNAL   Patent: US 6613567-A 43 02-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        775 CCTTTTCAGAGTGGCA 790
              ||||| ||||||||||
Db          1 CCTTTCCAGAGTGGCA 16


RESULT 83
AX041067
LOCUS       AX041067                 17 bp    DNA     linear   PAT 23-NOV-2000
DEFINITION  Sequence 10 from Patent WO0065098.
ACCESSION   AX041067
VERSION     AX041067.1  GI:11340637
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Dubiley,S., Kirillov,E. and Mirzabekov,A.
  TITLE     Nucleotide extension on a microarray of gel-immobilized primers
  JOURNAL   Patent: WO 0065098-A 10 02-NOV-2000;
            The University of Chicago (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:32630"
                     /note="Primer~'n' represents a, t, c or g"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        770 CAGTGCCTTTTCAG 783
              ||||||||||||||
Db          3 CAGTGCCTTTTCAG 16


RESULT 84
AX578428
LOCUS       AX578428                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 266 from Patent WO0211674.
ACCESSION   AX578428
VERSION     AX578428.1  GI:27647630
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 266 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||||||||||||||
Db          2 GATGGATCTGAAAT 15


RESULT 85
AX579016
LOCUS       AX579016                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 854 from Patent WO0211674.
ACCESSION   AX579016
VERSION     AX579016.1  GI:27648218
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 854 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||||||||||||||
Db          1 GATGGATCTGAAAT 14


RESULT 86
AX579350
LOCUS       AX579350                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1188 from Patent WO0211674.
ACCESSION   AX579350
VERSION     AX579350.1  GI:27648552
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1188 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              ||||||||||||||
Db          4 AGAACTGCAGCTGT 17


RESULT 87
AX579351
LOCUS       AX579351                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1189 from Patent WO0211674.
ACCESSION   AX579351
VERSION     AX579351.1  GI:27648553
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1189 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              ||||||||||||||
Db          1 AGAACTGCAGCTGT 14
```

```
RESULT 88
AX579523
LOCUS       AX579523                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1361 from Patent WO0211674.
ACCESSION   AX579523
VERSION     AX579523.1  GI:27648725
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1361 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              ||||||||||||||
Db          3 AGAACTGCAGCTGT 16


RESULT 89
AX579896
LOCUS       AX579896                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1734 from Patent WO0211674.
ACCESSION   AX579896
VERSION     AX579896.1  GI:27649098
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1734 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||||||||||||||
Db          4 GATGGATCTGAAAT 17


RESULT 90
AR181637/c
LOCUS       AR181637                  18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 99 from patent US 6335194.
ACCESSION   AR181637
VERSION     AR181637.1  GI:20223851
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,L.M.
  TITLE     Antisense modulation of survivin expression
  JOURNAL   Patent: US 6335194-A 99 01-JAN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 68;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCA 125
              ||||||||||||||
Db         16 TGGCGGCGGCGGCA 3


RESULT 91
AX041066
LOCUS       AX041066                  18 bp    DNA     linear   PAT 23-NOV-2000
DEFINITION  Sequence 9 from Patent WO0065098.
ACCESSION   AX041066
VERSION     AX041066.1  GI:11340636
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Dubiley,S., Kirillov,E. and Mirzabekov,A.
  TITLE     Nucleotide extension on a microarray of gel-immobilized primers
  JOURNAL   Patent: WO 0065098-A 9 02-NOV-2000;
            The University of Chicago (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer-'n' represents a, t, c or g"

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 68;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        770 CAGTGCCTTTTCAG 783
              ||||||||||||||
Db          4 CAGTGCCTTTTCAG 17


RESULT 92
BD088360/c
LOCUS       BD088360                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD088360
VERSION     BD088360.1  GI:22633970
KEYWORDS    JP 2001321190-A/604.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 604 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
```

```
            PN   JP 2001321190-A/604
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 68;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        983 GCAGCTGTGCACAT 996
              ||||||||||||||
Db         15 GCAGCTGTGCACAT 2


RESULT 93
AB067907/c
LOCUS       AB067907                 18 bp    DNA     linear   SYN 21-MAY-2003
DEFINITION  Synthetic construct DNA, reverse primer for human STS sts-stSG26879
            at 1p36.
ACCESSION   AB067907
VERSION     AB067907.1  GI:15128711
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
  TITLE     A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome 1p35-p36
  JOURNAL   Genomics 74 (1), 55-70 (2001)
  MEDLINE   21269192
   PUBMED   11374902
REFERENCE   2  (bases 1 to 18)
  AUTHORS   Horii,A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
     misc_feature    1. .18
                     /note="reverse primer for human STS sts-stSG26879 at 1p36
                     sts-stSG26879 obtained from clones B313L13, B244M15,
                     dJ890O3, Human BAC library RPCI-11"

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 68;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        983 GCAGCTGTGCACAT 996
              ||||||||||||||
Db         15 GCAGCTGTGCACAT 2


RESULT 94
BD254815/c
LOCUS       BD254815                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254815
VERSION     BD254815.1  GI:33064585
KEYWORDS    JP 2002541795-A/2608.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2608 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2608
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key              Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         77 GGGAGGCGGGCAGCGGG 93
              ||||||||| |||| ||
Db         17 GGGAGGCGGACAGCCGG 1


RESULT 95
BD259457
LOCUS       BD259457                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD259457
VERSION     BD259457.1  GI:33069227
KEYWORDS    JP 2002541795-A/7250.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 7250 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/7250
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
```

```
          C12R1:91),
          PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC   A61K37/02,
          PC   (C12N5/00,C12R1:91)
          CC   Regulation of repressor genes using nucleic acid molecules FH
           Key             Location/Qualifiers
          FT   source          1. .17
          FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        148 GAGCTGGACCAGCTGCC 164
              ||||||| ||||| |||
Db          1 GAGCTGGTCCAGCAGCC 17


RESULT 96
AR188820
LOCUS       AR188820                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 4308 from patent US 6346398.
ACCESSION   AR188820
VERSION     AR188820.1  GI:20234785
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 4308 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              |||||||  ||||||||
Db          1 TTTCCTGTATGGAGGAG 17


RESULT 97
AR196336
LOCUS       AR196336                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 801 from patent US 6350934.
ACCESSION   AR196336
VERSION     AR196336.1  GI:20245773
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
            Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
  TITLE     Nucleic acid encoding delta-9 desaturase
  JOURNAL   Patent: US 6350934-A 801 26-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        203 CCTCGACTTCCCCGTCG 219
              |||||| |||| |||||
Db          1 CCTCGAGTTCCTCGTCG 17


RESULT 98
AR286193/c
LOCUS       AR286193                 17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 565 from patent US 6528640.
ACCESSION   AR286193
VERSION     AR286193.1  GI:29723789
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 565 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 99
AR286209
LOCUS       AR286209                 17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 581 from patent US 6528640.
ACCESSION   AR286209
VERSION     AR286209.1  GI:29723805
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 581 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              ||| |||||||||| |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 100
AR324673
LOCUS       AR324673                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2075 from patent US 6566127.
ACCESSION   AR324673
VERSION     AR324673.1  GI:33710481
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2075 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              |||||||  ||||||||
Db          1 TTTCCTGTATGGAGGAG 17


RESULT 101
AR398183/c
LOCUS       AR398183                  17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 564 from patent US 6617438.
ACCESSION   AR398183
VERSION     AR398183.1  GI:40135789
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 564 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 102
AR398199
LOCUS       AR398199                  17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 580 from patent US 6617438.
ACCESSION   AR398199
VERSION     AR398199.1  GI:40135818
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 580 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              |||  |||||||||  |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 103
AX215373
LOCUS       AX215373                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 815 from Patent WO0159103.
ACCESSION   AX215373
VERSION     AX215373.1  GI:15525416
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 815 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        388 CCCGCCGCCGAGCCGTC 404
              ||||||||||  || |||
Db          1 CCCGCCGCCGGGCTGTC 17


RESULT 104
AX474943
LOCUS       AX474943                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 164 from Patent WO0224750.
ACCESSION   AX474943
VERSION     AX474943.1  GI:22214228
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 164 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         63 CGCGGGACTGCTGCGGG 79
              ||||||  |||||||||
Db          1 CGCGGGGTTGCTGCGGG 17


RESULT 105
AX474944
```

```
LOCUS       AX474944                17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 165 from Patent WO0224750.
ACCESSION   AX474944
VERSION     AX474944.1  GI:22214229
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 165 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 GCGGGACTGCTGCGGGA 80
              |||||  ||||||||||
Db          1 GCGGGGTTGCTGCGGGA 17


RESULT 106
AX474945
LOCUS       AX474945                17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 166 from Patent WO0224750.
ACCESSION   AX474945
VERSION     AX474945.1  GI:22214230
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 166 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         65 CGGGACTGCTGCGGGAG 81
              ||||  ||||||||||||
Db          1 CGGGGTTGCTGCGGGAG 17


RESULT 107
AX531299/c
LOCUS       AX531299                17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 808 from Patent EP1239051.
ACCESSION   AX531299
VERSION     AX531299.1  GI:25254384
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 808 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||| | |||||||||
Db         17 GCGGCTGGGGCAGCTGC 1


RESULT 108
AX531300/c
LOCUS       AX531300                17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 809 from Patent EP1239051.
ACCESSION   AX531300
VERSION     AX531300.1  GI:25254386
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 809 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTG 129
              |||||| | ||||||||
Db         17 GGCGGCTGGGGCAGCTG 1


RESULT 109
AX674185
LOCUS       AX674185                17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 2630 from Patent WO03004526.
ACCESSION   AX674185
VERSION     AX674185.1  GI:29332533
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 2630 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCAC 624
              ||||||||||  ||| ||
Db          1 GATCTGAAATCAATAAC 17


RESULT 110
AX759410
LOCUS       AX759410                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2731 from Patent WO03040369.
ACCESSION   AX759410                                        o
VERSION     AX759410.1  GI:32254026
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2731 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCAC 624
              ||||||  |||||  ||||
Db          1 GATCTGCAATGATTCAC 17


RESULT 111
AX781951
LOCUS       AX781951                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 282 from Patent WO03050284.
ACCESSION   AX781951
VERSION     AX781951.1  GI:32949800
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1                                             o
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 282 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        452 TCAAAGGGTTGCACAAG 468
              ||||  ||||||||||  |
Db          1 TCAATGGGTTGCACATG 17


RESULT 112
AX783270
LOCUS       AX783270                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1601 from Patent WO03050284.
ACCESSION   AX783270
VERSION     AX783270.1  GI:32951119
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1601 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        401 CGTCTCCTGCAGCGGCC 417
              |||  | ||||||||||
Db          1 CGTGTTCTGCAGCGGCC 17


RESULT 113
AX783521/c
LOCUS       AX783521                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1852 from Patent WO03050284.
ACCESSION   AX783521
VERSION     AX783521.1  GI:32951370
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1852 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        286 GGAGCCGCCAGCCGGCG 302
              |||||  ||||||  ||||
Db         17 GGAGCAGCCAGCAGGCG 1


RESULT 114
ATH524392/c
LOCUS       ATH524392                 17 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            074D03.
ACCESSION   AJ524392
VERSION     AJ524392.1  GI:26792628
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
```

```
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 17)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="074D03"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .17
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        411 AGCGGCCCCCCGCCGGTC 427
              ||| ||||||| |||||
Db         17 AGCCGCCCCCGGCGGTC 1


RESULT 115
A67594
LOCUS       A67594                   18 bp    DNA     linear   PAT 05-MAY-1999
DEFINITION  Sequence 14 from Patent WO9744485.
ACCESSION   A67594
VERSION     A67594.1  GI:4756457
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Goodfellow,P.N.
  TITLE     METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
  JOURNAL   Patent: WO 9744485-A 14 27-NOV-1997;
            HEXAGEN TECHNOLOGY LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 116
AR039657/c
LOCUS       AR039657                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 505 from patent US 5807743.
ACCESSION   AR039657
VERSION     AR039657.1  GI:5959020
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 505 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        967 ATTGGGCCTCAGAACTG 983
              ||||||| |||||| ||
Db         17 ATTGGGCGTCAGAATTG 1


RESULT 117
AR059531
LOCUS       AR059531                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 21 from patent US 5840491.
ACCESSION   AR059531
VERSION     AR059531.1  GI:5985981
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kakizuka,A.
  TITLE     DNA sequence encoding the Machado-Joseph disease gene and uses
            thereof
  JOURNAL   Patent: US 5840491-A 21 24-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        916 AACTCTTTCCTGATTGG 932
              |||||| ||||||| ||
Db          1 AACTCTGTCCTGATAGG 17


RESULT 118
AR089732
LOCUS       AR089732                 18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 14 from patent US 5994075.
ACCESSION   AR089732
VERSION     AR089732.1  GI:10016487
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
```

```
  AUTHORS   Goodfellow,P.N.
  TITLE     Methods for identifying a mutation in a gene of interest without a
            phenotypic guide
  JOURNAL   Patent: US 5994075-A 14 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 119
AR092795
LOCUS       AR092795                 18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 10 from patent US 5998206.
ACCESSION   AR092795
VERSION     AR092795.1  GI:10019547
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cowsert,L.M.
  TITLE     Antisense inhibiton of human G-alpha-12 expression
  JOURNAL   Patent: US 5998206-A 10 07-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGGAGG 29
              |||||| ||||| ||||
Db          2 GCAGGCAGCGGCTGAGG 18


RESULT 120
AR098789
LOCUS       AR098789                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 44 from patent US 6077672.
ACCESSION   AR098789
VERSION     AR098789.1  GI:12808555
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of TRADD expression
  JOURNAL   Patent: US 6077672-A 44 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| ||| |
Db          1 GCGGCGGCGGCGGCTTC 17


RESULT 121
AR098791
LOCUS       AR098791                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 46 from patent US 6077672.
ACCESSION   AR098791
VERSION     AR098791.1  GI:12808557
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of TRADD expression
  JOURNAL   Patent: US 6077672-A 46 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         12 GGCAGGCGGCGGCGGAG 28
              |||||| ||||||||| |
Db          2 GGCAGGTGGCGGCGGCG 18


RESULT 122
AR123678/c
LOCUS       AR123678                 18 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 16 from patent US 6171788.
ACCESSION   AR123678
VERSION     AR123678.1  GI:14109039
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Nguyen,T.D., Polansky,J.R., Chen,P. and Chen,H.
  TITLE     Methods for the diagnosis, prognosis and treatment of glaucoma and
            related disorders
  JOURNAL   Patent: US 6171788-A 16 09-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 123
BD237949/c
LOCUS       BD237949                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Nucleic acids, kits, and methods for the diagnosis, prognosis and
            treatment of glaucoma and related disorders.
ACCESSION   BD237949
VERSION     BD237949.1  GI:33047719
KEYWORDS    JP 2002534135-A/16.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Nguyen,T.D., Polansky,J.R., Chen,P. and Chen,H.
  TITLE     Nucleic acids, kits, and methods for the diagnosis, prognosis and
```

```
            treatment of glaucoma and related disorders
  JOURNAL   Patent: JP 2002534135-A 16 15-OCT-2002;
            THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002534135-A/16
            PD   15-OCT-2002
            PF   11-JAN-2000 JP 2000593777
            PR   11-JAN-1999 US    09/227881,07-MAY-1999 US    09/306828 PI
            THAI D NGUYEN,JON R POLANSKY,PU CHEN,HUA CHEN PC
            C12N15/09,A61K31/573,A61K45/00,A61P27/06,C12N1/15,C12N1/19, PC
            C12N1/21,
            PC   C12N5/10,C12Q1/68,G01N33/53,G01N33/566,C12N15/00,C12N5/00 CC
            Nucleic acids, kits, and methods for the diagnosis, prognosis  CC
                 and
            CC   treatment of glaucoma and related disorders
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 124
AR242175
LOCUS       AR242175                  18 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 14 from patent US 6472156.
ACCESSION   AR242175
VERSION     AR242175.1  GI:27287993
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Wittwer,C.T. and Herrmann,M.G.
  TITLE     Homogeneous multiplex hybridization analysis by color and Tm
  JOURNAL   Patent: US 6472156-A 14 29-OCT-2002;
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        337 GACAGCGGCGCCTCGAG 353
              ||||||| |||| ||||
Db          1 GACAGCGACGCCGCGAG 17


RESULT 125
AR242759/c
LOCUS       AR242759                  18 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 16 from patent US 6475724.
ACCESSION   AR242759
VERSION     AR242759.1  GI:27289398
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Nguyen,T.D., Polansky,J.R., Chen,P. and Chen,H.
  TITLE     Nucleic acids, kits, and methods for the diagnosis, prognosis and
            treatment of glaucoma and related disorders
  JOURNAL   Patent: US 6475724-A 16 05-NOV-2002;
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 126
AX014687
LOCUS       AX014687                  18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 24 from Patent WO9953091.
ACCESSION   AX014687
VERSION     AX014687.1  GI:10040961
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Holinski-Feder,E., Grimm,L., Ueffing,M. and Meitinger,T.
  TITLE     Dna coding for gdnf, parts of said dna and gdnf variants
  JOURNAL   Patent: WO 9953091-A 24 21-OCT-1999;
            HOLINSKI FEDER ELKE (DE); GRIMM LENA (DE); UEFFING MARIUS (DE);
            LUDWIG MAXIMILIANS UNI MUENCHE (DE); MEITINGER THOMAS (DE)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        143 GTGTGGAGCTGGACCAG 159
              ||||||||| | |||||
Db          2 GTGTGGAGCAGCACCAG 18


RESULT 127
BD065054/c
LOCUS       BD065054                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Methods for the diagnosis, prognosis and treatment of glaucoma and
            related disorders.
ACCESSION   BD065054
VERSION     BD065054.1  GI:22610657
KEYWORDS    JP 2001509669-A/16.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Nguyen,T.D., Polansky,J.R., Chen,P. and Chen,H.
  TITLE     Methods for the diagnosis, prognosis and treatment of glaucoma and
            related disorders
  JOURNAL   Patent: JP 2001509669-A 16 24-JUL-2001;
            THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
COMMENT     OS   Unidentified
            PN   JP 2001509669-A/16
            PD   24-JUL-2001
            PF   09-JAN-1998 JP 1998532017
            PR   28-JAN-1997 US    08/791154,26-SEP-1997 US    08/938669 PI
            THAI D NGUYEN,JON R POLANSKY,PU CHEN,HUA CHEN PC
            C12N15/12,C12Q1/68,C07K14/47,A61K31/70
            CC   Strandedness: Single;
```

```
            CC   Topology: Linear;
            CC   Methods for the diagnosis, prognosis and
            treatment of glaucoma
            CC            and related
            CC   disorders
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 128
BD190829/c
LOCUS       BD190829                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  G-rich oligo aptamers and methods of modulating an immune response.
ACCESSION   BD190829
VERSION     BD190829.1  GI:33000568
KEYWORDS    JP 2002512599-A/11.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Tam,R.
  TITLE     G-rich oligo aptamers and methods of modulating an immune response
  JOURNAL   Patent: JP 2002512599-A 11 23-APR-2002;
            ICN PHARMACEUTICALS INC
COMMENT     PN   JP 2002512599-A/11
            PD   23-APR-2002
            PF   19-DEC-1997 JP 1998530233
            PR   27-DEC-1996 US    60/034509
            PI   ROBERT TAM
            PC   C07H21/02,A01N43/04,C12Q1/68
            CC   Strandedness: Double;
            CC   Topology: Unknown;
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        803 CCCGAAGAGCCCCTTCA 819
              ||||| |||||||| ||
Db         18 CCCGAGGAGCCCCTCCA 2


RESULT 129
AR123065
LOCUS       AR123065                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 9 from patent US 6168950.
ACCESSION   AR123065
VERSION     AR123065.1  GI:14108031
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P., Gaarde,W., Ward,D.T. and Cowsert,L.M.
  TITLE     Antisense modulation of MEKK1 expression
  JOURNAL   Patent: US 6168950-A 9 02-JAN-2001;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         43 AGCAGCGCGCGCGCGGC 59
              ||| |||||||||| ||
Db          4 AGCCGCGCGCGCGCTGC 20


RESULT 130
AR033555
LOCUS       AR033555                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 321 from patent US 5869253.
ACCESSION   AR033555
VERSION     AR033555.1  GI:5949160
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 5869253-A 321 09-FEB-1999;
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              |||||| ||||||||
Db          1 GCGCCCTCCGCCGAG 15


RESULT 131
AR084532
LOCUS       AR084532                  15 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 21 from patent US 5981185.
ACCESSION   AR084532
VERSION     AR084532.1  GI:10011303
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
  TITLE     Oligonucleotide repeat arrays
  JOURNAL   Patent: US 5981185-A 21 09-NOV-1999;
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          1 GGCGGCGGCGGCGGC 15
```

```
RESULT 132
AR113377
LOCUS       AR113377                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 321 from patent US 6132966.
ACCESSION   AR113377
VERSION     AR113377.1  GI:14093699
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 6132966-A 321 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              |||||| ||||||||
Db          1 GCGCCCTCCGCCGAG 15


RESULT 133
I57784
LOCUS       I57784                    15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 321 from patent US 5610054.
ACCESSION   I57784
VERSION     I57784.1  GI:2482848
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Enzymatic RNA molecule targeted against Hepatitis C virus
  JOURNAL   Patent: US 5610054-A 321 11-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              |||||| ||||||||
Db          1 GCGCCCTCCGCCGAG 15


RESULT 134
AR278935
LOCUS       AR278935                  15 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 13 from patent US 6514693.
ACCESSION   AR278935
VERSION     AR278935.1  GI:29713578
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Lansdorp,P.
  TITLE     Method for detecting multiple copies of a repeat sequence in a
            nucleic acid molecule
  JOURNAL   Patent: US 6514693-A 13 04-FEB-2003;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          1 GGCGGCGGCGGCGGC 15


RESULT 135
BD207288
LOCUS       BD207288                  15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD207288
VERSION     BD207288.1  GI:33017058
KEYWORDS    JP 2002512791-A/878.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 878 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/878
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                 virus)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              |||||| ||||||||
Db          1 GCGCCCTCCGCCGAG 15


RESULT 136
AR105105
LOCUS       AR105105                  16 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 4 from patent US 6096505.
ACCESSION   AR105105
VERSION     AR105105.1  GI:12818702
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
```

```
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Selby,M., Thudium,K.B. and Dina,D.
  TITLE     Noncloning technique for expressing a gene of interest
  JOURNAL   Patent: US 6096505-A 4 01-AUG-2000;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 64;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        460 TTGCACAAGATGGAT 474
              ||| ||||||||||||
Db          1 TTGAACAAGATGGAT 15


RESULT 137
AX431337/c
LOCUS       AX431337                 16 bp    DNA     linear   PAT 28-JUN-2002
DEFINITION  Sequence 46 from Patent WO0240680.
ACCESSION   AX431337
VERSION     AX431337.1  GI:21656195
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Pawlowski,K., Fiorentino,L., Godzik,A., Lee,S.H., Reed,J.C.,
            Roth,W. and Stenner-Liewen,F.
  TITLE     Novel death domain proteins
  JOURNAL   Patent: WO 0240680-A 46 23-MAY-2002;
            BURNHAM INST (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic primer"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 64;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         14 CAGGCGGCGGCGGAG 28
              ||| ||||||||||||
Db         15 CAGACGGCGGCGGAG 1


RESULT 138
BD090038
LOCUS       BD090038                 16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD090038
VERSION     BD090038.1  GI:22635648
KEYWORDS    JP 2001321190-A/2282.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 2282 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/2282
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 64;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        716 CAGGTCGCACAGTGA 730
              ||||| |||||||||
Db          2 CAGGTGGCACAGTGA 16


RESULT 139
BD225504
LOCUS       BD225504                 16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Noncloning technique for expressing a gene of interest.
ACCESSION   BD225504
VERSION     BD225504.1  GI:33035274
KEYWORDS    JP 2002511257-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Selby,M., Thudium,K. and Dina,D.
  TITLE     Noncloning technique for expressing a gene of interest
  JOURNAL   Patent: JP 2002511257-A 4 16-APR-2002;
            CHIRON CORP
COMMENT     OS   Artificial Sequence
            PN   JP 2002511257-A/4
            PD   16-APR-2002
            PF   13-APR-1999 JP 2000543594
            PR   14-APR-1998 US    60/081777
            PI   MARK SELBY,KENT THUDIUM,DINO DINA
            PC   C12N15/09,C12N5/10,C12P21/02//C07K14/07,C12N15/00,C12N5/00 CC
                 Description of Artificial Sequence: mutant neo primer 93 FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 64;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        460 TTGCACAAGATGGAT 474
              ||| ||||||||||||
Db          1 TTGAACAAGATGGAT 15


RESULT 140
AR074598/c
LOCUS       AR074598                 17 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 1 from patent US 5955266.
ACCESSION   AR074598
VERSION     AR074598.1  GI:10001351
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Bray,P.F. and Goldschmidt-Clermont,P.J.
```

```
  TITLE     Use of platelet polymorphism P1A2 to diagnose risk of thrombotic
            disease
  JOURNAL   Patent: US 5955266-A 1 21-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              |||||| ||||||||
Db         15 GAGCCCAGAGGCAGG 1


RESULT 141
AR074600
LOCUS       AR074600                 17 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 3 from patent US 5955266.
ACCESSION   AR074600
VERSION     AR074600.1  GI:10001353
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Bray,P.F. and Goldschmidt-Clermont,P.J.
  TITLE     Use of platelet polymorphism P1A2 to diagnose risk of thrombotic
            disease
  JOURNAL   Patent: US 5955266-A 3 21-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              |||||| ||||||||
Db          3 GAGCCCAGAGGCAGG 17


RESULT 142
BD241683/c
LOCUS       BD241683                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241683
VERSION     BD241683.1  GI:33051453
KEYWORDS    JP 2002525127-A/630.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 630 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/630
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 74;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| ||||||  |||
Db         17 GGGKAGGGGGACCAGCT 1


RESULT 143
BD241714
LOCUS       BD241714                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241714
VERSION     BD241714.1  GI:33051484
KEYWORDS    JP 2002525127-A/661.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 661 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/661
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 74;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| ||||||  |||
Db          1 GGGKAGGGGGACCAGCT 17


RESULT 144
BD258290/c
LOCUS       BD258290                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258290
VERSION     BD258290.1  GI:33068060
KEYWORDS    JP 2002541795-A/6083.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
```

```
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6083 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6083
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match           1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        343 GGCGCCTCGAGTCCC 357
              || ||||||||||||
Db         17 GGAGCCTCGAGTCCC 3


RESULT 145
AR285940/c
LOCUS       AR285940                 17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 312 from patent US 6528640.
ACCESSION   AR285940
VERSION     AR285940.1  GI:29723536
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 312 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match           1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 146
AR328101/c
LOCUS       AR328101                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5503 from patent US 6566127.
ACCESSION   AR328101
VERSION     AR328101.1  GI:33713909
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5503 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match           1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGG 458
              ||||||||| |||||
Db         17 AGAAACTCTGAAAGG 3


RESULT 147
AR397930/c
LOCUS       AR397930                 17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 311 from patent US 6617438.
ACCESSION   AR397930
VERSION     AR397930.1  GI:40135323
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 311 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match           1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 148
AX214999/c
LOCUS       AX214999                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 441 from Patent WO0159103.
ACCESSION   AX214999
VERSION     AX214999.1  GI:15525042
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 441 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"
```

```
  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAA 615
              ||||||| |||||||
Db         15 GGAGATGAATCTGAA 1


RESULT 149
AX216346
LOCUS       AX216346                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1788 from Patent WO0159103.
ACCESSION   AX216346
VERSION     AX216346.1  GI:15526407
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1788 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCA 125
              | ||||||||||||||
Db          3 CCGGCGGCGGCGGCA 17


RESULT 150
AX216806/c
LOCUS       AX216806                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2248 from Patent WO0159103.
ACCESSION   AX216806
VERSION     AX216806.1  GI:15526867
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2248 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        602 GAGATGGATCTGAAA 616
              |||||| ||||||||
Db         17 GAGATGAATCTGAAA 3


RESULT 151
AX545238/c
LOCUS       AX545238                  17 bp    DNA     linear   PAT 26-NOV-2002
DEFINITION  Sequence 751 from Patent EP1243660.
ACCESSION   AX545238
VERSION     AX545238.1  GI:25810449
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J., Gu,Y. and Nguyen,C.T.
  TITLE     Human udp-galnac:polypeptide n-acetylgalatosaminyltransferase 10
  JOURNAL   Patent: EP 1243660-A 751 25-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         31 GCCCTCAAGGCGAGC 45
              |||||||| ||||||
Db         17 GCCCTCAATGCGAGC 3


RESULT 152
AX545241/c
LOCUS       AX545241                  17 bp    DNA     linear   PAT 26-NOV-2002
DEFINITION  Sequence 754 from Patent EP1243660.
ACCESSION   AX545241
VERSION     AX545241.1  GI:25810452
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J., Gu,Y. and Nguyen,C.T.
  TITLE     Human udp-galnac:polypeptide n-acetylgalatosaminyltransferase 10
  JOURNAL   Patent: EP 1243660-A 754 25-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAG 44
              ||||||||| |||||
Db         15 AGCCCTCAATGCGAG 1


RESULT 153
AX672762
LOCUS       AX672762                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1207 from Patent WO03004526.
ACCESSION   AX672762
VERSION     AX672762.1  GI:29331110
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1207 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCA 653
              ||||| |||||||||
Db          3 TCCAGTAGAGGTCCA 17


RESULT 154
AX676092/c
LOCUS       AX676092                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 45 from Patent WO02059381.
ACCESSION   AX676092
VERSION     AX676092.1  GI:29333776
KEYWORDS    .
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Slaugenhaupt,S. and Gusella,J.F.
  TITLE     Gene for identifying individuals with familial dysautonomia
  JOURNAL   Patent: WO 02059381-A 45 01-AUG-2002;
            The General Hospital Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10095"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              ||||||||| |||||
Db         15 CTGGAAGCAAGAATG 1


RESULT 155
AX693196
LOCUS       AX693196                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 5928 from Patent EP1281758.
ACCESSION   AX693196
VERSION     AX693196.1  GI:29416160
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 5928 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCA 653
              ||||||||||| |||
Db          3 TCCAGGAGAGGGCCA 17


RESULT 156
AX693199
LOCUS       AX693199                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 5931 from Patent EP1281758.
ACCESSION   AX693199
VERSION     AX693199.1  GI:29416163
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 5931 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        640 CCAGGAGAGGTCCAG 654
              ||||||||| ||||
Db          1 CCAGGAGAGGGCCAG 15


RESULT 157
AX726974
LOCUS       AX726974                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4661 from Patent WO03025176.
ACCESSION   AX726974
VERSION     AX726974.1  GI:30506317
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4661 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
```

```
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        741 TCCAGGAGTAAGGAG 755
              ||||||||| |||||
Db          3 TCCAGGAGTCAGGAG 17


RESULT 158
AX781949
LOCUS       AX781949                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 280 from Patent WO03050284.
ACCESSION   AX781949
VERSION     AX781949.1  GI:32949798
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 280 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        452 TCAAAGGGTTGCACA 466
              |||| ||||||||||
Db          3 TCAATGGGTTGCACA 17


RESULT 159
AX781950
LOCUS       AX781950                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 281 from Patent WO03050284.
ACCESSION   AX781950
VERSION     AX781950.1  GI:32949799
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 281 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        452 TCAAAGGGTTGCACA 466
              |||| ||||||||||
Db          2 TCAATGGGTTGCACA 16


RESULT 160
BD104660
LOCUS       BD104660                  17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104660
VERSION     BD104660.1  GI:22650234
KEYWORDS    WO 0192572-A/764.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 764 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/764
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
            MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 74;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         78 GGAGGCGGGCAGCGG 92
              |||||||||| ||||
Db          2 GGAGGCGGGCCGCGG 16


RESULT 161
BD208459
LOCUS       BD208459                  15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD208459
VERSION     BD208459.1  GI:33018229
KEYWORDS    JP 2002512791-A/2049.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2049 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2049
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
```

```
          CC   hepatitis C virus infection.
          FH   Key             Location/Qualifiers
          FT   source          1. .15
          FT                   /organism='Hepatitis virus (hepatitis C  FT
                          virus)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match              1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              |||||||||||||
Db          3 TCCTTCTCCTGGC 15


RESULT 162
BD208460
LOCUS       BD208460                 15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD208460
VERSION     BD208460.1  GI:33018230
KEYWORDS    JP 2002512791-A/2050.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2050 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2050
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US .  09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                      related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                          virus)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match              1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 63;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              |||||||||||||
Db          1 TCCTTCTCCTGGC 13


RESULT 163
AX328241
LOCUS       AX328241                 16 bp    RNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 13 from Patent WO0183754.
ACCESSION   AX328241
VERSION     AX328241.1  GI:18098222
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kruger,M., Welch,P.J. and Barber,J.R.
  TITLE     Cellular regulators of infectious agents and methods of use
  JOURNAL   Patent: WO 0183754-A 13 08-NOV-2001;
            Immusol Incorporated (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match              1.3%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 74;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        972 GCCTCAGAACTGC 984
              |||||||||||||
Db          4 GCCTCAGAACTGC 16


RESULT 164
BD254226/c
LOCUS       BD254226                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254226
VERSION     BD254226.1  GI:33063996
KEYWORDS    JP 2002541795-A/2019.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2019 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2019
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match              1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        363 GGCCGAGCCCGGG 375
```

```
                 ||||||||||||||
Db         13 GGCCGAGCCCGGG 1


RESULT 165
BD266292
LOCUS       BD266292                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Universal arrays.
ACCESSION   BD266292
VERSION     BD266292.1  GI:33076060
KEYWORDS    JP 2002539849-A/292.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
            Lockhart,D.J., Ryder,T. and Sklar,P.
  TITLE     Universal arrays
  JOURNAL   Patent: JP 2002539849-A 292 26-NOV-2002;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002539849-A/292
            PD   26-NOV-2002
            PF   27-MAR-2000 JP 2000608794
            PR   26-MAR-1999 US    60/126473,23-JUN-1999 US    60/140359 PI
            JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
            HUANG,PAUL KAPLAN,ERIC
            PI   S LANDER,
            PI   DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
            PC   C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
             G01N33/566,
            PC   G01N37/00,C12N15/00,C12N15/00,C12N15/00
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        253 GGCTTCCAGCCTG 265
              |||||||||||||
Db          3 GGCTTCCAGCCTG 15


RESULT 166
AX579452
LOCUS       AX579452                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1290 from Patent WO0211674.
ACCESSION   AX579452
VERSION     AX579452.1  GI:27648654
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1290 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        605 ATGGATCTGAAAT 617
              |||||||||||||
Db          1 ATGGATCTGAAAT 13


RESULT 167
AX579772
LOCUS       AX579772                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1610 from Patent WO0211674.
ACCESSION   AX579772
VERSION     AX579772.1  GI:27648974
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1610 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 GAACTGCAGCTGT 990
              |||||||||||||
Db          1 GAACTGCAGCTGT 13


RESULT 168
AX580186
LOCUS       AX580186                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 2024 from Patent WO0211674.
ACCESSION   AX580186
VERSION     AX580186.1  GI:27649388
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 2024 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
```

```
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAA 616
              |||||||||||||
Db          5 GATGGATCTGAAA 17


RESULT 169
AX722809
LOCUS       AX722809                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 496 from Patent WO03025176.
ACCESSION   AX722809
VERSION     AX722809.1  GI:30423310
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 496 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        582 AAAACCAATCCCA 594
              |||||||||||||
Db          5 AAAACCAATCCCA 17


RESULT 170
AX732611
LOCUS       AX732611                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4245 from Patent WO03025175.
ACCESSION   AX732611
VERSION     AX732611.1  GI:30511954
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4245 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        776 CTTTTCAGAGTGG 788
              |||||||||||||
Db          4 CTTTTCAGAGTGG 16


RESULT 171
AX732819/c
LOCUS       AX732819                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4453 from Patent WO03025175.
ACCESSION   AX732819
VERSION     AX732819.1  GI:30512162
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4453 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        750 AAGGAGAAAAAGA 762
              |||||||||||||
Db         15 AAGGAGAAAAAGA 3


RESULT 172
AX735020/c
LOCUS       AX735020                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 610 from Patent WO03025177.
ACCESSION   AX735020
VERSION     AX735020.1  GI:30514297
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 610 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         77 GGGAGGCGGGCAG 89
              |||||||||||||
Db         16 GGGAGGCGGGCAG 4


RESULT 173
AX757003/c
LOCUS       AX757003                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 324 from Patent WO03040369.
ACCESSION   AX757003
VERSION     AX757003.1  GI:32251619
KEYWORDS    .
```

```
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 324 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 86;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 CTGAGGCAGGCGG 20
              |||||||||||||
Db         16 CTGAGGCAGGCGG 4


RESULT 174
AX531299
LOCUS       AX531299                 17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 808 from Patent EP1239051.
ACCESSION   AX531299
VERSION     AX531299.1  GI:25254384
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 808 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 92;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        409 GCAGCGGCCCCCGCCG 424
              ||||| ||||| ||||
Db          1 GCAGCTGCCCCAGCCG 16


Search completed: June 28, 2004, 08:01:41
Job time : 3 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 28, 2004, 08:08:27 ; Search time 2 Seconds
(without alignments)
3.451 Million cell updates/sec

Title: US-10-069-079-1
Perfect score: 1000
Sequence: 1 ccgagccctgaggcaggcgg.....ctgcagctgtgcacatggaa 1000

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 192 seqs, 3451 residues

Total number of hits satisfying chosen parameters: 384

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 198 summaries

Database : rng1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	26	2.6	26	1	AAF27082	Human MEKK1 real-t
	2	23	2.3	23	1	AAF27080	Human MEKK1 real-t
c	3	21	2.1	21	1	AAF27081	Human MEKK1 real-t
c	4	20	2.0	20	1	AAF27086	Human MEKK1 phosph
c	5	20	2.0	20	1	AAF27091	Human MEKK1 phosph
c	6	20	2.0	20	1	AAF27088	Human MEKK1 phosph
c	7	20	2.0	20	1	AAF27089	Human MEKK1 phosph
c	8	20	2.0	20	1	AAF27090	Human MEKK1 phosph
c	9	20	2.0	20	1	AAF27092	Human MEKK1 phosph
c	10	20	2.0	20	1	AAF27087	Human MEKK1 phosph
	11	17.8	1.8	21	1	AAX80919	Sense primer-3 for
	12	17.8	1.8	21	1	AAZ25081	Human MEKK1 PCR pr
c	13	17.4	1.7	21	1	ABL56936	Rabies surface gly
c	14	16.4	1.6	20	1	AAT86501	S-adenosylmethioni
	15	16.4	1.6	20	1	AAT38134	Primer for LAMC2 g
	16	16.4	1.6	20	1	AAL42900	LAMC2 gene PCR pri
	17	16.2	1.6	21	1	AAV52008	Zea mays genome re
c	18	16.2	1.6	21	1	AAF55729	PCR primer R3. Pa
c	19	16	1.6	18	1	AAQ27316	PCR primer Cbetain
c	20	16	1.6	18	1	AAQ46300	Primer Cbeta-int.
c	21	16	1.6	18	1	AAQ99419	Human T cell recep
c	22	16	1.6	18	1	AAV64294	Human T cell recep
c	23	16	1.6	18	1	AAF85282	PCR primer used to
c	24	16	1.6	18	1	AAF27155	Human TCR beta-cha
	25	15.8	1.6	19	1	AAQ52159	Colon carcinoma sp
	26	15.8	1.6	19	1	AAZ70920	Human biallelic ma
	27	15.8	1.6	20	1	AAV47686	Unmethylated CpG d
	28	15.8	1.6	20	1	AAV74243	CpG-N motif O-ODN
c	29	15.8	1.6	20	1	AAZ75520	Human biallelic ma
	30	15.8	1.6	20	1	AAC83620	Human c-fos oligo
	31	15.8	1.6	20	1	AAC83625	Human c-fos Bodipy
	32	15.8	1.6	20	1	AAF99116	Immunostimulatory
	33	15.8	1.6	20	1	AAF91298	Human E2F transcri
	34	15.8	1.6	20	1	ABK90289	Bcl-2-targeting an
	35	15.8	1.6	20	1	ABS77759	Angiogenesis inhib
	36	15.8	1.6	20	1	ABL39008	Immunostimulatory
	37	15.8	1.6	20	1	ABQ78545	Antisense oligodeo
	38	15.8	1.6	20	1	ABL54173	Oligonucleotide.
	39	15.8	1.6	20	1	ABZ91148	Human oligonucleot
	40	15.8	1.6	20	1	ACD99549	Immunostimulatory
	41	15.8	1.6	20	1	ADB36618	Immunostimulatory
	42	15.8	1.6	21	1	AAZ44349	Protein kinase inh
c	43	15.8	1.6	21	1	ABK99279	Hepatitis C virus
	44	15.4	1.5	17	1	ABK02337	Human NOGO Amberzy
	45	15.4	1.5	17	1	ABK02338	Human NOGO Amberzy
	46	15.4	1.5	17	1	ABK00765	Human NOGO Inozyme
c	47	15.4	1.5	19	1	AAL51375	Human BCL2 gene PC
	48	15.4	1.5	20	1	ABZ88038	Human oligonucleot
c	49	15.2	1.5	20	1	AAQ52305	FKBP12C PCR primer
c	50	15.2	1.5	20	1	AAT41334	Human gene signatu
	51	15.2	1.5	20	1	AAZ06414	Primer C for PCR o
c	52	15.2	1.5	20	1	AAZ71977	Human biallelic ma
	53	15.2	1.5	20	1	AAF31798	Human RANK antisen
c	54	15.2	1.5	20	1	AAD15646	Human Bcl-2 protei
c	55	15.2	1.5	20	1	AAH46290	Human interferon r
c	56	15.2	1.5	20	1	ABZ88026	Human oligonucleot
	57	15.2	1.5	20	1	ABZ98578	Human ICAM oligonu
c	58	15	1.5	15	1	AAF45311	IGFBP2 oligonucleo
	59	15	1.5	17	1	ABK01789	Human NOGO Zinzyme
	60	15	1.5	17	1	ABZ61434	Human H-Ras DNAzym
c	61	15	1.5	18	1	AAQ96137	Human C-beta-inter
c	62	15	1.5	19	1	AAQ31559	NF-kB anti-sense p
	63	14.8	1.5	18	1	AAV30475	Canine beta-3 adre
	64	14.8	1.5	18	1	AAV94820	Human IL-2 recepto
c	65	14.8	1.5	18	1	AAZ48883	Human ICAM-1 antis
	66	14.8	1.5	18	1	ADA27361	Human microsatelli
	67	14.8	1.5	19	1	AAX55144	C/EBP-beta antisen
	68	14.8	1.5	19	1	AAA34591	Human adenosine re
c	69	14.8	1.5	19	1	AAA82751	cdk3 ribozyme bind
c	70	14.8	1.5	19	1	AAA82752	cdk3 ribozyme bind
	71	14.8	1.5	19	1	AAF20713	Human C/EBP polynu
c	72	14.8	1.5	19	1	AAH57913	Cell-cycle depende
c	73	14.8	1.5	19	1	AAH57914	Cell-cycle depende
	74	14.8	1.5	19	1	ABZ96407	Human C/EBP antise
c	75	14.4	1.4	17	1	AAV62480	Antisense oligonuc
c	76	14.4	1.4	17	1	AAV62481	Antisense oligonuc
	77	14.4	1.4	17	1	AAZ46753	Heterologous duple
	78	14.4	1.4	17	1	ABK01790	Human NOGO Zinzyme
	79	14.4	1.4	17	1	ABK01791	Human NOGO Zinzyme
c	80	14.4	1.4	17	1	ABK00440	Human NOGO Hammerh
c	81	14.4	1.4	17	1	ABV85759	Human pp-GaNTase 1
c	82	14.4	1.4	17	1	ABV85760	Human pp-GaNTase 1
c	83	14.4	1.4	17	1	ACC51948	Human tumour suppr
c	84	14.4	1.4	17	1	ABT39941	Tumour suppression
c	85	14.4	1.4	17	1	ABT39883	Tumour suppression
	86	14.4	1.4	17	1	ADB04944	Human MDZ12 scanni
	87	14.4	1.4	17	1	ADB04943	Human MDZ12 scanni
c	88	14.4	1.4	17	1	ACD59733	HCV DNAzyme substr
	89	14.4	1.4	17	1	ACC67622	Murine oligonucleo
c	90	14.4	1.4	17	1	ADB43670	Tumour suppression
c	91	14.4	1.4	17	1	ADB44198	Tumour suppression
	92	14.4	1.4	18	1	AAV16021	PCR primer used to
c	93	14.4	1.4	18	1	AAZ69854	Human biallelic ma
	94	14.4	1.4	18	1	AAZ43280	Murine Sox2 gene P
	95	14.4	1.4	18	1	AAA05265	PCR primer B-F use
	96	14.4	1.4	18	1	AAZ93475	TRADD antisense ol
	97	14.4	1.4	18	1	AAD38944	Human Her-2 antise
c	98	14	1.4	15	1	AAF45310	IGFBP2 oligonucleo
c	99	14	1.4	15	1	AAF45312	IGFBP2 oligonucleo
	100	14	1.4	17	1	ABK56817	Human CLCA1 gene e
	101	14	1.4	17	1	ABK56483	Human CLCA1 gene e
	102	14	1.4	17	1	ABK55895	Human CLCA1 gene e
	103	14	1.4	17	1	ABK56990	Human CLCA1 gene e
	104	14	1.4	17	1	ABK57363	Human CLCA1 gene e
c	105	14	1.4	17	1	ABX77386	Human lrba gene 5'
	106	14	1.4	17	1	ABZ61433	Human H-Ras DNAzym

c 107	14	1.4	18	1	AAS21619	Human Survivin ant
c 108	14	1.4	18	1	ABL43560	Human chromosome 1
109	13.8	1.4	17	1	AAX71558	Human KDR VEGF rec
110	13.8	1.4	17	1	AAX62926	Delta-9 desaturase
111	13.8	1.4	17	1	AAF07259	Hammerhead ribozym
c 112	13.8	1.4	17	1	AAF02617	Hammerhead ribozym
113	13.8	1.4	17	1	ABK00815	Human NOGO Inozyme
c 114	13.8	1.4	17	1	ABN08013	Human GDMLP-1 17-m
c 115	13.8	1.4	17	1	ABN06311	Human GDMLP-1 17-m
116	13.8	1.4	17	1	ABQ63388	Human KTOM1a porti
117	13.8	1.4	17	1	ABQ63389	Human KTOM1a porti
118	13.8	1.4	17	1	ABQ63390	Human KTOM1a porti
c 119	13.8	1.4	17	1	ABV90095	Human POSHL1 scann
c 120	13.8	1.4	17	1	ABV90096	Human POSHL1 scann
121	13.8	1.4	17	1	ACC53863	Human tumour suppr
122	13.8	1.4	17	1	ABZ59899	Human K-Ras DNAzym
123	13.8	1.4	17	1	ABZ59894	Human K-Ras DNAzym
124	13.8	1.4	17	1	ABZ64592	Human HER2 DNAzyme
125	13.8	1.4	17	1	ABZ61368	Human H-Ras DNAzym
c 126	13.8	1.4	17	1	ABZ64550	Human HER2 DNAzyme
127	13.8	1.4	17	1	ACD59841	HCV DNAzyme substr
c 128	13.8	1.4	17	1	ACD55421	HBV amberzyme subs
129	13.8	1.4	17	1	ADB42408	Tumour suppression
130	13.8	1.4	18	1	AAQ54286	Positive primer to
c 131	13.8	1.4	18	1	AAT36246	CD28 expression in
132	13.8	1.4	18	1	AAT27164	Human Machado-Jose
c 133	13.8	1.4	18	1	AAX90339	CD28 inhibiting ph
c 134	13.8	1.4	18	1	AAV51381	Human TIGR PCR pri
135	13.8	1.4	18	1	AAV16014	PCR primer G-R use
c 136	13.8	1.4	18	1	AAV94823	Human IL-2 recepto
137	13.8	1.4	18	1	AAZ24020	Human GDNF PCR pri
138	13.8	1.4	18	1	AAZ24038	Human GDNF PCR pri
c 139	13.8	1.4	18	1	AAZ20988	Human semaphorin Z
c 140	13.8	1.4	18	1	AAA07061	Human integrin bet
141	13.8	1.4	18	1	AAZ57670	Human G-alpha-12 a
142	13.8	1.4	18	1	AAZ91373	Human PTEN phospho
c 143	13.8	1.4	18	1	AAZ91373	Human PTEN phospho
144	13.8	1.4	18	1	AAZ43273	Murine Sox3 gene P
145	13.8	1.4	18	1	AAA05258	PCR primer G-R use
146	13.8	1.4	18	1	AAZ93474	TRADD antisense ol
147	13.8	1.4	18	1	AAZ93476	TRADD antisense ol
c 148	13.8	1.4	18	1	AAA57499	Primer used for SS
149	13.8	1.4	18	1	AAF85699	Multiple repeated
150	13.8	1.4	18	1	AAS13999	Human PTEN antisen
c 151	13.8	1.4	18	1	AAS13999	Human PTEN antisen
152	13.8	1.4	18	1	AAD40034	Human PTEN antisen
c 153	13.8	1.4	18	1	AAD40034	Human PTEN antisen
154	13.8	1.4	18	1	ABX16214	Human leukocyte an
155	13.8	1.4	20	1	AAF27087	Human MEKK1 phosph
156	13.4	1.3	15	1	AAT86420	Trinucleotide simp
157	13.4	1.3	15	1	AAZ62710	Substrate for HH r
c 158	13.4	1.3	15	1	AAF45309	IGFBP2 oligonucleo
159	13.4	1.3	15	1	AAF45371	IGFBP2 oligonucleo
c 160	13.4	1.3	15	1	AAF45305	IGFBP2 oligonucleo
c 161	13.4	1.3	15	1	AAF45308	IGFBP2 oligonucleo
162	13.4	1.3	15	1	AAF45368	IGFBP2 oligonucleo
163	13.4	1.3	15	1	AAF45369	IGFBP2 oligonucleo
164	13.4	1.3	15	1	AAF45448	IGFBP2 oligonucleo
165	13.4	1.3	15	1	ABX00561	Hepatitis C virus
166	13.4	1.3	16	1	AAZ31706	PCR primer 93 for
167	13.4	1.3	16	1	ABL45238	Human chromosome 1
c 168	13.4	1.3	16	1	AAD40092	Human DED4 (death
c 169	13.4	1.3	16	1	AAD59074	Primer #1 used to
170	13.4	1.3	17	1	AAZ08873	Fibrinogen recepto
c 171	13.4	1.3	17	1	AAZ08871	Fibrinogen recepto
c 172	13.4	1.3	17	1	AAA36571	Human genomic SNP
173	13.4	1.3	17	1	AAA36602	Human genomic SNP
c 174	13.4	1.3	17	1	AAF06092	Hammerhead ribozym
175	13.4	1.3	17	1	ABK01788	Human NOGO Zinzyme
c 176	13.4	1.3	17	1	ABK02248	Human NOGO DNAzyme
c 177	13.4	1.3	17	1	ABK00441	Human NOGO Hammerh
178	13.4	1.3	17	1	ABN02506	Human GDMLP-1 17-m
179	13.4	1.3	17	1	ABN08131	Human GDMLP-1 17-m
180	13.4	1.3	17	1	ABN08132	Human GDMLP-1 17-m
181	13.4	1.3	17	1	ABN02505	Human GDMLP-1 17-m
182	13.4	1.3	17	1	ABN08133	Human GDMLP-1 17-m
183	13.4	1.3	17	1	ABN02507	Human GDMLP-1 17-m
c 184	13.4	1.3	17	1	ABV85758	Human pp-GaNTase 1
c 185	13.4	1.3	17	1	ABV85761	Human pp-GaNTase 1
c 186	13.4	1.3	17	1	ABQ99697	Murine Ikbkap exon
187	13.4	1.3	17	1	ABL31275	Human HLA genotypi
188	13.4	1.3	17	1	ACC52440	Human tumour suppr
189	13.4	1.3	17	1	ABQ77407	Human vascular dis
190	13.4	1.3	17	1	ADB04942	Human MDZ12 scanni
191	13.4	1.3	17	1	ADB04945	Human MDZ12 scanni
c 192	13.4	1.3	17	1	ABZ64551	Human HER2 DNAzyme
193	13.4	1.3	17	1	ACD62936	HCV minus strand D
c 194	13.4	1.3	17	1	ACD52378	HBV inozyme substr
c 195	13.4	1.3	17	1	ACD50949	HBV hammerhead rib
196	13.4	1.3	17	1	ACC67414	Murine oligonucleo
c 197	13.2	1.3	20	1	ABZ88038	Human oligonucleot
198	12.8	1.3	17	1	ABV90095	Human POSHL1 scann

ALIGNMENTS

```
RESULT 1
AAF27082
ID   AAF27082 standard; DNA; 26 BP.
XX
AC   AAF27082;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 real-time quantitative PCR probe, SEQ ID NO:4.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense therapy; hyperproliferative disorder; cancer; inflammation;
KW   quantitative real-time PCR probe; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /note= "Conjugated to fluorescent reporter dye FAM"
FT   modified_base   26
FT                   /*tag=  b
FT                   /note= "Conjugated to fluorescent quencher dye TAMRA"
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
PT   activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT   or conditions associated with MEKK1 expression, or preventing
PT   inflammation or tumor formation.
XX
PS   Example 14; Col 39; 35pp; English.
```

```
XX
CC   The present sequence represents a human MEKK1 probe used in quantitative
CC   real-time PCR with primers AAF27080-AAF27081 in an exemplification of the
CC   present invention. The invention relates to antisense oligonucleotides
CC   targetted to the human MEKK1 gene, which inhibit its expression. A series
CC   of oligonucleotides (AAF27086-AAF27125) were designed to target different
CC   regions of the human MEKK1 RNA, and were analysed for their effect on
CC   MEKK1 mRNA levels by quantitative real-time PCR. GAPDH (glyceraldehyde-3-
CC   phosphate) mRNA levels were measured as a control. MEKK1 (also known as
CC   mitogen-activated protein kinase kinase kinase 1, MEK kinase 1 and
CC   MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase which
CC   mediates cellular responses to mitogenic stimuli, being involved in
CC   JNK/SAPK (Jun N-terminal kinase/stress-activated protein kinase) MAP
CC   kinase cascades. MEKK1 regulates signalling events associated with
CC   apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC   associated with the development of hyperproliferative disorders such as
CC   cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC   apoptotic signalling cascade, and plays a critical role in the control of
CC   NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC   cascade. The oligonucleotides of the invention are useful for diagnosis,
CC   prevention and treatment of conditions associated with MEKK1 expression,
CC   such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ   Sequence 26 BP; 9 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 26;  DB 1;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.3;
  Matches   26;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        478 CGTCCAGAGGAACGAATGATCAGGGA 503
              ||||||||||||||||||||||||||
Db          1 CGTCCAGAGGAACGAATGATCAGGGA 26


RESULT 2
AAF27080
ID   AAF27080 standard; DNA; 23 BP.
XX
AC   AAF27080;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 real-time quantitative PCR primer, SEQ ID NO:2.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense therapy; hyperproliferative disorder; cancer; inflammation;
KW   quantitative real-time PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
PT   activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT   or conditions associated with MEKK1 expression, or preventing
PT   inflammation or tumor formation.
XX
PS   Example 14; Col 39; 35pp; English.
XX
CC   Sequences AAF27080-AAF27081 represent human MEKK1 PCR primers used in
CC   quantitative real-time PCR with probe AAF27082 in an exemplification of
CC   the present invention. The invention relates to antisense
CC   oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC   expression. A series of oligonucleotides (AAF27086-AAF27125) were
CC   designed to target different regions of the human MEKK1 RNA, and were
CC   analysed for their effect on MEKK1 mRNA levels by quantitative real-time
CC   PCR. GAPDH (glyceraldehyde-3-phosphate) mRNA levels were measured as a
CC   control. MEKK1 (also known as mitogen-activated protein kinase kinase
CC   kinase 1, MEK kinase 1 and MAP/ERK kinase kinase 1) is a dual-specific
CC   serine/threonine kinase which mediates cellular responses to mitogenic
CC   stimuli, being involved in JNK/SAPK (Jun N-terminal kinase/stress-
CC   activated protein kinase) MAP kinase cascades. MEKK1 regulates signalling
CC   events associated with apoptosis (programmed cell death) and NF-kappa-B,
CC   both of which have been associated with the development of
CC   hyperproliferative disorders such as cancer. Specifically, MEKK1 lies
CC   directly downstream of Bcl-2 in an apoptotic signalling cascade, and
CC   plays a critical role in the control of NF-kappa-B-mediated transcription
CC   at multiple points in the apoptotic cascade. The oligonucleotides of the
CC   invention are useful for diagnosis, prevention and treatment of
CC   conditions associated with MEKK1 expression, such as inflammation, and
CC   cancer and other hyperproliferative disorders
XX
SQ   Sequence 23 BP; 9 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 3.4;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        445 GAAACTCTCAAAGGGTTGCACAA 467
              |||||||||||||||||||||||
Db          1 GAAACTCTCAAAGGGTTGCACAA 23


RESULT 3
AAF27081/c
ID   AAF27081 standard; DNA; 21 BP.
XX
AC   AAF27081;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 real-time quantitative PCR primer, SEQ ID NO:3.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense therapy; hyperproliferative disorder; cancer; inflammation;
KW   quantitative real-time PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
```

PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing
PT inflammation or tumor formation.
XX
PS Example 14; Col 39; 35pp; English.
XX
CC Sequences AAF27080-AAF27081 represent human MEKK1 PCR primers used in
CC quantitative real-time PCR with probe AAF27082 in an exemplification of
CC the present invention. The invention relates to antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. A series of oligonucleotides (AAF27086-AAF27125) were
CC designed to target different regions of the human MEKK1 RNA, and were
CC analysed for their effect on MEKK1 mRNA levels by quantitative real-time
CC PCR. GAPDH (glyceraldehyde-3-phosphate) mRNA levels were measured as a
CC control. MEKK1 (also known as mitogen-activated protein kinase kinase
CC kinase 1, MEK kinase 1 and MAP/ERK kinase kinase 1) is a dual-specific
CC serine/threonine kinase which mediates cellular responses to mitogenic
CC stimuli, being involved in JNK/SAPK (Jun N-terminal kinase/stress-
CC activated protein kinase) MAP kinase cascades. MEKK1 regulates signalling
CC events associated with apoptosis (programmed cell death) and NF-kappa-B,
CC both of which have been associated with the development of
CC hyperproliferative disorders such as cancer. Specifically, MEKK1 lies
CC directly downstream of Bcl-2 in an apoptotic signalling cascade, and
CC plays a critical role in the control of NF-kappa-B-mediated transcription
CC at multiple points in the apoptotic cascade. The oligonucleotides of the
CC invention are useful for diagnosis, prevention and treatment of
CC conditions associated with MEKK1 expression, such as inflammation, and
CC cancer and other hyperproliferative disorders
XX
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 2.1%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 509 TGAAGGCAACCTGTATGCCAG 529
||||||||||||||||||||
Db 21 TGAAGGCAACCTGTATGCCAG 1

RESULT 4
AAF27086/c
ID AAF27086 standard; DNA; 20 BP.
XX
AC AAF27086;
XX
DT 06-APR-2001 (first entry)
XX
DE Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:8.
XX
KW Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW apoptosis signal regulation; programmed cell death;
KW serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW NF-kappa-B-mediated transcription regulation; expression inhibition;
KW antisense; hyperproliferative disorder; cancer; inflammation;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6168950-B1.
XX
PD 02-JAN-2001.
XX
PF 23-JUL-1999; 99US-00359756.
XX
PR 23-JUL-1999; 99US-00359756.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM, Gaarde W, Ward DT;
XX
DR WPI; 2001-122264/13.
XX
PT New antisense compound targeting nucleic acid encoding human mitogen-
PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing
PT inflammation or tumor formation.
XX
PS Claim 14; Col 39; 35pp; English.
XX
CC Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. The antisense oligonucleotides were designed to target
CC different regions of the human MEKK1 RNA, and were analysed for their
CC effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC which mediates cellular responses to mitogenic stimuli, being involved in
CC JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC kinase cascades. MEKK1 regulates signalling events associated with
CC apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC associated with the development of hyperproliferative disorders such as
CC cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC apoptotic signalling cascade, and plays a critical role in the control of
CC NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC cascade. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with MEKK1 expression,
CC such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ Sequence 20 BP; 0 A; 12 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 GCAGGCGGCGGCGGAGGAGC 32
||||||||||||||||||||
Db 20 GCAGGCGGCGGCGGAGGAGC 1

RESULT 5
AAF27091/c
ID AAF27091 standard; DNA; 20 BP.
XX
AC AAF27091;
XX
DT 06-APR-2001 (first entry)
XX
DE Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:13.
XX
KW Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW apoptosis signal regulation; programmed cell death;
KW serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW NF-kappa-B-mediated transcription regulation; expression inhibition;
KW antisense; hyperproliferative disorder; cancer; inflammation;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6168950-B1.
XX
PD 02-JAN-2001.
XX
PF 23-JUL-1999; 99US-00359756.
XX
PR 23-JUL-1999; 99US-00359756.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM, Gaarde W, Ward DT;
XX
DR WPI; 2001-122264/13.

```
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
PT   activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT   or conditions associated with MEKK1 expression, or preventing
PT   inflammation or tumor formation.
XX
PS   Claim 14; Col 39; 35pp; English.
XX
CC   Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC   oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC   expression. The antisense oligonucleotides were designed to target
CC   different regions of the human MEKK1 RNA, and were analysed for their
CC   effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC   known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC   and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC   which mediates cellular responses to mitogenic stimuli, being involved in
CC   JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC   kinase cascades. MEKK1 regulates signalling events associated with
CC   apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC   associated with the development of hyperproliferative disorders such as
CC   cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC   apoptotic signalling cascade, and plays a critical role in the control of
CC   NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC   cascade. The oligonucleotides of the invention are useful for diagnosis,
CC   prevention and treatment of conditions associated with MEKK1 expression,
CC   such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ   Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.8;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        309 CCACCTTACCGAGTCGGTGG 328
              ||||||||||||||||||||
Db         20 CCACCTTACCGAGTCGGTGG 1


RESULT 6
AAF27088/c
ID   AAF27088 standard; DNA; 20 BP.
XX
AC   AAF27088;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:10.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense; hyperproliferative disorder; cancer; inflammation;
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
PT   activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT   or conditions associated with MEKK1 expression, or preventing
PT   inflammation or tumor formation.
XX
PS   Claim 14; Col 39; 35pp; English.
XX
CC   Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC   oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC   expression. The antisense oligonucleotides were designed to target
CC   different regions of the human MEKK1 RNA, and were analysed for their
CC   effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC   known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC   and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC   which mediates cellular responses to mitogenic stimuli, being involved in
CC   JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC   kinase cascades. MEKK1 regulates signalling events associated with
CC   apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC   associated with the development of hyperproliferative disorders such as
CC   cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC   apoptotic signalling cascade, and plays a critical role in the control of
CC   NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC   cascade. The oligonucleotides of the invention are useful for diagnosis,
CC   prevention and treatment of conditions associated with MEKK1 expression,
CC   such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ   Sequence 20 BP; 1 A; 11 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8.8;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         94 GGCCGCGAGCGGGCGGACTG 113
              ||||||||||||||||||||
Db         20 GGCCGCGAGCGGGCGGACTG 1


RESULT 7
AAF27089/c
ID   AAF27089 standard; DNA; 20 BP.
XX
AC   AAF27089;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:11.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense; hyperproliferative disorder; cancer; inflammation;
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
```

PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing
PT inflammation or tumor formation.
XX
PS Claim 14; Col 39; 35pp; English.
XX
CC Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. The antisense oligonucleotides were designed to target
CC different regions of the human MEKK1 RNA, and were analysed for their
CC effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC which mediates cellular responses to mitogenic stimuli, being involved in
CC JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC kinase cascades. MEKK1 regulates signalling events associated with
CC apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC associated with the development of hyperproliferative disorders such as
CC cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC apoptotic signalling cascade, and plays a critical role in the control of
CC NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC cascade. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with MEKK1 expression,
CC such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 148 GAGCTGGACCAGCTGCCTGA 167
||||||||||||||||||||
Db 20 GAGCTGGACCAGCTGCCTGA 1

RESULT 8
AAF27090/c
ID AAF27090 standard; DNA; 20 BP.
XX
AC AAF27090;
XX
DT 06-APR-2001 (first entry)
XX
DE Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:12.
XX
KW Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW apoptosis signal regulation; programmed cell death;
KW serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW NF-kappa-B-mediated transcription regulation; expression inhibition;
KW antisense; hyperproliferative disorder; cancer; inflammation;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6168950-B1.
XX
PD 02-JAN-2001.
XX
PF 23-JUL-1999; 99US-00359756.
XX
PR 23-JUL-1999; 99US-00359756.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM, Gaarde W, Ward DT;
XX
DR WPI; 2001-122264/13.
XX
PT New antisense compound targeting nucleic acid encoding human mitogen-
PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing
PT inflammation or tumor formation.
XX
PS Claim 14; Col 39; 35pp; English.
XX
CC Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. The antisense oligonucleotides were designed to target
CC different regions of the human MEKK1 RNA, and were analysed for their
CC effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC which mediates cellular responses to mitogenic stimuli, being involved in
CC JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC kinase cascades. MEKK1 regulates signalling events associated with
CC apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC associated with the development of hyperproliferative disorders such as
CC cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC apoptotic signalling cascade, and plays a critical role in the control of
CC NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC cascade. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with MEKK1 expression,
CC such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ Sequence 20 BP; 1 A; 12 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 230 CGGACGCAGCGGGGAGTGGG 249
||||||||||||||||||||
Db 20 CGGACGCAGCGGGGAGTGGG 1

RESULT 9
AAF27092/c
ID AAF27092 standard; DNA; 20 BP.
XX
AC AAF27092;
XX
DT 06-APR-2001 (first entry)
XX
DE Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:14.
XX
KW Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW apoptosis signal regulation; programmed cell death;
KW serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW NF-kappa-B-mediated transcription regulation; expression inhibition;
KW antisense; hyperproliferative disorder; cancer; inflammation;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6168950-B1.
XX
PD 02-JAN-2001.
XX
PF 23-JUL-1999; 99US-00359756.
XX
PR 23-JUL-1999; 99US-00359756.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM, Gaarde W, Ward DT;
XX
DR WPI; 2001-122264/13.
XX
PT New antisense compound targeting nucleic acid encoding human mitogen-
PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing

PT inflammation or tumor formation.
XX
PS Claim 14; Col 39; 35pp; English.
XX
CC Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. The antisense oligonucleotides were designed to target
CC different regions of the human MEKK1 RNA, and were analysed for their
CC effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC which mediates cellular responses to mitogenic stimuli, being involved in
CC JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC kinase cascades. MEKK1 regulates signalling events associated with
CC apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC associated with the development of hyperproliferative disorders such as
CC cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC apoptotic signalling cascade, and plays a critical role in the control of
CC NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC cascade. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with MEKK1 expression,
CC such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 444 AGAAACTCTCAAAGGGTTGC 463
||||||||||||||||||||
Db 20 AGAAACTCTCAAAGGGTTGC 1

RESULT 10
AAF27087/c
ID AAF27087 standard; DNA; 20 BP.
XX
AC AAF27087;
XX
DT 06-APR-2001 (first entry)
XX
DE Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:9.
XX
KW Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW apoptosis signal regulation; programmed cell death;
KW serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW NF-kappa-B-mediated transcription regulation; expression inhibition;
KW antisense; hyperproliferative disorder; cancer; inflammation;
KW phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN US6168950-B1.
XX
PD 02-JAN-2001.
XX
PF 23-JUL-1999; 99US-00359756.
XX
PR 23-JUL-1999; 99US-00359756.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowsert LM, Gaarde W, Ward DT;
XX
DR WPI; 2001-122264/13.
XX
PT New antisense compound targeting nucleic acid encoding human mitogen-
PT activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT or conditions associated with MEKK1 expression, or preventing
PT inflammation or tumor formation.
XX
PS Example 15; Col 39; 35pp; English.
XX
CC Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC expression. The antisense oligonucleotides were designed to target
CC different regions of the human MEKK1 RNA, and were analysed for their
CC effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC which mediates cellular responses to mitogenic stimuli, being involved in
CC JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC kinase cascades. MEKK1 regulates signalling events associated with
CC apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC associated with the development of hyperproliferative disorders such as
CC cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC apoptotic signalling cascade, and plays a critical role in the control of
CC NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC cascade. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with MEKK1 expression,
CC such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ Sequence 20 BP; 1 A; 9 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 2.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 44 GCAGCGCGCGCGCGGCTGCC 63
||||||||||||||||||||
Db 20 GCAGCGCGCGCGCGGCTGCC 1

RESULT 11
AAX80919
ID AAX80919 standard; DNA; 21 BP.
XX
AC AAX80919;
XX
DT 03-NOV-1999 (first entry)
XX
DE Sense primer-3 for amplifying human MEKK1 cDNA.
XX
KW Sense primer; amplify; antisense primer; PCR; cDNA;
KW human Mitogen ERK Kinase Kinase 1; MEKK1; ss.
XX
OS Synthetic.
XX
PN WO9941385-A1.
XX
PD 19-AUG-1999.
XX
PF 12-FEB-1999; 99WO-US002974.
XX
PR 13-FEB-1998; 98US-00023130.
XX
PA (CADU-) CADUS PHARM CORP.
XX
PI Johnson GL;
XX
DR WPI; 1999-508649/42.
XX
PT A new mammalian serine-threonine protein kinase for treating disorder
PT characterized by aberration of the enzyme gene.
XX
PS Example 1; Page 55; 149pp; English.
XX
CC The present sequence is a sense primer used in conjunction with an
CC antisense primer in PCR, to amplify the region from bases 580-1310 of
CC cDNA encoding human Mitogen ERK Kinase Kinase 1 (MEKK1)
XX
SQ Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

```
  Query Match             1.8%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 25;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        527 CAGCCTGGAAGCACGAATGGT 547
              | ||||||||||||||| ||||
Db          1 CGGCCTGGAAGCACGAGTGGT 21


RESULT 12
AAZ25081
ID   AAZ25081 standard; DNA; 21 BP.
XX
AC   AAZ25081;
XX
DT   09-DEC-1999  (first entry)
XX
DE   Human MEKK1 PCR primer SEQ ID NO:20.
XX
KW   MEKK1; MEKK2; MEKK3; mitogen-activated protein kinase; MAPK; ERK;
KW   extracellular regulated kinase; signal transduction; regulation;
KW   MAPK/ERK; MEK; MKKK; inflammation; cellular proliferation;
KW   differentiation; development; cell death; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9947686-A2.
XX
PD   23-SEP-1999.
XX
PF   15-MAR-1999;   99WO-US005556.
XX
PR   16-MAR-1998;   98US-0078153P.
PR   04-SEP-1998;   98US-0099165P.
XX
PA   (CADU-) CADUS PHARM CORP.
XX
PI   Johnson GL;
XX
DR   WPI; 1999-571843/48.
XX
PT   New human MEKK polynucleotides and polypeptides, used for regulating
PT   signal transduction in cells.
XX
PS   Example 1; Page 62; 159pp; English.
XX
CC   The present invention describes human mitogen-activated protein kinase/
CC   extracellular response kinase (MAPK/ERK) kinase kinase (MEKK),
CC   specifically designated MEKK1, MEKK2 and MEKK3. The MEKK proteins are
CC   used to modulate and regulate signal transduction in cells, as well as
CC   for regulation of gene transcription in a cell encoding MEKK, where the
CC   cell is involved in inflammation, regulation of cellular proliferation
CC   and differentiation, regulation of development, regulation of cell death
CC   or regulation of inflammation. They are also used to prepare antibodies.
CC   MEKK polynucleotides can be used to produce the protein recombinantly and
CC   as a source of probes and primers. The present sequence represents a PCR
CC   primer for human MEKK1, which is used in an example from the present
CC   invention
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 25;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        527 CAGCCTGGAAGCACGAATGGT 547
              | ||||||||||||||| ||||
Db          1 CGGCCTGGAAGCACGAGTGGT 21


RESULT 13
ABL56936/c
ID   ABL56936 standard; DNA; 21 BP.
XX
AC   ABL56936;
XX
DT   04-JUL-2002  (first entry)
XX
DE   Rabies surface glycoprotein 1 expression cassette PCR primer 1.
XX
KW   Expression cassette; polypeptide IX; pIX; human adenovirus; rabies;
KW   adenoviral expression vector; adenovirus; glycoprotein; gp1; PCR; primer;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO200222800-A2.
XX
PD   21-MAR-2002.
XX
PF   14-SEP-2001; 2001WO-EP010654.
XX
PR   15-SEP-2000; 2000DE-01045687.
XX
PA   (MICR-) MICROMUN PRIVATES INST MIKROBIOLOGISCHE.
XX
PI   Doehner L,  Becher D,  Salim S;
XX
DR   WPI; 2002-362344/39.
XX
PT   Expression cassette containing adenoviral pIX regulatory sequences,
PT   useful for preparing new adenoviral vector for large scale protein
PT   expression.
XX
PS   Example 4; Page 20; 54pp; German.
XX
CC   The invention relates to an expression cassette (EC1), comprising the
CC   regulatory elements (I) of the polypeptide IX (pIX) gene of human
CC   adenovirus of group C and a foreign DNA coding sequence (II). EC1 is used
CC   to prepare adenoviral expression vectors for protein production. EC1
CC   produce expression systems with high expression rates (associated with
CC   use of (I)) and allow simple production of genetically modified
CC   adenovirus without requiring ligation. The present sequence is that of a
CC   PCR primer used to generate a rabies surface glycoprotein 1 expression
CC   cassette used to exemplify the invention
XX
SQ   Sequence 21 BP; 3 A; 10 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   94.7%;  Pred. No. 29;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGCTGC 130
              ||||||||||||| |||||
Db         19 TGGCGGCGGCGGCTGCTGC 1


RESULT 14
AAT86501/c
ID   AAT86501 standard; DNA; 20 BP.
XX
AC   AAT86501;
XX
DT   12-MAR-1998  (first entry)
XX
DE   S-adenosylmethionine decarboxylase antisense oligonucleotide #2.
XX
KW   S-adenosylmethionine decarboxylase; SAMDC; antisense oligonucleotide;
KW   antitumour; diagnosis; phosphorothioate; psoriasis; spermine; spermidine;
KW   ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
```

```
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /note= "nucleotides are bonded via phosphorothioate
FT                   linkages"
XX
PN   WO9605298-A1.
XX
PD   22-FEB-1996.
XX
PF   27-JUL-1995;   95WO-EP002985.
XX
PR   09-AUG-1994;   94US-00287753.
XX
PA   (CIBA ) CIBA GEIGY AG.
XX
PI   Mett H,  Haner R,  Dean NM;
XX
DR   WPI; 1996-139694/14.
XX
PT   New oligo:nucleotide derivs. specific for S-adenosyl:methionine
PT   decarboxylase related nucleic acid - useful as anti:sense inhibitors of
PT   this enzyme, esp. for treatment of tumours but also as hybridisation
PT   probes for diagnosis.
XX
PS   Claim 11; Page 45; 81pp; English.
XX
CC   This sequence represents a phosphorothioate analogue of an antisense
CC   oligonucleotide which targets the 5' untranslated region of S-
CC   adenosylmethionine decarboxylase (SAMDC) around nucleotides at positions
CC   -80 to -61. Antisense oligonucleotide analogues (AAT86500-14) which
CC   target the SAMDC gene are used to diagnose conditions associated with
CC   expression of SAMDC by specifically hybridising to RNA or DNA derived
CC   from the SAMDC gene. These antisense molecules are useful for therapeutic
CC   modulation (especially inhibition) of SAMDC synthesis, particularly to
CC   treat tumours (e.g. leukaemia, prostatic carcinoma, colon or brain
CC   tumours, but especially bladder cancer), but also other hyper-
CC   proliferative diseases such as psoriasis. They cause tumour regression
CC   and prevent establishment/growth of (micro)metastases. Inhibition of
CC   SAMDC reduces the level of polyamines (spermine and spermidine in cells),
CC   resulting in cytostasis and possibly apoptosis
XX
SQ   Sequence 20 BP; 0 A; 13 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCG 131
              ||||||||||||||| |||
Db         20 GCGGCGGCGGCAGCGGCG 3


RESULT 15
AAT38134
ID   AAT38134 standard; DNA; 20 BP.
XX
AC   AAT38134;
XX
DT   13-NOV-1996  (first entry)
XX
DE   Primer for LAMC2 gamma chain amplification.
XX
KW   kalinin; laminin; epidermolysis bullosa; junctional; probe; detection;
KW   inhibit; monitor; malignancy; primer; PCR; ss.
XX
OS   Synthetic.
XX
PN   WO9610646-A1.
XX
PD   11-APR-1996.
XX
PF   04-OCT-1995;   95WO-EP003918.
XX
PR   04-OCT-1994;   94US-00317450.
XX
PA   (TRYG/) TRYGGVASON K.
XX
PI   Tryggvason K,  Kallunki P,  Pyke C;
XX
DR   WPI; 1996-209366/21.
XX
PT   Detection of kalinin or laminin 5 expression in cells - useful to detect,
PT   monitor and inhibit the invasive growth of cell in tissue, partic.
PT   malignant tissue.
XX
PS   Example 1; Page 8; 37pp; English.
XX
CC   AAT38133-43 are primers for the amplification of introns 8 and 16 of the
CC   gamma-2 chain gene LAMC2 (kalinin/laminin 5 gamma-2). The gamma-2 chain
CC   is of importance to patients suffering from epidermolysis bullosa, esp.
CC   the junctional form (JEB). PCR products were analysed and mutations
CC   correlating with JEB can be identified. Probes and antisense gamma-2
CC   sequences derived from this sequence can be used to detect, monitor and
CC   inhibit the invasive growth of cells in tissue, partic. malignant tissue
XX
SQ   Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              |||||||| |||||||||
Db          1 GAATCACTGAGCAGCTGA 18


RESULT 16
AAL42900
ID   AAL42900 standard; DNA; 20 BP.
XX
AC   AAL42900;
XX
DT   05-AUG-2002  (first entry)
XX
DE   LAMC2 gene PCR primer 2.
XX
KW   LAMC2; PCR; primer; ss; cancer; laminin gamma-2 chain inhibition;
KW   carcinogen inhibition; anti-gamma-2 chain antibody;
KW   epithelial cell adhesion; laminin-5.
XX
OS   Unidentified.
XX
PN   US2002052307-A1.
XX
PD   02-MAY-2002.
XX
PF   08-JAN-2001; 2001US-00756071.
XX
PR   04-OCT-1994;   94US-00317450.
PR   18-FEB-1997;   97US-00800593.
PR   07-JAN-2000; 2000US-0175005P.
PR   15-SEP-2000; 2000US-00663147.
XX
PA   (TRYG/) TRYGGVASON K.
PA   (KALL/) KALLUNKI P.
PA   (PYKE/) PYKE C.
XX
PI   Tryggvason K,  Kallunki P,  Pyke C;
XX
DR   WPI; 2002-434824/46.
XX
PT   Modulating laminin 5 gamma 2 chain interactions of invasive carcinogens
PT   for treating cancers and promoting attachment of cultured cells in vitro.
XX
PS   Example 1; Page 6; 51pp; English.
XX
```

```
CC   The invention comprises a method of inhibiting the laminin gamma-2 chain
CC   interactions of invasive carcinogens with surrounding tissues - by using
CC   anti-gamma-2 chain antibodies to inhibit the gamma-2 chain biological
CC   activity of the invasive carcinogens. The invention also comprises a
CC   method for promoting adhesion of epithelial cells by exposing the cells
CC   to intact laminin-5 molecules. The first method of the invention is
CC   useful for preventing gamma 2 chain interactions of invasive carcinogens
CC   with surrounding tissues. The second method of the invention is useful
CC   for promoting adhesion of cultured epithelial cells. The present DNA
CC   sequence represents a LAMC2 gene PCR primer
XX
SQ   Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 39;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       618 GAATCACTTAGCAGCTGA 635
             ||||||||.|||||||||
Db         1 GAATCACTGAGCAGCTGA 18


RESULT 17
AAV52008
ID   AAV52008 standard; DNA; 21 BP.
XX
AC   AAV52008;
XX
DT   02-FEB-1999  (first entry)
XX
DE   Zea mays genome reverse PCR primer #304.
XX
KW   Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW   hybridisation; plant; hybrid certification; genetic contribution;
KW   progeny; back-cross; hybrid; ancestry; corn; ss.
XX
OS   Synthetic.
OS   Zea mays.
XX
PN   WO9824796-A1.
XX
PD   11-JUN-1998.
XX
PF   01-DEC-1997;   97WO-US021782.
XX
PR   02-DEC-1996;   96US-0032069P.
PR   07-MAR-1997;   97US-00813507.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Lemieux B,  Landry BS,  Sapolsky RJ,  Murigneux A;
XX
DR   WPI; 1998-333252/29.
XX
PT   Brassica species allele-specific oligonucleotide probes and primers -
PT   useful for plant breeding.
XX
PS   Example 1; Page 55; 65pp; English.
XX
CC   AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
CC   Zea mays genome in order to detect polymorphic markers. Such markers can
CC   be used in the construction of allele-specific primers and probes for
CC   amplification or hybridisation, e.g. to determine common or disparate
CC   ancestry between 2 or more plants, to monitor the genetic contribution of
CC   an ancestral plant, to trace the progeny of proprietary plants, in
CC   certification of a hybrid plant or to identify the progeny of a back-
CC   crossed plant with an ancestral plant
XX
SQ   Sequence 21 BP; 4 A; 4 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 47;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        82 GCGGGCAGCGGGGGCCGCGAG 102
             | |||||||||||| | |||||
Db         1 GTGGGCAGCGGGGACAGCGAG 21


RESULT 18
AAF55729/c
ID   AAF55729 standard; DNA; 21 BP.
XX
AC   AAF55729;
XX
DT   12-APR-2001  (first entry)
XX
DE   PCR primer R3.
XX
KW   Insecticide; transgenic plant; insect-resistance; PCR primer; probe; ss.
XX
OS   Paecilomyces sp.
XX
PN   WO200100841-A1.
XX
PD   04-JAN-2001.
XX
PF   23-JUN-2000; 2000WO-GB002457.
XX
PR   29-JUN-1999;   99GB-00015215.
PR   23-DEC-1999;   99GB-00030536.
XX
PA   (ZENE ) ZENECA LTD.
XX
PI   Griffin J,  Carlile AJ,  Cayley PJ,  Mackay EA,  Warner SAJ;
PI   Vincent JL,  Lee MD;
XX
DR   WPI; 2001-123015/13.
XX
PT   Novel insecticidal protein obtained from species of Paecilomyces for
PT   controlling insects, and for insect-resistant transgenic plant
PT   production.
XX
PS   Example 6; Page 22; 72pp; English.
XX
CC   The present invention relates to novel insecticidal proteins obtained
CC   from Paecilomyces sp. (see AAB66899 to AAB66901 and AAB66913). The
CC   insecticidal proteins can be used to produce transgenic plants, which are
CC   insect-resistant. Also, the insecticidal proteins are useful for
CC   controlling insects by providing them at a locus where insects feed. The
CC   present sequence is a PCR primer used in the present invention
XX
SQ   Sequence 21 BP; 6 A; 5 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 47;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       171 GCCGCTCTTCCTTGCCGCCTC 191
             || |||||||||||| ||| |
Db        21 GCGGCTCTTCCTTGCTGCCCC 1


RESULT 19
AAQ27316/c
ID   AAQ27316 standard; DNA; 18 BP.
XX
AC   AAQ27316;
XX
DT   25-MAR-2003  (revised)
DT   01-FEB-1993  (first entry)
XX
DE   PCR primer Cbetaint for TCR Beta-Chain genes.
XX
KW   TCR; beta chain; rheumatoid arthritis; multiple sclerosis;
KW   autoimmune disease; diabetes; T-cell lymphoma; vaccination; immunisation;
```

```
KW   experimental allergic encephalomyelitis.
XX
OS   Synthetic.
XX
PN   WO9212996-A2.
XX
PD   06-AUG-1992.
XX
PF   21-JAN-1992;   92WO-US000482.
XX
PR   22-JAN-1991;   91US-00644611.
XX
PA   (IMMU-) IMMUNE RESPONSE CORP.
XX
PI   Howell MD,  Brostoff SW,  Carlo DJ;
XX
DR   WPI; 1992-284600/34.
XX
PT   Treatment of auto:immune diseases e.g. rheumatoid arthritis - using
PT   vaccine contg. T-cell receptors from surface of T-cells which mediate the
PT   diseases.
XX
PS   Example 10; Page 48; 87pp; English.
XX
CC   This sequence represents a PCR primer used to amplify the T cell receptor
CC   beta chain genes in a two stage amplification reaction with nested pairs
CC   of primers. See also AAQ27310-7. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 20
AAQ46300/c
ID   AAQ46300 standard; DNA; 18 BP.
XX
AC   AAQ46300;
XX
DT   25-MAR-2003  (revised)
DT   08-DEC-1993  (first entry)
XX
DE   Primer Cbeta-int.
XX
KW   CDR; T-cell receptor; TCR; vaccine; polymerase chain reaction; PCR;
KW   amplification; ss.
XX
OS   Synthetic.
XX
PN   WO9312814-A2.
XX
PD   08-JUL-1993.
XX
PF   21-DEC-1992;   92WO-US011159.
XX
PR   24-DEC-1991;   91US-00813867.
XX
PA   (IMMU-) IMMUNE RESPONSE CORP.
XX
PI   Howell MD,  Brostoff SW,  Carlo DJ;
XX
DR   WPI; 1993-227059/28.
XX
PT   Vaccine comprising T cell receptor from T cells which mediate pathology -
PT   for treating and preventing T cell lymphoma, rheumatoid arthritis,
PT   auto:immune diseases etc.
XX
PS   Example 10C; Fig 2B; 79pp; English.
XX
CC   TCR beta-chain genes were amplified with several combinations of the
CC   primers given in AAQ46294-301. The Vbeta16mer primer is a degenerate
CC   Vbeta primer (n=265) which is predicted to bind 85% of human TCR beta-
CC   chain genes at all 16 residues and 95% at 15 residues. This primer has
CC   been used to amplify TCR beta-chains from more than 25 different human T-
CC   cell clones, lines or primary tissue prepns. A spectrum of Vbeta genes
CC   has been sequenced from these amplified DNAs, arguing against a
CC   significant bias of the primer for certain Vbeta families. Thus, PCR
CC   amplification with the Vbeta16mer primer facilitates analysis of T-cell
CC   populations for which a priori knowledge of Vbeta gene usage is
CC   unavailble. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 21
AAQ99419/c
ID   AAQ99419 standard; DNA; 18 BP.
XX
AC   AAQ99419;
XX
DT   28-FEB-1996  (first entry)
XX
DE   Human T cell receptor beta-chain constant region antisense primer.
XX
KW   Human T cell receptor; TCR; beta-chain constant region; psoriasis;
KW   prevention; reduction; antisense primer; ss.
XX
OS   Synthetic.
XX
PN   WO9519375-A1.
XX
PD   20-JUL-1995.
XX
PF   13-JAN-1995;   95WO-US000658.
XX
PR   14-JAN-1994;   94US-00182967.
XX
PA   (IMMU-) IMMUNE RESPONSE CORP.
XX
PI   Chang JCC,  Brostoff SW,  Carlo DJ;
XX
DR   WPI; 1995-263831/34.
XX
PT   Prevention or reduction in the severity of psoriasis - by preventing the
PT   attachment of a psoriasis associated T cell receptor to its binding
PT   partner.
XX
PS   Example 1; Page 21; 46pp; English.
XX
CC   AAQ99419 is an antisense primer for the human T cell receptor (TCR) beta-
CC   chain constant region. CDR 2 peptides from the beta-chain variable
CC   regions of hTCR can be used to prevent or reduce psoriasis, by preventing
CC   the attachment of a psoriasis associated TCR to its binding partner
XX
SQ   Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
```

```
                  ||||||||||||||||
Db          16 CTGCCTGAGCAGCCGC 1


RESULT 22
AAV64294/c
ID   AAV64294 standard; DNA; 18 BP.
XX
AC   AAV64294;
XX
DT   25-JAN-1999  (first entry)
XX
DE   Human T cell receptor beta chain PCR primer C beta int.
XX
KW   T cell receptor; human; TCR; beta chain; detection; prevention;
KW   treatment; rheumatoid arthritis; autoaggressive; immune response;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US5837246-A.
XX
PD   17-NOV-1998.
XX
PF   20-JAN-1995;   95US-00376049.
XX
PR   21-MAR-1989;   89US-00326314.
PR   18-JUL-1989;   89US-00382085.
PR   18-JUL-1989;   89US-00382086.
PR   30-MAY-1990;   90US-00530229.
PR   28-JAN-1993;   93US-00010483.
XX
PA   (IMMU-) IMMUNE RESPONSE CORP.
XX
PI   Howell MD,  Brostoff SW,  Carlo DJ;
XX
DR   WPI; 1999-023376/02.
XX
PT   New immunogenic peptides for treating rheumatoid arthritis - has amino
PT   acid sequence for T cell receptor present of surface of autoaggressive T
PT   cells mediating rheumatoid arthritis.
XX
PS   Example IX; Fig 1B; 15pp; English.
XX
CC   AAV64289-V64295 are PCR primers used in the amplification of human T cell
CC   receptor (TCR) beta chain genes. These genes are used in a method for the
CC   detection, prevention and treatment of rheumatoid arthritis (RA). The
CC   method involves an amino acid sequence for a TCR which is present on the
CC   surface of autoaggressive T cells mediating rheumatoid arthritis where
CC   the peptide induces an immune response against the autoaggressive T cell
CC   that reduces the severity of RA
XX
SQ   Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
                  ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 23
AAF85282/c
ID   AAF85282 standard; DNA; 18 BP.
XX
AC   AAF85282;
XX
DT   23-JUL-2001  (first entry)
XX
DE   PCR primer used to amplify T cell receptor b-chain genes.
XX
KW   Vbeta14; Vbeta17; T cell; rheumatoid arthritis; multiple sclerosis;
KW   T cell-mediated pathology; autoimmune disease; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6221352-B1.
XX
PD   24-APR-2001.
XX
PF   06-JUN-1995;   95US-00471209.
XX
PR   21-MAR-1989;   89US-00326314.
PR   18-JUL-1989;   89US-00382085.
PR   18-JUL-1989;   89US-00382086.
PR   30-MAY-1990;   90US-00530229.
PR   22-JAN-1991;   91US-00644611.
PR   24-DEC-1991;   91US-00813867.
PR   18-JUL-1994;   94US-00276776.
XX
PA   (IMMU-) IMMUNE RESPONSE CORP.
XX
PI   Howell MD,  Brostoff SW,  Carlo DJ;
XX
DR   WPI; 2001-315571/33.
XX
PT   Preventing proliferation of Vbeta14 or 17-expressing T cells, for
PT   preventing, treating T-cell mediated pathologies such as autoimmune
PT   diseases, by administering antibody that binds to Vbeta region of T cell
PT   receptor.
XX
PS   Example 10; Col 23; 40pp; English.
XX
CC   The specification describes a method for preventing the proliferation of
CC   Vbeta14 or Vbeta17-expressing T cells in a human individual having
CC   rheumatoid arthritis. The method comprises administering a cytotoxic or
CC   cytostatic agent which comprises an antibody selectively binding to
CC   Vbeta14 or Vbeta17 expressed by the T cells. The method is useful for
CC   preventing the proliferation of T cells, which in turn is useful for
CC   preventing, ameliorating or treating T cell-mediated pathologies of
CC   autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
CC   PCR primers AAF85275-83 were used to amplify T cell receptor beta-chain
CC   gene, in the course of the invention
XX
SQ   Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
                  ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 24
AAF27155/c
ID   AAF27155 standard; DNA; 18 BP.
XX
AC   AAF27155;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human TCR beta-chain PCR primer, C-beta-int.
XX
KW   T-cell receptor; TCR; beta-chain; V-beta-17; rheumatoid arthritis;
KW   autoimmune disease; vaccine; antibody; targetting moiety; drug delivery;
KW   antirheumatic; antiarthritic; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6159470-A.
XX
```

PD 12-DEC-2000.
XX
PF 05-JUN-1995; 95US-00464506.
XX
PR 21-MAR-1989; 89US-00326314.
PR 18-JUL-1989; 89US-00382085.
PR 18-JUL-1989; 89US-00382086.
PR 30-MAY-1990; 90US-00530229.
PR 28-JAN-1993; 93US-00010483.
PR 20-JAN-1995; 95US-00376049.
XX
PA (IMMU-) IMMUNE RESPONSE CORP.
XX
PI Howell MD, Brostoff SW, Carlo DJ;
XX
DR WPI; 2001-090268/10.
XX
PT Treating rheumatoid arthritis in humans involves binding Vbeta17, a
PT variable chain region of T cell receptor in the individual with antibody
PT reactive with Vbeta17, so as to kill or inhibit proliferation of T cells.
XX
PS Example IX; Fig 1B; 16pp; English.
XX
CC The invention relates to a method of treating rheumatoid arthritis in
CC human patients by specifically targetting T-cells expressing the T-cell
CC receptor (TCR) V-beta-17 beta-chain variable region (AAB60303) with a
CC cytotoxic or cytostatic agent to inhibit the proliferation of or to kill
CC the T-cells. An antibody specific for V-beta-17 is used as the targetting
CC moiety, and is attached to the therapeutic moiety (e.g., a radioactive
CC moiety, a chemotherapeutic moiety or a chemotoxic moiety). The V-beta-17
CC antibody may also be used in the detection and prevention of rheumatoid
CC arthritis. The invention is based on the discovery that a specific TCR
CC beta-chain variable region, V-beta-17, is central to the pathogenesis of
CC rheumatoid arthritis. The TCR beta-chain is also involved in other
CC autoimmune diseases. In particular, the TCR beta-chain VDJ junction
CC regions of myelin basic protein (MBP)-specific T-cells have significant
CC sequence similarity (see AAB60311, AAB60312). Such MBP-specific T-cells
CC are involved in the pathogenesis of multiple sclerosis in humans and in
CC experimental allergic encephalitis (EAE, an animal model of autoimmune
CC disease) in mice and rats. This means that antibodies specific to this
CC region can be used as targetting moieties in therapeutic applications.
CC The present sequence represents a human TCR beta-chain PCR primer used in
CC an exemplification of the invention
XX
SQ Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 160 CTGCCTGAGCAGCCGC 175
||||||||||||||||
Db 16 CTGCCTGAGCAGCCGC 1

RESULT 25
AAQ52159
ID AAQ52159 standard; RNA; 19 BP.
XX
AC AAQ52159;
XX
DT 25-MAR-2003 (revised)
DT 26-MAY-1994 (first entry)
XX
DE Colon carcinoma specific mRNA ribozyme cleavable nucleotide (18).
XX
KW Multiple drug resistance; mdr-1; ribozyme; membrane protein; liver;
KW resistance; chemotherapeutic agent; colchicine; doxorubicin; colon;
KW actinomycin D; vinblastine; small intestine; kidney; adrenal gland;
KW adenocarcinoma; bowel; transformed phenotype; promyelocytic leukemia;
KW human; chronic myelogenous leukemia; CML; follicular lymphoma;
KW B-cell acute lymphocytic leukemia; breast cancer; colon carcinoma;
KW neuroblastoma; lung cancer; genetic drift; mutation; hammerhead motif;
KW hairpin; hepatitis delta virus; group I intron; RNaseP; leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO9323057-A1.
XX
PD 25-NOV-1993.
XX
PF 13-MAY-1993; 93WO-US004573.
XX
PR 14-MAY-1992; 92US-00882822.
PR 14-MAY-1992; 92US-00882885.
PR 26-AUG-1992; 92US-00936110.
PR 26-AUG-1992; 92US-00936421.
PR 26-AUG-1992; 92US-00936422.
PR 26-AUG-1992; 92US-00936531.
PR 26-AUG-1992; 92US-00936532.
PR 07-DEC-1992; 92US-00987131.
PR 19-JAN-1993; 93US-00006122.
PR 19-JAN-1993; 93US-00008910.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Draper KG;
XX
DR WPI; 1993-386203/48.
XX
PT New enzymatic RNA molecules (ribozymes) - which cleave mRNA associated
PT with tumours or mRNA expressed from gene encoding multiple drug
PT resistance.
XX
PS Claim 3; Fig 9; 69pp; English.
XX
CC The sequences given in AAQ51825-2266 represent areas of mRNAs which are
CC associated with development or maintenance of chronic myelogenous
CC leukemia (CML), promyelocytic leukemia, Burkitt's lymphoma, or acute
CC lymphocytic leukemia, follicular lymphoma, B-cell acute lymphocytic
CC leukemia, breast cancer, colon carcinoma, neuroblastoma and lung cancer.
CC The full length mRNAs containing these target sequences, encode aberant
CC cellular proteins which are able to control cellular proliferation and
CC are directly linked to a leukemic phenotype. These target sequences are
CC identified by the ribozyme of the invention. The ribozymes is formed in a
CC hammerhead motif, but may also be formed in the motif of a hairpin,
CC hepatitis delta virus, group I intron or RNaseP-like RNA. These ribozymes
CC may be used to inhibit the development or expression of a transformed
CC phenotype in man and other animals by modulating expression of the
CC corresponding gene. Cleavage of target mRNAs expressed in pre-neoplastic
CC and transformed cells elicits inhibition of the transformed state.
CC Multiple drug resistance (mdr-1) mRNA specific ribozymes remove the
CC mechanism of drug resistance used by transformed cells and thus enhances
CC drug therapies for tumours. The ribozymes may also be used to study
CC genetic drift and mutations within cells. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 19 BP; 3 A; 5 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGCTGCG 131
||||||| |||||| |||
Db 1 GGCGGCGGAGGCAGCAGCG 19

RESULT 26
AAZ70920
ID AAZ70920 standard; DNA; 19 BP.
XX
AC AAZ70920;
XX
DT 10-SEP-2001 (first entry)
XX

DE Human biallelic marker upstream amplification primer SEQ ID NO:5276.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1356; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 11 A; 1 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 745 GGAGTAAGGAGAAAAAGAG 763
||| |||||||||||||
Db 1 GGAACAAGGAGAAAAAGAG 19

RESULT 27
AAV47686
ID AAV47686 standard; DNA; 20 BP.
XX
AC AAV47686;
XX
DT 20-NOV-1998 (first entry)
XX
DE Unmethylated CpG dinucleotide 2001.
XX
KW Unmethylated CpG dinucleotide; immune response; bacterial meningitis;
KW natural killer cell activation; NK cell; Th2 response; neonatal sepsis;
KW pulmonary disorder; asthma; environmentally induced airway disease;
KW bacterial infection; endotoxaemia; therapy; cystic fibrosis;
KW inflammatory bowel disease; ss.
XX
OS Synthetic.
XX
PN WO9837919-A1.
XX
PD 03-SEP-1998.
XX
PF 25-FEB-1998; 98WO-US003678.
XX
PR 28-FEB-1997; 97US-0039405P.
XX
PA (IOWA) UNIV IOWA RES FOUND.
XX
PI Schwartz DA, Krieg AM;
XX
DR WPI; 1998-480941/41.
XX
PT Use of nucleic acids containing an unmethylated CpG - for treating a
PT subject having or at risk of having an acute decrement in air flow or
PT inhibiting an inflammatory response.
XX
PS Claim 35; Page 27; 65pp; English.
XX
CC This sequence represents an unmethylated CpG dinucleotide, and can be
CC used in the method of the invention. The method is for treating a subject
CC having, or at risk of having an acute decrement in air flow, comprising
CC administering a nucleic acid sequence containing at least one
CC unmethylated CpG. The nucleic acids containing an unmethylated CpG
CC dinucleotide affect an immune response in a subject by activating natural
CC killer cells (NK) or redirecting a subject's immune response from a Th2
CC to a Th1 response by inducing monocytic and other cells to produce Th1
CC cytokines. They can be used to treat pulmonary disorders having an
CC immunologic component, such as asthma or environmentally induced airway
CC disease. They can also be used to treat diseases associated with Gram-
CC positive bacterial infections or endotoxaemia including bacterial
CC meningitis, neonatal sepsis, cystic fibrosis, inflammatory bowel disease
CC and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal
CC abscess, haemorrhagic shock, disseminated intravascular coagulation, or
CC an inflammatory response to lipopolysaccharide
XX
SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGCTGCG 131
||||||||||||| || |||
Db 1 GGCGGCGGCGGCGGCGGCG 19

RESULT 28
AAV74243
ID AAV74243 standard; DNA; 20 BP.
XX
AC AAV74243;
XX
DT 20-MAR-2003 (revised)
DT 15-MAR-1999 (first entry)
XX
DE CpG-N motif O-ODN 2001 DNA.
XX
KW CpG-N motif; immunostimulation; antigen; CpG-S motif; immunisation; ODN;
KW viral antigen; bacterial antigen; parasite; therapeutic; growth factor;
KW toxin; tumour suppressor; cytokine; apoptotic protein; interferon;
KW hormone; clotting factor; ligand; receptor; oligodeoxynucleotide; ss.
XX
OS Synthetic.
XX
PN WO9852581-A1.
XX
PD 26-NOV-1998.
XX
PF 20-MAY-1998; 98WO-US010408.

XX
PR 20-MAY-1997; 97US-0047209P.
PR 20-MAY-1997; 97US-0047233P.
XX
PA (OTTA-) OTTAWA CIVIC HOSPITAL LOEB RES INST.
PA (IOWA) UNIV IOWA RES FOUND.
PA (QIAG-) QIAGEN GMBH.
XX
PI Davis HL, Krieg AM, Schorr J, Wu T;
XX
DR WPI; 1999-059712/05.
XX
PT Use of neutralising CpG and stimulating CpG motifs in DNA vectors - for
PT enhancing the immunostimulatory effect of an antigen or enhancing the
PT expression of a therapeutic polypeptide.
XX
PS Example 1; Page 64; 109pp; English.
XX
CC AAV74237-V74253 are oligodeoxynucleotide (ODN) primers used to describe a
CC method for enhancing the immunostimulatory effect of an antigen encoded
CC by nucleic acid contained in a nucleic acid construct. The method
CC involves determining the CpG-N and CpG-S motifs present in the construct,
CC removing neutralising CpG (CpG-N) motifs and optionally inserting
CC stimulatory CpG (CpG-S) motifs in the construct, thereby producing a
CC nucleic acid construct having enhanced immunostimulatory efficacy. The
CC method can be used for immunisation against viral antigens, e.g. from
CC hepatitis B virus (HBV), bacterial antigens or an antigen derived from a
CC parasite. They can also be used for expression of a therapeutic
CC polypeptide, e.g. growth factors, toxins, tumour suppressors, cytokines,
CC apoptotic proteins, interferons, hormones, clotting factors, ligands and
CC receptors. (Updated on 20-MAR-2003 to correct PA field.)
XX
SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGCTGCG 131
||||||||||||| || |||
Db 1 GGCGGCGGCGGCGGCGGCG 19

RESULT 29
AAZ75520/c
ID AAZ75520 standard; DNA; 20 BP.
XX
AC AAZ75520;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:9876.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 2336; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 20 BP; 3 A; 8 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 428 GTGAGATGGAGAATAAAGA 446
|||||||||| | ||||||
Db 20 GTGAGATGGAAAGTAAAGA 2

RESULT 30
AAC83620
ID AAC83620 standard; DNA; 20 BP.
XX
AC AAC83620;
XX
DT 27-FEB-2001 (first entry)
XX
DE Human c-fos oligo DNA D4.
XX
KW Human; c-fos; fluorescent probe; cytoplasmic nucleic acid detection; ss.
XX
OS Homo sapiens.
XX
PN EP1052293-A1.
XX
PD 15-NOV-2000.
XX
PF 27-DEC-1999; 99EP-00126030.
XX
PR 12-MAY-1999; 99JP-00131838.
XX
PA (MOLE-) LAB MOLECULAR BIOPHOTONICS.
XX
PI Tsuji A, Hirano M, Koshimoto H, Ishibashi K;
XX
DR WPI; 2001-018062/03.
XX
PT Detection of a target nucleic acid in the cytoplasm of a living cell
PT comprises using a fluorescent probe linked to a component that cannot
PT permeate through the nuclear membrane.
XX
PS Example 1; Page 11; 53pp; English.
XX
CC The present sequence is a probe which was used in a method for nucleic
CC acid detection in cytoplasm. The method comprises detecting a target
CC nucleic acid using a fluorescent hybridisation probe linked to a
CC component that cannot permeate through the nuclear membrane of the cell.

```
CC   The present sequence was used for detecting cytoplasmic human c-fos mRNA
CC   molecules. The detection probe of this method is not readily degraded by
CC   endogenous cytoplasmic nucleases unlike currently available detection
CC   probes, as it has a specified structure which does not rapidly move to
CC   the nucleus when introduced into the cytoplasm of a living cell
XX
SQ   Sequence 20 BP; 11 A; 1 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 31
AAC83625
ID   AAC83625 standard; DNA; 20 BP.
XX
AC   AAC83625;
XX
DT   27-FEB-2001  (first entry)
XX
DE   Human c-fos Bodipy493/503-labelled oligo DNA D4F.
XX
KW   Human; c-fos; fluorescent probe; cytoplasmic nucleic acid detection; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "attached to fluorescent dye Bodipy493/503"
XX
PN   EP1052293-A1.
XX
PD   15-NOV-2000.
XX
PF   27-DEC-1999;   99EP-00126030.
XX
PR   12-MAY-1999;   99JP-00131838.
XX
PA   (MOLE-) LAB MOLECULAR BIOPHOTONICS.
XX
PI   Tsuji A,  Hirano M,  Koshimoto H,  Ishibashi K;
XX
DR   WPI; 2001-018062/03.
XX
PT   Detection of a target nucleic acid in the cytoplasm of a living cell
PT   comprises using a fluorescent probe linked to a component that cannot
PT   permeate through the nuclear membrane.
XX
PS   Example 1; Page 13; 53pp; English.
XX
CC   The present sequence is a probe which was used in a method for nucleic
CC   acid detection in cytoplasm. The method comprises detecting a target
CC   nucleic acid using a fluorescent hybridisation probe linked to a
CC   component that cannot permeate through the nuclear membrane of the cell.
CC   The present sequence was used for detecting cytoplasmic human c-fos mRNA
CC   molecules. The detection probe of this method is not readily degraded by
CC   endogenous cytoplasmic nucleases unlike currently available detection
CC   probes, as it has a specified structure which does not rapidly move to
CC   the nucleus when introduced into the cytoplasm of a living cell
XX
SQ   Sequence 20 BP; 11 A; 1 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 32
AAF99116
ID   AAF99116 standard; DNA; 20 BP.
XX
AC   AAF99116;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #232.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 43; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              |||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 33
AAF91298
ID   AAF91298 standard; DNA; 20 BP.
```

```
XX
AC   AAF91298;
XX
DT   04-MAY-2001  (first entry)
XX
DE   Human E2F transcription factor 1 antisense oligonucleotide #4.
XX
KW   Antisense; E2F transcription factor 1; human; infection; inflammation;
KW   tumour; ss.
XX
OS   Homo sapiens.
XX
PN   US6187587-B1.
XX
PD   13-FEB-2001.
XX
PF   02-MAR-2000; 2000US-00517584.
XX
PR   02-MAR-2000; 2000US-00517584.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Popoff I,  Brown-Driver VL,  Cowsert LM;
XX
DR   WPI; 2001-190981/19.
XX
PT   Antisense compound capable of inhibiting the expression of E2F
PT   transcription factor 1, useful for preventing or delaying infection,
PT   inflammation or tumor formation.
XX
PS   Example 15; Col 42; 40pp; English.
XX
CC   The present invention relates to antisense compounds up to 30 nucleobases
CC   in length targeted to a E2F transcription factor 1 The invention is
CC   useful for inhibiting the expression of E2F transcription factor 1 in
CC   cells or tissues. The antisense oligonucleotides may also be used as a
CC   research agent and to prevent infection, inflammation or tumours
XX
SQ   Sequence 20 BP; 1 A; 7 C; 12 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 CAGGCGGCGGCGGAGGAGC 32
              ||||||||||||| || ||
Db          1 CAGGCGGCGGCGGCGGCGC 19


RESULT 34
ABK90289
ID   ABK90289 standard; DNA; 20 BP.
XX
AC   ABK90289;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Bcl-2-targeting antisense oligonucleotide #22.
XX
KW   Antisense; ss; probe; Bcl-2; cell proliferative disorder; cancer; CRE;
KW   cAMP response element; bacterial infection; viral infection;
KW   inflammation; anaphylaxis; allergy; arthritis; asthma; cytostatic;
KW   autoimmune disorder; parasitic infection; virucide; hyperplasia;
KW   tumourigenesis; hepatitis B infection; human.
XX
OS   Homo sapiens.
XX
PN   WO200257480-A2.
XX
PD   25-JUL-2002.
XX
PF   22-JAN-2002; 2002WO-US001967.
XX
PR   22-JAN-2001; 2001US-0263244P.
XX
PA   (GENT-) GENTA INC.
XX
PI   Klem RE;
XX
DR   WPI; 2002-590754/63.
XX
PT   Hybrid oligomer comprises a cyclic AMP response element sequence and a
PT   sequence that hybridizes to the bcl-2 pre-mRNA or mRNA useful for
PT   preventing or treating cell-proliferative disorders e.g., cancer.
XX
PS   Disclosure; Page 13; 78pp; English.
XX
CC   The invention relates to a hybrid oligomer comprising a cyclic AMP
CC   response element (CRE) sequence and a sequence that hybridises to the bcl
CC   -2 pre-mRNA or mRNA. Also included are: (1) inhibiting the growth of
CC   cancer cells in vitro, which comprises contacting the cancer cells with a
CC   hybrid oligomer or a bcl-2 antisense oligomer and a CRE decoy oligomer;
CC   (2) treating or preventing cancer in a human, which comprises
CC   administering a hybrid oligomer or a bcl-2 antisense oligomer and a CRE
CC   decoy oligomer; and (3) a pharmaceutical composition comprising a hybrid
CC   oligomer or a bcl-2 antisense oligomer and a CRE decoy oligomer and a
CC   carrier. The pharmaceutical composition of the invention is useful for
CC   preventing or treating cell-proliferative disorders e.g., cancer,
CC   hyperplasia or tumourigenesis and also bacterial infection, viral
CC   infection, inflammation, anaphylaxis, allergy, arthritis, asthma,
CC   autoimmune disorders and parasitic infection. The CRE decoy oligomer and
CC   bcl-2 antisense oligomer are also useful for preventing or treating
CC   hepatitis B virus infection. The hybrid oligomers can also be used for
CC   screening candidate transcription factors or other molecules e.g., gene
CC   regulatory proteins or for diagnostic assays. The present sequence is a
CC   Bcl-2 antisense oligonucleotide
XX
SQ   Sequence 20 BP; 2 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 35
ABS77759
ID   ABS77759 standard; DNA; 20 BP.
XX
AC   ABS77759;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Angiogenesis inhibitory oligonucleotide #243.
XX
KW   Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW   tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW   diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW   corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW   rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW   plaque neovascularisation; telangiectasia; haemophiliac joint;
KW   angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW   scleroderma; hypertrophic scar.
XX
OS   Synthetic.
XX
PN   WO200253141-A2.
XX
PD   11-JUL-2002.
XX
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
```

```
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
XX
PS   Claim 2; Page 23; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 36
ABL39008
ID   ABL39008 standard; DNA; 20 BP.
XX
AC   ABL39008;
XX
DT   16-APR-2002  (first entry)
XX
DE   Immunostimulatory nucleic acid SEQ ID NO: 410.
XX
KW   Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW   angiogenesis; metastasis; cytostatic; ss.
XX
OS   Synthetic.
XX
PN   WO200197843-A2.
XX
PD   27-DEC-2001.
XX
PF   22-JUN-2001; 2001WO-US020154.
XX
PR   22-JUN-2000; 2000US-0213346P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Weiner G,  Hartmann G;
XX
DR   WPI; 2002-154611/20.
XX
PT   Treating or preventing cancer, such as basal cell carcinoma, comprises
PT   administering immunostimulatory nucleic acids that induce expression of
PT   cell surface antigens and antibodies to a subject having or at risk of
PT   developing cancer.
XX
PS   Disclosure; Page 199; 312pp; English.
XX
CC   The present invention relates to methods for treating or preventing
CC   cancer, involving administering to a subject having or at risk of
CC   developing cancer immunostimulatory nucleic acids that induce expression
CC   of cell surface antigens and antibodies. The methods are useful for
CC   treating or preventing cancer such as basal cell carcinoma, bladder
CC   cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC   breast cancer, cervical cancer, colon and rectum cancer, connective
CC   tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC   cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC   Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC   cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC   cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC   present sequence is an immunostimulatory oligonucleotide described in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 37
ABQ78545
ID   ABQ78545 standard; DNA; 20 BP.
XX
AC   ABQ78545;
XX
DT   25-NOV-2002  (first entry)
XX
DE   Antisense oligodeoxynucleotide of the human bcl-2 gene.
XX
KW   Antisense oligonucleotide; B cell lymphoma/leukemia-2 gene; bcl-2 gene;
KW   cancer; lymphoma; leukemia; chemotherapeutic agent; bone marrow purging;
KW   autoimmune disease; ss.
XX
OS   Homo sapiens.
XX
PN   US6414134-B1.
XX
PD   02-JUL-2002.
XX
PF   28-NOV-2000; 2000US-00724426.
XX
PR   22-DEC-1988;   88US-00288692.
PR   21-FEB-1992;   92US-00840716.
PR   20-SEP-1993;   93US-00124256.
PR   05-JUN-1995;   95US-00465485.
PR   18-MAY-1998;   98US-00080285.
PR   17-AUG-1999;   99US-00375514.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Reed JC;
XX
DR   WPI; 2002-641579/69.
XX
PT   Novel antisense oligonucleotide complementary to B cell lymphoma/leukemia
PT   -2 mRNA, useful for inhibiting cancer cell growth, for treating
PT   autoimmune disorders, and for ex vivo bone marrow purging.
XX
PS   Disclosure; Fig 13C; 41pp; English.
XX
CC   The present sequence represents an antisense oligonucleotide
CC   complementary to B cell lymphoma/leukemia-2 (bcl-2) mRNA. The antisense
CC   oligonucleotide is useful for inhibiting cancer cell (lymphoma or
CC   leukemia cells) growth, for increasing the sensitivity of cancer cells to
CC   cancer chemotherapeutic agents, or for inducing cancer cell death alone
```

```
CC   or in combination with any one or more cancer chemotherapeutic agents. It
CC   is also useful for reducing the bcl-2 gene expression or impairing bcl-2
CC   protein function, for ex vivo bone marrow purging, for removing residual
CC   malignant cells from the bone marrow, for inhibiting cancer of neoplastic
CC   cell growth, and for treating autoimmune disease
XX
SQ   Sequence 20 BP; 2 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 38
ABL54173
ID   ABL54173 standard; DNA; 20 BP.
XX
AC   ABL54173;
XX
DT   12-JUL-2002  (first entry)
XX
DE   Oligonucleotide.
XX
KW   B cell lymphoma/leukaemia-2; bcl-2; oncogene; antisense; lymphoma;
KW   leukaemia; colon carcinoma; rectal carcinoma; pancreatic cancer;
KW   breast cancer; ovarian cancer; prostate cancer; renal cell carcinoma;
KW   hepatoma; bile duct carcinoma; choriocarcinoma; cervical cancer;
KW   testicular cancer; lung carcinoma; bladder carcinoma; melanoma;
KW   head and neck cancer; brain cancer; cytostatic; human; gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200217852-A2.
XX
PD   07-MAR-2002.
XX
PF   23-AUG-2001; 2001WO-US026414.
XX
PR   25-AUG-2000; 2000US-0227970P.
PR   29-SEP-2000; 2000US-0237009P.
PR   10-NOV-2000; 2000US-00709170.
XX
PA   (GENT-) GENTA INC.
XX
PI   Warrel RP,  Klem RE,  Fingert H;
XX
DR   WPI; 2002-371796/40.
XX
PT   Treating or preventing cancer, tumors and carcinomas, comprises
PT   administering B cell lymphoma/leukemia-2 antisense oligonucleotide at
PT   high doses for short period for time with one or more cancer
PT   therapeutics.
XX
PS   Disclosure; Page 64; 64pp; English.
XX
CC   The present invention is related to the use of a B cell
CC   lymphoma/leukaemia-2 (bcl-2) antisense oligonucleotide, particularly
CC   G3139 (see ABL54148), to treat and prevent bcl-2 related disorders.
CC   Administration at high doses results in significant therapeutic
CC   responses, including low toxicity, high tolerance and prolonged survival.
CC   Administration at high doses for short periods of time (less than 14
CC   days) also provides significant therapeutic responses in the treatment of
CC   cancer. The bcl-2 antisense oligomer may also be used to increase the
CC   sensitivity of a subject to cancer therapeutics, and in combination with
CC   hormone treatment or gene therapy. Conditions that may be treated or
CC   prevented include cancer of the haematopoietic system, skin, bone and
CC   soft tissue, reproductive system, genitourinary system, breast, endocrine
CC   system, brain, central nervous system, peripheral nervous system, kidney,
CC   lung, respiratory system, thorax, gastrointestinal and alimentary canal,
CC   lymph nodes, pancreas, hepatobiliary system, or cancer of unknown primary
CC   site, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukaemia, colon
CC   carcinoma, rectal carcinoma, pancreatic, breast, ovarian, prostate,
CC   cervical, testicular, head and neck or brain cancer, renal cell
CC   carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, lung
CC   carcinoma, bladder carcinoma and melanoma (all claimed). Note: The
CC   present sequence is given in the Sequence Listing from the present
CC   invention but the Seq ID No. is not referred to within the specification
XX
SQ   Sequence 20 BP; 2 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 39
ABZ91148
ID   ABZ91148 standard; DNA; 20 BP.
XX
AC   ABZ91148;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 6390; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
```

```
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        971 GGCCTCAGAACTGCAGCTG 989
              || ||| ||||||||||||
Db          1 GGGCTCTGAACTGCAGCTG 19


RESULT 40
ACD99549
ID   ACD99549 standard; DNA; 20 BP.
XX
AC   ACD99549;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #235.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 15; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 41
ADB36618
ID   ADB36618 standard; DNA; 20 BP.
XX
AC   ADB36618;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #232.
XX
KW   ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW   hypo-responsive subject; immunostimulatory.
XX
OS   Synthetic.
XX
PN   US2003087848-A1.
XX
PD   08-MAY-2003.
XX
PF   02-FEB-2001; 2001US-00776479.
XX
PR   03-FEB-2000; 2000US-0179991P.
XX
PA   (BRAT/) BRATZLER R L.
PA   (PETE/) PETERSEN D M.
PA   (FOUR/) FOURON Y.
XX
PI   Bratzler RL,  Petersen DM,  Fouron Y;
XX
DR   WPI; 2003-657977/62.
XX
PT   Treating and/or preventing allergy or asthma using an immunostimulatory
PT   nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS   Disclosure; Page 8; 221pp; English.
XX
CC   The invention relates to a method of treating or preventing allergy or
CC   asthma which comprises administering to a subject a poly-G nucleic acid
CC   in an aerosol formulation. The methods and compositions of the present
CC   invention are useful for diagnosing and/or treating asthma and allergy
CC   especially in a hypo-responsive subject. The present sequence represents
CC   an immunostimulatory nucleic acid of the invention.
XX
SQ   Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 42
AAZ44349
ID   AAZ44349 standard; DNA; 21 BP.
XX
AC   AAZ44349;
XX
DT   04-APR-2000  (first entry)
XX
DE   Protein kinase inhibiting primer #11.
XX
KW   Antimicrobial; cytostatic; immunosuppressive; protein kinase;
KW   prophylactic; therapy; treatment; cancer; autoimmune disease;
KW   pathogenic microorganism; primer; ss.
XX
```

OS Unidentified.
XX
PN US5998596-A.
XX
PD 07-DEC-1999.
XX
PF 04-APR-1995; 95US-00416214.
XX
PR 04-APR-1995; 95US-00416214.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Bergan R, Neckers L;
XX
DR WPI; 2000-104623/09.
XX
PT Oligonucleotides inhibiting protein kinase, useful for treating diseases
PT such as cancer and autoimmune disease.
XX
PS Example 3; Col 27-28; 26pp; English.
XX
CC This invention describes novel purified aptameric oligonucleotides which
CC have antimicrobial, cytostatic and immunosuppressive activity. The
CC oligonucleotides are useful for binding to and preventing or inhibiting
CC the biological function of a protein kinase or a target molecule and for
CC detecting the presence or absence of a target molecule in biological
CC samples. The oligonucleotides are also useful for prophylactic and
CC therapeutic treatment of diseases such as cancer, autoimmune diseases and
CC diseases caused by pathogenic microorganisms. This sequence represents a
CC primer used in the method of the invention
XX
SQ Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 55;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGCTGCG 131
||||||||||||| || |||
Db 1 GGCGGCGGCGGCGGCGGCG 19

RESULT 43
ABK99279/c
ID ABK99279 standard; RNA; 21 BP.
XX
AC ABK99279;
XX
DT 21-OCT-2002 (first entry)
XX
DE Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #9.
XX
KW Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.
XX
OS Synthetic.
XX
PN US2002064771-A1.
XX
PD 30-MAY-2002.
XX
PF 06-APR-2001; 2001US-00828034.
XX
PR 07-APR-2000; 2000US-0195852P.
XX
PA (ZHON/) ZHONG W.
PA (HONG/) HONG Z.
PA (FERR/) FERRARI E.
XX
PI Zhong W, Hong Z, Ferrari E;
XX
DR WPI; 2002-582330/62.
XX
PT Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3
PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,
PT and template and primer which do not form a stable duplex in the absence
PT of HCV NS5B.
XX
PS Example; Page 6; 17pp; English.
XX
CC The invention relates to a replicase complex comprising a hepatitis C
CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
CC complementary nucleic acid primer which is annealed to the 3' terminus of
CC the template, where the template is at least three nucleotides and the
CC primer is two or three nucleotides, and the template and primer do not
CC form a stable duplex in solution in the absence of the HCV NS5B protein.
CC The complex is useful for detecting HCV replicase activity and permits
CC establishment of sensitive RNA-dependent RNA polymerase assays to screen
CC and evaluate antiviral inhibitors and to improve the specificity and
CC efficacy of the inhibitors. The complex is also useful in the development
CC of a reliable system for determining kinetic and thermodynamic constants
CC of HCV NS5B-catalysed nucleotide incorporation and investigation of
CC mechanistic inhibitors for mis-incorporation or chain termination.
CC Specifically, the short RNA template and primer pairs are useful in
CC screening assays which are used for determining kinetic, thermodynamic
CC and mechanistic properties of NS5B replication and ultimately in the
CC development of inhibitors of NS5B. Newly identified inhibitors of
CC replicase activity may be used for developing anti-HCV pharmaceuticals.
CC Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis
CC templates
XX
SQ Sequence 21 BP; 0 A; 14 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 55;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGCTGCG 131
||||||||||||| || |||
Db 21 GGCGGCGGCGGCGGCGGCG 3

RESULT 44
ABK02337
ID ABK02337 standard; RNA; 17 BP.
XX
AC ABK02337;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Amberzyme #9.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.

```
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 130; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 41;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCAGC 127
              | ||||||||||||||||
Db          1 CCGGCGGCGGCGGCAGC 17


RESULT 45
ABK02338
ID   ABK02338 standard; RNA; 17 BP.
XX
AC   ABK02338;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #10.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 130; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 9 G; 0 T; 0 U; 0 Other;
```

```
  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 41;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||||| ||
Db          1 GCGGCGGCGGCAGCAGC 17


RESULT 46
ABK00765
ID   ABK00765 standard; RNA; 17 BP.
XX
AC   ABK00765;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #35.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 78; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 41;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||| |||||:||
Db          1 GCGGCGGCAGCAGCUGC 17


RESULT 47
AAL51375/c
ID   AAL51375 standard; DNA; 19 BP.
XX
AC   AAL51375;
XX
DT   27-MAR-2003  (first entry)
XX
DE   Human BCL2 gene PCR primer - SEQ ID No 18.
XX
KW   Human; PCR; primer; ss; probe preparation; chromosomal translocation;
KW   fluorescence in-situ hybridisation; FISH; chromosomal re-arrangement;
KW   chromosomal deletion; haematological malignancy; solid tumour.
XX
OS   Homo sapiens.
XX
PN   WO200293130-A2.
XX
PD   21-NOV-2002.
XX
PF   14-MAY-2002; 2002WO-US015492.
XX
PR   14-MAY-2001; 2001US-0291121P.
PR   08-NOV-2001; 2001US-0337653P.
PR   13-FEB-2002; 2002US-0357195P.
XX
PA   (CANC-) CANCER GENETICS INC.
XX
PI   Palanisamy N,  Chaganti RS;
XX
DR   WPI; 2003-120711/11.
XX
PT   Preparing probes for detecting chromosomal re-arrangements and/or
PT   deletions, comprises hybridizing fragments using fluorescence in situ
PT   hybridization.
XX
PS   Example 5; Page 74; 125pp; English.
XX
CC   The invention comprises a method of preparing probes for detecting
CC   chromosomal translocation, the method involves hybridising fragments
CC   using fluorescence in-situ hybridisation (FISH). The method of the
CC   invention is useful for analysing chromosomal re-arrangements and/or
```

```
CC   deletions. The chromosomal re-arrangements may be used as diagnostic and
CC   follow-up markers for haematological malignancies or solid tumours. The
CC   present DNA sequence represents a PCR primer that was used to produce a
CC   probe in the method of the invention
XX
SQ   Sequence 19 BP; 4 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 52;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        606 TGGATCTGAAATGAATC 622
              ||||||  ||||||||||
Db         19 TGGATCAGAAATGAATC 3


RESULT 48
ABZ88038
ID   ABZ88038 standard; DNA; 20 BP.
XX
AC   ABZ88038;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 3280; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 3 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 58;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              |||||||| ||||||||
Db          1 GCGGCGGCAGCAGCTGC 17


RESULT 49
AAQ52305/c
ID   AAQ52305 standard; cDNA; 20 BP.
XX
AC   AAQ52305;
XX
DT   25-MAR-2003  (revised)
DT   03-JUN-1994  (first entry)
XX
DE   FKBP12C PCR primer VX10201.
XX
KW   Transplant rejection; monitoring; FK506 immunosuppressant therapy;
KW   tissue specific; polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9323548-A2.
XX
PD   25-NOV-1993.
XX
PF   20-MAY-1993;   93WO-US004916.
XX
PR   20-MAY-1992;   92US-00886611.
XX
PA   (VERT-) VERTEX PHARM INC.
XX
PI   Peattie DA;
XX
DR   WPI; 1993-386579/48.
XX
PT   New cDNA for tissue specific FK506 binding proteins - and detection of
PT   its mRNA to monitor transplant rejection and effect or FK506
PT   immunosuppressant therapy.
XX
PS   Example 4; Page 35; 54pp; English.
XX
CC   The sequence is that of a PCR primer VX10201 which was used to amplify
CC   DNA specific to FKBP12C. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 1 A; 11 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCGC 132
              ||||||||||| |||| ||
Db         20 GGCGGCGGCGGACGCTGAGC 1


RESULT 50
AAT41334/c
ID   AAT41334 standard; DNA; 20 BP.
XX
AC   AAT41334;
XX
DT   04-DEC-1996  (first entry)
```

XX
DE Human gene signature HUMGS00732-derived anti-sense primer.
XX
KW Gene signature; messenger RNA; mRNA; relative abundance; frequency;
KW human; cloning; mapping; non-biased library; diagnosis; detection;
KW cell typing; abnormal cell function; primer; PCR; amplification;
KW polymerase chain reaction; ss.
XX
OS Synthetic.
XX
PN WO9514772-A1.
XX
PD 01-JUN-1995.
XX
PF 11-NOV-1994; 94WO-JP001916.
XX
PR 12-NOV-1993; 93JP-00355504.
XX
PA (MATS/) MATSUBARA K.
PA (OKUB/) OKUBO K.
XX
PI Matsubara K, Okubo K;
XX
DR WPI; 1995-206931/27.
XX
PT Single-stranded DNA for identifying gene signatures - isolated from 3'-
PT directed human cDNA library that reflects relative abundance of corresp.
PT mRNA in specific human tissues.
XX
PS Example 7; Fig 10; 2245pp; Japanese.
XX
CC Primers T41001-T41382 are derived from novel human gene signature (GS)
CC sequences which did not match with sequences deposited in Genbank release
CC 76. The GS sequences (T19001-T26837) were obtained from 3'-directed cDNA
CC libraries prepared from various human tissues; synthesis of cDNA was
CC initiated from the 3'-end of mRNA by using poly(T) as the sole primer.
CC Each library is constructed so as to reflect accurately the relative
CC abundance of different mRNAs in the particular tissue from which it was
CC derived. The appearance frequency of a given GS in a cDNA library can be
CC determined (esp. using primers and probes derived from the GS sequences)
CC as a means of diagnosing abnormal cell function or for recognising
CC different cell types. The primers T41333-4 amplify clone pml452 which
CC comprises the GS HUMGS000732 (T19732). This amplification reaction gave a
CC prod. indistinguisable from the same PCR using mouse or Chinese hamster
CC ovary DNA as a template
XX
SQ Sequence 20 BP; 2 A; 5 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.5%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        604 GATGGATCTGAAATGAATCA 623
              || ||| |||||||||| ||
Db         20 GAAGGAACTGAAATGAACCA 1
```

RESULT 51
AAZ06414
ID AAZ06414 standard; DNA; 20 BP.
XX
AC AAZ06414;
XX
DT 09-NOV-1999 (first entry)
XX
DE Primer C for PCR of gamma-4 germline transcription initiation sites.
XX
KW Immunoglobulin G4; allergy; germline; transcription; Ig G4; promoter;
KW assay; blocking antibody; inhibition; RT-PCR; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9941380-A1.
XX
PD 19-AUG-1999.
XX
PF 08-FEB-1999; 99WO-IT000026.
XX
PR 10-FEB-1998; 98IT-MI000252.
XX
PA (VERC/) VERCELLI D.
PA (AGRE/) AGRESTI A.
XX
PI Vercelli D, Agresti A;
XX
DR WPI; 1999-518450/43.
XX
PT Promoter for gamma4 germline transcription, used for, e.g. screening for
PT anti-allergic compounds.
XX
PS Disclosure; Fig 2; 34pp; English.
XX
CC This primer sequence was used to identify the region where gamma-4
CC germline transcription initiates. Reverse transcription polymerase chain
CC reaction was performed using 5' primers AAZ06412, AAZ06413, AAZ06414 and
CC AAZ06415. The primer binding site were located approximately 150 bp from
CC each other in the 500 bp region upstream of the I-gamma-4 forward primer.
CC Hinge gamma-4 reverse oligonucleotide was used as a reverse primer
XX
SQ Sequence 20 BP; 3 A; 4 C; 12 G; 1 T; 0 U; 0 Other;

Query Match 1.5%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        367 GAGCCCGGGGAGAAGCGGGC 386
              ||| | ||||||| ||||||
Db          1 GAGGCTGGGGAGACGCGGGC 20
```

RESULT 52
AAZ71977/c
ID AAZ71977 standard; DNA; 20 BP.
XX
AC AAZ71977;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:6333.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.

```
XX
PS   Claim 9; Page 1581; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 20 BP; 2 A; 7 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        550 GAAAGGAGAAATAGGCGAGG 569
              |||| ||||||||||  |||
Db         20 GAAATGAGAAATAGGAAAGG 1


RESULT 53
AAF31798
ID   AAF31798 standard; DNA; 20 BP.
XX
AC   AAF31798;
XX
DT   10-APR-2001  (first entry)
XX
DE   Human RANK antisense oligonucleotide, SEQ ID NO: 56.
XX
KW   Human; cytostatic; antiinflammatory; antisense oligonucleotide; cancer;
KW   receptor activator of NF-kappaB; RANK; infection; inflammation; ss.
XX
OS   Homo sapiens.
XX
PN   US6171860-B1.
XX
PD   09-JAN-2001.
XX
PF   05-NOV-1999;   99US-00435296.
XX
PR   05-NOV-1999;   99US-00435296.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM;
XX
DR   WPI; 2001-136876/14.
XX
PT   Novel antisense compounds capable of modulating expression of human
PT   receptor activator of NF-kappaB useful for diagnosis, prophylaxis and
PT   treatment of diseases associated with expression of RANK.
XX
PS   Claim 14; Col 43; 40pp; English.
XX
CC   The present sequence is one of a number of antisense compounds of 8 to 30
CC   nucleobases in length that have been designed to target a 5'untranslated
CC   region, start codon, coding region or 3'untranslated region of the human
CC   receptor activator of NF-kappaB (RANK). The antisense compounds
CC   specifically hybridise with and inhibit the expression of RANK. The
CC   antisense oligonucleotides are useful for inhibiting the expression of
CC   human RANK in human cells or tissues. They can be utilised for
CC   diagnostics, therapeutics for the treatment of diseases associated with
CC   the expression of RANK, prophylaxis e.g. to prevent or delay infection,
CC   inflammation or tumour formation, and as research reagent. The antisense
CC   compounds are safely and effectively administered to humans
XX
SQ   Sequence 20 BP; 1 A; 13 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        294 CAGCCGGCGCGGCGCCCACC 313
              |||||| ||| |||||| ||
Db          1 CAGCCGCCGCCGCGCCCTCC 20


RESULT 54
AAD15646/c
ID   AAD15646 standard; DNA; 20 BP.
XX
AC   AAD15646;
XX
DT   15-NOV-2001  (first entry)
XX
DE   Human Bcl-2 protein target DNA #20.
XX
KW   Human; Bcl-2 protein; genetic disease; antisense target; therapeutic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200161030-A2.
XX
PD   23-AUG-2001.
XX
PF   14-FEB-2001; 2001WO-US004732.
XX
PR   14-FEB-2000; 2000US-00504653.
XX
PA   (BOLL/) BOLLON A P.
PA   (GRAY/) GRAY D M.
PA   (JUSE/) JU-SEOG L.
XX
PI   Bollon AP,  Gray DM,  Ju-Seog L;
XX
DR   WPI; 2001-529916/58.
XX
PT   Selecting optimal subsequence antisense targets for inhibition of mRNA
PT   expression of target mRNA for the therapeutic treatment of genetic
PT   disease.
XX
PS   Example 9; Page 28; 87pp; English.
XX
CC   The invention relates to a method for selecting optimal subsequence
CC   antisense targets. The method involves preparing an antisense
CC   oligonucleotide capable of inhibiting mRNA expression of target mRNA
CC   sequences, as well as antisense oligonucleotides capable of binding DNA.
CC   The antisense and antigene libraries are useful for preparing therapeutic
CC   agents for the treatment of genetic disease. The present DNA sequence is
CC   human Bcl-2 protein target DNA related to the invention. Note: The
CC   present sequence is shown as DNA in the specification; however, in vivo,
CC   this target sequence would be mRNA
XX
SQ   Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        299 GGCGCGGCGCCCACCTTACC 318
              |||||||||||||| |  ||
Db         20 GGCGCGGCGCCCACATCTCC 1


RESULT 55
```

```
AAH46290/c
ID   AAH46290 standard; DNA; 20 BP.
XX
AC   AAH46290;
XX
DT   25-SEP-2001  (first entry)
XX
DE   Human interferon regulatory factor-1 (IRF-1) reverse RFLP PCR primer.
XX
KW   Human; interferon regulatory factor-1; IRF-1; promoter; upstream region;
KW   genotyping; polymorphism; hepatitis C virus; HCV infection;
KW   interferon therapy efficacy; IFN; RFLP analysis;
KW   restriction fragment length polymorphism; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001136973-A.
XX
PD   22-MAY-2001.
XX
PF   16-NOV-1999;   99JP-00324975.
XX
PR   16-NOV-1999;   99JP-00324975.
XX
PA   (SAKA ) OTSUKA PHARM CO LTD.
XX
DR   WPI; 2001-460211/50.
XX
PT   Detection of abnormal human interferon regulatory factor-1 (IRF-1) gene.
XX
PS   Example 2; Page 6; 8pp; Japanese.
XX
CC   The invention relates to a method for the detection of an abnormal allele
CC   of the human interferon regulatory factor-1 (IRF-1) gene. The abnormal
CC   allele (AAH46293) is present in PLC/PRF/5 liver cancer cells and contains
CC   a G to A substitution at position 196 of the IRF-1 promoter region
CC   (normal alleles given in AAH46293 and AAH46294). The abnormal allele
CC   confers an insensitivity to the effects of interferon (IFN). In the
CC   method of the invention, the presence or absence of adenine at position
CC   196 of the IRF-1 promoter is detected using procedures such as
CC   restriction fragment length polymorphism (RFLP) analysis. Prior to
CC   analysis, an IRF-1 gene fragment containing the polymorphic site can
CC   optionally be prepared (e.g., by PCR). The invention also discloses the
CC   use of IRF-1 gene fragments as probes to detect the A polymorphism. The
CC   method of the invention is used to genotype a patient with hepatitis C
CC   virus (HCV) infection in order to predict whether interferon therapy will
CC   be effective. Sequences AAH46289-AAH46290 represent PCR primers used in
CC   an exemplification of the invention to amplify wild-type and polymorphic
CC   IRF-1 promoter region fragments containing the position 196 polymorphic
CC   site for RFLP analysis
XX
SQ   Sequence 20 BP; 6 A; 3 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        203 CCTCGACTTCCCCGTCGCCG 222
              |||  |||||||| ||||||
Db         20 CCTGTACTTCCCCTTCGCCG 1


RESULT 56
ABZ88026/c
ID   ABZ88026 standard; DNA; 20 BP.
XX
AC   ABZ88026;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 3268; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 62;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        155 ACCAGCTGCCTGAGCAGCCG 174
              |||||||| ||||| ||| |
Db         20 ACCAGCTGACTGAGGAGCAG 1


RESULT 57
ABZ98578
ID   ABZ98578 standard; DNA; 20 BP.
XX
AC   ABZ98578;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human ICAM oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
```

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13820; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 6 C; 13 G; 0 T; 0 U; 0 Other;

Query Match 1.5%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 84 GGGCAGCGGGGGCCGCGAGC 103
||||||||| |||||| | ||
Db 1 GGGCAGCGCGGGCCGGGGGC 20

RESULT 58
AAF45311/c
ID AAF45311 standard; DNA; 15 BP.
XX
AC AAF45311;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #150.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 35; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 0 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.5%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGC 127
||||||||||||||
Db 15 GGCGGCGGCGGCAGC 1

RESULT 59
ABK01789
ID ABK01789 standard; RNA; 17 BP.
XX
AC ABK01789;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Zinzyme #111.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;

KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 97; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zinzyme molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 1.5%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 113 GGCGGCGGCGGCAGC 127
||||||||||||||
Db 2 GGCGGCGGCGGCAGC 16

RESULT 60
ABZ61434
ID ABZ61434 standard; RNA; 17 BP.
XX
AC ABZ61434;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #225.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 115; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.5%; Score 15; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 48;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 767 CCCCAGTGCCTTTTC 781
||||||:|||:::|
Db 2 CCCCAGUGCCUUUUC 16

RESULT 61
AAQ96137/c
ID AAQ96137 standard; DNA; 18 BP.
XX

```
AC   AAQ96137;
XX
DT   13-APR-1996  (first entry)
XX
DE   Human C-beta-internal DNA primer.
XX
KW   Diabetes; adoptive immunotherapy; gene therapy;
KW   T-cell receptor beta-chain; PCR; polymerase chain reaction; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9521623-A1.
XX
PD   17-AUG-1995.
XX
PF   10-FEB-1995;   95WO-US001572.
XX
PR   14-FEB-1994;   94US-00195963.
XX
PA   (UYVE-) UNIV VERMONT.
XX
PI   Albertini RJ,  Falta MT;
XX
DR   WPI; 1995-292941/38.
XX
PT   Preventing or reducing severity of diabetes - by inhibiting the activity
PT   of specific T-cells, partic. by interfering with diabetes-associated T
PT   cell receptors.
XX
PS   Example; Page 20; 42pp; English.
XX
CC   The T-cell receptor beta chain repertoire of normal and diabetic
CC   individuals was examined by PCR amplification of cDNA using the primers
CC   given in AAQ96135-37, with sequencing of the product using the primer
CC   given in AAQ96138. The results indicated predominant usage of V-beta-6 or
CC   V-beta-14 in diabetics
XX
SQ   Sequence 18 BP; 3 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 55;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        161 TGCCTGAGCAGCCGC 175
              |||||||||||||||
Db         15 TGCCTGAGCAGCCGC 1


RESULT 62
AAQ31559/c
ID   AAQ31559 standard; DNA; 19 BP.
XX
AC   AAQ31559;
XX
DT   25-MAR-2003  (revised)
DT   20-APR-1993  (first entry)
XX
DE   NF-kB anti-sense primer for tissue distribution analysis by PCR.
XX
KW   IkappaB; NF-kappa-B-binding protein; inhibits NF-kappa-B-;
KW   transcriptional activator; treatment of viral diseases; IkB; cytokines;
KW   viral proteins; immunoglobulin; Antibody.
XX
OS   Homo sapiens.
XX
PN   WO9220795-A1.
XX
PD   26-NOV-1992.
XX
PF   14-MAY-1992;   92WO-US004073.
XX
PR   17-MAY-1991;   91US-00702770.
XX
PA   (CETU ) CETUS ONCOLOGY CORP.
PA   (UYNC-) UNIV NORTH CAROLINA.
XX
PI   Haskill JS,  Baldwin AS,  Ralph P;
XX
DR   WPI; 1992-415773/50.
XX
PT   New NF- kappa-B-binding protein which inhibits NF- kappa-B
PT   transcriptional activator - useful for diagnosing, treating and
PT   preventing diseases resulting from gene over-expression.
XX
PS   Example 4; Page 26; 40pp; English.
XX
CC   This sequence represents an anti-sense PCR primer used for the PCR
CC   determination of IkB inhibitor tissue distribution. Total RNA was
CC   isolated from the tissue under test and converted into first strand DNA
CC   using random hexamers. So that transcript frequencies could be compared
CC   from one tissue type to another dose response curves were determined at
CC   the same PCR cycle (30) as test samples. Standards included IkB cDNA at
CC   various dilutions, as well as RNA isolated from monocytes that had
CC   adhered for 4 hours to a substratum that induces IkB expression. This
CC   primer was used with AAQ31558. The analysis revealed IkB expression in
CC   HSB and RAJI cells, glioblastoma cells, G82, HUVE cells. The amount of
CC   IkB could be increased by activation of HUVE cells by LPS, causing
CC   approx. a 9 fold increase in IkB expression. Adherence of HUVE cells
CC   caused an 80 fold increase in expression. Expression of NF-kB was also
CC   shown for To and 4 hour plastic adherent monocytes. IkB was also observed
CC   to be present in several melanoma cell lines, and the level of expression
CC   is enhanced 2-3fold by exposure to PMA, but little or no increase is seen
CC   after IL-2 or TNF exposure. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 19 BP; 2 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 15;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         16 CTGGAAGCACGAATG 2


RESULT 63
AAV30475
ID   AAV30475 standard; DNA; 18 BP.
XX
AC   AAV30475;
XX
DT   14-OCT-1998  (first entry)
XX
DE   Canine beta-3 adrenergic receptor antisense primer TR21.
XX
KW   Canine; beta-adrenergic receptor; brown adipose tissue; probe; human;
KW   hybridisation; ligand; primer; ss.
XX
OS   Synthetic.
OS   Canis familiaris.
XX
PN   WO9735973-A2.
XX
PD   02-OCT-1997.
XX
PF   26-MAR-1997;   97WO-FR000537.
XX
PR   26-MAR-1996;   96FR-00003730.
XX
PA   (VETI-) VETIGEN.
XX
PI   Lenzen G,  Pietri-Rouxel F,  Drumare M,  Strosberg AD;
XX
DR   WPI; 1998-032136/03.
XX
PT   Canine beta 2 and beta 3 adrenergic receptors and coding sequences -
```

PT useful for identifying specific ligands and (ant)agonists to develop
PT specific treatments for obesity in dogs.
XX
PS Claim 17; Page 49; 79pp; French.
XX
CC Primers AAV30470-V30490 were used for sequencing the coding region of the
CC canine beta 3-adrenergic receptor (RA-Ca-b3) gene (AAV30469). RA-Ca-b3
CC has been implicated in obesity and obesity-related metabolic disorders
CC e.g. diabetes. The canine version of RA-Ca-b3 can be used to develop
CC treatments specific for dogs. The sequence can also be used in
CC differential screening for ligands for RA-Ca-b3 as compared to the beta-2
CC adrenergic receptor (AAW44932)
XX
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 59;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 390 CGCCGCCGAGCCGTCTCC 407
||||||| ||| |||||||
Db 1 CGCCGCAGAGACGTCTCC 18

RESULT 64
AAV94820
ID AAV94820 standard; RNA; 18 BP.
XX
AC AAV94820;
XX
DT 24-FEB-1999 (first entry)
XX
DE Human IL-2 receptor g-chain substrate position 58.
XX
KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
OS Homo sapiens.
XX
PN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
PF 02-DEC-1997; 97WO-US021748.
XX
PR 03-DEC-1996; 96US-00758306.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen JA;
XX
DR WPI; 1998-333332/29.
XX
PT Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
PT autoimmune disease and allergies.
XX
PS Claim 4; Page 38; 61pp; English.
XX
CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC and other inflammatory conditions. The ribozymes are also used to induce
CC tolerance in a recipient to alloantigen from a donor
XX
SQ Sequence 18 BP; 1 A; 9 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 59;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 405 TCCTGCAGCGGCCCCCGC 422
:||:||||| ||||| ||
Db 1 UCCUGCAGCUGCCCCUGC 18

RESULT 65
AAZ48883/c
ID AAZ48883 standard; DNA; 18 BP.
XX
AC AAZ48883;
XX
DT 29-MAR-2000 (first entry)
XX
DE Human ICAM-1 antisense inhibitor, ISIS #16861.
XX
KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.
XX
OS Homo sapiens.
XX
PN WO9961462-A1.
XX
PD 02-DEC-1999.
XX
PF 26-MAY-1999; 99WO-US011548.
XX
PR 27-MAY-1998; 98US-00085759.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Baker BF;
XX
DR WPI; 2000-072600/06.
XX
PT New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX
PS Claim 5; Page 193; 199pp; English.
XX
CC This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell:cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus

```
CC   vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC   myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC   myocarditis, ischaemic heart disease or stroke
XX
SQ   Sequence 18 BP; 1 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 59;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         27 AGGAGCCCTCAAGGCGAG 44
              |||||| ||||||| |||
Db         18 AGGAGCACTCAAGGGGAG 1


RESULT 66
ADA27361
ID   ADA27361 standard; DNA; 18 BP.
XX
AC   ADA27361;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human microsatellite repeat M2_3_8.
XX
KW   ds; HLA-related research; HLA class II-associated disease;
KW   transplantation matching; recombination hot spot identification;
KW   linkage disequilibrium study; human; microsatellite.
XX
OS   Homo sapiens.
XX
PN   US2003108940-A1.
XX
PD   12-JUN-2003.
XX
PF   06-DEC-2002; 2002US-00314405.
XX
PR   15-NOV-2000; 2000US-00713616.
XX
PA   (INOK/) INOKO H.
XX
PI   Inoko H,  Tamiya G,  Matsuzaka Y;
XX
DR   WPI; 2003-616782/58.
XX
PT   New oligonucleotide primer capable of specifically hybridizing to a DNA
PT   having the sequence of the flanking regions of a microsatellite (e.g.
PT   M249), useful for HLA-related research, e.g. transplantation matching.
XX
PS   Example 2; Page 5; 20pp; English.
XX
CC   The invention relates to an oligonucleotide primer capable of
CC   specifically hybridising to a DNA having the sequence of the flanking
CC   regions of a microsatellite selected from M2-4-9, M2-2-9, M2-2-12, M2-3-
CC   11, M2-2-20, M2-2-21, M2-2-22, M2-2-23, M2-2-24, M2-4-25, M2-4-26, M2-2-
CC   29, M2-2-32, M2-4-32, M2-4-33, M2-4-37, M2-3-22, M2-2-36, M2-5-11, M2-2-
CC   46, and M2-2-48. The primer is useful for determining the number of
CC   repeat units of the microsatellite cited above. The primer is useful in
CC   HLA-related research, such as genetic mapping of HLA class II-associated
CC   diseases, transplantation matching, population genetics, and
CC   identification of recombination hot spots as well as linkage
CC   disequilibrium studies. The present sequence represents the human
CC   microsatellite repeat M2_3_8.
XX
SQ   Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 59;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCG 131
              |||||||||||  || |||
Db          1 GCGGCGGCGGCGGCGGCG 18


RESULT 67
AAX55144
ID   AAX55144 standard; DNA; 19 BP.
XX
AC   AAX55144;
XX
DT   05-JUL-1999  (first entry)
XX
DE   C/EBP-beta antisense oligonucleotide fragment.
XX
KW   Antisense oligonucleotide; multiple target; antisense treatment;
KW   impaired respiration; inflammation; lung disease;
KW   pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW   acute asthma; allergy; asthma; impeded respiration;
KW   respiratory distress syndrome; pain; cystic fibrosis;
KW   pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW   chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW   colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW   hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW   prostate cancer; ss.
XX
OS   Synthetic.
XX
PN   WO9913886-A1.
XX
PD   25-MAR-1999.
XX
PF   17-SEP-1998;   98WO-US019419.
XX
PR   17-SEP-1997;   97US-0059160P.
PR   09-JUN-1998;   98US-00093972.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW;
XX
DR   WPI; 1999-229400/19.
XX
PT   New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT   vasoconstriction.
XX
PS   Disclosure; Page 72; 120pp; English.
XX
CC   The specification describes antisense oligonucleotides (AAX52869-X55271)
CC   directed against at least 2 mRNAs selected from target genes, coding and
CC   non-coding regions of RNAs corresponding to target genes, gene initiation
CC   codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'
CC   -end and the juxta-section between coding and non-coding regions and all
CC   segments of RNAs encoding proteins associated with one or more diseases,
CC   conditions or mixtures. The antisense oligonucleotides may be derived
CC   from sequences AAX55272-74. These multiple target oligonucleotides
CC   (specifically AAX55180-271) can be used for the antisense treatment of
CC   diseases and conditions. Typical diseases and conditions are those
CC   associated with impaired respiration and inflammation, including lung
CC   diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC   acute asthma, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC   pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC   disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC   colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC   hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC   well as all types of cancers which may metastasize or have metastasized
CC   to the lungs, including breast and prostate cancer
XX
SQ   Sequence 19 BP; 0 A; 9 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 66;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         47 GCGCGCGCGCGGCTGCCG 64
```

```
                    |||| ||||| |||||||
Db          1 GCGCTCGCGCCGCTGCCG 18


RESULT 68
AAA34591
ID   AAA34591 standard; DNA; 19 BP.
XX
AC   AAA34591;
XX
DT   28-JUL-2000  (first entry)
XX
DE   Human adenosine receptor related polynucleotide SEQ ID NO:2280.
XX
KW   Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW   phosphorothioate; impaired respiration; inflammation; allergy;
KW   allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW   antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW   lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW   respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW   pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW   cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200009525-A2.
XX
PD   24-FEB-2000.
XX
PF   03-AUG-1999;   99WO-US017712.
XX
PR   03-AUG-1998;   98US-0095212P.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW;
XX
DR   WPI; 2000-205971/18.
XX
PT   New antisense oligonucleotides useful for treating e.g. pulmonary
PT   vasoconstruction, inflammation, allergies, asthma, hypertension,
PT   bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT   cancers.
XX
PS   Disclosure; Page 550; 1343pp; English.
XX
CC   The present invention describes a new composition comprising an antisense
CC   oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC   nucleic acids involved in bronchoconstriction, allergies, and/or
CC   inflammation. The ON can have antiinflammatory, antiallergic,
CC   antiasthmatic, cytostatic and analgesic activities. The compositions are
CC   useful for the treatment of diseases associated with inflammation,
CC   impaired airways, including lung disease and diseases whose secondary
CC   effects afflict the lungs of a subject. They can be used for treating
CC   e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC   impeded respiration, respiratory distress syndrome, pain, cystic
CC   fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC   pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC   carcinomas, and cancers which may metastasise to the lungs, including
CC   breast and prostate cancer. The reduction of the adenosine content of the
CC   ONs reduces side effects. The A-containing ONs break down with the
CC   release of deoxyadenosine which activates adenosine receptors causing
CC   bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC   nucleotide sequences given in the sequence listing from the present
CC   invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC   sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC   from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC   AAA33992) are specifically claimed ONs from the present invention. N.B.
CC   Sequences given in the disclosure of the present invention do not match
CC   up with their corresponding SEQ ID NO: sequences given in the sequence
CC   listing
XX
SQ   Sequence 19 BP; 0 A; 9 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 66;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         47 GCGCGCGCGCGGCTGCCG 64
              |||| ||||| |||||||
Db          1 GCGCTCGCGCCGCTGCCG 18


RESULT 69
AAA82751/c
ID   AAA82751 standard; DNA; 19 BP.
XX
AC   AAA82751;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk3 ribozyme binding site #36.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 51; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 66;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        783 GAGTGGCAGAATCACACC 800
              |||||||||||| | ||||
Db         19 GAGTGGCAGAAACTCACC 2


RESULT 70
AAA82752/c
ID   AAA82752 standard; DNA; 19 BP.
XX
AC   AAA82752;
XX
DT   04-DEC-2000  (first entry)
XX
DE   cdk3 ribozyme binding site #37.
```

XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 51; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 3 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 783 GAGTGGCAGAATCACACC 800
||||||||||| | ||||
Db 18 GAGTGGCAGAAACTCACC 1

RESULT 71
AAF20713
ID AAF20713 standard; DNA; 19 BP.
XX
AC AAF20713;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human C/EBP polynucleotide fragment #2280.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US008020.
XX
PR 06-APR-1999; 99US-0127958P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
PS Claim 14; Page 266; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX
SQ Sequence 19 BP; 0 A; 9 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 47 GCGCGCGCGCGGCTGCCG 64
|||| ||||| |||||||
Db 1 GCGCTCGCGCCGCTGCCG 18

RESULT 72
AAH57913/c
ID AAH57913 standard; DNA; 19 BP.
XX
AC AAH57913;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cell-cycle dependent kinase cdk3 ribozyme binding site SEQ ID NO:337.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 96; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 783 GAGTGGCAGAATCACACC 800
||||||||||| | ||||
Db 19 GAGTGGCAGAAACTCACC 2

RESULT 73
AAH57914/c
ID AAH57914 standard; DNA; 19 BP.
XX
AC AAH57914;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cell-cycle dependent kinase cdk3 ribozyme binding site SEQ ID NO:338.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 96; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 3 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 783 GAGTGGCAGAATCACACC 800
||||||||||| | ||||
Db 18 GAGTGGCAGAAACTCACC 1

RESULT 74
ABZ96407
ID ABZ96407 standard; DNA; 19 BP.
XX
AC ABZ96407;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human C/EBP antisense fragment no.2267.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

```
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI   Miller S, Tang L, Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 11649; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 19 BP; 0 A; 9 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 66;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         47 GCGCGCGCGCGGCTGCCG 64
              |||| ||||| |||||||
Db          1 GCGCTCGCGCCGCTGCCG 18


RESULT 75
AAV62480/c
ID   AAV62480 standard; mRNA; 17 BP.
XX
AC   AAV62480;
XX
DT   18-JAN-1999  (first entry)
XX
DE   Antisense oligonucleotide to human MAP kinases, ERK-1 and ERK-2.
XX
KW   ERK-1; ERK-2; mitogen-activated protein kinase; MAP kinase; human;
KW   inhibition; malignant; neoplastic growth; epithelial cell; mammal;
KW   endothelial cell; antisense oligonucleotide; primary cancer;
KW   metastatic cancer; breast cancer; prostate cancer; angiosarcoma;
KW   endocrine tissue cancer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9844101-A1.
XX
PD   08-OCT-1998.
XX
PF   19-MAR-1998;   98WO-US005471.
XX
PR   28-MAR-1997;   97US-00827520.
PR   01-APR-1997;   97US-00831994.
PR   12-AUG-1997;   97US-00909742.
XX
PA   (UYNY ) UNIV NEW YORK STATE RES FOUND.
XX
PI   Sivaraman VS, Wang H, Malbon CC;
XX
DR   WPI; 1998-557109/47.
XX
PT   Treatment of e.g. breast or prostate cancer or angiosarcoma - by
PT   administering antisense oligonucleotides to genes encoding mitogen-
PT   activating protein kinases ERK1 and ERK2.
XX
PS   Claim 5; Page 41; 59pp; English.
XX
CC   Sequences AAV62480 and AAV62481 represent antisense oligonucleotides to
CC   the the human mitogen-activated protein (MAP) kinases, ERK-1 and ERK-2.
CC   These oligonucleotides are used in the method of the invention for
CC   inhibiting malignant neoplastic growth of epithelial or endothelial cell
CC   in a mammal. The method comprises administering to the mammal an
CC   effective amount of an oligonucleotide complementary to part of the mRNA
CC   for the MAP kinases, ERK-1 or ERK2 which is over-expressed in the mammal.
CC   Also provided is a method for identifying and monitoring potentially
CC   malignant neoplastic cells by measuring the levels of ERK1 and ERK2 mRNA
CC   in epithelial or endothelial cells and comparing it to the levels from
CC   normal cells of the same origin. Administration of the ERK1 and ERK2
CC   antisense oligonucleotides to neoplastic endothelial or epithelial cells
CC   inhibits over-expression of ERK1 and ERK2. This can be used to treat
CC   epithelial and endothelial malignancies including primary or metastatic
CC   cancers of e.g. the breast, prostate, other endocrine tissue or
CC   angiosarcoma
XX
SQ   Sequence 17 BP; 1 A; 10 C; 5 G; 0 T; 1 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 76
AAV62481/c
ID   AAV62481 standard; DNA; 17 BP.
XX
AC   AAV62481;
XX
DT   18-JAN-1999  (first entry)
XX
DE   Antisense oligonucleotide to human MAP kinases, ERK-1 and ERK-2.
XX
KW   ERK-1; ERK-2; mitogen-activated protein kinase; MAP kinase; human;
KW   inhibition; malignant; neoplastic growth; epithelial cell; mammal;
KW   endothelial cell; antisense oligonucleotide; primary cancer;
KW   metastatic cancer; breast cancer; prostate cancer; angiosarcoma;
KW   endocrine tissue cancer; ss.
XX
```

OS Synthetic.
OS Homo sapiens.
XX
PN WO9844101-A1.
XX
PD 08-OCT-1998.
XX
PF 19-MAR-1998; 98WO-US005471.
XX
PR 28-MAR-1997; 97US-00827520.
PR 01-APR-1997; 97US-00831994.
PR 12-AUG-1997; 97US-00909742.
XX
PA (UYNY) UNIV NEW YORK STATE RES FOUND.
XX
PI Sivaraman VS, Wang H, Malbon CC;
XX
DR WPI; 1998-557109/47.
XX
PT Treatment of e.g. breast or prostate cancer or angiosarcoma - by
PT administering antisense oligonucleotides to genes encoding mitogen-
PT activating protein kinases ERK1 and ERK2.
XX
PS Claim 5; Page 41; 59pp; English.
XX
CC Sequences AAV62480 and AAV62481 represent antisense oligonucleotides to
CC the the human mitogen-activated protein (MAP) kinases, ERK-1 and ERK-2.
CC These oligonucleotides are used in the method of the invention for
CC inhibiting malignant neoplastic growth of epithelial or endothelial cell
CC in a mammal. The method comprises administering to the mammal an
CC effective amount of an oligonucleotide complementary to part of the mRNA
CC for the MAP kinases, ERK-1 or ERK2 which is over-expressed in the mammal.
CC Also provided is a method for identifying and monitoring potentially
CC malignant neoplastic cells by measuring the levels of ERK1 and ERK2 mRNA
CC in epithelial or endothelial cells and comparing it to the levels from
CC normal cells of the same origin. Administration of the ERK1 and ERK2
CC antisense oligonucleotides to neoplastic endothelial or epithelial cells
CC inhibits over-expression of ERK1 and ERK2. This can be used to treat
CC epithelial and endothelial malignancies including primary or metastatic
CC cancers of e.g. the breast, prostate, other endocrine tissue or
CC angiosarcoma
XX
SQ Sequence 17 BP; 1 A; 10 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1
```

RESULT 77
AAZ46753
ID AAZ46753 standard; DNA; 17 BP.
XX
AC AAZ46753;
XX
DT 27-MAR-2000 (first entry)
XX
DE Heterologous duplex flanking polynucleotide sequence.
XX
KW Genetic regulatory region; gene expression; DPRS; DFPS; gene therapy;
KW duplex polynucleotide regulatory sequence; transcription factor;
KW duplex flanking polynucleotide sequence; biopharmaceutical; cytostatic;
KW antiproliferative; ss.
XX
OS Synthetic.
XX
PN WO9963074-A2.
XX
PD 09-DEC-1999.
XX
PF 04-JUN-1999; 99WO-US012515.
XX
PR 04-JUN-1998; 98US-0087945P.
PR 03-JUN-1999; 99US-00323244.
XX
PA (TMTE-) TM TECHNOLOGIES INC.
XX
PI Lane MJ, Benight AS, Faldasz BD;
XX
DR WPI; 2000-086976/07.
XX
PT DNA sequences useful for modifying the expression of genes by altering
PT flanking regions of regulatory regions.
XX
PS Claim 3; Page 21; 29pp; English.
XX
CC The invention provides DNA sequences comprising altered nucleotide
CC sequence in the regions flanking a genetic regulatory region, useful for
CC modifying the expression of genes. The DNA sequences comprise a duplex
CC polynucleotide regulatory sequence (DPRS) of sequences with at least 80%
CC homology to AAZ46751-52, adjacent to and 3' of a heterologous duplex
CC flanking polynucleotide sequence (DFPS) of sequences with at least 80%
CC homology to AAZ46753-54, where the heterologous DFPS confers a relatively
CC higher binding affinity for a ligand to the DPRS as compared to the
CC naturally occurring DFPSs. The methods and constructs can be used for
CC increasing or decreasing the expression levels of genes. They can be used
CC to provide binding or transcription factors and/or RNA polymerases to
CC bind to a promoter with relatively higher or lower binding affinities, to
CC increase the cellular output of a biopharmaceutical and increase the
CC expression of a gene in vivo, e.g. to induce premature death of unwanted
CC cells or cells that have lost control of their own growth. Alternatively,
CC they can be utilized to reduce and even entirely inhibit the expression
CC of undesirable genes whose protein products can lead to the manifestation
CC of pathological conditions
XX
SQ Sequence 17 BP; 1 A; 5 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy         93 GGGCCGCGAGCGGGCG 108
              |||||||| |||||||
Db          1 GGGCCGCGGGCGGGCG 16
```

RESULT 78
ABK01790
ID ABK01790 standard; RNA; 17 BP.
XX
AC ABK01790;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Zinzyme #112.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX

PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 97; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a zinzyme molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 115 CGGCGGCGGCAGCTGC 130
||||||||||||| ||
Db 1 CGGCGGCGGCAGCAGC 16

RESULT 79
ABK01791
ID ABK01791 standard; RNA; 17 BP.
XX
AC ABK01791;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Zinzyme #113.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 97; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident

```
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a zinzyme molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 61;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGC 130
              ||||||| |||||:||
Db          1 CGGCGGCAGCAGCUGC 16


RESULT 80
ABK00440/c
ID   ABK00440 standard; RNA; 17 BP.
XX
AC   ABK00440;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Hammerhead Ribozyme #440.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 73; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a hammerhead ribozyme of the invention
XX
SQ   Sequence 17 BP; 4 A; 5 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAAA 616
              ||||||| ||||||||
Db         16 GGAGATGAATCTGAAA 1


RESULT 81
ABV85759/c
ID   ABV85759 standard; DNA; 17 BP.
XX
AC   ABV85759;
XX
DT   11-DEC-2002  (first entry)
XX
DE   Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:752.
XX
KW   Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KW   pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW   ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   EP1243660-A2.
XX
PD   25-SEP-2002.
XX
PF   25-JAN-2002; 2002EP-00001161.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   30-AUG-2001; 2001US-0315984P.
```

```
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J,  Gu Y,  Nguyen C;
XX
DR   WPI; 2002-724954/79.
XX
PT   Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT   cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT   and treat disorders associated with reduced or over expression of the
PT   encoded protein.
XX
PS   Example 2; SEQ ID NO 752; 59pp; English.
XX
CC   The present invention describes an isolated nucleic acid (I) encoding a
CC   human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC   GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC   chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC   present invention can be used in therapy, particularly to prevent or
CC   treat a disorder associated with decreased expression or activity of pp-
CC   GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC   ABP53504 are given in the exemplification of the present invention. N.B.
CC   The sequence data for this patent is not represented in the printed
CC   specification but is based on sequence information supplied by the
CC   European Patent Office
XX
SQ   Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              |||||||||| ||||||
Db         17 AGCCCTCAATGCGAGC 2


RESULT 82
ABV85760/c
ID   ABV85760 standard; DNA; 17 BP.
XX
AC   ABV85760;
XX
DT   11-DEC-2002  (first entry)
XX
DE   Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:753.
XX
KW   Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KW   pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW   ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   EP1243660-A2.
XX
PD   25-SEP-2002.
XX
PF   25-JAN-2002; 2002EP-00001161.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   30-AUG-2001; 2001US-0315984P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J,  Gu Y,  Nguyen C;
XX
DR   WPI; 2002-724954/79.
XX
PT   Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT   cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT   and treat disorders associated with reduced or over expression of the
PT   encoded protein.
XX
PS   Example 2; SEQ ID NO 753; 59pp; English.
XX
CC   The present invention describes an isolated nucleic acid (I) encoding a
CC   human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC   GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC   chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC   present invention can be used in therapy, particularly to prevent or
CC   treat a disorder associated with decreased expression or activity of pp-
CC   GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC   ABP53504 are given in the exemplification of the present invention. N.B.
CC   The sequence data for this patent is not represented in the printed
CC   specification but is based on sequence information supplied by the
CC   European Patent Office
XX
SQ   Sequence 17 BP; 2 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              |||||||||| ||||||
Db         16 AGCCCTCAATGCGAGC 1


RESULT 83
ACC51948/c
ID   ACC51948 standard; DNA; 17 BP.
XX
AC   ACC51948;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #715.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 205; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
```

CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 3 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 463 CACAAGATGGATGATC 478
|| |||||||||||||
Db 16 CAAAAGATGGATGATC 1

RESULT 84
ABT39941/c
ID ABT39941 standard; DNA; 17 BP.
XX
AC ABT39941;
XX
DT 13-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5578.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 686; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 61;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 463 CACAAGATGGATGATC 478
|| |||||||||||||
Db 16 CAAAAGATGGATGATC 1

RESULT 85
ABT39883/c
ID ABT39883 standard; DNA; 17 BP.
XX
AC ABT39883;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5520.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 679; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention

```
XX
SQ   Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 86
ADB04944
ID   ADB04944 standard; DNA; 17 BP.
XX
AC   ADB04944;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ12 scanning oligonucleotide SEQ ID 5930.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 5930; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCAG 654
              |||||||||||| ||||
Db          1 TCCAGGAGAGGGCCAG 16
```

o

```
RESULT 87
ADB04943
ID   ADB04943 standard; DNA; 17 BP.
XX
AC   ADB04943;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ12 scanning oligonucleotide SEQ ID 5929.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 5929; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 4 A; 7 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCAG 654
              |||||||||||| ||||
Db          2 TCCAGGAGAGGGCCAG 17


RESULT 88
ACD59733/c
ID   ACD59733 standard; RNA; 17 BP.
XX
```

```
AC   ACD59733;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #1479.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 260; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 0 A; 3 C; 9 G; 0 T; 5 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAGA 810
              ||||||||||||| ||
Db         16 CACACCACCCCGACGA 1


RESULT 89
ACC67622
ID   ACC67622 standard; DNA; 17 BP.
XX
AC   ACC67622;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 4869.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 600; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCA 623
              ||||||||||||| ||
Db          1 GATCTGAAATGAACCA 16


RESULT 90
ADB43670/c
ID   ADB43670 standard; DNA; 17 BP.
XX
AC   ADB43670;
XX
DT   18-DEC-2003  (revised)
```

```
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #3993.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 498; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 3 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 91
ADB44198/c
ID   ADB44198 standard; DNA; 17 BP.
XX
AC   ADB44198;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4521.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 560; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 61;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        463 CACAAGATGGATGATC 478
              || |||||||||||||
Db         16 CAAAAGATGGATGATC 1


RESULT 92
AAV16021
ID   AAV16021 standard; DNA; 18 BP.
XX
AC   AAV16021;
XX
DT   21-MAY-1998  (first entry)
XX
DE   PCR primer used to identify Sox-2 gene mutations in mice.
XX
KW   Mutation; Sox-2; mutational screening; recessive; phenotypic alteration;
KW   mouse model; FGF-4; PCR primer; amplify; ss.
XX
OS   Synthetic.
```

OS Mus sp.
XX
PN WO9744485-A1.
XX
PD 27-NOV-1997.
XX
PF 16-MAY-1997; 97WO-GB001354.
XX
PR 17-MAY-1996; 96GB-00010355.
XX
PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI Goodfellow PN;
XX
DR WPI; 1998-018536/02.
XX
PT Identification of mutation(s) in genes of interest - without prior
PT observation of phenotypic alteration in the mutated organism or cell.
XX
PS Example 6; Page 43; 66pp; English.
XX
CC PCR primers AAV16019-36 were used to identify mutations in Sox-2 using
CC the method of the invention. The method comprises testing a nucleic acid
CC sample from a mutated organism for a mutation in a gene of interest
CC without the prior observation of a phenotypic alteration in the mutated
CC organism resulting from the mutation. Sox-2 is a member of the Sox gene
CC family, and is involved in transcriptional regulation of the FGF-4 gene.
CC FGF-4 codes for a signalling protein whose expression is essential for
CC postimplantation mouse development, and, at later embryonic stages, for
CC limb patterning and growth. Mutagenised mice in which a Sox-2 mutation is
CC identified can be studied and provide a mouse model for a mutant human
CC sox-2 gene. The method provides mutational screening based on genomic and
CC genetic techniques rather than on phenotypic observation. The method
CC identifies and characterises genes via mutagenesis to identify genes
CC encoding products which may have therapeutic benefit. The method also
CC identifies the presence of mutations in a gene which do not rely solely
CC upon prior matching of a gene with a disease. Heterozygotic organisms can
CC also be screened to identify those carrying a mutation in a copy of a
CC gene of interest even though the gene may be recessive and therefore
CC causes no phenotypic alteration
XX
SQ Sequence 18 BP; 4 A; 4 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 18 CGGCGGCGGAGGAGCC 33
||||||||||||||| |
Db 1 CGGCGGCGGAGGAGGC 16

RESULT 93
AAZ69854/c
ID AAZ69854 standard; DNA; 18 BP.
XX
AC AAZ69854;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:4210.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1128; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 18 BP; 2 A; 8 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 1.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 549 GGAAAGGAGAAATAGG 564
||||||||||||||| |
Db 17 GGAAAGGAGAAATATG 2

RESULT 94
AAZ43280
ID AAZ43280 standard; DNA; 18 BP.
XX
AC AAZ43280;
XX
DT 11-FEB-2000 (first entry)
XX
DE Murine Sox2 gene PCR primer 3.
XX
KW Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
XX
OS Mus musculus.
XX
PN US5994075-A.
XX
PD 30-NOV-1999.
XX
PF 16-MAY-1997; 97US-00857946.
XX
PR 17-MAY-1996; 96US-0017824P.
XX
PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI Goodfellow PN;
XX
DR WPI; 2000-038255/03.
XX
PT Identifying a mutation in a gene of interest in an organism useful for

```
PT   identifying genes encoding products which may have therapeutic benefits.
XX
PS   Example 7; Col 67-68; 70pp; English.
XX
CC   This invention describes a novel mutational screening method based on
CC   genomic and genetic techniques to identify and characterize a mutation in
CC   a gene of interest without first selecting a phenotypic characteristic.
CC   The screening methods are useful for identifying genes encoding products
CC   which may have therapeutic benefit for treating human or animal diseases.
CC   The method can be used for the DNA mutation screening of a class or a
CC   family of genes providing a rapid assay for identifying mutant genes. The
CC   methods produce organisms which can be used for drug discovery e.g.
CC   providing a model for the study and treatment of a disease state, allow
CC   in vitro assessment of drug activity and interbreeding of mutants which
CC   allow investigation of gene interactions in the overall phenotype. A
CC   range of phenotypes associated with different mutations, and specified
CC   mutations in a gene of interest can be determined. The method can be
CC   adapted to screen for a mutation in two or more genes of interest in an
CC   organism. The methods allow mutations in a gene of interest to be
CC   identified without having to rely on matching a gene with a disease.
CC   AAZ43260-Z43421 represent PCR primers used in the method of the invention
XX
SQ   Sequence 18 BP; 4 A; 4 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match           1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 69;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
              ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 95
AAA05265
ID   AAA05265 standard; DNA; 18 BP.
XX
AC   AAA05265;
XX
DT   19-MAY-2000  (first entry)
XX
DE   PCR primer B-F used in Sox-2 amplimer generation.
XX
KW   PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;
KW   Pax-6; mutation detection; therapeutic target identification; mouse;
KW   mast cell growth factor; ss.
XX
OS   Mus sp.
XX
PN   US6015670-A.
XX
PD   18-JAN-2000.
XX
PF   14-NOV-1997;   97US-00970740.
XX
PR   17-MAY-1996;   96US-0017824P.
PR   16-MAY-1997;   97US-00857946.
XX
PA   (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI   Goodfellow PN;
XX
DR   WPI; 2000-181139/16.
XX
PT   Detecting mutations in selected genes, useful e.g. for identifying
PT   therapeutic targets or products, by analyzing DNA in mutated embryonic
PT   stem cells without phenotypic characterization.
XX
PS   Example 6; Col 32; 66pp; English.
XX
CC   PCR primers AAA05245-A05406 are used to generate amplimers from the mouse
CC   Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,
CC   MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The
CC   primers are used in a method for the identification of a mutation in a
CC   selected gene in a tissue without the prior observation of a phenotypic
CC   alteration in the mutated organism or cell. The method is used to
CC   identify mutations in a selected gene that encode products of potential
CC   therapeutic activity or that are potential targets, particularly where
CC   the gene of interest has been identified as a candidate gene by
CC   positional cloning. Other applications are determining functions of genes
CC   ; detecting the range of phenotypes associated with different mutations
CC   in a particular gene and identification of particular mutations. Animals
CC   containing an identified mutation are used as models for studying
CC   diseases or their treatment, and cells from them for in vitro assessment
CC   of drug action. Interbreeding of mutant mice is used to investigate
CC   genetic interaction in the overall phenotype
XX
SQ   Sequence 18 BP; 4 A; 4 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match           1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 69;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
              ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 96
AAZ93475
ID   AAZ93475 standard; DNA; 18 BP.
XX
AC   AAZ93475;
XX
DT   24-JUL-2000  (first entry)
XX
DE   TRADD antisense oligonucleotide.
XX
KW   TRADD; TNF; tumour necrosis factor; NF-kappa-B; apoptosis;
KW   programmed cell death; antisense; inhibition; treatment; therapy;
KW   septic shock; inflammation; cancer; antiinflammatory; human; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    complement(1. .18)
FT                   /*tag= a
FT                   /note= "Complementary to bases 641-624 of the human TRADD
FT                   sequence described in GENESEQ record AAZ93431"
XX
PN   WO200012527-A1.
XX
PD   09-MAR-2000.
XX
PF   25-AUG-1999;   99WO-US019614.
XX
PR   28-AUG-1998;   98US-00143212.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-237846/20.
XX
PT   New antisense compounds that limit the expression of human TRADD protein,
PT   useful in the treatment and diagnosis of cancer, inflammation and septic
PT   shock.
XX
PS   Example 15; Page 52; 85pp; English.
XX
CC   The intracellular protein TRADD has been identified as a critical link
CC   between tumour necrosis factor (TNF) receptor binding and downstream
CC   activation of NF-kappa-B. Overexpression of native TRADD activates NF-
CC   kappa-B in the absence of TNF and dominant negative mutants of TRADD
CC   block TNF-induced NF-kappa-B activation. A second effect of TNF in many
CC   cell types is the induction of apoptosis (programmed cell death). TRADD
```

```
CC   overexpression has been shown to mimic TNF induction of apoptosis as
CC   well. Data indicates that TRADD and other downstream effector proteins
CC   are the rate limiting step of TNF action and would therefore serve as the
CC   most efficient targets for inhibition of TNF-induced events. Antisense
CC   oligonucleotides capable of inhibiting TRADD function may therefore be
CC   useful in a number of therapeutic, diagnostic and research applications.
CC   Inhibiting expression of TRADD by contacting human cells or tissues with
CC   the antisense compound may be used to treat a disease or condition
CC   associated with TRADD expression, for example, septic shock,
CC   inflammation, or cancer. TRADD antisense oligonucleotides of varying
CC   inhibitory capabilities are listed in GENESEQ records AAZ93438-Z93517.
CC   The antisense oligonucleotides exhibit enhanced inhibitory capabilities
CC   when they have 2'-MOE wings and a deoxy gap
XX
SQ   Sequence 18 BP; 0 A; 5 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 69;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          3 TGGCGGCGGCGGCGGC 18


RESULT 97
AAD38944
ID   AAD38944 standard; DNA; 18 BP.
XX
AC   AAD38944;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human Her-2 antisense oligonucleotide, ISIS #27971.
XX
KW   Human; Her-2; epidermal growth factor receptor 2; infection; cancer;
KW   hyperproliferative disorder; prophylaxis; inflammation; antisense;
KW   tumour; gene therapy; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   1
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   2
FT                   /*tag=  e
FT                   /mod_base= m5c
FT   modified_base   6
FT                   /*tag=  f
FT                   /mod_base= m5c
FT   modified_base   7
FT                   /*tag=  g
FT                   /mod_base= m5c
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   15
FT                   /*tag=  h
FT                   /mod_base= m5c
FT   modified_base   17
FT                   /*tag=  i
FT                   /mod_base= m5c
FT   modified_base   18
FT                   /*tag=  j
FT                   /mod_base= m5c
XX
PN   WO200222636-A1.
XX
PD   21-MAR-2002.
XX
PF   12-SEP-2001; 2001WO-US028572.
XX
PR   15-SEP-2000; 2000US-00663834.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2002-471192/50.
XX
PT   Novel antisense oligonucleotide which modulates the expression of Human
PT   Epidermal Growth Factor receptor, Her2, is useful for treating tumors
PT   inflammation or to prevent infection in humans.
XX
PS   Claim 1; Page 89; 116pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding Her2 (human Epidermal Growth Factor receptor 2) that
CC   specifically hybridises with and inhibits the expression of Her2.
CC   Antisense compounds of the invention are used for treating diseases or
CC   conditions associated with Her2 such as hyperproliferative disorders e.g.
CC   lung, breast, gastric, oesophageal, colon, bladder, salivary, neural or
CC   cardiac cancer. They are also useful prophylactically e.g. to prevent or
CC   delay infection, inflammation and tumour formation. The invention is also
CC   used in gene therapy. The present sequence is an antisense
CC   oligonucleotide targetted to human Her-2
XX
SQ   Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 69;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        775 CCTTTTCAGAGTGGCA 790
              ||||| ||||||||||
Db          1 CCTTTCCAGAGTGGCA 16


RESULT 98
AAF45310/c
ID   AAF45310 standard; DNA; 15 BP.
XX
AC   AAF45310;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #149.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
```

```
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGC 127
              ||||||||||||||
Db         15 GCGGCGGCGGCAGC 2


RESULT 99
AAF45312/c
ID   AAF45312 standard; DNA; 15 BP.
XX
AC   AAF45312;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #151.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 56;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAG 126
              ||||||||||||||
Db         14 GGCGGCGGCGGCAG 1


RESULT 100
ABK56817
ID   ABK56817 standard; RNA; 17 BP.
XX
AC   ABK56817;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1188.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
```

PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 82; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.4%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 72;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy        977 AGAACTGCAGCTGT 990
              |||||:|||||:|:
Db          4 AGAACUGCAGCUGU 17
```

RESULT 101
ABK56483
ID ABK56483 standard; RNA; 17 BP.
XX
AC ABK56483;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #854.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 72; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 1 C; 5 G; 0 T; 6 U; 0 Other;

Query Match 1.4%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 72;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```
Qy        604 GATGGATCTGAAAT 617
              ||:|||:|:||||:
Db          1 GAUGGAUCUGAAAU 14
```

RESULT 102
ABK55895
ID ABK55895 standard; RNA; 17 BP.
XX
AC ABK55895;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #266.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 57; 152pp; English.
XX

```
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 1 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 72;
  Matches   10;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||:|||:|:||||:
Db          2 GAUGGAUCUGAAAU 15


RESULT 103
ABK56990
ID   ABK56990 standard; RNA; 17 BP.
XX
AC   ABK56990;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1361.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 88; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 72;
  Matches   11;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              |||||:|||||:|:
Db          3 AGAACUGCAGCUGU 16


RESULT 104
ABK57363
ID   ABK57363 standard; RNA; 17 BP.
XX
AC   ABK57363;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1734.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 112; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
```

```
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 4 G; 0 T; 5 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 72;
  Matches   10;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||:|||:|:||||:
Db          4 GAUGGAUCUGAAAU 17


RESULT 105
ABX77386/c
ID   ABX77386 standard; DNA; 17 BP.
XX
AC   ABX77386;
XX
DT   09-APR-2003  (first entry)
XX
DE   Human lrba gene 5' splice donor site for Exon 5.
XX
KW   LPS responsive CHS1/beige-like anchor gene; lrba; cancer;
KW   tumour growth inhibitor; cytostatic; gene therapy; tumour; melanoma;
KW   chronic myelogenous leukaemia; adenocarcinoma; lymphoblastic leukaemia;
KW   lung carcinoma; ds; human; mouse.
XX
OS   Homo sapiens.
XX
PN   WO200278614-A2.
XX
PD   10-OCT-2002.
XX
PF   02-APR-2002; 2002WO-US010350.
XX
PR   02-APR-2001; 2001US-0280107P.
XX
PA   (UYSF-) UNIV SOUTH FLORIDA.
XX
PI   Kerr WG,  Wang J;
XX
DR   WPI; 2003-103233/09.
XX
PT   A new isolated LPS-responsive and Beige-like Anchor polypeptide useful
PT   for inhibiting growth of tumors in a patient.
XX
PS   Example 5; Page 45; 79pp; English.
XX
CC   This invention relates to a novel isolated LPS-responsive and Beige- like
CC   Anchor (Irba) polypeptide which may be used to inhibit tumour growth. The
CC   invention also comprises an interfering RNA sequence which may be used to
CC   suppress lrba function and inhibit tumour growth. The polypeptide and
CC   small interfering RNA (siRNA) molecules of the invention may have
CC   cytostatic activity and may be used in gene therapy. Also disclosed is a
CC   method for inhibiting tumour growth in a patient comprising administering
CC   to the patient an agent that suppresses Irba function in the patient. The
CC   agent may be a polynucleotide fragment of an Irba gene or its variant, or
CC   a polypeptide fragment of an Irba gene or its variant or an RNA sequence
CC   that interferes with the expression of the Irba gene. The method of the
CC   invention may be used to treat a patient who is suffering from a tumour
CC   or a cancer, such as breast, prostate, melanoma, cervical or colorectal
CC   cancer, chronic myelogenous leukemia, adenocarcinoma, lymphoblastic
CC   leukemia or lung carcinoma. The present sequence represents a DNA
CC   sequence used within the scope of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 72;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        892 TACTTACTGCAGCA 905
              ||||||||||||||
Db         16 TACTTACTGCAGCA 3


RESULT 106
ABZ61433
ID   ABZ61433 standard; RNA; 17 BP.
XX
AC   ABZ61433;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #224.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 115; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 72;
  Matches    9;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        767 CCCCAGTGCCTTTT 780
              ||||||:|||::::
```

```
Db          4 CCCCAGUGCCUUUU 17


RESULT 107
AAS21619/c
ID   AAS21619 standard; DNA; 18 BP.
XX
AC   AAS21619;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human Survivin antisense oligonucleotide #84.
XX
KW   Survivin; human; mouse; cytostatic; antisense oligonucleotide;
KW   hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200157059-A1.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US002939.
XX
PR   02-FEB-2000; 2000US-00496694.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Ackermann EJ,  Swayze EE,  Cowsert LM;
XX
DR   WPI; 2001-488863/53.
XX
PT   Novel antisense compounds for modulating the expression of Survivin and
PT   treatment of cancer.
XX
PS   Example 17; Page 57; 120pp; English.
XX
CC   The invention relates to antisense oligonucleotides targeted to a nucleic
CC   acid molecule encoding human Survivin, where the antisense
CC   oligonucleotide inhibits the expression of human Survivin. These
CC   antisense oligonucleotides are used in the treatment of an animal
CC   suffering from a disease or condition associated with Survivin, e.g. a
CC   hyperproliferative condition such as cancer, and comprises administering
CC   a therapeutically or prophylactically effective amount of the antisense
CC   oligonucleotide so that expression of Survivin is inhibited. The
CC   oligonucleotides can also be used to treat a human suffering from a
CC   disease or condition characterised by a reduction in apoptosis comprising
CC   administering the antisense oligonucleotide to a human. In addition, the
CC   antisense oligonucleotide and a cytotoxic chemotherapeutic agent e.g.
CC   taxol or cisplatin, can be used to modulate apoptosis, cytokinesis or the
CC   cell cycle, or inhibit the proliferation in a cancer cell by contacting
CC   the cell with the antisense oligonucleotide. AAS21521-AAS21768 represent
CC   Survivin nucleic acids, and antisense oligonucleotides targeted to
CC   Survivin, used in the method of the invention
XX
SQ   Sequence 18 BP; 2 A; 11 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCA 125
              ||||||||||||||
Db         16 TGGCGGCGGCGGCA 3


RESULT 108
ABL43560/c
ID   ABL43560 standard; DNA; 18 BP.
XX
AC   ABL43560;
XX
DT   11-APR-2002  (first entry)
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:604.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 16; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
CC   plates are specified from the detected result; and (i) the clones are
CC   reconstituted as the positions on the chromosome and arrayed. The
CC   microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC   PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC   represent PCR primers for human chromosome 21q22.1, which are
CC   specifically claimed for use in the present invention
XX
SQ   Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        983 GCAGCTGTGCACAT 996
              ||||||||||||||
Db         15 GCAGCTGTGCACAT 2


RESULT 109
AAX71558
ID   AAX71558 standard; RNA; 17 BP.
XX
AC   AAX71558;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human KDR VEGF receptor hammerhead ribozyme substrate #570.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
```

KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 114; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 2 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 78;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 921 TTTCCTGATTGGAGGAG 937
::::||:| :|||||||
Db 1 UUUCCUGUAUGGAGGAG 17

RESULT 110
AAX62926
ID AAX62926 standard; RNA; 17 BP.
XX
AC AAX62926;
XX
DT 16-JUL-1999 (first entry)
XX
DE Delta-9 desaturase hamerhead ribozyme target SEQ ID NO:801.
XX
KW Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW modulation; gene expression; transgenic plant; cleavage; canola plant;
KW caffeine synthesis; coffee plant; nicotine production; tobacco;
KW fruit ripening; flower pigmentation; lignin production; ss.
XX
OS Zea mays.
XX
PN WO9710328-A2.
XX
PD 20-MAR-1997.
XX
PF 12-JUL-1996; 96WO-US011689.
XX
PR 13-JUL-1995; 95US-0001135P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (DOWC) DOWELANCO.
XX
PI Zwick MG, Edington BE, Mcswiggen JA, Merlo PAO, Guo L, Skokut TA;
PI Young SA, Folkerts O, Merlo DJ;
XX
DR WPI; 1997-202224/18.
XX
PT Ribozyme which modulates plant gene expression - preferably modulates
PT expression of DELTA-9 desaturase or granule bound starch synthase in
PT maize or canola.
XX
PS Claim 38; Page 86; 155pp; English.
XX
CC The present invention describes an enzymatic nucleic acid molecule (I)
CC with RNA cleaving activity, which modulates the expression of a plant
CC gene. Also described is a gene comprising a cDNA sequence encoding maize
CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
CC modulate caffeine synthesis in a coffee plant, nicotine production in a
CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
CC plant
XX
SQ Sequence 17 BP; 1 A; 7 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 78;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 203 CCTCGACTTCCCCGTCG 219
||:||| ::|| ||:||
Db 1 CCUCGAGUUCCUCGUCG 17

RESULT 111
AAF07259
ID AAF07259 standard; DNA; 17 BP.
XX
AC AAF07259;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #3516.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 54; Page 136; 164pp; English.
XX

```
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        148 GAGCTGGACCAGCTGCC 164
              ||||||| ||||| |||
Db          1 GAGCTGGTCCAGCAGCC 17


RESULT 112
AAF02617/c
ID   AAF02617 standard; DNA; 17 BP.
XX
AC   AAF02617;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #912.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 76; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 0 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         77 GGGAGGCGGGCAGCGGG 93
              ||||||||| |||| ||
Db         17 GGGAGGCGGACAGCCGG 1


RESULT 113
ABK00815
ID   ABK00815 standard; RNA; 17 BP.
XX
AC   ABK00815;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #85.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 79; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
```

```
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 0 A; 9 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 78;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        388 CCCGCCGCCGAGCCGTC 404
              ||||||||||| || |:|
Db          1 CCCGCCGCCGGGCUGUC 17


RESULT 114
ABN08013/c
ID   ABN08013 standard; DNA; 17 BP.
XX
AC   ABN08013;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8005.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8005; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        147 GGAGCTGGACCAGCTGC 163
              |||||||  ||||||||
Db         17 GGAGCTGCTCCAGCTGC 1


RESULT 115
ABN06311/c
ID   ABN06311 standard; DNA; 17 BP.
XX
AC   ABN06311;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6303.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
```

```
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 6303; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         25 GGAGGAGCCCTCAAGGC 41
              ||||| |||||| ||||
Db         17 GGAGGTGCCCTCCAGGC 1


RESULT 116
ABQ63388
ID   ABQ63388 standard; DNA; 17 BP.
XX
AC   ABQ63388;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 101.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 170; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 0 A; 4 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         63 CGCGGGACTGCTGCGGG 79
              ||||||  |||||||||
Db          1 CGCGGGGTTGCTGCGGG 17


RESULT 117
ABQ63389
ID   ABQ63389 standard; DNA; 17 BP.
XX
AC   ABQ63389;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 102.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
```

```
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 171; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 1 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 GCGGGACTGCTGCGGGA 80
              |||||  ||||||||||
Db          1 GCGGGGTTGCTGCGGGA 17


RESULT 118
ABQ63390
ID   ABQ63390 standard; DNA; 17 BP.
XX
AC   ABQ63390;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 103.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 171; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 1 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         65 CGGGACTGCTGCGGGAG 81
              ||||  ||||||||||
Db          1 CGGGGTTGCTGCGGGAG 17


RESULT 119
ABV90095/c
ID   ABV90095 standard; DNA; 17 BP.
XX
AC   ABV90095;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 808.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
```

```
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 808; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||| | |||||||||
Db         17 GCGGCTGGGGCAGCTGC 1


RESULT 120
ABV90096/c
ID   ABV90096 standard; DNA; 17 BP.
XX
AC   ABV90096;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 809.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 809; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 2 A; 10 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTG 129
              |||||| | ||||||||
Db         17 GGCGGCTGGGGCAGCTG 1


RESULT 121
ACC53863
ID   ACC53863 standard; DNA; 17 BP.
XX
AC   ACC53863;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #2630.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
```

```
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 647; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 8 A; 3 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCAC 624
              ||||||||||  ||| ||
Db          1 GATCTGAAATCAATAAC 17


RESULT 122
ABZ59899
ID   ABZ59899 standard; RNA; 17 BP.
XX
AC   ABZ59899;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #11.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 85; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||||||||  |||
Db          1 CGGCGGCGGCAGUGGCG 17


RESULT 123
ABZ59894
ID   ABZ59894 standard; RNA; 17 BP.
XX
AC   ABZ59894;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #6.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 85; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
```

```
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||  ||||||  |||
Db          1 CGGCGGAGGCAGCAGCG 17


RESULT 124
ABZ64592
ID   ABZ64592 standard; RNA; 17 BP.
XX
AC   ABZ64592;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #49.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 134; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 2 A; 9 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              |||  |||||||||  |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 125
ABZ61368
ID   ABZ61368 standard; RNA; 17 BP.
XX
AC   ABZ61368;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #159.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 114; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 0 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||||||  ||  |||
Db          1 CGGCGGCGGCGGCGGCG 17


RESULT 126
ABZ64550/c
ID   ABZ64550 standard; RNA; 17 BP.
XX
AC   ABZ64550;
XX
DT   21-MAR-2003  (first entry)
```

```
XX
DE   Human HER2 DNAzyme substrate #7.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 133; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 9 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 127
ACD59841
ID   ACD59841 standard; RNA; 17 BP.
XX
AC   ACD59841;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #1531.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 261; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 78;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        620 ATCACTTAGCAGCTGAG 636
              |:|||: ||| ||:|||
Db          1 AUCACUCAGCUGCUGAG 17


RESULT 128
ACD55421/c
ID   ACD55421 standard; RNA; 17 BP.
XX
AC   ACD55421;
XX
DT   23-SEP-2003  (first entry)
```

```
XX
DE   HBV amberzyme substrate sequence #42.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 203; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        474 TGATCGTCCAGAGGAAC 490
              |||| ||||||| ||||
Db         17 TGATAGTCCAGAAGAAC 1


RESULT 129
ADB42408
ID   ADB42408 standard; DNA; 17 BP.
XX
AC   ADB42408;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #2731.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 351; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        608 GATCTGAAATGAATCAC 624
              |||||| ||||| ||||
Db          1 GATCTGCAATGATTCAC 17
```

RESULT 130
AAQ54286
ID AAQ54286 standard; DNA; 18 BP.
XX
AC AAQ54286;
XX
DT 25-MAR-2003 (revised)
DT 30-JUN-1994 (first entry)
XX
DE Positive primer to amplify HSV fragment of specific mol.wt.
XX
KW Herpes Simplex Virus; Herpes viridae; amplification reaction;
KW DNA polymerase; conserved sequence; ss.
XX
OS Synthetic.
XX
PN WO9325707-A2.
XX
PD 23-DEC-1993.
XX
PF 04-JUN-1993; 93WO-ES000048.
XX
PR 05-JUN-1992; 92ES-00001174.
XX
PA (SALU-) INST SALUD CARLOS III.
XX
PI Tenorio Matanzo A;
XX
DR WPI; 1994-007564/01.
XX
PT Amplification of genome(s) and initiator oligo-nucleotide(s) mixts. -
PT using single reaction mixt. to detect and identify infections by related
PT viruses.
XX
PS Claim 15(i); Page 27; 41pp; Spanish.
XX
CC The known amino acid sequences of DNA polymerases from 6 different
CC members of the herpes viridae family were aligned so that conserved
CC regions could be identified. A set of primers (AAQ54286-Q54290) was
CC designed based on the sequences. The primers each amplify a fragment of
CC specific mol.wt. to allow different viruses to be detected. Sequence
CC AAQ54286 is specific for HSV. This primer is partially self-complementary
CC so to minimise any interaction between primers, a modified version was
CC synthesised (see AAQ54326). (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 1 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        271 GTGCCGCCGCCCCACGG 287
              ||||||| ||| |||||
Db          2 GTGCCGCGGCCTCACGG 18
```

RESULT 131
AAT36246/c
ID AAT36246 standard; DNA; 18 BP.
XX
AC AAT36246;
XX
DT 25-MAR-2003 (revised)
DT 16-APR-1997 (first entry)
XX
DE CD28 expression inhibiting oligonucleotide, RT25s.
XX
KW Reduction; T cell; CD28; gene expression; treatment; immune system;
KW disorder; graft versus host disease; septic shock; viral disease;
KW psoriasis; type I diabetes mellitus; thyroiditis; sarcoides;
KW multiple sclerosis; uveitis; rheumatoid arthritis; interleukin 2;
KW systemic lupus erythematosus; inflammatory bowel disease; IL-2;
KW production; antisense; inhibition; ss.
XX
OS Synthetic.
XX
PN WO9624380-A1.
XX
PD 15-AUG-1996.
XX
PF 05-FEB-1996; 96WO-US001507.
XX
PR 09-FEB-1995; 95US-00387041.
PR 18-SEP-1995; 95US-00529878.
XX
PA (ICNC) ICN PHARM INC.
XX
PI Tam RC;
XX
DR WPI; 1996-384228/38.
XX
PT Oligo:nucleotide which reduces CD28 gene expression in T cells - for
PT treating immune system diseases, e.g. graft vs. host disease, septic
PT shock, psoriasis, etc.
XX
PS Example 2; Page 45; 77pp; English.
XX
CC The present oligonucleotide reduces CD28 dependent interleukin-2 (IL-2)
CC production and T cell CD28 gene expression, useful in the treatment of
CC CD28 mediated diseases, particularly immune system disorders, e.g. graft
CC versus host disease, septic shock, viral disease, psoriasis, type I
CC diabetes mellitus, thyroiditis, sarcoides, multiple sclerosis, uveitis,
CC rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel
CC disease, etc. . Reducing CD28 expression may reduce the effects of
CC antigenic stimulation of CD28 positive T cells, with a consequent
CC reduction in cytokine release. (Updated on 25-MAR-2003 to correct PR
CC field.)
XX
SQ Sequence 18 BP; 1 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        803 CCCGAAGAGCCCCTTCA 819
              ||||| |||||||| ||
Db         18 CCCGAGGAGCCCCTCCA 2
```

RESULT 132
AAT27164
ID AAT27164 standard; DNA; 18 BP.
XX
AC AAT27164;
XX
DT 11-DEC-1996 (first entry)
XX
DE Human Machado-Joseph disease gene primer (5).
XX
KW Human; Machado-Joseph disease; mature protein; repeat motif; probe;
KW cerebral temporal fossa lobe cortex; primer; amplification; PCR; ss;
KW polymerase chain reaction.
XX
OS Synthetic.
XX
PN JP08092289-A.
XX
PD 09-APR-1996.
XX
PF 21-SEP-1994; 94JP-00251600.
XX
PR 21-SEP-1994; 94JP-00251600.
XX
PA (ONOY) ONO PHARM CO LTD.
XX

```
DR   WPI; 1996-236099/24.
XX
PT   Human Machado-Joseph disease-related protein and DNA encoding it - used
PT   in the diagnosis and treatment of MJD.
XX
PS   Example 2; Page 7; 12pp; Japanese.
XX
CC   The primers AAT27161-4 were used to amplify the nucleotide sequence of a
CC   human Machado-Joseph disease-related gene (AAT27151) or fragments. This
CC   primer corresp. to nucleotides 1025-1008 of the gene. The gene was
CC   isolated from a human cerebral temporal fossa lobe cortex mRNA-derived
CC   cDNA library using the probe AAT27160. 8 highly positive clones were
CC   isolated including the clone CAG-27 (AAT26151). The BamHI-BglII and DraII
CC   -SacI fragments of this clone were then used to isolate other clones
CC   (sequences not in specification). The clones or fragments can be used in
CC   the diagnosis and treatment of Machado-Joseph disease
XX
SQ   Sequence 18 BP; 4 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        916 AACTCTTTCCTGATTGG 932
              |||||| ||||||| ||
Db          1 AACTCTGTCCTGATAGG 17


RESULT 133
AAX90339/c
ID   AAX90339 standard; DNA; 18 BP.
XX
AC   AAX90339;
XX
DT   24-SEP-1999  (first entry)
XX
DE   CD28 inhibiting phosphorothioate oligonucleotide RT25S.
XX
KW   CD28; inhibition; antisense oligonucleotide; interleukin 2; IL-2;
KW   immune system mediated disease; gamma-interferon; IL-8; phosphorothioate;
KW   ss.
XX
OS   Synthetic.
XX
PN   US5932556-A.
XX
PD   03-AUG-1999.
XX
PF   18-SEP-1995;   95US-00529878.
XX
PR   09-FEB-1995;   95US-00387041.
PR   18-SEP-1995;   95US-00529878.
XX
PA   (TAMR/) TAM R C.
XX
PI   Tam RC;
XX
DR   WPI; 1996-384228/38.
XX
PT   Oligo:nucleotide which reduces CD28 gene expression in T cells - for
PT   treating immune system diseases, e.g. graft vs. host disease, septic
PT   shock, psoriasis, etc.
XX
PS   Example; Col 24; 45pp; English.
XX
CC   The present invention describes a method for inhibiting the expression of
CC   CD28, IL-2, gamma-interferon or IL-8 in a mammal. The method comprises
CC   subcutaneous administration of an oligonucleotide (OGN). AAX90288 to
CC   AAX90291 represent specifically claimed OGNs for use in the method. The
CC   OGNs are used for the treatment of immune system-mediated diseases. The
CC   present sequence represents a CD28 inhibiting phosphorothioate
CC   oligonucleotide used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 1 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        803 CCCGAAGAGCCCCTTCA 819
              ||||| |||||||| ||
Db         18 CCCGAGGAGCCCCTCCA 2


RESULT 134
AAV51381/c
ID   AAV51381 standard; DNA; 18 BP.
XX
AC   AAV51381;
XX
DT   27-OCT-1998  (first entry)
XX
DE   Human TIGR PCR primer Pr+1(4A).
XX
KW   TIGR; trabecular meshwork induced glucocorticoid response protein; human;
KW   diagnosis; glaucoma; polymorphism; steroid sensitivity; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9832850-A1.
XX
PD   30-JUL-1998.
XX
PF   09-JAN-1998;   98WO-US000468.
XX
PR   28-JAN-1997;   97US-00791154.
PR   26-SEP-1997;   97US-00938669.
XX
PA   (REGC ) UNIV CALIFORNIA.
XX
PI   Nguyen TD,  Polansky JR,  Chen P,  Chen H;
XX
DR   WPI; 1998-427946/36.
XX
PT   Use of TIGR nucleic acid sequences - used for, e.g. developing products
PT   for diagnosis, prognosis and treatment of glaucoma.
XX
PS   Claim 9; Page 9; 105pp; English.
XX
CC   AAV51371-V51390 are PCR primers used in the amplification of a novel
CC   human trabecular meshwork induced glucocorticoid response protein (TIGR)
CC   promoter region which is used in a method for diagnosing glaucoma in a
CC   patient. The method involves the detection of polymorphisms whose
CC   presence is predictive of a mutation affecting TIGR response in the
CC   patient and can be diagnostic of glaucoma or steroid sensitivity. Base
CC   substitutions and base additions upstream of and within TIGR exons can
CC   also be used to diagnose glaucoma
XX
SQ   Sequence 18 BP; 4 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 135
AAV16014
ID   AAV16014 standard; DNA; 18 BP.
XX
AC   AAV16014;
XX
```

DT 21-MAY-1998 (first entry)
XX
DE PCR primer G-R used to identify Sox-3 gene mutations in mice.
XX
KW Mutation; Sox-3; ENU mutagenesis; mutational screening; recessive;
KW single strand conformation polymorphism; SSCP; phenotypic alteration;
KW PCR primer; amplify; ss.
XX
OS Synthetic.
OS Mus sp.
XX
PN WO9744485-A1.
XX
PD 27-NOV-1997.
XX
PF 16-MAY-1997; 97WO-GB001354.
XX
PR 17-MAY-1996; 96GB-00010355.
XX
PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI Goodfellow PN;
XX
DR WPI; 1998-018536/02.
XX
PT Identification of mutation(s) in genes of interest - without prior
PT observation of phenotypic alteration in the mutated organism or cell.
XX
PS Example 4; Page 41; 66pp; English.
XX
CC PCR primers AAV16001-18 were used to identify mutations in Sox-3 using
CC the method of the invention. The primers are located throughout the gene
CC and are unique to Sox-3. The method comprises testing a nucleic acid
CC sample from a mutated organism for a mutation in a gene of interest
CC without the prior observation of a phenotypic alteration in the mutated
CC organism resulting from the mutation. Sox-3 is a member of the Sox gene
CC family, a family of about 20 genes which all encode a "HMG" box, which is
CC a DNA-binding domain. Mice were mutagenised using ENU mutagenesis. The
CC mutagenised mice were tested by PCR with each primer set and fluorescent
CC single strand conformation polymorphism (SSCP), which identifies mice
CC carrying mutations in Sox-3. The method provides mutational screening
CC based on genomic and genetic techniques rather than on phenotypic
CC observation. The method identifies and characterises genes via
CC mutagenesis to identify genes encoding products which may have
CC therapeutic benefit. The method also identifies the presence of mutations
CC in a gene which do not rely solely upon prior matching of a gene with a
CC disease. Heterozygotic organisms can also be screened to identify those
CC carrying a mutation in a copy of a gene of interest even though the gene
CC may be recessive and therefore causes no phenotypic alteration
XX
SQ Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 114 GCGGCGGCGGCAGCTGC 130
||||||||||| || ||
Db 1 GCGGCGGCGGCGGCGGC 17

RESULT 136
AAV94823/c
ID AAV94823 standard; RNA; 18 BP.
XX
AC AAV94823;
XX
DT 24-FEB-1999 (first entry)
XX
DE Human IL-2 receptor g-chain substrate position 97.
XX
KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
OS Homo sapiens.
XX
PN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
PF 02-DEC-1997; 97WO-US021748.
XX
PR 03-DEC-1996; 96US-00758306.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen JA;
XX
DR WPI; 1998-333332/29.
XX
PT Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
PT autoimmune disease and allergies.
XX
PS Claim 4; Page 38; 61pp; English.
XX
CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC and other inflammatory conditions. The ribozymes are also used to induce
CC tolerance in a recipient to alloantigen from a donor
XX
SQ Sequence 18 BP; 5 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 967 ATTGGGCCTCAGAACTG 983
||||||| |||||| ||
Db 17 ATTGGGCGTCAGAATTG 1

RESULT 137
AAZ24020
ID AAZ24020 standard; DNA; 18 BP.
XX
AC AAZ24020;
XX
DT 04-FEB-2000 (first entry)
XX
DE Human GDNF PCR primer XL-1.r.
XX
KW GDNF; human; glial cell line-derived neurotrophic factor; diagnosis;
KW treatment; neurodegenerative disease; Alzheimer's disease; detection;
KW Parkinson's disease; amyotrophic lateral sclerosis; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN DE19816186-A1.
XX
PD 21-OCT-1999.
XX
PF 14-APR-1998; 98DE-01016186.
XX
PR 14-APR-1998; 98DE-01016186.
XX
PA (UYLU-) UNIV MUENCHEN MAXIMILIANS LUDWIG.
XX
DR WPI; 1999-591830/51.
XX

```
PT   Novel nucleic acids used for diagnosis and treatment of neurodegenerative
PT   diseases.
XX
PS   Claim 5; Fig 4; 14pp; German.
XX
CC   This invention describes a novel human DNA (I), encoding glial cell line-
CC   derived neurotrophic factor (GDNF). (I), also its promoter, exon
CC   fragments and primer pairs able to hybridize to it, and GDNF variants
CC   (II) encoded by the exon fragments, are used (i) to investigate
CC   regulation of GDNF at the molecular level, and to design methods for
CC   influencing this regulation and (ii) for diagnosis and treatment of
CC   neurodegenerative diseases, specifically Alzheimer's and Parkinson's
CC   diseases or amyotrophic lateral sclerosis, either by administration of
CC   GDNF variants or by inhibition with e.g. antisense nucleic acid. The
CC   promoter fragment of can also be used to identify agents that regulate
CC   (up or down) GDNF expression. (II) can be used to raise (or detect)
CC   specific antibodies (Ab) for detection of (II), in usual immunoassays. Ab
CC   are also useful therapeutically to inhibit specific GDNF variants.
CC   AAZ24019-Z324040 represent PCR primers used to amplify the human GDNF
CC   sequence described in the method of the invention
XX
SQ   Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        143 GTGTGGAGCTGGACCAG 159
              ||||||||| | |||||
Db          2 GTGTGGAGCAGCACCAG 18


RESULT 138
AAZ24038
ID   AAZ24038 standard; DNA; 18 BP.
XX
AC   AAZ24038;
XX
DT   04-FEB-2000  (first entry)
XX
DE   Human GDNF PCR primer IP2.r.
XX
KW   GDNF; human; glial cell line-derived neurotrophic factor; diagnosis;
KW   treatment; neurodegenerative disease; Alzheimer's disease; detection;
KW   Parkinson's disease; amyotrophic lateral sclerosis; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   DE19816186-A1.
XX
PD   21-OCT-1999.
XX
PF   14-APR-1998;   98DE-01016186.
XX
PR   14-APR-1998;   98DE-01016186.
XX
PA   (UYLU-) UNIV MUENCHEN MAXIMILIANS LUDWIG.
XX
DR   WPI; 1999-591830/51.
XX
PT   Novel nucleic acids used for diagnosis and treatment of neurodegenerative
PT   diseases.
XX
PS   Claim 5; Fig 4; 14pp; German.
XX
CC   This invention describes a novel human DNA (I), encoding glial cell line-
CC   derived neurotrophic factor (GDNF). (I), also its promoter, exon
CC   fragments and primer pairs able to hybridize to it, and GDNF variants
CC   (II) encoded by the exon fragments, are used (i) to investigate
CC   regulation of GDNF at the molecular level, and to design methods for
CC   influencing this regulation and (ii) for diagnosis and treatment of
CC   neurodegenerative diseases, specifically Alzheimer's and Parkinson's
CC   diseases or amyotrophic lateral sclerosis, either by administration of
CC   GDNF variants or by inhibition with e.g. antisense nucleic acid. The
CC   promoter fragment of can also be used to identify agents that regulate
CC   (up or down) GDNF expression. (II) can be used to raise (or detect)
CC   specific antibodies (Ab) for detection of (II), in usual immunoassays. Ab
CC   are also useful therapeutically to inhibit specific GDNF variants.
CC   AAZ24019-Z324040 represent PCR primers used to amplify the human GDNF
CC   sequence described in the method of the invention
XX
SQ   Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        143 GTGTGGAGCTGGACCAG 159
              ||||||||| | |||||
Db          2 GTGTGGAGCAGCACCAG 18


RESULT 139
AAZ20988/c
ID   AAZ20988 standard; DNA; 18 BP.
XX
AC   AAZ20988;
XX
DT   01-DEC-1999  (first entry)
XX
DE   Human semaphorin ZSMF-7 antisense PCR primer ZC16085.
XX
KW   Semaphorin; transmembrane; secreted; neuroregeneration;
KW   immunosuppression; diabetes; multiple sclerosis; rheumatoid arthritis;
KW   proliferation; differentiation; PCR; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9945114-A2.
XX
PD   10-SEP-1999.
XX
PF   03-MAR-1999;   99WO-US004758.
XX
PR   03-MAR-1998;   98US-0076611P.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Holloway JL,  Lofton-Day CE;
XX
DR   WPI; 1999-540845/45.
XX
PT   New isolated human semaphorin ZSMF-7 polypeptides, used to develop
PT   products for treating e.g. immunodeficiencies, autoimmune diseases,
PT   inflammation, graft rejection and infective diseases.
XX
PS   Example 3; Page 105; 124pp; English.
XX
CC   This sequence represents sense PCR primer ZC16085 used with antisense
CC   primer ZC16086 (AAZ20987) in the localisation of the human ZSMF-7
CC   semaphorin gene to 15q24.3. The cDNA was isolated and amplified from a
CC   human testis cDNA library using PCR primers ZC16189 (AAZ20989) and
CC   ZC16188 (AAZ20990) which had been designed based upon an incomplete clone
CC   obtained from a human placenta library. Semaphorins have a variety of
CC   roles. They influence the direction and degree of axon and dendrite
CC   growth in nervous tissue, and may thus be useful as therapeutic agents
CC   for various neurodegenerative conditions. They are active in defining and
CC   directing development of various tissues and organs including those
CC   associated with muscle, fibroblasts, reproductive, endocrine and
CC   lymphatic tissues. ZSMF-7 plays a role as a mediator of
CC   immunosuppression, in particularly the activation and regulation of T
CC   lymphocytes. ZSMF-7 polypeptides would be useful additions to therapies
CC   for treating immunodeficiencies. ZSMF-7 is expressed in activated
CC   lymphocytes (MRL cells) and not in resting lymphocyte cells (CD4+ and
```

```
CC   CD8+) suggesting that it would be a useful tool for diagnosis and
CC   treatment of conditions where selective elimination of inappropriately
CC   activated T cells would be beneficial, such as in autoimmune diseases, in
CC   particular insulin dependent diabetes mellitus, rheumatoid arthritis and
CC   multiple sclerosis. ZSMF-7 polypeptides can be used in vivo as anti-
CC   inflammatory agents, for inhibition of antigen in humoral and cellular
CC   immunity and for immunosuppression in graft and organ transplants
XX
SQ   Sequence 18 BP; 6 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        200 CCTCCTCGACTTCCCCG 216
              |||| | ||||||||||
Db         18 CCTCTTTGACTTCCCCG 2


RESULT 140
AAA07061/c
ID   AAA07061 standard; DNA; 18 BP.
XX
AC   AAA07061;
XX
DT   03-JUL-2000  (first entry)
XX
DE   Human integrin beta 3 antisense oligonucleotide, SEQ ID NO:34.
XX
KW   Integrin beta 3; human endothelial glycoprotein; GP3A; GPIIIa; ITGB3;
KW   CD61; platelet glycoprotein 3a; cellular adhesion; vitronectin receptor;
KW   fibronectin receptor; expression inhibition; antisense; tumour formation;
KW   cancer invasion; bleeding disorder; inflammation; ss.
XX
OS   Homo sapiens.
XX
PN   US6037176-A.
XX
PD   14-MAR-2000.
XX
PF   25-JUN-1999;   99US-00344520.
XX
PR   25-JUN-1999;   99US-00344520.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM,  Monia BP;
XX
DR   WPI; 2000-246189/21.
XX
PT   New antisense compound that inhibits human integrin beta3, useful e.g.
PT   for treating or preventing infection, inflammation and tumors.
XX
PS   Example 15; Col 40; 33pp; English.
XX
CC   Sequences AAA07035-A07074 represent antisense oligonucleotides targetted
CC   to the human integrin beta 3 gene, which inhibit its expression. The
CC   antisense oligonucleotides were designed to target different regions of
CC   the human integrin beta 3 RNA, and were analysed for their effect on
CC   integrin beta 3 mRNA levels by quantitative real-time PCR. GAPDH
CC   (glyceraldehyde-3-phosphate) mRNA levels were measured as a control.
CC   Integrins constitute one of four classes of cellular adhesion molecules,
CC   and play an important role in cell migration, cell anchorage to
CC   substrates and cytoadhesion signalling pathways. They are heterodimeric
CC   cation-dependent membrane glycoproteins composed of an alpha and beta
CC   subunit. Integrin beta 3 (also known as human endothelial glycoprotein,
CC   GP3A, GPIIIa, ITGB3, CD61 and platelet glycoprotein 3a) is the common
CC   beta subunit partner of the members of the beta-3 subfamily of integrins.
CC   This family consists of the vitronectin receptor (alpha-V-beta-3) and the
CC   fibronectin receptor (alpha-IIb-beta-3). Cells expressing this class of
CC   integrin can adhere to various matrix proteins and participate in various
CC   cytoadhesion-driven cellular responses. Integrin beta 3 is implicated in
CC   conditions such as vascular restenosis, excessive bone resorption,
CC   angiogenesis (in melanoma), tumour invasion, platelet aggregation and
CC   Glanzmann's thrombasthenia. The oligonucleotides of the invention are
CC   useful for diagnosis, prevention and treatment of conditions associated
CC   with integrin beta 3 expression, such as tumour formation, inflammation,
CC   infections and the diseases mentioned above
XX
SQ   Sequence 18 BP; 4 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        701 CTGGCAACTCCCCATCA 717
              |||| |||||| |||||
Db         18 CTGGAAACTCCTCATCA 2


RESULT 141
AAZ57670
ID   AAZ57670 standard; DNA; 18 BP.
XX
AC   AAZ57670;
XX
DT   05-APR-2000  (first entry)
XX
DE   Human G-alpha-12 antisense inhibitor ISIS# 20658.
XX
KW   G-alpha-12 inhibitor; antisense compound; cell differentiation; cancer;
KW   cell growth; metastatic growth; ss; ISIS# 20658.
XX
OS   Homo sapiens.
XX
PN   US5998206-A.
XX
PD   07-DEC-1999.
XX
PF   23-FEB-1999;   99US-00256496.
XX
PR   23-FEB-1999;   99US-00256496.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM;
XX
DR   WPI; 2000-095920/08.
XX
PT   Antisense inhibition of human G-alpha-12 expression.
XX
PS   Example 15; Col 38; 36pp; English.
XX
CC   This is a human G-alpha-12 antisense nucleotide sequence. G-alpha-12 is a
CC   member of the G12/13 subfamily of G-proteins. The primary function of G-
CC   alpha-12 is in cell differentiation and growth. The invention relates to
CC   antisense compounds which are 8-30 nucleotides long (see AAZ57668-
CC   Z57746). The antisense molecules are targeted to the human G-alpha-12
CC   nucleic acid molecule, and inhibit the expression of G-alpha-12. The
CC   molecules preferably have a modified internucleotide linkage, and at
CC   least one modified sugar moiety. The compounds target different regions
CC   of the human G-alpha-12 RNA. The expression of human G-alpha 12 is
CC   inhibited by contacting human cells or tissues in vitro with the
CC   antisense molecules. The oligonucleotides are used in modulating the
CC   function of nucleic acid molecules encoding G-alpha-12, ultimately
CC   modulating the amount of G-alpha-12 produced. The antisense compounds can
CC   be utilized for diagnostics, therapeutics, prophylaxis and as research
CC   agents and kits. They may be useful in the treatment of cancer, and
CC   metastatic growth
XX
SQ   Sequence 18 BP; 4 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy         13 GCAGGCGGCGGCGGAGG 29
              |||||| ||||| ||||
Db          2 GCAGGCAGCGGCTGAGG 18


RESULT 142
AAZ91373
ID   AAZ91373 standard; DNA; 18 BP.
XX
AC   AAZ91373;
XX
DT   22-MAY-2000  (first entry)
XX
DE   Human PTEN phosphorothioate antisense oligonucleotide #29539.
XX
KW   Human; PTEN; MMAC1; TEP1; phosphorothioate; antisense oligonucleotide;
KW   inhibition; protein phosphatase; tumour; diagnosis; inflammation;
KW   anticancer; anti-inflammatory; anti-infective; infection; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "phosphorothioate linkages"
XX
PN   US6020199-A.
XX
PD   01-FEB-2000.
XX
PF   21-JUL-1999;   99US-00358381.
XX
PR   21-JUL-1999;   99US-00358381.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-181363/16.
XX
PT   New antisense compounds useful for treating, preventing or diagnosing
PT   e.g. tumors or inflammation, are targeted to the human dual specificity
PT   protein phosphatase (PTEN) sequence.
XX
PS   Claim 16; Col 40; 32pp; English.
XX
CC   The present invention describes phosphorothioate antisense
CC   oligonucleotides that are targeted to the 3'-untranslated region (UTR) of
CC   the sequence encoding a human dual specificity protein phosphatase
CC   designated PTEN (also known as MMAC1 and TEP1), and hybridise
CC   specifically to the human PTEN nucleotide sequence given in AAZ91361. The
CC   antisense oligonucleotides have anticancer, anti-inflammatory and anti-
CC   infective activities. The phosphorothioate antisense oligonucleotides can
CC   be used for diagnosis, treatment and prevention of PTEN-related diseases,
CC   e.g. infections, inflammation and tumours. The present sequence
CC   represents a phosphorothioate antisense oligonucleotide for human PTEN,
CC   from the present invention
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 143
AAZ91373/c
ID   AAZ91373 standard; DNA; 18 BP.
XX
AC   AAZ91373;
XX
DT   22-MAY-2000  (first entry)
XX
DE   Human PTEN phosphorothioate antisense oligonucleotide #29539.
XX
KW   Human; PTEN; MMAC1; TEP1; phosphorothioate; antisense oligonucleotide;
KW   inhibition; protein phosphatase; tumour; diagnosis; inflammation;
KW   anticancer; anti-inflammatory; anti-infective; infection; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "phosphorothioate linkages"
XX
PN   US6020199-A.
XX
PD   01-FEB-2000.
XX
PF   21-JUL-1999;   99US-00358381.
XX
PR   21-JUL-1999;   99US-00358381.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-181363/16.
XX
PT   New antisense compounds useful for treating, preventing or diagnosing
PT   e.g. tumors or inflammation, are targeted to the human dual specificity
PT   protein phosphatase (PTEN) sequence.
XX
PS   Claim 16; Col 40; 32pp; English.
XX
CC   The present invention describes phosphorothioate antisense
CC   oligonucleotides that are targeted to the 3'-untranslated region (UTR) of
CC   the sequence encoding a human dual specificity protein phosphatase
CC   designated PTEN (also known as MMAC1 and TEP1), and hybridise
CC   specifically to the human PTEN nucleotide sequence given in AAZ91361. The
CC   antisense oligonucleotides have anticancer, anti-inflammatory and anti-
CC   infective activities. The phosphorothioate antisense oligonucleotides can
CC   be used for diagnosis, treatment and prevention of PTEN-related diseases,
CC   e.g. infections, inflammation and tumours. The present sequence
CC   represents a phosphorothioate antisense oligonucleotide for human PTEN,
CC   from the present invention
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||| || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 144
AAZ43273
ID   AAZ43273 standard; DNA; 18 BP.
XX
AC   AAZ43273;
XX
DT   11-FEB-2000  (first entry)
XX
DE   Murine Sox3 gene PCR primer 14.
XX
KW   Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
XX
OS   Mus musculus.
```

```
XX
PN   US5994075-A.
XX
PD   30-NOV-1999.
XX
PF   16-MAY-1997;   97US-00857946.
XX
PR   17-MAY-1996;   96US-0017824P.
XX
PA   (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI   Goodfellow PN;
XX
DR   WPI; 2000-038255/03.
XX
PT   Identifying a mutation in a gene of interest in an organism useful for
PT   identifying genes encoding products which may have therapeutic benefits.
XX
PS   Example 5; Col 65-66; 70pp; English.
XX
CC   This invention describes a novel mutational screening method based on
CC   genomic and genetic techniques to identify and characterize a mutation in
CC   a gene of interest without first selecting a phenotypic characteristic.
CC   The screening methods are useful for identifying genes encoding products
CC   which may have therapeutic benefit for treating human or animal diseases.
CC   The method can be used for the DNA mutation screening of a class or a
CC   family of genes providing a rapid assay for identifying mutant genes. The
CC   methods produce organisms which can be used for drug discovery e.g.
CC   providing a model for the study and treatment of a disease state, allow
CC   in vitro assessment of drug activity and interbreeding of mutants which
CC   allow investigation of gene interactions in the overall phenotype. A
CC   range of phenotypes associated with different mutations, and specified
CC   mutations in a gene of interest can be determined. The method can be
CC   adapted to screen for a mutation in two or more genes of interest in an
CC   organism. The methods allow mutations in a gene of interest to be
CC   identified without having to rely on matching a gene with a disease.
CC   AAZ43260-Z43421 represent PCR primers used in the method of the invention
XX
SQ   Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 145
AAA05258
ID   AAA05258 standard; DNA; 18 BP.
XX
AC   AAA05258;
XX
DT   19-MAY-2000  (first entry)
XX
DE   PCR primer G-R used in Sox-3 amplimer generation.
XX
KW   PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;
KW   Pax-6; mutation detection; therapeutic target identification; mouse;
KW   mast cell growth factor; ss.
XX
OS   Mus sp.
XX
PN   US6015670-A.
XX
PD   18-JAN-2000.
XX
PF   14-NOV-1997;   97US-00970740.
XX
PR   17-MAY-1996;   96US-0017824P.
PR   16-MAY-1997;   97US-00857946.
XX
PA   (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
PI   Goodfellow PN;
XX
DR   WPI; 2000-181139/16.
XX
PT   Detecting mutations in selected genes, useful e.g. for identifying
PT   therapeutic targets or products, by analyzing DNA in mutated embryonic
PT   stem cells without phenotypic characterization.
XX
PS   Example 5; Col 31; 66pp; English.
XX
CC   PCR primers AAA05245-A05406 are used to generate amplimers from the mouse
CC   Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,
CC   MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The
CC   primers are used in a method for the identification of a mutation in a
CC   selected gene in a tissue without the prior observation of a phenotypic
CC   alteration in the mutated organism or cell. The method is used to
CC   identify mutations in a selected gene that encode products of potential
CC   therapeutic activity or that are potential targets, particularly where
CC   the gene of interest has been identified as a candidate gene by
CC   positional cloning. Other applications are determining functions of genes
CC   ; detecting the range of phenotypes associated with different mutations
CC   in a particular gene and identification of particular mutations. Animals
CC   containing an identified mutation are used as models for studying
CC   diseases or their treatment, and cells from them for in vitro assessment
CC   of drug action. Interbreeding of mutant mice is used to investigate
CC   genetic interaction in the overall phenotype
XX
SQ   Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 146
AAZ93474
ID   AAZ93474 standard; DNA; 18 BP.
XX
AC   AAZ93474;
XX
DT   24-JUL-2000  (first entry)
XX
DE   TRADD antisense oligonucleotide.
XX
KW   TRADD; TNF; tumour necrosis factor; NF-kappa-B; apoptosis;
KW   programmed cell death; antisense; inhibition; treatment; therapy;
KW   septic shock; inflammation; cancer; antiinflammatory; human; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_binding    complement(1. .18)
FT                   /*tag=  a
FT                   /note= "Complementary to bases 634-617 of the human TRADD
FT                   sequence described in GENESEQ record AAZ93431"
XX
PN   WO200012527-A1.
XX
PD   09-MAR-2000.
XX
PF   25-AUG-1999;   99WO-US019614.
XX
PR   28-AUG-1998;   98US-00143212.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
```

PI Monia BP, Cowsert LM;
XX
DR WPI; 2000-237846/20.
XX
PT New antisense compounds that limit the expression of human TRADD protein,
PT useful in the treatment and diagnosis of cancer, inflammation and septic
PT shock.
XX
PS Claim 3; Page 52; 85pp; English.
XX
CC The intracellular protein TRADD has been identified as a critical link
CC between tumour necrosis factor (TNF) receptor binding and downstream
CC activation of NF-kappa-B. Overexpression of native TRADD activates NF-
CC kappa-B in the absence of TNF and dominant negative mutants of TRADD
CC block TNF-induced NF-kappa-B activation. A second effect of TNF in many
CC cell types is the induction of apoptosis (programmed cell death). TRADD
CC overexpression has been shown to mimic TNF induction of apoptosis as
CC well. Data indicates that TRADD and other downstream effector proteins
CC are the rate limiting step of TNF action and would therefore serve as the
CC most efficient targets for inhibition of TNF-induced events. Antisense
CC oligonucleotides capable of inhibiting TRADD function may therefore be
CC useful in a number of therapeutic, diagnostic and research applications.
CC Inhibiting expression of TRADD by contacting human cells or tissues with
CC the antisense compound may be used to treat a disease or condition
CC associated with TRADD expression, for example, septic shock,
CC inflammation, or cancer. TRADD antisense oligonucleotides of varying
CC inhibitory capabilities are listed in GENESEQ records AAZ93438-Z93517.
CC The antisense oligonucleotides exhibit enhanced inhibitory capabilities
CC when they have 2'-MOE wings and a deoxy gap
XX
SQ Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 114 GCGGCGGCGGCAGCTGC 130
||||||||||| ||| |
Db 1 GCGGCGGCGGCGGCTTC 17

RESULT 147
AAZ93476
ID AAZ93476 standard; DNA; 18 BP.
XX
AC AAZ93476;
XX
DT 24-JUL-2000 (first entry)
XX
DE TRADD antisense oligonucleotide.
XX
KW TRADD; TNF; tumour necrosis factor; NF-kappa-B; apoptosis;
KW programmed cell death; antisense; inhibition; treatment; therapy;
KW septic shock; inflammation; cancer; antiinflammatory; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_binding complement(1. .18)
FT /*tag= a
FT /note= "Complementary to bases 646-629 of the human TRADD
FT sequence described in GENESEQ record AAZ93431"
XX
PN WO200012527-A1.
XX
PD 09-MAR-2000.
XX
PF 25-AUG-1999; 99WO-US019614.
XX
PR 28-AUG-1998; 98US-00143212.
XX
PA (ISIS-) ISIS PHARM INC.
XX

PI Monia BP, Cowsert LM;
XX
DR WPI; 2000-237846/20.
XX
PT New antisense compounds that limit the expression of human TRADD protein,
PT useful in the treatment and diagnosis of cancer, inflammation and septic
PT shock.
XX
PS Claim 3; Page 52; 85pp; English.
XX
CC The intracellular protein TRADD has been identified as a critical link
CC between tumour necrosis factor (TNF) receptor binding and downstream
CC activation of NF-kappa-B. Overexpression of native TRADD activates NF-
CC kappa-B in the absence of TNF and dominant negative mutants of TRADD
CC block TNF-induced NF-kappa-B activation. A second effect of TNF in many
CC cell types is the induction of apoptosis (programmed cell death). TRADD
CC overexpression has been shown to mimic TNF induction of apoptosis as
CC well. Data indicates that TRADD and other downstream effector proteins
CC are the rate limiting step of TNF action and would therefore serve as the
CC most efficient targets for inhibition of TNF-induced events. Antisense
CC oligonucleotides capable of inhibiting TRADD function may therefore be
CC useful in a number of therapeutic, diagnostic and research applications.
CC Inhibiting expression of TRADD by contacting human cells or tissues with
CC the antisense compound may be used to treat a disease or condition
CC associated with TRADD expression, for example, septic shock,
CC inflammation, or cancer. TRADD antisense oligonucleotides of varying
CC inhibitory capabilities are listed in GENESEQ records AAZ93438-Z93517.
CC The antisense oligonucleotides exhibit enhanced inhibitory capabilities
CC when they have 2'-MOE wings and a deoxy gap
XX
SQ Sequence 18 BP; 1 A; 4 C; 12 G; 1 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 12 GGCAGGCGGCGGCGGAG 28
|||||| |||||||| |
Db 2 GGCAGGTGGCGGCGGCG 18

RESULT 148
AAA57499/c
ID AAA57499 standard; DNA; 18 BP.
XX
AC AAA57499;
XX
DT 20-OCT-2000 (first entry)
XX
DE Primer used for SSCP screening of the human TIGR gene.
XX
KW TIGR; trabecular meshwork inducible glucocorticoid receptor; promoter;
KW glaucoma; steroid sensitivity; progressive ocular hypertension;
KW vision loss; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200042220-A1.
XX
PD 20-JUL-2000.
XX
PF 11-JAN-2000; 2000WO-US000559.
XX
PR 11-JAN-1999; 99US-00227881.
PR 07-MAY-1999; 99US-00306828.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Nguyen TD, Polansky JR, Chen P, Chen H;
XX
DR WPI; 2000-491060/43.
XX
PT Diagnosis, prognosis and treatment of glaucoma, based on detecting

```
PT   specific polymorphisms in the promoter of the trabecular meshwork
PT   inducible glucocorticoid receptor gene.
XX
PS   Claim 9; Page 53; 122pp; English.
XX
CC   Primers AAA57489-A57508 were used for single strand conformational
CC   polymorphism (SSCP) screening of the human TIGR (trabecular meshwork
CC   inducible glucocorticoid receptor) gene. The primers correspond to
CC   sequences found within the TIGR promoter and two of the exons of TIGR,
CC   and are used in the method of the invention. The specification describes
CC   a method for the diagnosis, prognosis and treatment of glaucoma, based on
CC   detecting specific polymorphisms in the promoter of the TIGR gene. The
CC   method is used for diagnosis and prognosis of glaucoma (of all types),
CC   steroid sensitivity and progressive ocular hypertension that leads to
CC   loss of vision. Glaucoma can be treated by administering an agent that
CC   binds to cis-acting elements within the TIGR promoter. The TIGR promoter
CC   (or other regulatory regions) can be used to express homologous or
CC   heterologous genes, particularly for tissue-specific expression of
CC   therapeutic transgenes for treating glaucoma, also to generate transgenic
CC   animals and in screening for compounds (specific modulators) with
CC   diagnostic or therapeutic potential. Fragments of the TIGR sequence can
CC   be used as amplification primers or probes, e.g. for isolating related
CC   sequences in non-human animals
XX
SQ   Sequence 18 BP; 4 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 149
AAF85699
ID   AAF85699 standard; DNA; 18 BP.
XX
AC   AAF85699;
XX
DT   13-JUL-2001  (first entry)
XX
DE   Multiple repeated heat process PCR related oligonucleotide #3.
XX
KW   Multiple repeated heat circulation; polymerase chain reaction; PCR;
KW   target DNA production; DNA synthesis; ds.
XX
OS   Unidentified.
XX
PN   CN1278558-A.
XX
PD   03-JAN-2001.
XX
PF   22-JUN-1999;   99CN-00114949.
XX
PR   22-JUN-1999;   99CN-00114949.
XX
PA   (XIAQ/) XIA Q.
XX
PI   Xia Q;
XX
DR   WPI; 2001-245741/26.
XX
PT   Asynchronous chain-extending polymerase chain reaction for producing lots
PT   of target DNA fragments, comprises a multiple repeated heat circulation
PT   process.
XX
PS   Disclosure; Page 3; 4pp; Chinese.
XX
CC   The present invention relates to a kind of two chains asynchronously-
CC   elongated DNA amplification technology in vitro, which is characterized
CC   by that firstly, a pair of specific primers is synthesized according to
CC   the target DNA sequence to be amplified, then a repetitive sequence
CC   complementary oligo-repetitive sequence of 3' target DNA chain whose tail
CC   end is modified and elongation vitality is lost, then the oligo-
CC   repetitive sequence, chain primer, heat-resisting DNA polymerase, dNTP
CC   substrate, template DNA, magnesium ion, polymerase chain reaction (PCR)
CC   buffer solution and ultra-pure water are mixed uniformly and made into a
CC   reaction system. The reaction system then undergoes the processes of high
CC   -temp., low-temp., medium-low temp., medium-temp, and repeated heat
CC   circulation treatment in the heat-circulating instrument to obtain
CC   million copies of specific target DNA fragments. The invention adopts a
CC   multiple repeated heat circulation process, so that it can produce lots
CC   of target DNA fragments. The present sequence was used in the
CC   exemplification of the invention
XX
SQ   Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              |||||||||| || |||
Db          1 CGGCGGCGGCGGCGGCG 17


RESULT 150
AAS13999
ID   AAS13999 standard; DNA; 18 BP.
XX
AC   AAS13999;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PTEN antisense oligonucleotide ISIS 29539.
XX
KW   Human; PTEN; MMAC1; TEP1; protein phosphatase; antisense; ss;
KW   antiinflammatory; cytostatic; antidiabetic; antilipaemic; infection;
KW   inflammation; tumour; diabetes; insulin resistance; insulin sensitivity;
KW   triglyceride control; cholesterol control; ISIS 29539.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   1-4 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   15-18 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
XX
PN   US6284538-B1.
XX
PD   04-SEP-2001.
XX
PF   24-MAY-2000; 2000US-00577902.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2001-588976/66.
XX
```

```
PT   New antisense oligonucleotides targeting nucleic acids encoding PTEN,
PT   useful for treating diabetes, increasing insulin sensitivity, or
PT   decreasing insulin resistance, blood triglyceride or cholesterol levels
PT   in a diabetic animal.
XX
PS   Claim 1; Col 41; 38pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid encoding
CC   PTEN (a dual specificity protein phosphatase), where the compound is an
CC   antisense oligonucleotide. The antisense oligonucleotides are useful in
CC   modulating the function of nucleic acids encoding PTEN, ultimately
CC   modulating the amount of PTEN produced. The antisense compounds can used
CC   as diagnostics, therapeutics, prophylactics (e.g. to prevent or delay
CC   infection, inflammation or tumour formation), and as research agents and
CC   kits. The antisense compounds are also useful in treating diabetes,
CC   decreasing insulin resistance, increasing insulin sensitivity and
CC   decreasing blood triglyceride or cholesterol levels in a diabetic animal.
CC   The present sequence is an antisense oligonucleotide targetting the DNA
CC   encoding PTEN (also known as MMAC1/TEP1)
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 151
AAS13999/c
ID   AAS13999 standard; DNA; 18 BP.
XX
AC   AAS13999;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PTEN antisense oligonucleotide ISIS 29539.
XX
KW   Human; PTEN; MMAC1; TEP1; protein phosphatase; antisense; ss;
KW   antiinflammatory; cytostatic; antidiabetic; antilipaemic; infection;
KW   inflammation; tumour; diabetes; insulin resistance; insulin sensitivity;
KW   triglyceride control; cholesterol control; ISIS 29539.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   1-4 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   15-18 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
XX
PN   US6284538-B1.
XX
PD   04-SEP-2001.
XX
PF   24-MAY-2000; 2000US-00577902.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2001-588976/66.
XX
PT   New antisense oligonucleotides targeting nucleic acids encoding PTEN,
PT   useful for treating diabetes, increasing insulin sensitivity, or
PT   decreasing insulin resistance, blood triglyceride or cholesterol levels
PT   in a diabetic animal.
XX
PS   Claim 1; Col 41; 38pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid encoding
CC   PTEN (a dual specificity protein phosphatase), where the compound is an
CC   antisense oligonucleotide. The antisense oligonucleotides are useful in
CC   modulating the function of nucleic acids encoding PTEN, ultimately
CC   modulating the amount of PTEN produced. The antisense compounds can used
CC   as diagnostics, therapeutics, prophylactics (e.g. to prevent or delay
CC   infection, inflammation or tumour formation), and as research agents and
CC   kits. The antisense compounds are also useful in treating diabetes,
CC   decreasing insulin resistance, increasing insulin sensitivity and
CC   decreasing blood triglyceride or cholesterol levels in a diabetic animal.
CC   The present sequence is an antisense oligonucleotide targetting the DNA
CC   encoding PTEN (also known as MMAC1/TEP1)
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||  || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 152
AAD40034
ID   AAD40034 standard; DNA; 18 BP.
XX
AC   AAD40034;
XX
DT   22-OCT-2002  (first entry)
XX
DE   Human PTEN antisense oligonucleotide, ISIS 29579.
XX
KW   Human; phosphoinositide phosphatase; PTEN; liver; kidney; cholesterol;
KW   metabolic disease; diabetes; hyperproliferative; glucose; insulin; PEPCK;
KW   triglyceride; antisense gene therapy; cytostatic; adipose cell;
KW   antiproliferative; antisense; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   15
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   16
FT                   /*tag=  e
```

```
FT                   /mod_base= m5c
FT   modified_base   18
FT                   /*tag=  f
FT                   /mod_base= m5c
XX
PN   US2002058638-A1.
XX
PD   16-MAY-2002.
XX
PF   11-JUN-2001; 2001US-00878582.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
PR   24-MAY-2000; 2000US-00577902.
XX
PA   (MONI/) MONIA B P.
PA   (COWS/) COWSERT L M.
PA   (MCKA/) MCKAY R.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2002-479187/51.
XX
PT   New compound, preferably an antisense oligonucleotide, that hybridizes
PT   and inhibits the expression of phosphoinositide phosphatase (PTEN), for
PT   treating diseases such as diabetes, or a hyperproliferative condition.
XX
PS   Claim 7; Page 31; 39pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of phosphoinositide phosphatase (PTEN). The
CC   antisense compound is used to inhibit the expression of PTEN in cells or
CC   tissues, preferably human, or rodent, such as mouse or rat, liver, kidney
CC   or adipose cells or tissues. It is used to treat a disease or condition
CC   associated with PTEN, such as a metabolic disease or condition,
CC   preferably diabetes, especially Type 2 diabetes, or a hyperproliferative
CC   condition. It is also used to decrease blood glucose or insulin levels in
CC   an animal, preferably a diabetic human or rodent. It is also used to
CC   inhibit expression of PEPCK in cells or tissues. It is also used to
CC   decrease insulin resistance, or increase insulin sensitivity, in an
CC   animal, preferably a diabetic human or rodent. It is used to decrease
CC   blood triglyceride or cholesterol levels in an animal, preferably a
CC   diabetic human or rodent. It is also used in antisense gene therapy. The
CC   present sequence is an antisense oligonucleotide targetted to human PTEN
CC   DNA
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 153
AAD40034/c
ID   AAD40034 standard; DNA; 18 BP.
XX
AC   AAD40034;
XX
DT   22-OCT-2002  (first entry)
XX
DE   Human PTEN antisense oligonucleotide, ISIS 29579.
XX
KW   Human; phosphoinositide phosphatase; PTEN; liver; kidney; cholesterol;
KW   metabolic disease; diabetes; hyperproliferative; glucose; insulin; PEPCK;
KW   triglyceride; antisense gene therapy; cytostatic; adipose cell;
KW   antiproliferative; antisense; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   15
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   16
FT                   /*tag=  e
FT                   /mod_base= m5c
FT   modified_base   18
FT                   /*tag=  f
FT                   /mod_base= m5c
XX
PN   US2002058638-A1.
XX
PD   16-MAY-2002.
XX
PF   11-JUN-2001; 2001US-00878582.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
PR   24-MAY-2000; 2000US-00577902.
XX
PA   (MONI/) MONIA B P.
PA   (COWS/) COWSERT L M.
PA   (MCKA/) MCKAY R.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2002-479187/51.
XX
PT   New compound, preferably an antisense oligonucleotide, that hybridizes
PT   and inhibits the expression of phosphoinositide phosphatase (PTEN), for
PT   treating diseases such as diabetes, or a hyperproliferative condition.
XX
PS   Claim 7; Page 31; 39pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of phosphoinositide phosphatase (PTEN). The
CC   antisense compound is used to inhibit the expression of PTEN in cells or
CC   tissues, preferably human, or rodent, such as mouse or rat, liver, kidney
CC   or adipose cells or tissues. It is used to treat a disease or condition
CC   associated with PTEN, such as a metabolic disease or condition,
CC   preferably diabetes, especially Type 2 diabetes, or a hyperproliferative
CC   condition. It is also used to decrease blood glucose or insulin levels in
CC   an animal, preferably a diabetic human or rodent. It is also used to
CC   inhibit expression of PEPCK in cells or tissues. It is also used to
CC   decrease insulin resistance, or increase insulin sensitivity, in an
CC   animal, preferably a diabetic human or rodent. It is used to decrease
CC   blood triglyceride or cholesterol levels in an animal, preferably a
CC   diabetic human or rodent. It is also used in antisense gene therapy. The
CC   present sequence is an antisense oligonucleotide targetted to human PTEN
CC   DNA
XX
SQ   Sequence 18 BP; 1 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
```

```
                ||||||||||||| || |
Db          18 GCGGCGGCGGCACCTCC 2


RESULT 154
ABX16214
ID   ABX16214 standard; DNA; 18 BP.
XX
AC   ABX16214;
XX
DT   09-APR-2003  (first entry)
XX
DE   Human leukocyte antigen, HLA-A, exon 2 PCR primer #1.
XX
KW   Human; ss; human leukocyte antigen; HLA-A; HLA-DRB1; PCR; primer;
KW   genotyping; fluorescence resonance energy transfer; FRET;
KW   emission spectrum; mutations detection; common thermolabile mutation;
KW   polymorphism; ligase chain reaction; LCR; genetic disorder; cancer;
KW   infectious disease; translocation testing.
XX
OS   Homo sapiens.
XX
PN   US6472156-B1.
XX
PD   29-OCT-2002.
XX
PF   30-AUG-2000; 2000US-00651374.
XX
PR   30-AUG-1999;   99US-0151494P.
XX
PA   (UTAH ) UNIV UTAH.
XX
PI   Wittwer CT,  Herrmann MG;
XX
DR   WPI; 2003-196846/19.
XX
PT   Nucleic acid sample analysis method for detecting mutations and genetic
PT   disorders, comprises measuring emission of fluorescence resonance energy
PT   transfer acceptors at different temperatures.
XX
PS   Example 3; Col 26; 44pp; English.
XX
CC   The invention relates to analysing a nucleic acid sample comprising 3 or
CC   more loci, comprising using three pairs of oligonucleotide probes, each
CC   comprising a fluorescence resonance energy transfer (FRET) donor, and
CC   FRET acceptors having different emission spectrums, where the emission of
CC   the acceptors is measured at different temperatures to provide an
CC   indication of the alleles present at the loci of the nucleic acid. The
CC   method is used for analysing nucleic acid samples in clinical
CC   laboratories for detecting mutations such as common thermolabile
CC   mutation, polymorphisms, PCR and ligase chain reaction (LCR) products,
CC   genetic disorders, cancers and for infectious disease and translocation
CC   testing. The emission measurements allow for precise measurements of
CC   temporal coincidence of fluorescent emission and provide most accurate
CC   Tm, allowing for maximum discrimination between Tm of probes from
CC   different alleles, and thus maximising the number of allelic species that
CC   can be discriminated for a given FRET donor and FRET acceptor pair. The
CC   method was demonstrated by analysing the polymorphic regions of human
CC   leukocyte antigen, HLA (hypervariable region in exon 2) and HLA-DRB1
CC   (also in exon 2). The present sequence is a primer which amplifies a
CC   182bp region flanking the HLA-A hypervariable region
XX
SQ   Sequence 18 BP; 4 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 87;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        337 GACAGCGGCGCCTCGAG 353
              ||||||| |||| ||||
Db          1 GACAGCGACGCCGCGAG 17
```

```
RESULT 155
AAF27087
ID   AAF27087 standard; DNA; 20 BP.
XX
AC   AAF27087;
XX
DT   06-APR-2001  (first entry)
XX
DE   Human MEKK1 phosphorothioate antisense oligonucleotide, SEQ ID NO:9.
XX
KW   Human MEKK1; mitogen-activated protein kinase kinase kinase 1;
KW   MEK kinase 1; MAP/ERK kinase kinase 1; pro-apoptotic;
KW   apoptosis signal regulation; programmed cell death;
KW   serine/threonine kinase; MAP kinase cascade; JNK/SAPK;
KW   Jun N-terminal kinase/stress-activated protein kinase; Bcl-2 substrate;
KW   NF-kappa-B-mediated transcription regulation; expression inhibition;
KW   antisense; hyperproliferative disorder; cancer; inflammation;
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
PN   US6168950-B1.
XX
PD   02-JAN-2001.
XX
PF   23-JUL-1999;   99US-00359756.
XX
PR   23-JUL-1999;   99US-00359756.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Gaarde W,  Ward DT;
XX
DR   WPI; 2001-122264/13.
XX
PT   New antisense compound targeting nucleic acid encoding human mitogen-
PT   activated protein kinase kinase 1 (MEKK1), useful for treating diseases
PT   or conditions associated with MEKK1 expression, or preventing
PT   inflammation or tumor formation.
XX
PS   Example 15; Col 39; 35pp; English.
XX
CC   Sequences AAF27086-AAF27125 represent phosphorothioate antisense
CC   oligonucleotides targetted to the human MEKK1 gene, which inhibit its
CC   expression. The antisense oligonucleotides were designed to target
CC   different regions of the human MEKK1 RNA, and were analysed for their
CC   effect on MEKK1 mRNA levels by quantitative real-time PCR. MEKK1 (also
CC   known as mitogen-activated protein kinase kinase kinase 1, MEK kinase 1
CC   and MAP/ERK kinase kinase 1) is a dual-specific serine/threonine kinase
CC   which mediates cellular responses to mitogenic stimuli, being involved in
CC   JNK/SAPK (Jun N-terminal kinase/stress- activated protein kinase) MAP
CC   kinase cascades. MEKK1 regulates signalling events associated with
CC   apoptosis (programmed cell death) and NF-kappa-B, both of which have been
CC   associated with the development of hyperproliferative disorders such as
CC   cancer. Specifically, MEKK1 lies directly downstream of Bcl-2 in an
CC   apoptotic signalling cascade, and plays a critical role in the control of
CC   NF-kappa-B-mediated transcription at multiple points in the apoptotic
CC   cascade. The oligonucleotides of the invention are useful for diagnosis,
CC   prevention and treatment of conditions associated with MEKK1 expression,
CC   such as inflammation, and cancer and other hyperproliferative disorders
XX
SQ   Sequence 20 BP; 1 A; 9 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         43 AGCAGCGCGCGCGCGGC 59
              ||| |||||||||| ||
Db          4 AGCCGCGCGCGCGCTGC 20


RESULT 156
```

```
AAT86420
ID   AAT86420 standard; DNA; 15 BP.
XX
AC   AAT86420;
XX
DT   28-JAN-1998  (first entry)
XX
DE   Trinucleotide simple tandem repeat (GGC)5, peptide nucleic acid probe.
XX
KW   Peptide nucleic acid; PNA; hybridisation probe; polyamide backbone;
KW   trinucleotide tandem repeat sequence; satellite; quantitation; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .15
FT                   /*tag=  b
FT                   /note= "This sequence is a peptide nucleic acid, i.e. it
FT                   contains a polyamide backbone instead of a deoxyribose
FT                   backbone"
FT   repeat_unit     1. .3
FT                   /*tag=  a
FT                   /rpt_type= TANDEM
XX
PN   WO9714026-A2.
XX
PD   17-APR-1997.
XX
PF   10-OCT-1996;   96WO-CA000676.
XX
PR   12-OCT-1995;   95US-0005590P.
PR   28-NOV-1995;   95US-0007616P.
XX
PA   (LANS/) LANSDORP P.
XX
PI   Lansdorp P;
XX
DR   WPI; 1997-236021/21.
XX
PT   Detection of multiple copies of repeat sequences in telomeres - useful
PT   for determining replicative potential of cells.
XX
PS   Disclosure; Page 9; 38pp; English.
XX
CC   This is a peptide nucleic acid (PNA) probe which is used for detecting
CC   and optionally quantitating the trinucleotide simple tandem repeat CCG.
CC   The probe is suitable for use in a new method for detecting and
CC   optionally quantitating multiple copies of a repeat sequence. For use in
CC   the method, the probe is labelled, preferably with a fluorescent
CC   molecule, and the length of the repeat region can be determined based on
CC   the intensity of the label signal
XX
SQ   Sequence 15 BP; 0 A; 5 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          1 GGCGGCGGCGGCGGC 15


RESULT 157
AAZ62710
ID   AAZ62710 standard; RNA; 15 BP.
XX
AC   AAZ62710;
XX
DT   28-MAR-2000  (first entry)
XX
DE   Substrate for HH ribozyme HCV-5965 which cleaves HCV RNA at nt. 5965.
XX
KW   Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW   cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW   autoimmune disease; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO9955847-A2.
XX
PD   04-NOV-1999.
XX
PF   26-APR-1999;   99WO-US009027.
XX
PR   27-APR-1998;   98US-0083217P.
PR   18-SEP-1998;   98US-0100842P.
PR   25-FEB-1999;   99US-00257608.
PR   23-MAR-1999;   99US-00274553.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Mcswiggen JA,  Roberts E,  Pavco PA,  Macejak D;
XX
DR   WPI; 2000-062023/05.
XX
PT   Novel ribozymes for the treatment of diseases and conditions related to
PT   hepatitis C infection.
XX
PS   Claim 1; Page 60; 123pp; English.
XX
CC   The present sequence represents the preferred target sequence of an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC   the descriptor line. The HCV sequence was screened for optimal ribozyme
CC   target sites using a computer folding algorithm and regions of the mRNA
CC   which did not form secondary folding structures and contained potential
CC   ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC   target these sites and their activities optimised by either varying the
CC   length of the binding arms or by modification to prevent degradation by
CC   nucleases. The ribozymes of the invention inhibit gene expression and/or
CC   viral replication, and are used to treat diseases associated with
CC   Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC   hepatocellular carcinoma. The ribozymes may be used in combination with
CC   interferon to treat HCV infection, other infectious diseases, autoimmune
CC   diseases, and cancer
XX
SQ   Sequence 15 BP; 1 A; 8 C; 5 G; 0 T; 1 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              |||||| ||||||||
Db          1 GCGCCCUCCGCCGAG 15


RESULT 158
AAF45309/c
ID   AAF45309 standard; DNA; 15 BP.
XX
AC   AAF45309;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #148.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTG 129
              ||||||||||||| |
Db         15 CGGCGGCGGCAGCGG 1


RESULT 159
AAF45371
ID   AAF45371 standard; DNA; 15 BP.
XX
AC   AAF45371;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #210.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAG 126
              ||||||||||||| |
Db          1 TGGCGGCGGCGGCGG 15


RESULT 160
AAF45305/c
ID   AAF45305 standard; DNA; 15 BP.
XX
AC   AAF45305;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #144.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
```

```
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    .0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||  ||||||||
Db         15 GGCGGCAGCGGCAGC 1


RESULT 161
AAF45308/c
ID   AAF45308 standard; DNA; 15 BP.
XX
AC   AAF45308;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #147.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        116 GGCGGCGGCAGCTGC 130
              ||||||||||||  ||
Db         15 GGCGGCGGCAGCGGC 1


RESULT 162
AAF45368
ID   AAF45368 standard; DNA; 15 BP.
XX
AC   AAF45368;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #207.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
```

```
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 3 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        109 GACTGGCGGCGGCGG 123
              || |||||||||||||
Db          1 GAGTGGCGGCGGCGG 15


RESULT 163
AAF45369
ID   AAF45369 standard; DNA; 15 BP.
XX
AC   AAF45369;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #208.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 1 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        110 ACTGGCGGCGGCGGC 124
              | |||||||||||||
Db          1 AGTGGCGGCGGCGGC 15


RESULT 164
AAF45448
ID   AAF45448 standard; DNA; 15 BP.
XX
AC   AAF45448;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #287.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 35; 201pp; English.
XX
```

CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 0 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 414 GGCCCCCGCCGGTCG 428
||||||||||||| |
Db 1 GGCCCCCGCCGGTTG 15

RESULT 165
ABX00561
ID ABX00561 standard; RNA; 15 BP.
XX
AC ABX00561;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #343 for HCV hammerhead ribozyme #343.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytostatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 31; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 15 BP; 1 A; 8 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 385 GCGCCCGCCGCCGAG 399
|||||| ||||||||
Db 1 GCGCCCUCCGCCGAG 15

RESULT 166
AAZ31706
ID AAZ31706 standard; DNA; 16 BP.
XX
AC AAZ31706;
XX
DT 19-JAN-2000 (first entry)
XX
DE PCR primer 93 for mutant neo gene.
XX
KW PCR primer; preS2 antigen; protein expression; selectable marker gene;
KW internal ribosome entry site; IRES; vaccine; therapy; diagnosis; antigen;
KW immune response; HBV; ss.
XX
OS Synthetic.
XX
PN WO9953046-A2.
XX
PD 21-OCT-1999.
XX
PF 13-APR-1999; 99WO-US008069.
XX
PR 14-APR-1998; 98US-0081777P.
XX
PA (CHIR) CHIRON CORP.
XX
PI Selby M, Thudium K, Dina D;
XX
DR WPI; 1999-620421/53.
XX
PT Expressing recombinant polypeptide in mammalian cells, particularly for
PT producing hepatitis B antigen for vaccination.
XX
PS Example 1; Page 32; 51pp; English.
XX
CC This sequence represents a PCR primer for the mutant neo gene. The
CC invention relates to a method for expressing recombinant polypeptide (I)
CC in mammalian cells without subcloning the coding sequence. The method
CC comprises co-transfecting mammalian cells with three nucleic acid
CC elements: (1) containing a promoter; (2) containing a selectable marker
CC gene (SMG), internal ribosome entry site (IRES) and transcription
CC terminator (TT); and (3) containing a gene encoding (I). The cells are
CC cultured so that (I) and SMG are expressed, those expressing SMG are
CC selected, and selected cells that also express (I) are identified. In
CC (2), IRES is upstream of SMG and TT is downstream of SMG. The method is
CC used to produce (I) that are useful in vaccines, therapy and diagnosis,
CC e.g. antigens (from a wide variety of viruses, bacteria, parasites, fungi
CC or tumours, for generating an immune response), hormones, mediators of

CC transcription or translation, enzymes, metabolic intermediates,
CC immunomodulators etc. Specifically it is used to produce the preS2
CC antigen of hepatitis B virus. When the 3 elements are co-transfected,
CC they become linked together such that expression of SMG requires co-
CC expression of (I), eliminating the need for subcloning of (I) into an
CC expression cassette. The method allows direct use of polymerase chain
CC reaction products and synthetic or natural DNA, for rapid expression of
CC one or more genes (e.g. from a cDNA library) in mammalian cells.
CC Expressing SMG and (I) from a single promoter reduces the problem of
CC false positives and, putting (I) upstream of IRES means that it is
CC expressed at higher level than SMG, i.e. selected cells will be high-
CC level expressors of (I)
XX
SQ Sequence 16 BP; 6 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 460 TTGCACAAGATGGAT 474
||| ||||||||||
Db 1 TTGAACAAGATGGAT 15

RESULT 167
ABL45238
ID ABL45238 standard; DNA; 16 BP.
XX
AC ABL45238;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:2282.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 4; Page 49; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 16 BP; 4 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 716 CAGGTCGCACAGTGA 730
||||| |||||||||
Db 2 CAGGTGGCACAGTGA 16

RESULT 168
AAD40092/c
ID AAD40092 standard; DNA; 16 BP.
XX
AC AAD40092;
XX
DT 22-OCT-2002 (first entry)
XX
DE Human DED4 (death effector domain) cDNA amplifying primer #1.
XX
KW Human; death domain; DD; death effector domain; DED; Chlamydia infection;
KW NB-ARC domain; apoptosis; oncogenic protein; bacterial infection; sepsis;
KW inflammation; allergy; autoimmunity; allograft rejection; cell division;
KW immune-based pathology; fibrosis; arthritis; graft versus host disease;
KW immunosuppressive; gene therapy; antisense therapy; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200240680-A2.
XX
PD 23-MAY-2002.
XX
PF 15-NOV-2001; 2001WO-US044844.
XX
PR 17-NOV-2000; 2000US-00715893.
PR 29-JUN-2001; 2001US-0301889P.
XX
PA (BURN-) BURNHAM INST.
XX
PI Reed JC, Godzik A, Pawlowski K, Fiorentino L, Lee SH, Roth W;
PI Stenner-Liewen F;
XX
DR WPI; 2002-500222/53.
XX
PT New polypeptide comprising a death domain or death effector domain,
PT useful for discovery of drugs that suppress infection, inflammation,
PT allergy, sepsis, autoimmunity, allograft rejection and other diseases.
XX
PS Example 7; Page 118; 209pp; English.
XX
CC The invention relates to an isolated polypeptide comprising a death
CC domain (DD), death effector domain (DED) or NB-ARC domain. The invention
CC is useful for identifying a binding agent, preferably a protein or a drug
CC that binds a DD, DED or NB-ARC domain, by contacting a DD, DED or NB-ARC
CC domain from DAP3, IRAK4, CTDD (Chlamydia trachomatis DD protein), DED4 or
CC NIDD (NGFR-interacting Death Domain), with a candidate binding agent and
CC detecting the association of the domain and the candidate binding agent,
CC by yeast two hybrid assay, immunoprecipitation, SPA, ultraviolet (UV) or
CC chemical crosslinking, nuclear magnetic resonance (NMR), mass
CC spectroscopy (MS) and FPA. The invention is useful for modulating the
CC level of a cell process such as cell proliferation, cell adhesion, cell
CC stress responses, responses to microbial infection and B cell
CC immunoglobulin class switching, in particular apoptosis within a cell.
CC Antibody specifically reactive with CTDD DD of C. trachomatis , C.
CC muridarum, C. pneumoniae, and C. psittaci or a nucleic acid encoding the
CC CTDD DD protein is useful for detecting a Chlamydia infection. The
CC invention is useful for modulating the activity of oncogenic proteins,

CC for treating a pathology caused by the oncogenic proteins and for
CC treating bacterial infections by modulating the activity of bacterial
CC proteins. The protein and antibody specific for it are useful for
CC discovery of drugs that suppress infection, inflammation, allergy,
CC sepsis, autoimmunity, allograft rejection and other diseases. The protein
CC is useful for treating immune-based pathologies, pathologies associated
CC with cell division, inflammatory diseases such as sepsis, fibrosis,
CC arthritis, graft versus host disease. The invention is used in antisense
CC therapy and gene therapy. The present sequence is human DED4 cDNA
CC amplifying primer
XX
SQ Sequence 16 BP; 0 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 14 CAGGCGGCGGCGGAG 28
||| ||||||||||
Db 15 CAGACGGCGGCGGAG 1

RESULT 169
AAD59074/c
ID AAD59074 standard; DNA; 16 BP.
XX
AC AAD59074;
XX
DT 18-DEC-2003 (first entry)
XX
DE Primer #1 used to amplify human DED4 cDNA.
XX
KW Human; death Domain; DD; death effector domain; DED; cell proliferation;
KW Chlamydia trachomatis death domain containing protein; fibrosis; sepsis;
KW neural growth factor receptor-interacting death domain; cell adhesion;
KW vasotropic; microbial infection; inflammation; allograft rejection; CTDD;
KW cell stress response; benign prostatic hypertrophy; antibacterial; NIDD;
KW apoptosis; infection; autoimmunity; allergy; hyperplasia; gene therapy;
KW neoplasia; restenosis; immunosuppressive; antibody therapy; cytostatic;
KW keloid; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003049702-A1.
XX
PD 13-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00001254.
XX
PR 17-NOV-2000; 2000US-00715893.
PR 17-NOV-2000; 2000US-0367360P.
PR 29-JUN-2001; 2001US-0301889P.
XX
PA (REED/) REED J C.
PA (GODZ/) GODZIK A.
PA (PAWL/) PAWLOWSKI K.
PA (FIOR/) FIORENTINO L.
PA (LEES/) LEE S H.
PA (ROTH/) ROTH W.
PA (STEN/) STENNER-LIEWEN F.
XX
PI Reed JC, Godzik A, Pawlowski K, Fiorentino L, Lee SH, Roth W;
PI Stenner-Liewen F;
XX
DR WPI; 2002-500222/53.
XX
PT New polypeptide comprising a death domain or death effector domain,
PT useful for discovery of drugs that suppress infection, inflammation,
PT allergy, sepsis, autoimmunity, allograft rejection and other diseases.
XX
PS Example 7; Page 30; 99pp; English.
XX
CC The present invention provides novel death Domain (DD) and death effector
CC domain (DED) proteins and nucleic acids encoding them. The invention also
CC provides death domain containing protein such as Chlamydia trachomatis
CC death domain containing protein (CTDD) DD and neural growth factor
CC receptor-interacting death domain (NIDD) DD. The invention is useful for
CC identifying a binding agent (e.g. protein or drug) that binds a DD, DED
CC or NB-ARC domain from DAP3, IRAK4, CTDD, DED4 or NIDD with a candidate
CC binding agent and identifying an effective agent (e.g. protein or drug)
CC that modulates the association of a DD, DED or NB-ARC domain with protein
CC that binds the DD, DED or NB-ARC domain. The invention is also useful for
CC modulating the level of cell process such as apoptosis, cell adhesion,
CC cell proliferation, cell stress responses, responses to microbial
CC infection and B cell immunoglobulin class switching. DDs, DEDs and NB-ARC
CC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are
CC useful for discovery of drugs that suppress infection, autoimmunity,
CC inflammation, allergy, allograft rejection, sepsis and other diseases.
CC DD, DED or NB-ARC domain proteins are used to treat infection, allergy,
CC autoimmunity, inflammation, allograft rejection, sepsis, keratinocyte
CC hyperplasia, neoplasia, keloid, benign prostatic hypertrophy, fibrosis,
CC inflammatory hyperplasia and smooth muscle cell proliferation in arteries
CC following balloon angioplasty (restenosis). The invention is also used in
CC antibody therapy and gene therapy. The present sequence is a primer used
CC to amplify human DED4 cDNA
XX
SQ Sequence 16 BP; 0 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 14 CAGGCGGCGGCGGAG 28
||| ||||||||||
Db 15 CAGACGGCGGCGGAG 1

RESULT 170
AAZ08873
ID AAZ08873 standard; DNA; 17 BP.
XX
AC AAZ08873;
XX
DT 08-NOV-1999 (first entry)
XX
DE Fibrinogen receptor glycoprotein IIIa allele specific oligonucleotide.
XX
KW Fibrinogen receptor; glycoprotein IIb-IIIa; GPIIb-IIIa; GPIIIa;
KW thrombotic disease; platelet polymorphism; PIA2 polymorphism;
KW coronary heart disease; premature stroke; coronary artery thrombosis;
KW myocardial infarction; cerebrovascular disease; unstable angina;
KW restenosis; diagnosis; allele specific oligonucleotide; ASO; probe; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5955266-A.
XX
PD 21-SEP-1999.
XX
PF 01-APR-1996; 96US-00626023.
XX
PR 01-APR-1996; 96US-00626023.
XX
PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI Bray PF, Goldschmidt-Clermont PJ;
XX
DR WPI; 1999-539564/45.
XX
PT Use of a platelet polymorphism to diagnose risk of thrombotic disease.
XX
PS Claim 10; Col 18; 13pp; English.
XX
CC A method has been developed for diagnosing a subject at risk of having a
CC thrombotic disease. The method comprises detecting the presence of a PIA2

```
CC   polymorphism in the fibrinogen receptor glycoprotein IIIa (GPIIIa) gene.
CC   The method is useful for diagnosing risk of thrombotic diseases including
CC   coronary heart disease (CHD), premature stroke, coronary artery
CC   thrombosis, myocardial infarction, cerebrovascular disease, unstable
CC   angina, and restenosis. The present sequence represents a specifically
CC   claimed GPIIIa allele specific oligonucleotide (ASO) probe for use in the
CC   method of the invention
XX
SQ   Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              |||||| ||||||||
Db          3 GAGCCCAGAGGCAGG 17


RESULT 171
AAZ08871/c
ID   AAZ08871 standard; DNA; 17 BP.
XX
AC   AAZ08871;
XX
DT   08-NOV-1999  (first entry)
XX
DE   Fibrinogen receptor glycoprotein IIIa wild type target sequence.
XX
KW   Fibrinogen receptor; glycoprotein IIb-IIIa; GPIIb-IIIa; GPIIIa;
KW   thrombotic disease; platelet polymorphism; PIA2 polymorphism;
KW   coronary heart disease; premature stroke; coronary artery thrombosis;
KW   myocardial infarction; cerebrovascular disease; unstable angina;
KW   restenosis; diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   US5955266-A.
XX
PD   21-SEP-1999.
XX
PF   01-APR-1996;   96US-00626023.
XX
PR   01-APR-1996;   96US-00626023.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI   Bray PF,  Goldschmidt-Clermont PJ;
XX
DR   WPI; 1999-539564/45.
XX
PT   Use of a platelet polymorphism to diagnose risk of thrombotic disease.
XX
PS   Claim 9; Col 18; 13pp; English.
XX
CC   A method has been developed for diagnosing a subject at risk of having a
CC   thrombotic disease. The method comprises detecting the presence of a PIA2
CC   polymorphism in the fibrinogen receptor glycoprotein IIIa (GPIIIa) gene.
CC   The method is useful for diagnosing risk of thrombotic diseases including
CC   coronary heart disease (CHD), premature stroke, coronary artery
CC   thrombosis, myocardial infarction, cerebrovascular disease, unstable
CC   angina, and restenosis. The present sequence represents a specifically
CC   claimed wild type GPIIIa target sequence for use in the method of the
CC   invention
XX
SQ   Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              |||||| ||||||||
Db         15 GAGCCCAGAGGCAGG 1


RESULT 172
AAA36571/c
ID   AAA36571 standard; DNA; 17 BP.
XX
AC   AAA36571;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:636.
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 72; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
SQ   Sequence 17 BP; 1 A; 9 C; 3 G; 3 T; 0 U; 1 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 90;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| |||||| |||
Db         17 GGGKAGGGGGACCAGCT 1


RESULT 173
AAA36602
ID   AAA36602 standard; DNA; 17 BP.
XX
AC   AAA36602;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:667.
```

```
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 72; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
SQ   Sequence 17 BP; 3 A; 3 C; 9 G; 1 T; 0 U; 1 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 90;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| ||||||  |||
Db          1 GGGKAGGGGGACCAGCT 17


RESULT 174
AAF06092/c
ID   AAF06092 standard; DNA; 17 BP.
XX
AC   AAF06092;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #2889.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 122; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        343 GGCGCCTCGAGTCCC 357
              || ||||||||||||
Db         17 GGAGCCTCGAGTCCC 3


RESULT 175
ABK01788
ID   ABK01788 standard; RNA; 17 BP.
XX
AC   ABK01788;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Zinzyme #110.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
```

```
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 97; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a zinzyme molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 8 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCA 125
              | ||||||||||||||
Db          3 CCGGCGGCGGCGGCA 17


RESULT 176
ABK02248/c
ID   ABK02248 standard; RNA; 17 BP.
XX
AC   ABK02248;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO DNAzyme #160.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 115; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a DNAzyme molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        602 GAGATGGATCTGAAA 616
              ||||||  ||||||||
Db         17 GAGATGAATCTGAAA 3
```

RESULT 177
ABK00441/c
ID ABK00441 standard; RNA; 17 BP.
XX
AC ABK00441;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #441.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 73; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a hammerhead ribozyme of the invention
XX
SQ Sequence 17 BP; 5 A; 5 C; 1 G; 0 T; 6 U; 0 Other;

```
  Query Match              1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAA 615
              |||||||  |||||||
Db         15 GGAGATGAATCTGAA 1
```

RESULT 178
ABN02506
ID ABN02506 standard; DNA; 17 BP.
XX
AC ABN02506;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2498.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser

```
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2498; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          2 CCTGCACCAGATGGC 16


RESULT 179
ABN08131
ID   ABN08131 standard; DNA; 17 BP.
XX
AC   ABN08131;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8123.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8123; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          3 GCGGCTTCATCAGCT 17


RESULT 180
ABN08132
ID   ABN08132 standard; DNA; 17 BP.
XX
AC   ABN08132;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8124.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
```

```
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8124; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          2 GCGGCTTCATCAGCT 16


RESULT 181
ABN02505
ID   ABN02505 standard; DNA; 17 BP.
XX
AC   ABN02505;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2497.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2497; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          3 CCTGCACCAGATGGC 17


RESULT 182
ABN08133
```

```
ID   ABN08133 standard; DNA; 17 BP.
XX
AC   ABN08133;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8125.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8125; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          1 GCGGCTTCATCAGCT 15


RESULT 183
ABN02507
ID   ABN02507 standard; DNA; 17 BP.
XX
AC   ABN02507;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2499.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2499; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
```

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 90;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 814 CCTTCACCAGATGGC 828
||| ||||||||||
Db 1 CCTGCACCAGATGGC 15

RESULT 184
ABV85758/c
ID ABV85758 standard; DNA; 17 BP.
XX
AC ABV85758;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:751.
XX
KW Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KW pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 751; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 90;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 31 GCCCTCAAGGCGAGC 45
||||||| ||||||
Db 17 GCCCTCAATGCGAGC 3

RESULT 185
ABV85761/c
ID ABV85761 standard; DNA; 17 BP.
XX
AC ABV85761;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:754.
XX
KW Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KW pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 754; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed

```
CC   specification but is based on sequence information supplied by the
CC   European Patent Office
XX
SQ   Sequence 17 BP; 2 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAG 44
              ||||||||| |||||
Db         15 AGCCCTCAATGCGAG 1


RESULT 186
ABQ99697/c
ID   ABQ99697 standard; DNA; 17 BP.
XX
AC   ABQ99697;
XX
DT   08-NOV-2002  (first entry)
XX
DE   Murine Ikbkap exon 37 acceptor site.
XX
KW   Murine; IKBKAP; Familial Dysautonomia; FD; Riley-Day syndrome; ds;
KW   Hereditary Sensory and Autonomic Neuropathy Type III; carrier screening.
XX
OS   Mus sp.
XX
PN   WO200259381-A2.
XX
PD   01-AUG-2002.
XX
PF   07-JAN-2002; 2002WO-US000473.
XX
PR   06-JAN-2001; 2001US-0260080P.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Slaugenhaupt S,  Gusella JF;
XX
DR   WPI; 2002-674806/72.
XX
PT   New IKBKAP genes with mutations, useful for identifying a subject with
PT   familial dysautonomia (FD), or for rapid carrier screening in the
PT   Ashkenazi Jewish population, e.g. screening presymptomatic homozygotes or
PT   prenatal diagnosis.
XX
PS   Disclosure; Fig 11; 109pp; English.
XX
CC   The present invention relates to methods and compositions useful for
CC   detecting mutations which cause Familial Dysautonomia (FD, Riley-Day
CC   syndrome, Hereditary Sensory and Autonomic Neuropathy Type III) [OMIM
CC   223900]. It was found that mutations in the IKBKAP gene (see ABQ80565)
CC   are associated with FD. The mutation associated with the major haplotype
CC   of FD, FD1 mutation, is a base pair (bp) mutation, where the thymine
CC   nucleotide located at bp 6 of intron 20 in the IKBKAP gene is replaced
CC   with a cytosine. This results in skipping of exon 20 in the mRNA from FD
CC   patients, although they continue to express varying levels of wild-type
CC   message in a tissue-specific manner. The mutation associated with the
CC   minor haplotype, FD2 mutation, is a bp mutation, where the guanine
CC   nucleotide at bp 2397 (bp 73 of exon 19) is replaced with a cytosine.
CC   This bp mutation causes an arginine to proline missense mutation (R696P)
CC   in the IKBKAP protein, which is predicted to disrupt a potential
CC   phosphorylation site. The IKBKAP nucleic acid sequences are useful for
CC   identifying a subject with FD and for rapid carrier screening. The IKBKAP
CC   gene maps to chromosome 9q31. A mouse model of FD was created in an
CC   example from the invention. Expression of murine Ikbkap was examined
CC   using both mouse embryo and adult mouse multiple tissue Northern blots.
CC   The blots were probes with a 1045bp PCR fragent that contains exons 2
CC   through 11, which was generated using PCR primers ABQ80563-ABQ80564.
CC   ABQ99662-ABQ99733 are the murine Ikbkap exon and intron boundaries
XX
SQ   Sequence 17 BP; 3 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              ||||||||| |||||
Db         15 CTGGAAGCAAGAATG 1


RESULT 187
ABL31275
ID   ABL31275 standard; DNA; 17 BP.
XX
AC   ABL31275;
XX
DT   21-MAR-2002  (first entry)
XX
DE   Human HLA genotyping oligonucleotide SEQ ID NO 764.
XX
KW   Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW   immunogenetic; transplantation; genetic disease; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192572-A1.
XX
PD   06-DEC-2001.
XX
PF   01-JUN-2001; 2001WO-JP004662.
XX
PR   01-JUN-2000; 2000JP-00164798.
XX
PA   (NISN ) NISSHINBO IND INC.
PA   (SYST-) SYSTEM RES INC.
XX
PI   Inoko H,  Kagiya T,  Ichihara T,  Matsumura Y,  Moriya S,  Nishida M;
XX
DR   WPI; 2002-122074/16.
XX
PT   Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT   individuals e.g. by determining immunogenetic differences when
PT   transplanting between them.
XX
PS   Claim 10; Page 238; 345pp; Japanese.
XX
CC   The invention relates to a typing kit for judging human leukocyte antigen
CC   (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC   oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC   genes e.g. belonging to HLA class I antigens on human genome and
CC   containing gene polymorphisms as alloantigens have been immobilised as
CC   primers for amplification of cleaved nucleic acids relating to gene
CC   polymorphisms. The method is useful for judging HLA genotypes of
CC   individuals by determining immunogenetic differences before transplanting
CC   between them, providing genetic information to decide compatibility of
CC   organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC   pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC   diagnosis of genetic diseases and identifying individuals
XX
SQ   Sequence 17 BP; 1 A; 5 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         78 GGAGGCGGGCAGCGG 92
              |||||||||| ||||
Db          2 GGAGGCGGGCCGCGG 16


RESULT 188
ACC52440
```

```
ID   ACC52440 standard; DNA; 17 BP.
XX
AC   ACC52440;
XX
DT   27-JUN-2003 (first entry)
XX
DE   Human tumour suppressor sequence #1207.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 319; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCA 653
              ||||| |||||||||
Db          3 TCCAGTAGAGGTCCA 17


RESULT 189
ABQ77407
ID   ABQ77407 standard; DNA; 17 BP.
XX
AC   ABQ77407;
XX
DT   10-MAY-2003  (first entry)
XX
DE   Human vascular disease-associated primer SEQ ID 15.
XX
KW   Human; THBS2; vascular disease; cardiant; antiarteriosclerotic; stroke;
KW   cerebroprotective; gene therapy; coronary artery disease; ischaemia;
KW   myocardial infarction; peripheral vascular disease; pulmonary embolism;
KW   venous thromboembolism; forensic; paternity testing; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003016494-A2.
XX
PD   27-FEB-2003.
XX
PF   16-AUG-2002; 2002WO-US026343.
XX
PR   16-AUG-2001; 2001US-0313097P.
PR   05-OCT-2001; 2001US-0327485P.
PR   14-DEC-2001; 2001US-00020141.
XX
PA   (VITI-) VITIVITY INC.
XX
PI   Mccarthy J,  Ableson A;
XX
DR   WPI; 2003-300617/29.
XX
PT   Identifying a subject as a candidate for a particular course of therapy
PT   to treat a vascular disease or disorder, e.g. stroke, myocardial
PT   infarction or ischemia by determining the identity of the nucleotide
PT   present at specific positions.
XX
PS   Claim 64; Page 567; 568pp; English.
XX
CC   This invention describes a novel method for identifying a subject as a
CC   candidate for a particular course of therapy to treat a vascular disease
CC   or disorder. The method comprises determining the identity of the
CC   nucleotide present at specific positions, or their complements, and
CC   identifying the subject as a candidate for a particular clinical course
CC   of therapy based on the identity of the nucleotide present in that
CC   specific position. The method can be used for identifying a subject who
CC   is a candidate for further diagnostic evaluation of a vascular disease or
CC   disorder and selecting a clinical course of therapy. The products of the
CC   invention have cardiant, antiarteriosclerotic and cerebroprotective
CC   activity and can be used for gene therapy. The methods disclosed are
CC   useful for treating a vascular disease, e.g. atherosclerosis, coronary
CC   artery disease, myocardial infarction, ischaemia, stroke, peripheral
CC   vascular diseases, venous thromboembolism and pulmonary embolism. The DNA
CC   sequences are useful as fingerprint for detecting different individuals
CC   within the same species applicable in forensic studies and paternity
CC   testing. This sequence represents a primer used to illustrate the method
CC   of the invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              ||||||| ||||||||
Db          3 GAGCCCGGAGGCAGG 17


RESULT 190
ADB04942
ID   ADB04942 standard; DNA; 17 BP.
XX
AC   ADB04942;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ12 scanning oligonucleotide SEQ ID 5928.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
```

```
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 5928; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCA 653
              ||||||||||| |||
Db          3 TCCAGGAGAGGGCCA 17


RESULT 191
ADB04945
ID   ADB04945 standard; DNA; 17 BP.
XX
AC   ADB04945;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ12 scanning oligonucleotide SEQ ID 5931.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 5931; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        640 CCAGGAGAGGTCCAG 654
              ||||||||||| ||||
Db          1 CCAGGAGAGGGCCAG 15


RESULT 192
ABZ64551/c
ID   ABZ64551 standard; RNA; 17 BP.
XX
AC   ABZ64551;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #8.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 133; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
```

```
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 9 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 193
ACD62936
ID   ACD62936 standard; RNA; 17 BP.
XX
AC   ACD62936;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #799.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 289; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 4 A; 10 C; 3 G; 0 T; 0 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAG 809
              ||||||||||||| |
Db          3 CACACCACCCCGACG 17


RESULT 194
ACD52378/c
ID   ACD52378 standard; RNA; 17 BP.
XX
AC   ACD52378;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV inozyme substrate sequence #355.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
```

```
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 157; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 0 A; 11 C; 3 G; 0 T; 3 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | ||||||||||||||
Db         16 GCGGAGAAGCGGGCG 2


RESULT 195
ACD50949/c
ID   ACD50949 standard; RNA; 17 BP.
XX
AC   ACD50949;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HBV hammerhead ribozyme substrate sequence #313.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 142; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 0 A; 10 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 90;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | ||||||||||||||
Db         15 GCGGAGAAGCGGGCG 1


RESULT 196
ACC67414
ID   ACC67414 standard; DNA; 17 BP.
XX
AC   ACC67414;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 4661.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
```

PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 575; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 90;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 TCCAGGAGTAAGGAG 755
||||||||| |||||
Db 3 TCCAGGAGTCAGGAG 17

RESULT 197
ABZ88038/c
ID ABZ88038 standard; DNA; 20 BP.
XX
AC ABZ88038;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 3280; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 7 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 1.3%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 407 CTGCAGCGGCCCCCGCCG 424
||||||| || ||||||
Db 19 CTGCAGCTGCTGCCGCCG 2

RESULT 198
ABV90095
ID ABV90095 standard; DNA; 17 BP.
XX
AC ABV90095;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 808.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.

PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 808; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 1.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        409 GCAGCGGCCCCCGCCG 424
              ||||| ||||| ||||
Db          1 GCAGCTGCCCCAGCCG 16
```

Search completed: June 28, 2004, 08:08:31
Job time : 4 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 28, 2004, 08:13:57 ; Search time 2 Seconds
(without alignments)
3.071 Million cell updates/sec

Title: US-10-069-079-1
Perfect score: 1000
Sequence: 1 ccgagccctgaggcaggcgg.....ctgcagctgtgcacatggaa 1000

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 177 seqs, 3071 residues

Total number of hits satisfying chosen parameters: 354

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 185 summaries

Database : rnil.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	26	2.6	26	1	US-09-359-756-4	Sequence 4, Appli
	2	23	2.3	23	1	US-09-359-756-2	Sequence 2, Appli
c	3	21	2.1	21	1	US-09-359-756-3	Sequence 3, Appli
c	4	20	2.0	20	1	US-09-359-756-8	Sequence 8, Appli
c	5	20	2.0	20	1	US-09-359-756-9	Sequence 9, Appli
c	6	20	2.0	20	1	US-09-359-756-10	Sequence 10, Appl
c	7	20	2.0	20	1	US-09-359-756-11	Sequence 11, Appl
c	8	20	2.0	20	1	US-09-359-756-12	Sequence 12, Appl
c	9	20	2.0	20	1	US-09-359-756-13	Sequence 13, Appl
c	10	20	2.0	20	1	US-09-359-756-14	Sequence 14, Appl
	11	17.8	1.8	21	1	US-09-423-890-20	Sequence 20, Appl
	12	16.4	1.6	20	1	US-08-317-450B-2	Sequence 2, Appli
c	13	16.4	1.6	20	1	US-08-914-961-2	Sequence 2, Appli
	14	16.4	1.6	20	1	US-08-800-593-2	Sequence 2, Appli
c	15	16	1.6	18	1	US-08-466-860-54	Sequence 54, Appl
c	16	16	1.6	18	1	US-08-472-040A-54	Sequence 54, Appl
c	17	16	1.6	18	1	US-08-276-776-54	Sequence 54, Appl
c	18	16	1.6	18	1	US-08-471-209-54	Sequence 54, Appl
c	19	16	1.6	18	1	US-08-182-967-4	Sequence 4, Appli
	20	15.8	1.6	19	1	US-07-936-110-2	Sequence 2, Appli
	21	15.8	1.6	19	1	US-08-777-918-2	Sequence 2, Appli
	22	15.8	1.6	19	1	US-09-422-978-5276	Sequence 5276, Ap
	23	15.8	1.6	20	1	US-08-465-485A-28	Sequence 28, Appl
	24	15.8	1.6	20	1	US-09-080-285-28	Sequence 28, Appl
	25	15.8	1.6	20	1	US-09-517-584A-13	Sequence 13, Appl
	26	15.8	1.6	20	1	US-09-030-701-65	Sequence 65, Appl
	27	15.8	1.6	20	1	US-09-476-256-7	Sequence 7, Appli
	28	15.8	1.6	20	1	US-09-476-256-12	Sequence 12, Appl
	29	15.8	1.6	20	1	US-09-082-649B-57	Sequence 57, Appl
	30	15.8	1.6	20	1	US-09-724-426-28	Sequence 28, Appl
c	31	15.8	1.6	20	1	US-09-422-978-9876	Sequence 9876, Ap
c	32	15.8	1.6	21	1	US-08-863-639A-52	Sequence 52, Appl
c	33	15.8	1.6	21	1	US-08-863-639A-55	Sequence 55, Appl
	34	15.8	1.6	21	1	US-08-863-639A-56	Sequence 56, Appl
c	35	15.8	1.6	21	1	US-08-863-639A-67	Sequence 67, Appl
	36	15.8	1.6	21	1	US-08-863-639A-68	Sequence 68, Appl
	37	15.8	1.6	21	1	US-08-863-639A-71	Sequence 71, Appl
	38	15.8	1.6	21	1	US-08-416-214A-11	Sequence 11, Appl
	39	15.2	1.5	20	1	US-09-435-296-56	Sequence 56, Appl
c	40	15.2	1.5	20	1	US-09-422-978-6333	Sequence 6333, Ap
c	41	15	1.5	18	1	US-08-466-337A-15	Sequence 15, Appl
c	42	15	1.5	18	1	US-08-475-359-15	Sequence 15, Appl
c	43	15	1.5	18	1	US-08-465-887A-15	Sequence 15, Appl
	44	14.8	1.5	18	1	US-08-758-306-499	Sequence 499, App
c	45	14.8	1.5	18	1	US-09-085-759-95	Sequence 95, Appl
c	46	14.4	1.4	17	1	US-08-909-742-3	Sequence 3, Appli
c	47	14.4	1.4	17	1	US-08-909-742-4	Sequence 4, Appli
c	48	14.4	1.4	17	1	US-09-412-289-3	Sequence 3, Appli
c	49	14.4	1.4	17	1	US-09-412-289-4	Sequence 4, Appli
	50	14.4	1.4	18	1	US-08-857-946-21	Sequence 21, Appl
	51	14.4	1.4	18	1	US-08-970-740-21	Sequence 21, Appl
	52	14.4	1.4	18	1	US-09-143-212-45	Sequence 45, Appl
c	53	14.4	1.4	18	1	US-09-422-978-4210	Sequence 4210, Ap
	54	14.4	1.4	18	1	US-09-663-834A-43	Sequence 43, Appl
c	55	14	1.4	18	1	US-09-496-694B-99	Sequence 99, Appl
	56	13.8	1.4	17	1	US-08-584-040-4308	Sequence 4308, Ap
	57	13.8	1.4	17	1	US-08-679-645-801	Sequence 801, App
c	58	13.8	1.4	17	1	US-09-474-432B-565	Sequence 565, App
	59	13.8	1.4	17	1	US-09-474-432B-581	Sequence 581, App
	60	13.8	1.4	17	1	US-09-371-772B-2075	Sequence 2075, Ap
c	61	13.8	1.4	17	1	US-09-476-387-564	Sequence 564, App
	62	13.8	1.4	17	1	US-09-476-387-580	Sequence 580, App
c	63	13.8	1.4	17	1	US-09-866-108A-6303	Sequence 6303, Ap
c	64	13.8	1.4	17	1	US-09-866-108A-8005	Sequence 8005, Ap
c	65	13.8	1.4	18	1	US-08-758-306-505	Sequence 505, App
	66	13.8	1.4	18	1	US-08-531-927B-21	Sequence 21, Appl
	67	13.8	1.4	18	1	US-08-857-946-14	Sequence 14, Appl
	68	13.8	1.4	18	1	US-09-256-496-10	Sequence 10, Appl
	69	13.8	1.4	18	1	US-08-970-740-14	Sequence 14, Appl
	70	13.8	1.4	18	1	US-09-358-381-13	Sequence 13, Appl
c	71	13.8	1.4	18	1	US-09-358-381-13	Sequence 13, Appl
c	72	13.8	1.4	18	1	US-09-344-520-34	Sequence 34, Appl
	73	13.8	1.4	18	1	US-09-143-212-44	Sequence 44, Appl
	74	13.8	1.4	18	1	US-09-143-212-46	Sequence 46, Appl
c	75	13.8	1.4	18	1	US-08-938-669A-16	Sequence 16, Appl
	76	13.8	1.4	18	1	US-09-577-902-13	Sequence 13, Appl
c	77	13.8	1.4	18	1	US-09-577-902-13	Sequence 13, Appl
	78	13.8	1.4	18	1	US-09-651-374A-14	Sequence 14, Appl
c	79	13.8	1.4	18	1	US-09-306-828-16	Sequence 16, Appl
	80	13.8	1.4	20	1	US-09-359-756-9	Sequence 9, Appli
	81	13.4	1.3	15	1	US-08-182-968A-321	Sequence 321, App
	82	13.4	1.3	15	1	US-08-774-306A-321	Sequence 321, App
	83	13.4	1.3	15	1	US-08-863-639A-21	Sequence 21, Appl
	84	13.4	1.3	15	1	US-09-064-156A-321	Sequence 321, App
	85	13.4	1.3	15	1	US-08-730-635-13	Sequence 13, Appl
	86	13.4	1.3	16	1	US-09-290-449-4	Sequence 4, Appli
c	87	13.4	1.3	17	1	US-08-626-023-1	Sequence 1, Appli
	88	13.4	1.3	17	1	US-08-626-023-3	Sequence 3, Appli
c	89	13.4	1.3	17	1	US-09-474-432B-312	Sequence 312, App
c	90	13.4	1.3	17	1	US-09-371-772B-5503	Sequence 5503, Ap
c	91	13.4	1.3	17	1	US-09-476-387-311	Sequence 311, App
	92	13.4	1.3	17	1	US-09-866-108A-2497	Sequence 2497, Ap
	93	13.4	1.3	17	1	US-09-866-108A-2498	Sequence 2498, Ap
	94	13.4	1.3	17	1	US-09-866-108A-2499	Sequence 2499, Ap
	95	13.4	1.3	17	1	US-09-866-108A-8123	Sequence 8123, Ap
	96	13.4	1.3	17	1	US-09-866-108A-8124	Sequence 8124, Ap
	97	13.4	1.3	17	1	US-09-866-108A-8125	Sequence 8125, Ap
	98	13	1.3	17	1	US-09-866-108A-8640	Sequence 8640, Ap
	99	13	1.3	17	1	US-09-866-108A-8641	Sequence 8641, Ap
	100	13	1.3	17	1	US-09-866-108A-8642	Sequence 8642, Ap
	101	13	1.3	17	1	US-09-866-108A-8643	Sequence 8643, Ap
	102	13	1.3	17	1	US-09-866-108A-8644	Sequence 8644, Ap
c	103	12.8	1.3	16	1	US-08-753-147-164	Sequence 164, App
	104	12.8	1.3	16	1	US-09-593-012-161	Sequence 161, App
	105	12.8	1.3	16	1	US-09-371-772B-5828	Sequence 5828, Ap
	106	12.8	1.3	16	1	US-09-479-005A-1	Sequence 1, Appli

c 107	12.8	1.3	17	1	US-08-250-740-11	Sequence 11, Appl
c 108	12.8	1.3	17	1	US-07-695-472B-21	Sequence 21, Appl
109	12.8	1.3	17	1	US-08-584-040-1925	Sequence 1925, Ap
110	12.8	1.3	17	1	US-08-584-040-4327	Sequence 4327, Ap
111	12.8	1.3	17	1	US-08-584-040-5867	Sequence 5867, Ap
112	12.8	1.3	17	1	US-08-584-040-7609	Sequence 7609, Ap
c 113	12.8	1.3	17	1	US-08-679-645-210	Sequence 210, App
c 114	12.8	1.3	17	1	US-08-679-645-212	Sequence 212, App
115	12.8	1.3	17	1	US-08-679-645-803	Sequence 803, App
116	12.8	1.3	17	1	US-09-343-698-1	Sequence 1, Appli
117	12.8	1.3	17	1	US-09-673-809-97	Sequence 97, Appl
c 118	12.8	1.3	17	1	US-09-673-809-97	Sequence 97, Appl
c 119	12.8	1.3	17	1	US-09-474-432B-736	Sequence 736, App
c 120	12.8	1.3	17	1	US-09-474-432B-789	Sequence 789, App
c 121	12.8	1.3	17	1	US-09-106-375-21	Sequence 21, Appl
122	12.8	1.3	17	1	US-09-371-772B-470	Sequence 470, App
123	12.8	1.3	17	1	US-09-371-772B-2094	Sequence 2094, Ap
124	12.8	1.3	17	1	US-09-371-772B-2720	Sequence 2720, Ap
125	12.8	1.3	17	1	US-09-371-772B-4761	Sequence 4761, Ap
126	12.8	1.3	17	1	US-09-371-772B-6336	Sequence 6336, Ap
127	12.8	1.3	17	1	US-09-371-772B-6337	Sequence 6337, Ap
128	12.8	1.3	17	1	US-08-325-955-1	Sequence 1, Appli
c 129	12.8	1.3	17	1	US-09-476-387-735	Sequence 735, App
c 130	12.8	1.3	17	1	US-09-476-387-788	Sequence 788, App
131	12.8	1.3	17	1	US-09-827-998-76	Sequence 76, Appl
132	12.8	1.3	17	1	US-09-827-998-77	Sequence 77, Appl
c 133	12.8	1.3	17	1	US-09-827-998-136	Sequence 136, App
c 134	12.8	1.3	17	1	US-09-827-998-137	Sequence 137, App
c 135	12.8	1.3	17	1	US-09-866-108A-1547	Sequence 1547, Ap
c 136	12.8	1.3	17	1	US-09-866-108A-1548	Sequence 1548, Ap
c 137	12.8	1.3	17	1	US-09-866-108A-6302	Sequence 6302, Ap
c 138	12.8	1.3	17	1	US-09-866-108A-6304	Sequence 6304, Ap
c 139	12.8	1.3	17	1	US-09-866-108A-6376	Sequence 6376, Ap
c 140	12.8	1.3	17	1	US-09-866-108A-6377	Sequence 6377, Ap
c 141	12.8	1.3	17	1	US-09-866-108A-8004	Sequence 8004, Ap
c 142	12.8	1.3	17	1	US-09-866-108A-8006	Sequence 8006, Ap
143	12.8	1.3	17	1	US-09-866-108A-9603	Sequence 9603, Ap
144	12.8	1.3	17	1	US-09-866-108A-9604	Sequence 9604, Ap
145	12.8	1.3	17	1	US-09-866-108A-9943	Sequence 9943, Ap
146	12.8	1.3	17	1	US-09-866-108A-9944	Sequence 9944, Ap
c 147	12.8	1.3	20	1	US-08-465-485A-28	Sequence 28, Appl
c 148	12.8	1.3	20	1	US-09-080-285-28	Sequence 28, Appl
c 149	12.8	1.3	20	1	US-09-724-426-28	Sequence 28, Appl
150	12.6	1.3	20	1	US-08-914-961-2	Sequence 2, Appli
c 151	12.4	1.2	14	1	US-08-244-188-1	Sequence 1, Appli
c 152	12.4	1.2	14	1	US-08-244-188-2	Sequence 2, Appli
153	12.4	1.2	14	1	US-08-393-734-6	Sequence 6, Appli
154	12.4	1.2	14	1	US-08-836-022A-6	Sequence 6, Appli
155	12.4	1.2	14	1	US-08-894-489-6	Sequence 6, Appli
156	12.4	1.2	14	1	US-09-427-048A-6	Sequence 6, Appli
c 157	12.4	1.2	14	1	US-08-872-056-8	Sequence 8, Appli
c 158	12.4	1.2	14	1	US-09-529-157-8	Sequence 8, Appli
c 159	12.4	1.2	15	1	US-07-791-213D-42	Sequence 42, Appl
160	12.4	1.2	15	1	US-08-050-073-201	Sequence 201, App
c 161	12.4	1.2	15	1	US-08-050-073-202	Sequence 202, App
162	12.4	1.2	15	1	US-08-050-073-301	Sequence 301, App
c 163	12.4	1.2	15	1	US-08-050-073-302	Sequence 302, App
164	12.4	1.2	15	1	US-08-363-240A-148	Sequence 148, App
165	12.4	1.2	15	1	US-08-363-240A-149	Sequence 149, App
c 166	12.4	1.2	15	1	US-08-293-150A-42	Sequence 42, Appl
c 167	12.4	1.2	15	1	US-08-292-620A-56	Sequence 56, Appl
c 168	12.4	1.2	15	1	US-08-292-620A-597	Sequence 597, App
c 169	12.4	1.2	15	1	US-08-585-684B-2297	Sequence 2297, Ap
c 170	12.4	1.2	15	1	US-09-071-845-56	Sequence 56, Appl
c 171	12.4	1.2	15	1	US-09-071-845-597	Sequence 597, App
c 172	12.4	1.2	15	1	US-09-038-073-2297	Sequence 2297, Ap
173	12.4	1.2	15	1	US-09-056-995-22	Sequence 22, Appl
c 174	12.4	1.2	15	1	US-09-056-995-23	Sequence 23, Appl
c 175	12.4	1.2	15	1	US-09-180-437-175	Sequence 175, App
176	12.4	1.2	15	1	US-09-549-853-38	Sequence 38, Appl
177	12.4	1.2	15	1	US-09-753-362-14	Sequence 14, Appl
178	12.4	1.2	15	1	US-09-475-947A-322	Sequence 322, App
179	12.4	1.2	15	1	US-09-953-242-14	Sequence 14, Appl
c 180	12.4	1.2	16	1	US-08-050-073-235	Sequence 235, App
c 181	12.4	1.2	16	1	US-08-050-073-250	Sequence 250, App
c 182	12.4	1.2	16	1	US-08-373-124A-135	Sequence 135, App
c 183	12.4	1.2	16	1	US-08-435-628-135	Sequence 135, App
184	12.4	1.2	16	1	US-09-549-853-34	Sequence 34, Appl
185	12.4	1.2	16	1	US-09-479-005A-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-09-359-756-4
; Sequence 4, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Donna T. Ward
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
; FILE REFERENCE: RTS-0077
; CURRENT APPLICATION NUMBER: US/09/359,756
; CURRENT FILING DATE: 1999-07-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 4
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-359-756-4

Query Match 2.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.1;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        478 CGTCCAGAGGAACGAATGATCAGGGA 503
              ||||||||||||||||||||||||||
Db          1 CGTCCAGAGGAACGAATGATCAGGGA 26
```

RESULT 2
US-09-359-756-2
; Sequence 2, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Donna T. Ward
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
; FILE REFERENCE: RTS-0077
; CURRENT APPLICATION NUMBER: US/09/359,756
; CURRENT FILING DATE: 1999-07-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 2
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-359-756-2

Query Match 2.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        445 GAAACTCTCAAAGGGTTGCACAA 467
              |||||||||||||||||||||||
Db          1 GAAACTCTCAAAGGGTTGCACAA 23
```

```
RESULT 3
US-09-359-756-3/c
; Sequence 3, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-09-359-756-3

  Query Match             2.1%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 4.8;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        509 TGAAGGCAACCTGTATGCCAG 529
              |||||||||||||||||||||
Db         21 TGAAGGCAACCTGTATGCCAG 1


RESULT 4
US-09-359-756-8/c
; Sequence 8, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 8
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-8

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGGAGGAGC 32
              ||||||||||||||||||||
Db         20 GCAGGCGGCGGCGGAGGAGC 1


RESULT 5
US-09-359-756-9/c
; Sequence 9, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-9

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         44 GCAGCGCGCGCGCGGCTGCC 63
              ||||||||||||||||||||
Db         20 GCAGCGCGCGCGCGGCTGCC 1


RESULT 6
US-09-359-756-10/c
; Sequence 10, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-10

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         94 GGCCGCGAGCGGGCGGACTG 113
              ||||||||||||||||||||
Db         20 GGCCGCGAGCGGGCGGACTG 1


RESULT 7
US-09-359-756-11/c
; Sequence 11, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 11
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-11
```

```
  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        148 GAGCTGGACCAGCTGCCTGA 167
              ||||||||||||||||||||
Db         20 GAGCTGGACCAGCTGCCTGA 1


RESULT 8
US-09-359-756-12/c
; Sequence 12, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-12

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        230 CGGACGCAGCGGGGAGTGGG 249
              ||||||||||||||||||||
Db         20 CGGACGCAGCGGGGAGTGGG 1


RESULT 9
US-09-359-756-13/c
; Sequence 13, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-13

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        309 CCACCTTACCGAGTCGGTGG 328
              ||||||||||||||||||||
Db         20 CCACCTTACCGAGTCGGTGG 1


RESULT 10
US-09-359-756-14/c
; Sequence 14, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-14

  Query Match             2.0%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.3;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGGGTTGC 463
              ||||||||||||||||||||
Db         20 AGAAACTCTCAAAGGGTTGC 1


RESULT 11
US-09-423-890-20
; Sequence 20, Application US/09423890
; Patent No. 6312934
; GENERAL INFORMATION:
;  APPLICANT:  CADUS PHARMACEUTICAL CORPORATION
;  TITLE OF INVENTION:  HUMAN MEKK PROTEIN AND NUCLEIC ACID MOLECULES
;  TITLE OF INVENTION:  AND USES THEREFOR
;  FILE REFERENCE:  CPI-085CPPC
;  CURRENT APPLICATION NUMBER: US/09/423,890
;  CURRENT FILING DATE:  2000-03-06
;  PRIOR APPLICATION NUMBER:  USSN 60/078,153
;  PRIOR FILING DATE:  1998-03-16
;  PRIOR APPLICATION NUMBER:  USSN 60/099,165
;  PRIOR FILING DATE:  1998-09-04
;  NUMBER OF SEQ ID NOS:  38
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic construct
US-09-423-890-20

  Query Match             1.8%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 20;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        527 CAGCCTGGAAGCACGAATGGT 547
              | |||||||||||||| ||||
Db          1 CGGCCTGGAAGCACGAGTGGT 21


RESULT 12
US-08-317-450B-2
; Sequence 2, Application US/08317450B
; Patent No. 5660982
;  GENERAL INFORMATION:
;    APPLICANT:  Tryggvason, Karl
;    APPLICANT:  Kallunki, Pekka
;    APPLICANT:  Pyke, Charles
;    TITLE OF INVENTION:  Laminin Chains: Diagnostic and
;    TITLE OF INVENTION:  Therapeutic Use
```

```
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BANNER & ALLEGRETTI, LTD.
;      STREET:  Ten South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60606
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/317,450B
;      FILING DATE:  04-OCT-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Chao, Mark
;      REGISTRATION NUMBER:  37,293
;      REFERENCE/DOCKET NUMBER:  94,778
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-715-1000
;      TELEFAX:  312-715-1234
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "OLIGOMER PRIMER"
US-08-317-450B-2

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 31;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              ||||||||  |||||||||
Db          1 GAATCACTGAGCAGCTGA 18


RESULT 13
US-08-914-961-2/c
; Sequence 2, Application US/08914961
; Patent No. 6018042
;  GENERAL INFORMATION:
;    APPLICANT:  Mett, Helmut
;    APPLICANT:  Haner, Robert
;    APPLICANT:  Dean, Nicholas Mark
;    TITLE OF INVENTION:  Antitumor Antisense Oligonucleotides
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CIBA-GEIGY Corporation
;      STREET:  7 Skyline Drive
;      CITY:  Hawthorne
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10532
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII Editor
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/914,961
;      FILING DATE:  20-AUG-1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/287,753
;      FILING DATE:  09-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spruill, W. Murray
;      REGISTRATION NUMBER:  32,943
;      REFERENCE/DOCKET NUMBER:  4-20047/P1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919) 541-8615
;      TELEFAX:  (919) 541-8689
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
;    POSITION IN GENOME:
;      MAP POSITION:  -80
;      UNITS:  bp
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..20
;      OTHER INFORMATION:  /note= "All nucleotides are of the
;      OTHER INFORMATION:  phosphorothioate type"
US-08-914-961-2

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 31;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCG 131
              ||||||||||||||| |||
Db         20 GCGGCGGCGGCAGCGGCG 3


RESULT 14
US-08-800-593-2
; Sequence 2, Application US/08800593
; Patent No. 6143505
;  GENERAL INFORMATION:
;    APPLICANT:  Tryggvason, Karl
;    APPLICANT:  Kallunki, Pekka
;    APPLICANT:  Pyke, Charles
;    TITLE OF INVENTION:  Laminin Chains: Diagnostic and
;    TITLE OF INVENTION:  Therapeutic Use
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  McDonnell Boehnen Hulbert & Berghoff
;      STREET:  300 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60606
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/800,593
;      FILING DATE:  18-FEB-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/317,450
;      FILING DATE:  04-OCT-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Chao, Mark
;      REGISTRATION NUMBER:  37,293
;      REFERENCE/DOCKET NUMBER:  94,778-B
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-913-0001
;      TELEFAX:  312-913-0002
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "OLIGOMER PRIMER"
US-08-800-593-2

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 31;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              ||||||||| |||||||||
Db          1 GAATCACTGAGCAGCTGA 18


RESULT 15
US-08-466-860-54/c
; Sequence 54, Application US/08466860
; Patent No. 5985552
;  GENERAL INFORMATION:
;    APPLICANT:  HOWELL, MARK D.
;    APPLICANT:  BROSTOFF, STEVEN W.
;    APPLICANT:  CARLO, DENNIS J.
;    TITLE OF INVENTION:  VACCINATION AND METHODS AGAINST DISEASES
;    TITLE OF INVENTION:  RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL
;    TITLE OF INVENTION:  POPULATIONS
;    NUMBER OF SEQUENCES:  75
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CAMPBELL AND FLORES
;      STREET:  4370 LA JOLLA VILLAGE DRIVE, SUITE 700
;      CITY:  SAN DIEGO
;      STATE:  CALIFORNIA
;      COUNTRY:  UNITED STATES
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/466,860
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,867
;      FILING DATE:  24-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CAMPBELL, CATHRYN
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-IM 9107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-535-9001
;      TELEFAX:  619-535-8949
;  INFORMATION FOR SEQ ID NO:  54:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-466-860-54

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 16
US-08-472-040A-54/c
; Sequence 54, Application US/08472040A
; Patent No. 6090387
;  GENERAL INFORMATION:
;    APPLICANT:  HOWELL, MARK D.
;    APPLICANT:  BROSTOFF, STEVEN W.
;    APPLICANT:  CARLO, DENNIS J.
;    TITLE OF INVENTION:  VACCINATION AND METHODS AGAINST DISEASES
;    TITLE OF INVENTION:  RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL
;    TITLE OF INVENTION:  POPULATIONS
;    NUMBER OF SEQUENCES:  77
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CAMPBELL & FLORES LLP
;      STREET:  4370 LA JOLLA VILLAGE DRIVE, SUITE 700
;      CITY:  SAN DIEGO
;      STATE:  CALIFORNIA
;      COUNTRY:  UNITED STATES
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/472,040A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CAMPBELL, CATHRYN
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-IM 1641
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-535-9001
;      TELEFAX:  619-535-8949
;  INFORMATION FOR SEQ ID NO:  54:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-472-040A-54

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 17
US-08-276-776-54/c
; Sequence 54, Application US/08276776
; Patent No. 6207645
;  GENERAL INFORMATION:
;    APPLICANT:  HOWELL, MARK D.
;    APPLICANT:  BROSTOFF, STEVEN W.
;    APPLICANT:  CARLO, DENNIS J.
;    TITLE OF INVENTION:  VACCINATION AND METHODS AGAINST DISEASES
;    TITLE OF INVENTION:  RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL
;    TITLE OF INVENTION:  POPULATIONS
;    NUMBER OF SEQUENCES:  75
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CAMPBELL AND FLORES
;      STREET:  4370 LA JOLLA VILLAGE DRIVE, SUITE 700
;      CITY:  SAN DIEGO
;      STATE:  CALIFORNIA
;      COUNTRY:  UNITED STATES
;      ZIP:  92122
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/276,776
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/813,867
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  CAMPBELL, CATHRYN
;       REGISTRATION NUMBER:  31,815
;       REFERENCE/DOCKET NUMBER:  P-IM 9107
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  619-535-9001
;       TELEFAX:  619-535-8949
;   INFORMATION FOR SEQ ID NO:  54:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-276-776-54

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 18
US-08-471-209-54/c
; Sequence 54, Application US/08471209
; Patent No. 6221352
;  GENERAL INFORMATION:
;    APPLICANT:  HOWELL, MARK D.
;    APPLICANT:  BROSTOFF, STEVEN W.
;    APPLICANT:  CARLO, DENNIS J.
;    TITLE OF INVENTION:  VACCINATION AND METHODS AGAINST DISEASES
;    TITLE OF INVENTION:  RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL
;    TITLE OF INVENTION:  POPULATIONS
;    NUMBER OF SEQUENCES:  75
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CAMPBELL AND FLORES
;      STREET:  4370 LA JOLLA VILLAGE DRIVE, SUITE 700
;      CITY:  SAN DIEGO
;      STATE:  CALIFORNIA
;      COUNTRY:  UNITED STATES
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,209
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,867
;      FILING DATE:  24-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CAMPBELL, CATHRYN
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-IM 9107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-535-9001
;      TELEFAX:  619-535-8949
;  INFORMATION FOR SEQ ID NO:  54:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-471-209-54

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 19
US-08-182-967-4/c
; Sequence 4, Application US/08182967
; Patent No. 6413516
;  GENERAL INFORMATION:
;    APPLICANT:  Chang, Jennie C.C.
;    APPLICANT:  Brostoff, Steven W.
;    APPLICANT:  Carlo, Dennis J.
;    TITLE OF INVENTION:  Peptides and Methods Against Psoriasis
;    NUMBER OF SEQUENCES:  34
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,967
;      FILING DATE:  14-JAN-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/462,471
;      FILING DATE:  05-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,867
;      FILING DATE:  14-DEC-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/644,611
;      FILING DATE:  22-JAN-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/530,229
;      FILING DATE:  30-MAY-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/382,085
;      FILING DATE:  18-JUL-1989
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/382,086
;      FILING DATE:  18-JUL-1989
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/326,314
;      FILING DATE:  21-MAR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-IM 9830
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
```

```
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-967-4

  Query Match             1.6%;  Score 16;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        160 CTGCCTGAGCAGCCGC 175
              ||||||||||||||||
Db         16 CTGCCTGAGCAGCCGC 1


RESULT 20
US-07-936-110-2
; Sequence 2, Application US/07936110
; Patent No. 5610052
;  GENERAL INFORMATION:
;    APPLICANT:  James D. Thompson
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  TREATMENT OF COLON CARCINOMA
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/936,110
;      FILING DATE:  19920826
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    none
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/246
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-07-936-110-2

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 34;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||  ||||||  |||
Db          1 GGCGGCGGAGGCAGCAGCG 19


RESULT 21
US-08-777-918-2
; Sequence 2, Application US/08777918
; Patent No. 5801158
;  GENERAL INFORMATION:
;    APPLICANT:  James D. Thompson
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  TREATMENT OF COLON CARCINOMA
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/777,918
;      FILING DATE:  23-DEC-1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/936,110
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/246
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-777-918-2

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 34;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||  ||||||  |||
Db          1 GGCGGCGGAGGCAGCAGCG 19


RESULT 22
US-09-422-978-5276
; Sequence 5276, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
```

```
; SEQ ID NO 5276
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-23123 for SEQ 1342,
US-09-422-978-5276

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 34;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        745 GGAGTAAGGAGAAAAAGAG 763
              |||  ||||||||||||||
Db          1 GGAACAAGGAGAAAAAGAG 19


RESULT 23
US-08-465-485A-28
; Sequence 28, Application US/08465485A
; Patent No. 5831066
;  GENERAL INFORMATION:
;    APPLICANT:  Reed, John
;    TITLE OF INVENTION:  Regulation of bcl-2 Gene Expression
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 S. Jefferson Davis Hwy., Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/465,485A
;      FILING DATE:  05-JUN-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/124,256
;      FILING DATE:  20-SEP-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/840,716
;      FILING DATE:  21-FEB-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/288,692
;      FILING DATE:  22-DEC-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fortney, Andrew D.
;      REGISTRATION NUMBER:  34,600
;      REFERENCE/DOCKET NUMBER:  3335-070-55 CONT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 436-2070
;      TELEFAX:  (408) 436-2075
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Synthetic DNA
;    ANTI-SENSE:  YES
;    FEATURE:
;      NAME/KEY:  Modified_base
;      LOCATION:  18..19
;      OTHER INFORMATION:  Last two internucleoside linkages are
;      OTHER INFORMATION:  phosphorothioates
US-08-465-485A-28

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 24
US-09-080-285-28
; Sequence 28, Application US/09080285
; Patent No. 6040181
;  GENERAL INFORMATION:
;    APPLICANT:  Reed, John
;    TITLE OF INVENTION:  Regulation of bcl-2 Gene Expression
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 S. Jefferson Davis Hwy., Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/080,285
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/465,485
;      FILING DATE:  05-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/124,256
;      FILING DATE:  20-SEP-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/840,716
;      FILING DATE:  21-FEB-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/288,692
;      FILING DATE:  22-DEC-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fortney, Andrew D.
;      REGISTRATION NUMBER:  34,600
;      REFERENCE/DOCKET NUMBER:  3335-070-55 CONT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (408) 436-2070
;      TELEFAX:  (408) 436-2075
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Synthetic DNA
;    ANTI-SENSE:  YES
;    FEATURE:
;      NAME/KEY:  Modified_base
;      LOCATION:  18..19
;      OTHER INFORMATION:  Last two internucleoside linkages are
;      OTHER INFORMATION:  phosphorothioates
US-09-080-285-28

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
```

```
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 25
US-09-517-584A-13
; Sequence 13, Application US/09517584A
; Patent No. 6187587
; GENERAL INFORMATION:
;  APPLICANT:      Ian Popoff
;  APPLICANT:  Vickie L. Brown-Driver
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 1 EXPRESSIO
;  FILE REFERENCE:      RTS-0121
;  CURRENT APPLICATION NUMBER: US/09/517,584A
;  CURRENT FILING DATE:  2000-03-22
;  NUMBER OF SEQ ID NOS:      89
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-584A-13

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 CAGGCGGCGGCGGAGGAGC 32
              ||||||||||||| || ||
Db          1 CAGGCGGCGGCGGCGGCGC 19


RESULT 26
US-09-030-701-65
; Sequence 65, Application US/09030701B
; Patent No. 6214806
; GENERAL INFORMATION:
;  APPLICANT:  Krieg, Arthur M.
;  APPLICANT:  Schwartz, David A.
;  TITLE OF INVENTION:  USE OF NUCLEIC ACIDS CONTAINING
;  TITLE OF INVENTION:  UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF
;  TITLE OF INVENTION:  LPS-ASSOCIATED DISORDERS
;  FILE REFERENCE:  C1039/7011
;  CURRENT APPLICATION NUMBER: US/09/030,701B
;  CURRENT FILING DATE:  1998-02-25
;  PRIOR APPLICATION NUMBER:  60/039,405
;  PRIOR FILING DATE:  1997-02-28
;  NUMBER OF SEQ ID NOS:  65
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-030-701-65

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 27
US-09-476-256-7
; Sequence 7, Application US/09476256
; Patent No. 6228592
; GENERAL INFORMATION:
;  APPLICANT: Laboratory of Molecular Biophotonics
;  TITLE OF INVENTION: Nucleic Acid Detection in Cytoplasm
;  FILE REFERENCE: BBP99-02
;  CURRENT APPLICATION NUMBER: US/09/476,256
;  CURRENT FILING DATE: 1999-12-30
;  NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 7
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: probe
US-09-476-256-7

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 28
US-09-476-256-12
; Sequence 12, Application US/09476256
; Patent No. 6228592
; GENERAL INFORMATION:
;  APPLICANT: Laboratory of Molecular Biophotonics
;  TITLE OF INVENTION: Nucleic Acid Detection in Cytoplasm
;  FILE REFERENCE: BBP99-02
;  CURRENT APPLICATION NUMBER: US/09/476,256
;  CURRENT FILING DATE: 1999-12-30
;  NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 12
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: probe
US-09-476-256-12

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        744 AGGAGTAAGGAGAAAAAGA 762
              |||| |||||||||| |||
Db          2 AGGACTAAGGAGAAAGAGA 20


RESULT 29
US-09-082-649B-57
; Sequence 57, Application US/09082649B
; Patent No. 6339068
; GENERAL INFORMATION:
;  APPLICANT:  Davis, Heather L.
;  APPLICANT:  Krieg, Arthur M.
;  APPLICANT:  Schorr, Joachim
;  APPLICANT:  Wu, Tong
;  TITLE OF INVENTION:  Vectors and Methods for Immunization or
;  TITLE OF INVENTION:  Therapeutic Protocols
;  FILE REFERENCE:  C1039/7009
;  CURRENT APPLICATION NUMBER: US/09/082,649B
;  CURRENT FILING DATE:  1998-05-20
;  PRIOR APPLICATION NUMBER:  US 60/047,233
;  PRIOR FILING DATE:  1997-05-20
;  PRIOR APPLICATION NUMBER:  US 60/047,209
;  PRIOR FILING DATE:  1997-05-20
```

```
;  NUMBER OF SEQ ID NOS:  85
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 57
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-082-649B-57

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 30
US-09-724-426-28
; Sequence 28, Application US/09724426
; Patent No. 6414134
; GENERAL INFORMATION:
;  APPLICANT: Reed, John
;  TITLE OF INVENTION: Regulation of BCL-2 Gene Expression
;  FILE REFERENCE: 10412-024
;  CURRENT APPLICATION NUMBER: US/09/724,426
;  CURRENT FILING DATE:  2000-11-28
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-724-426-28

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||| || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 31
US-09-422-978-9876/c
; Sequence 9876, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9876
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: downstream amplification primer 99-7985 for SEQ 2011, in compleme
US-09-422-978-9876

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 41;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        428 GTGAGATGGAGAATAAAGA 446
              ||||||||||| | ||||||
Db         20 GTGAGATGGAAAGTAAAGA 2


RESULT 32
US-08-863-639A-52/c
; Sequence 52, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  52:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-52

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db         20 GGCGGCGGCGGCGGCGGCG 2


RESULT 33
US-08-863-639A-55/c
; Sequence 55, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
```

```
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  55:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-55

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db         19 GGCGGCGGCGGCGGCGGCG 1


RESULT 34
US-08-863-639A-56
; Sequence 56, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  56:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-56

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          2 GGCGGCGGCGGCGGCGGCG 20


RESULT 35
US-08-863-639A-67/c
; Sequence 67, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  67:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-67

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db         21 GGCGGCGGCGGCGGCGGCG 3
```

```
RESULT 36
US-08-863-639A-68
; Sequence 68, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  68:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-68

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          3 GGCGGCGGCGGCGGCGGCG 21


RESULT 37
US-08-863-639A-71
; Sequence 71, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  71:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-71

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 48;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 38
US-08-416-214A-11
; Sequence 11, Application US/08416214A
; Patent No. 5998596
;  GENERAL INFORMATION:
;    APPLICANT:  Bergan, Raymond; Neckers, Len
;    TITLE OF INVENTION:  Inhibition Of Protein
;    TITLE OF INVENTION:  Kinase Activity By Aptameric Action Of
;    TITLE OF INVENTION:  Oligonucleotides
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORGAN & FINNEGAN
;      STREET:  345 PARK AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/416,214A
;      FILING DATE:  04-APR-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Brown, Kathryn M.
;      REGISTRATION NUMBER:  34,556
;      REFERENCE/DOCKET NUMBER:  2026-4166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 758-4800
;      TELEFAX:  (212) 751-6849
;      TELEX:  421792
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  Nucleic acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    MOLECULE TYPE:  Other nucleic acid
;    HYPOTHETICAL:  Yes
;    ANTI-SENSE:  No
```

US-08-416-214A-11

Query Match 1.6%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 48;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19
```

RESULT 39
US-09-435-296-56
; Sequence 56, Application US/09435296
; Patent No. 6171860
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF RANK EXPRESSION
; FILE REFERENCE: RTS-0116
; CURRENT APPLICATION NUMBER: US/09/435,296
; CURRENT FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-435-296-56

Query Match 1.5%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        294 CAGCCGGCGCGGCGCCCACC 313
              ||||||  |||  ||||||  ||
Db          1 CAGCCGCCGCCGCGCCCTCC 20
```

RESULT 40
US-09-422-978-6333/c
; Sequence 6333, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6333
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10776 for SEQ 2399,
US-09-422-978-6333

Query Match 1.5%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        550 GAAAGGAGAAATAGGCGAGG 569
              ||||  ||||||||||  |||
Db         20 GAAATGAGAAATAGGAAAGG 1
```

RESULT 41
US-08-466-337A-15/c
; Sequence 15, Application US/08466337A
; Patent No. 5830756
; GENERAL INFORMATION:
; APPLICANT: Haskill, John S.
; APPLICANT: Baldwin Jr., Albert S.
; APPLICANT: Ralph, Peter
; TITLE OF INVENTION: Inhibitor of NF-kB Transcriptional
; TITLE OF INVENTION: Activator and Uses Thereof
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower/ 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,337A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Pochopien, Donald J.
; REGISTRATION NUMBER: 32,167
; REFERENCE/DOCKET NUMBER: 0899.008/33518
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-466-337A-15

Query Match 1.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1
```

RESULT 42
US-08-475-359-15/c
; Sequence 15, Application US/08475359
; Patent No. 5846714
; GENERAL INFORMATION:
; APPLICANT: Haskill, John S.
; APPLICANT: Baldwin Jr., Albert S.
; APPLICANT: Ralph, Peter
; TITLE OF INVENTION: Inhibitor of NF-kB Transcriptional
; TITLE OF INVENTION: Activator and Uses Thereof
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower/ 233 South Wacker Drive
; CITY: Chicago

```
;       STATE:  Illinois
;       COUNTRY:  United States
;       ZIP:  60606-6402
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/475,359
;       FILING DATE:  07-JUN-1995
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Pochopien, Donald J.
;       REGISTRATION NUMBER:  32,167
;       REFERENCE/DOCKET NUMBER:  0899.004.33514
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  312/474-6300
;       TELEFAX:  312/474-0448
;       TELEX:  25-3856
;   INFORMATION FOR SEQ ID NO:  15:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-475-359-15

  Query Match             1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1


RESULT 43
US-08-465-887A-15/c
; Sequence 15, Application US/08465887A
; Patent No. 6001582
;  GENERAL INFORMATION:
;    APPLICANT:  Haskill, John S.
;    APPLICANT:  Baldwin Jr., Albert S.
;    APPLICANT:  Ralph, Peter
;    TITLE OF INVENTION:  Inhibitor of NF-kB Transcriptional
;    TITLE OF INVENTION:  Activator and Uses Thereof
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  6300 Sears Tower/ 233 South Wacker Drive
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/465,887A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Pochopien, Donald J.
;      REGISTRATION NUMBER:  32,167
;      REFERENCE/DOCKET NUMBER:  0899.006/33516
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/474-6300
;      TELEFAX:  312/474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-465-887A-15

  Query Match             1.5%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              |||||||||||||||
Db         15 CTGGAAGCACGAATG 1


RESULT 44
US-08-758-306-499
; Sequence 499, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  499:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-499

; Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   77.8%;  Pred. No. 44;
  Matches   14;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 TCCTGCAGCGGCCCCCGC 422
```

```
              :||:||||| ||||| ||
Db          1 UCCUGCAGCUGCCCCUGC 18


RESULT 45
US-09-085-759-95/c
; Sequence 95, Application US/09085759
; Patent No. 6096722
;  GENERAL INFORMATION:
;    APPLICANT:  C. Frank Bennett, Christopher Mirabelli,
;    APPLICANT:  Brenda Baker
;    TITLE OF INVENTION:  Antisense Modulation of Cell Adhesion
;    TITLE OF INVENTION:  Molecule Expression and Treatment of Cell Adhesion
;    TITLE OF INVENTION:  Molecule-Associated Diseases
;    NUMBER OF SEQUENCES:  109
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/085,759
;      FILING DATE:  herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/440,740
;      FILING DATE:  May 12, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  063,167
;      FILING DATE:  May 17, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 20, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0311
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  95:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
US-09-085-759-95

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 44;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         27 AGGAGCCCTCAAGGCGAG 44
              |||||| ||||||| |||
Db         18 AGGAGCACTCAAGGGGAG 1


RESULT 46
US-08-909-742-3/c
; Sequence 3, Application US/08909742
; Patent No. 6007991
;  GENERAL INFORMATION:
;    APPLICANT:  Vimala S. Sivaraman
;    APPLICANT:  Hsien-Yu Wang
;    APPLICANT:  Craig C. Malbon
;    TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDES FOR MITOGEN-
;    TITLE OF INVENTION:  ACTIVATED PROTEIN KINASES AS THERAPY FOR
;    TITLE OF INVENTION:  BREAST CANCER
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann & Baron, LLP
;      STREET:  350 Jericho Turnpike
;      CITY:  Jericho
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  11753
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Word Perfect 6.1 for windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/909,742
;      FILING DATE:  August 12, 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/831,994
;      FILING DATE:  April 1, 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/827,520
;      FILING DATE:  March 28, 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Adams, Lindsay S.
;      REGISTRATION NUMBER:  36,425
;      REFERENCE/DOCKET NUMBER:  178-225 CIP II
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 822-3550
;      TELEFAX:  (516) 822-3582
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  mRNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-909-742-3

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              |||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 47
US-08-909-742-4/c
; Sequence 4, Application US/08909742
; Patent No. 6007991
;  GENERAL INFORMATION:
;    APPLICANT:  Vimala S. Sivaraman
;    APPLICANT:  Hsien-Yu Wang
;    APPLICANT:  Craig C. Malbon
;    TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDES FOR MITOGEN-
;    TITLE OF INVENTION:  ACTIVATED PROTEIN KINASES AS THERAPY FOR
;    TITLE OF INVENTION:  BREAST CANCER
;    NUMBER OF SEQUENCES:  4
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann & Baron, LLP
;      STREET:  350 Jericho Turnpike
;      CITY:  Jericho
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  11753
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Word Perfect 6.1 for windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/909,742
;      FILING DATE:  August 12, 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/831,994
;      FILING DATE:  April 1, 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/827,520
;      FILING DATE:  March 28, 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Adams, Lindsay S.
;      REGISTRATION NUMBER:  36,425
;      REFERENCE/DOCKET NUMBER:  178-225 CIP II
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 822-3550
;      TELEFAX:  (516) 822-3582
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-909-742-4

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 48
US-09-412-289-3/c
; Sequence 3, Application US/09412289
; Patent No. 6271210
; GENERAL INFORMATION:
;  APPLICANT: Sivaraman, Vimala S.
;  APPLICANT: Wang, Hsien-Yu
;  APPLICANT: Malbon, Craig C.
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR MITOGEN-ACTIVATED
;  TITLE OF INVENTION: PROTEIN KINASES AS THERAPY FOR CANCER
;  FILE REFERENCE: Seq. 1-4 (178-225 CIP II/CON)
;  CURRENT APPLICATION NUMBER: US/09/412,289
;  CURRENT FILING DATE: 1999-10-05
;  EARLIER APPLICATION NUMBER: 08/909,742
;  EARLIER FILING DATE: 1997-08-12
;  EARLIER APPLICATION NUMBER: 08/831,994
;  EARLIER FILING DATE: 1997-04-01
;  EARLIER APPLICATION NUMBER: 08/827,520
;  EARLIER FILING DATE: 1997-03-28
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: synthesized
;   OTHER INFORMATION: antisense oligonucleotide
US-09-412-289-3

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 49
US-09-412-289-4/c
; Sequence 4, Application US/09412289
; Patent No. 6271210
; GENERAL INFORMATION:
;  APPLICANT: Sivaraman, Vimala S.
;  APPLICANT: Wang, Hsien-Yu
;  APPLICANT: Malbon, Craig C.
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR MITOGEN-ACTIVATED
;  TITLE OF INVENTION: PROTEIN KINASES AS THERAPY FOR CANCER
;  FILE REFERENCE: Seq. 1-4 (178-225 CIP II/CON)
;  CURRENT APPLICATION NUMBER: US/09/412,289
;  CURRENT FILING DATE: 1999-10-05
;  EARLIER APPLICATION NUMBER: 08/909,742
;  EARLIER FILING DATE: 1997-08-12
;  EARLIER APPLICATION NUMBER: 08/831,994
;  EARLIER FILING DATE: 1997-04-01
;  EARLIER APPLICATION NUMBER: 08/827,520
;  EARLIER FILING DATE: 1997-03-28
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: synthesized
;   OTHER INFORMATION: antisense oligonucleotide
US-09-412-289-4

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 43;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db         16 TGGCGGCGGCGGCGGC 1


RESULT 50
US-08-857-946-21
; Sequence 21, Application US/08857946
; Patent No. 5994075
;  GENERAL INFORMATION:
;    APPLICANT:  Goodfellow, P.N.
;    TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;    TITLE OF INVENTION:  GENE OF INTEREST
;    NUMBER OF SEQUENCES:  162
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  75 State Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109-1807
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
```

```
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  WordPerfect 6.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/857,946
;       FILING DATE:  16-MAY-1997
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/60/017,824
;       FILING DATE:  17-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kathleen M. Williams
;       REGISTRATION NUMBER:  34,380
;       REFERENCE/DOCKET NUMBER:  3529/05573
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617-345-9100
;       TELEFAX:  617-345-9111
;   INFORMATION FOR SEQ ID NO:  21:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 bases
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
US-08-857-946-21

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
               ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 51
US-08-970-740-21
; Sequence 21, Application US/08970740
; Patent No. 6015670
;  GENERAL INFORMATION:
;     APPLICANT:  Goodfellow, P.N.
;     TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;     TITLE OF INVENTION:  GENE OF INTEREST
;     NUMBER OF SEQUENCES:  162
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Banner & Witcoff, Inc.
;       STREET:  28 State Street, 28th Floor
;       CITY:  Boston
;       STATE:  Massachusetts
;       COUNTRY:  USA
;       ZIP:  02109
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  WordPerfect 6.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/970,740
;       FILING DATE:  14-NOV-1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/857,946
;       FILING DATE:  16-MAY-1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/017,824
;       FILING DATE:  17-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kathleen M. Williams
;       REGISTRATION NUMBER:  34,380
;       REFERENCE/DOCKET NUMBER:  3529/59829
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617-227-7111
;       TELEFAX:  617-227-4399
;   INFORMATION FOR SEQ ID NO:  21:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 bases
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
US-08-970-740-21

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         18 CGGCGGCGGAGGAGCC 33
               ||||||||||||||| |
Db          1 CGGCGGCGGAGGAGGC 16


RESULT 52
US-09-143-212-45
; Sequence 45, Application US/09143212B
; Patent No. 6077672
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia and Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
;  FILE REFERENCE: RTS-0005
;  CURRENT APPLICATION NUMBER: US/09/143,212B
;  CURRENT FILING DATE: 1998-08-28
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 45
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-143-212-45

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          3 TGGCGGCGGCGGCGGC 18


RESULT 53
US-09-422-978-4210/c
; Sequence 4210, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4210
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-1394 for SEQ 276,
US-09-422-978-4210
```

```
  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        549 GGAAAGGAGAAATAGG 564
              ||||||||||||||| |
Db         17 GGAAAGGAGAAATATG 2


RESULT 54
US-09-663-834A-43
; Sequence 43, Application US/09663834A
; Patent No. 6613567
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF HER-2 EXPRESSION
;  FILE REFERENCE: RTS-0033
;  CURRENT APPLICATION NUMBER: US/09/663,834A
;  CURRENT FILING DATE:  2000-09-15
;  NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 43
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-663-834A-43

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 52;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        775 CCTTTTCAGAGTGGCA 790
              ||||| ||||||||||
Db          1 CCTTTCCAGAGTGGCA 16


RESULT 55
US-09-496-694B-99/c
; Sequence 99, Application US/09496694B
; Patent No. 6335194
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Elizabeth J. Ackermann
;  APPLICANT:  Eric E. Swayze
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: ISPH-0439
;  CURRENT APPLICATION NUMBER: US/09/496,694B
;  CURRENT FILING DATE:  2000-02-02
;  PRIOR APPLICATION NUMBER: 09/286,407
;  PRIOR FILING DATE: 1999-04-05
;  PRIOR APPLICATION NUMBER: 09/163,162
;  PRIOR FILING DATE: 1998-09-29
;  NUMBER OF SEQ ID NOS: 249
; SEQ ID NO 99
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-496-694B-99

  Query Match             1.4%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        112 TGGCGGCGGCGGCA 125
              ||||||||||||||
Db         16 TGGCGGCGGCGGCA 3


RESULT 56
US-08-584-040-4308
; Sequence 4308, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4308:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4308

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 56;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              :::||:|  :|||||||
Db          1 UUUCCUGUAUGGAGGAG 17


RESULT 57
US-08-679-645-801
; Sequence 801, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
```

```
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  801:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-801

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 56;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        203 CCTCGACTTCCCCGTCG 219
              ||:||| ::|| ||:||
Db          1 CCUCGAGUUCCUCGUCG 17


RESULT 58
US-09-474-432B-565/c
; Sequence 565, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 565
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-565

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 59
US-09-474-432B-581
; Sequence 581, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 581
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-581

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              ||| |||||||||| |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 60
US-09-371-772B-2075
; Sequence 2075, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
```

```
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2075
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2075

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 56;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              :::||:|  :|||||||
Db          1 UUUCCUGUAUGGAGGAG 17


RESULT 61
US-09-476-387-564/c
; Sequence 564, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 564
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-564

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 62
US-09-476-387-580
; Sequence 580, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 580
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-580

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              ||| |||||||||| |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 63
US-09-866-108A-6303/c
; Sequence 6303, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6303
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6303

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         25 GGAGGAGCCCTCAAGGC 41
              ||||| |||||| ||||
Db         17 GGAGGTGCCCTCCAGGC 1


RESULT 64
US-09-866-108A-8005/c
; Sequence 8005, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8005
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8005

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        147 GGAGCTGGACCAGCTGC 163
              ||||||| ||||||||
Db         17 GGAGCTGCTCCAGCTGC 1


RESULT 65
US-08-758-306-505/c
; Sequence 505, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  505:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-505

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        967 ATTGGGCCTCAGAACTG 983
              ||||||| |||||| ||
Db         17 ATTGGGCGTCAGAATTG 1


RESULT 66
US-08-531-927B-21
; Sequence 21, Application US/08531927B
; Patent No. 5840491
;  GENERAL INFORMATION:
;    APPLICANT:  Kakizuka, Akira
;    TITLE OF INVENTION:  DNA Sequence Encoding the Machado-Joseph
; Patent No. 5840491
;    TITLE OF INVENTION:  Disease Gene and Uses Thereof
```

```
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02173-4799
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/531,927B
;      FILING DATE:  21-SEP-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP H6-251600
;      FILING DATE:  21-SEP-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  ATH95-01A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-531-927B-21

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        916 AACTCTTTCCTGATTGG 932
              |||||| ||||||| ||
Db          1 AACTCTGTCCTGATAGG 17


RESULT 67
US-08-857-946-14
; Sequence 14, Application US/08857946
; Patent No. 5994075
;  GENERAL INFORMATION:
;    APPLICANT:  Goodfellow, P.N.
;    TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;    TITLE OF INVENTION:  GENE OF INTEREST
;    NUMBER OF SEQUENCES:  162
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  75 State Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109-1807
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/857,946
;      FILING DATE:  16-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/60/017,824
;      FILING DATE:  17-MAY-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kathleen M. Williams
;      REGISTRATION NUMBER:  34,380
;      REFERENCE/DOCKET NUMBER:  3529/05573
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-345-9100
;      TELEFAX:  617-345-9111
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-857-946-14

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              |||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 68
US-09-256-496-10
; Sequence 10, Application US/09256496
; Patent No. 5998206
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
;  FILE REFERENCE: RTS-0056
;  CURRENT APPLICATION NUMBER: US/09/256,496
;  CURRENT FILING DATE: 1999-02-23
;  NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-10

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGGAGG 29
              |||||| ||||| ||||
Db          2 GCAGGCAGCGGCTGAGG 18


RESULT 69
US-08-970-740-14
; Sequence 14, Application US/08970740
; Patent No. 6015670
;  GENERAL INFORMATION:
;    APPLICANT:  Goodfellow, P.N.
;    TITLE OF INVENTION:  METHODS FOR IDENTIFYING A MUTATION IN A
;    TITLE OF INVENTION:  GENE OF INTEREST
;    NUMBER OF SEQUENCES:  162
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  28 State Street, 28th Floor
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;       SOFTWARE:  WordPerfect 6.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/970,740
;       FILING DATE:  14-NOV-1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/857,946
;       FILING DATE:  16-MAY-1997
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/017,824
;       FILING DATE:  17-MAY-1996
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Kathleen M. Williams
;       REGISTRATION NUMBER:  34,380
;       REFERENCE/DOCKET NUMBER:  3529/59829
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617-227-7111
;       TELEFAX:  617-227-4399
;   INFORMATION FOR SEQ ID NO:  14:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 bases
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
US-08-970-740-14

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || ||
Db          1 GCGGCGGCGGCGGCGGC 17


RESULT 70
US-09-358-381-13
; Sequence 13, Application US/09358381
; Patent No. 6020199
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: RTS-0079
;  CURRENT APPLICATION NUMBER: US/09/358,381
;  CURRENT FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-381-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 71
US-09-358-381-13/c
; Sequence 13, Application US/09358381
; Patent No. 6020199
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: RTS-0079
;  CURRENT APPLICATION NUMBER: US/09/358,381
;  CURRENT FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-381-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 72
US-09-344-520-34/c
; Sequence 34, Application US/09344520
; Patent No. 6037176
; GENERAL INFORMATION:
;  APPLICANT: Frank Bennett
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF integrin beta 3 EXPRESSION
;  FILE REFERENCE: RTS-0070
;  CURRENT APPLICATION NUMBER: US/09/344,520
;  CURRENT FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 34
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-520-34

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        701 CTGGCAACTCCCCATCA 717
              |||| |||||| |||||
Db         18 CTGGAAACTCCTCATCA 2


RESULT 73
US-09-143-212-44
; Sequence 44, Application US/09143212B
; Patent No. 6077672
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia and Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
;  FILE REFERENCE: RTS-0005
;  CURRENT APPLICATION NUMBER: US/09/143,212B
;  CURRENT FILING DATE: 1998-08-28
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 44
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-143-212-44

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||| ||| |
Db          1 GCGGCGGCGGCGGCTTC 17


RESULT 74
US-09-143-212-46
; Sequence 46, Application US/09143212B
; Patent No. 6077672
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia and Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
;  FILE REFERENCE: RTS-0005
;  CURRENT APPLICATION NUMBER: US/09/143,212B
;  CURRENT FILING DATE: 1998-08-28
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 46
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-143-212-46

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         12 GGCAGGCGGCGGCGGAG 28
              ||||||  |||||||| |
Db          2 GGCAGGTGGCGGCGGCG 18


RESULT 75
US-08-938-669A-16/c
; Sequence 16, Application US/08938669A
; Patent No. 6171788
;  GENERAL INFORMATION:
;    APPLICANT:  Nguyen, Thai D.
;    APPLICANT:  Polansky, Jon R.
;    TITLE OF INVENTION:  METHODS FOR THE DIAGNOSIS,
;    TITLE OF INVENTION:  PROGNOSIS AND TREATMENT OF GLAUCOMA AND
;    TITLE OF INVENTION:  RELATED DISEASES
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Howrey & Simon
;      STREET:  1299 Pennsylvania Avenue, N.W.
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20004-2402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/938,669A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/791,154
;      FILING DATE:  28-JAN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mendelson, Elliot
;      REGISTRATION NUMBER:  P-42,878
;      REFERENCE/DOCKET NUMBER:  07425-0034
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202 383-6857
;      TELEFAX:  202 383-6610
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-938-669A-16

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 76
US-09-577-902-13
; Sequence 13, Application US/09577902
; Patent No. 6284538
; GENERAL INFORMATION:
;  APPLICANT:    Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION:    ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE:    ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/577,902
;  CURRENT FILING DATE:  2000-05-24
;  PRIOR APPLICATION NUMBER:  US 09/358,381
;  PRIOR FILING DATE:  1999-07-21
;  PRIOR APPLICATION NUMBER:  PCT/US99/29594,
;  PRIOR FILING DATE:  1999-12-14
;  NUMBER OF SEQ ID NOS:    51
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-577-902-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 77
US-09-577-902-13/c
; Sequence 13, Application US/09577902
; Patent No. 6284538
; GENERAL INFORMATION:
;  APPLICANT:    Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION:    ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE:    ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/577,902
;  CURRENT FILING DATE:  2000-05-24
;  PRIOR APPLICATION NUMBER:  US 09/358,381
;  PRIOR FILING DATE:  1999-07-21
;  PRIOR APPLICATION NUMBER:  PCT/US99/29594,
;  PRIOR FILING DATE:  1999-12-14
;  NUMBER OF SEQ ID NOS:    51
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-577-902-13
```

```
  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||| || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 78
US-09-651-374A-14
; Sequence 14, Application US/09651374A
; Patent No. 6472156
; GENERAL INFORMATION:
;  APPLICANT: Wittwer, Carl
;  APPLICANT:  Hermann, Mark
;  TITLE OF INVENTION: Homogenous Multiplex Hybridization Analysis by Color and TM
;  FILE REFERENCE: A-68197/RFT
;  CURRENT APPLICATION NUMBER: US/09/651,374A
;  CURRENT FILING DATE:  2000-08-30
;  PRIOR APPLICATION NUMBER: US 60/151,494
;  PRIOR FILING DATE: 1999-08-30
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic.
US-09-651-374A-14

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        337 GACAGCGGCGCCTCGAG 353
              ||||||| |||| ||||
Db          1 GACAGCGACGCCGCGAG 17


RESULT 79
US-09-306-828-16/c
; Sequence 16, Application US/09306828
; Patent No. 6475724
; GENERAL INFORMATION:
;  APPLICANT: Nguyen, Thai D.
;  APPLICANT: Polansky, Jon R.
;  APPLICANT: Chen, Pu
;  APPLICANT: Chen, Hua
;  TITLE OF INVENTION: Nucleic Acids, Kits, And Methods For The Diagnosis, Prognosis And
;  CURRENT APPLICATION NUMBER: US/09/306,828
;  CURRENT FILING DATE: 1999-05-07
;  EARLIER APPLICATION NUMBER: US 09/227,881
;  EARLIER FILING DATE: 1999-01-11
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: Microsoft Word 97
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-306-828-16

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 67;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 80
US-09-359-756-9
; Sequence 9, Application US/09359756
; Patent No. 6168950
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: William Gaarde
;  APPLICANT: Donna T. Ward
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEKK1 EXPRESSION
;  FILE REFERENCE: RTS-0077
;  CURRENT APPLICATION NUMBER: US/09/359,756
;  CURRENT FILING DATE: 1999-07-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-359-756-9

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 92;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         43 AGCAGCGCGCGCGCGGC 59
              ||| |||||||||| ||
Db          4 AGCCGCGCGCGCGCTGC 20


RESULT 81
US-08-182-968A-321
; Sequence 321, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  321:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-321

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 43;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              ||||||  ||||||||
Db          1 GCGCCCUCCGCCGAG 15


RESULT 82
US-08-774-306A-321
; Sequence 321, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  321:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-321

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 43;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              ||||||  ||||||||
Db          1 GCGCCCUCCGCCGAG 15


RESULT 83
US-08-863-639A-21
; Sequence 21, Application US/08863639A
; Patent No. 5981185
;  GENERAL INFORMATION:
;    APPLICANT:  Matson, Robert S.
;    APPLICANT:  Coassin, Peter J.
;    APPLICANT:  Rampal, Jang B.
;    APPLICANT:  Caskey, C. T.
;    TITLE OF INVENTION:  OLIGONUCLEOTIDE REPEAT ARRAYS
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sheldon & Mak
;      STREET:  225 South Lake Avenue, 9th Floor
;      CITY:  Pasadena
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  91101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  Corel WordPerfect 8 version
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/863,639A
;      FILING DATE:  May 28, 1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph E. Mueth
;      REGISTRATION NUMBER:  20,532
;      REFERENCE/DOCKET NUMBER:  11859-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (626) 796-4000
;      TELEFAX:  (626) 795-6321
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
US-08-863-639A-21

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 43;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||  ||
Db          1 GGCGGCGGCGGCGGC 15


RESULT 84
US-09-064-156A-321
; Sequence 321, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
```

```
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/064,156A
;       FILING DATE:  April 21, 1998
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/774,306
;       FILING DATE:  December 26, 1996
;       APPLICATION NUMBER:  08/182,968
;       FILING DATE:  January 13, 1994
;       APPLICATION NUMBER:  07/882,888
;       FILING DATE:  May 14, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  234/083
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  321:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-064-156A-321

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 43;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        385 GCGCCCGCCGCCGAG 399
              ||||||  ||||||||
Db          1 GCGCCCUCCGCCGAG 15


RESULT 85
US-08-730-635-13
; Sequence 13, Application US/08730635
; Patent No. 6514693
;  GENERAL INFORMATION:
;    APPLICANT:  Lansdorp, Peter
;    TITLE OF INVENTION:  Method for Detecting Multiple Copies of
;    TITLE OF INVENTION:  a Repeat Sequence in a Nucleic Acid Molecule
; Patent No. 6514693
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  HOWSON & HOWSON
;      STREET:  321 No. 6514693ristown Road
;      CITY:  Spring House
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19477
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/730,635
;      FILING DATE:  11-OCT-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bak, Mary E.
;      REGISTRATION NUMBER:  31,215
;      REFERENCE/DOCKET NUMBER:  B&P7USA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 540-9200
;      TELEFAX:  (215) 540-5818
;      TELEX:  N/A
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-730-635-13

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 43;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          1 GGCGGCGGCGGCGGC 15


RESULT 86
US-09-290-449-4
; Sequence 4, Application US/09290449A
; Patent No. 6096505
; GENERAL INFORMATION:
;  APPLICANT: SELBY, Mark
;  APPLICANT: THUDIUM, Kent
;  APPLICANT: DINA, Dino
;  TITLE OF INVENTION: NONCLONING TECHNIQUE FOR EXPRESSING A GENE OF INTEREST
;  FILE REFERENCE: 1448.002
;  CURRENT APPLICATION NUMBER: US/09/290,449A
;  CURRENT FILING DATE: 1999-04-13
;  EARLIER APPLICATION NUMBER: US 60/081,777
;  EARLIER FILING DATE: 1998-04-14
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: mutant neo
;   OTHER INFORMATION: primer 93
US-09-290-449-4

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 54;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        460 TTGCACAAGATGGAT 474
              ||| ||||||||||||
Db          1 TTGAACAAGATGGAT 15


RESULT 87
US-08-626-023-1/c
; Sequence 1, Application US/08626023
; Patent No. 5955266
;  GENERAL INFORMATION:
;    APPLICANT:  Bray, Paul F.
;    APPLICANT:  Goldschmidt-Clermont, Pascal
;    APPLICANT:  J.
;    TITLE OF INVENTION:  USE OF PLATELET POLYMORPHISM P1A2 TO
;    TITLE OF INVENTION:  DIAGNOSE RISK OF THROMBOTIC DISEASE
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  4225 Executive Square, Suite 1400
;      CITY:  La Jolla
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92037
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/626,023
```

```
;       FILING DATE:  01-APR-1996
;       CLASSIFICATION:  536
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Haile Ph.D., Lisa A.,
;       REGISTRATION NUMBER:  38,347
;       REFERENCE/DOCKET NUMBER:  07265/087001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  619/678-5070
;       TELEFAX:  619/678-5099
;   INFORMATION FOR SEQ ID NO:  1:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     FEATURE:
;       NAME/KEY:  CDS
;       LOCATION:  1..17
US-08-626-023-1

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              ||||||  ||||||||
Db         15 GAGCCCAGAGGCAGG 1


RESULT 88
US-08-626-023-3
; Sequence 3, Application US/08626023
; Patent No. 5955266
;  GENERAL INFORMATION:
;    APPLICANT:  Bray, Paul F.
;    APPLICANT:  Goldschmidt-Clermont, Pascal
;    APPLICANT:  J.
;    TITLE OF INVENTION:  USE OF PLATELET POLYMORPHISM P1A2 TO
;    TITLE OF INVENTION:  DIAGNOSE RISK OF THROMBOTIC DISEASE
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  4225 Executive Square, Suite 1400
;      CITY:  La Jolla
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92037
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/626,023
;      FILING DATE:  01-APR-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Haile Ph.D., Lisa A.,
;      REGISTRATION NUMBER:  38,347
;      REFERENCE/DOCKET NUMBER:  07265/087001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619/678-5070
;      TELEFAX:  619/678-5099
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
US-08-626-023-3

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              ||||||  ||||||||
Db          3 GAGCCCAGAGGCAGG 17


RESULT 89
US-09-474-432B-312/c
; Sequence 312, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 312
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-312

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 90
US-09-371-772B-5503/c
; Sequence 5503, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
```

```
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5503
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5503

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGG 458
              ||||||||| |||||
Db         17 AGAAACTCTGAAAGG 3


RESULT 91
US-09-476-387-311/c
; Sequence 311, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 311
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-311

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | |||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 92
US-09-866-108A-2497
; Sequence 2497, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2497
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2497

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          3 CCTGCACCAGATGGC 17


RESULT 93
US-09-866-108A-2498
; Sequence 2498, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2498
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2498

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          2 CCTGCACCAGATGGC 16


RESULT 94
US-09-866-108A-2499
; Sequence 2499, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2499
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2499

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          1 CCTGCACCAGATGGC 15


RESULT 95
US-09-866-108A-8123
; Sequence 8123, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8123
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8123

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          3 GCGGCTTCATCAGCT 17


RESULT 96
US-09-866-108A-8124
; Sequence 8124, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
```

```
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8124
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8124

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          2 GCGGCTTCATCAGCT 16


RESULT 97
US-09-866-108A-8125
; Sequence 8125, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8125
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8125

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          1 GCGGCTTCATCAGCT 15


RESULT 98
US-09-866-108A-8640
; Sequence 8640, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8640
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8640

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
```

```
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          5 AGAACTGCAGCTG 17


RESULT 99
US-09-866-108A-8641
; Sequence 8641, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8641
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8641

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          4 AGAACTGCAGCTG 16


RESULT 100
US-09-866-108A-8642
; Sequence 8642, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8642
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8642

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          3 AGAACTGCAGCTG 15


RESULT 101
US-09-866-108A-8643
; Sequence 8643, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8643
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8643

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          2 AGAACTGCAGCTG 14


RESULT 102
US-09-866-108A-8644
; Sequence 8644, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8644
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8644

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          1 AGAACTGCAGCTG 13


RESULT 103
US-08-753-147-164/c
; Sequence 164, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  164:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-164

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 69;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        605 ATGGATCTGAAATGAA 620
              | ||| ||||||||||
Db         16 AGGGAGCTGAAATGAA 1


RESULT 104
US-09-593-012-161
; Sequence 161, Application US/09593012
; Patent No. 6387652
; GENERAL INFORMATION:
;  APPLICANT: HAUGLAND, Richard
;  APPLICANT:  VESPER, Stephen
;  TITLE OF INVENTION: METHOD OF IDENTIFYING AND QUANTIFYING SPECIFIC FUNGI AND BACTERIA
;  FILE REFERENCE: HAUGLAND=1A
;  CURRENT APPLICATION NUMBER: US/09/593,012
;  CURRENT FILING DATE:  2000-06-13
;  PRIOR APPLICATION NUMBER: US 09/290,990
```

```
;  PRIOR FILING DATE: 1999-04-14
;  PRIOR APPLICATION NUMBER: US 60/081,773
;  PRIOR FILING DATE: 1998-04-15
;  NUMBER OF SEQ ID NOS: 225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 161
;    LENGTH: 16
;    TYPE: DNA
;    ORGANISM: Penicillium simplicissimum/ochrochloron
US-09-593-012-161

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 69;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        185 CCGCCTCACCGCCGGC 200
              ||||||||| |||| |
Db          1 CCGCCTCACGGCCGCC 16


RESULT 105
US-09-371-772B-5828
; Sequence 5828; Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5828
;    LENGTH: 16
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-09-371-772B-5828

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   62.5%;  Pred. No. 69;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        566 GAGGGCCTGTGGTGGT 581
              |||||||: :| :||:
Db          1 GAGGGCCUCUGAUGGU 16


RESULT 106
US-09-479-005A-1
; Sequence 1, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;    LENGTH: 16
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-09-479-005A-1

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 69;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        116 GGCGGCGGCAGCTGCG 131
              ||||||||| || |||
Db          1 GGCGGCGGCCGCGGCG 16


RESULT 107
US-08-250-740-11/c
; Sequence 11, Application US/08250740
; Patent No. 5686240
;  GENERAL INFORMATION:
;    APPLICANT:  Schuchman, Edward H.
;    APPLICANT:  Desnick, Robert J.
;    TITLE OF INVENTION:  Acid Sphingomyelinase Gene and Diagnosis
;    TITLE OF INVENTION:  of Niemann-Pick Disease
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/250,740
;      FILING DATE:  27-MAY-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Coruzzi, Laura A.
;      REGISTRATION NUMBER:  30742
;      REFERENCE/DOCKET NUMBER:  6923-038
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-250-740-11

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        714 ATCAGGTCGCACAGTG 729
              ||||||| |||||| |
Db         17 ATCAGGTGGCACAGAG 2


RESULT 108
US-07-695-472B-21/c
; Sequence 21, Application US/07695472B
; Patent No. 5773278
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Schuchman, Edward H.
;    APPLICANT:  Desnick, Robert J.
;    TITLE OF INVENTION:  The Acid Sphingomyelinase Gene and
;    TITLE OF INVENTION:  Diagnosis of Niemann-Pick Disease
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/695,472B
;      FILING DATE:  19910503
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  6923-014
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 7908864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
US-07-695-472B-21

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        714 ATCAGGTCGCACAGTG 729
              ||||||| |||||| |
Db         17 ATCAGGTGGCACAGAG 2


RESULT 109
US-08-584-040-1925
; Sequence 1925, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1925:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-1925

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 84;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        566 GAGGGCCTGTGGTGGT 581
              |||||||: :| :||:
Db          1 GAGGGCCUCUGAUGGU 16


RESULT 110
US-08-584-040-4327
; Sequence 4327, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
```

```
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  4327:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-4327

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 84;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        580 GTAAAACCAATCCCAG 595
              |:||||  ||:|||||
Db          1 GUAAAAGUAAUCCCAG 16


RESULT 111
US-08-584-040-5867
; Sequence 5867, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5867:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5867

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 84;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGA 936
              :::||:|  :||||||
Db          1 UUUCCUGUAUGGAGGA 16


RESULT 112
US-08-584-040-7609
; Sequence 7609, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7609:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7609

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 84;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        566 GAGGGCCTGTGGTGGT 581
              |||||||: :| :||:
Db          1 GAGGGCCUCUGAUGGU 16


RESULT 113
```

```
US-08-679-645-210/c
; Sequence 210, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  210:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-210

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        640 CCAGGAGAGGTCCAGG 655
              ||||||||| ||| ||
Db         17 CCAGGAGAGATCCTGG 2


RESULT 114
US-08-679-645-212/c
; Sequence 212, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  212:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-212

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        639 TCCAGGAGAGGTCCAG 654
              |||||||||| ||| |
Db         16 TCCAGGAGAGATCCTG 1


RESULT 115
US-08-679-645-803
; Sequence 803, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
```

```
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  803:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-803

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 84;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        204 CTCGACTTCCCCGTCG 219
              |:||| ::|| ||:||
Db          1 CUCGAGUUCCUCGUCG 16


RESULT 116
US-09-343-698-1
; Sequence 1, Application US/09343698
; Patent No. 6475486
;   GENERAL INFORMATION:
;        APPLICANT: Seeman, Gerhard
;                   Bosslet, Klaus
;                   Czech, Joerg
;                   Kolar, Cenek
;                   Hoffman, Dieter
;                   Sedlacek, Hans-Harald
;        TITLE OF INVENTION: Glycosyl-Etoposide Prodrugs, A Process For
;                            Preparation Thereof And The Use Thereof In Combination With
;                            Functionalized Tumor-Specific Enzyme Conjugates
;        NUMBER OF SEQUENCES: 8
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
;                        Dunner
;             STREET: 1300 I Street, N.W., Suite 700
;             CITY: Washington
;             STATE: D.C.
;             COUNTRY: USA
;             ZIP: 20005
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/343,698
;             FILING DATE: 30-Jun-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/325,955
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ogden, Stasia L.
;             REGISTRATION NUMBER: 36,228
;             REFERENCE/DOCKET NUMBER: 05552.0981-04000
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 202-408-4000
;             TELEFAX: 202-408-4400
;   INFORMATION FOR SEQ ID NO: 1:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 17 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-343-698-1

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         17 GCGGCGGCGGAGGAGC 32
              |||||||||| || ||
Db          1 GCGGCGGCGGCGGTGC 16


RESULT 117
US-09-673-809-97
; Sequence 97, Application US/09673809
; Patent No. 6528261
; GENERAL INFORMATION:
;  APPLICANT:  INNOGENETICS N.V.
;  TITLE OF INVENTION:  Method for typing of HLA alleles.
;  FILE REFERENCE:  PCT99.86.HLA
;  CURRENT APPLICATION NUMBER: US/09/673,809
;  CURRENT FILING DATE:  2000-10-20
;  PRIOR APPLICATION NUMBER:  98870088.6
;  PRIOR FILING DATE:  1998-04-20
;  NUMBER OF SEQ ID NOS:  107
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 97
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-673-809-97

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        341 GCGGCGCCTCGAGTCC 356
              ||| |||| |||||||
Db          1 GCGACGCCGCGAGTCC 16


RESULT 118
US-09-673-809-97/c
; Sequence 97, Application US/09673809
; Patent No. 6528261
; GENERAL INFORMATION:
```

```
;  APPLICANT:  INNOGENETICS N.V.
;  TITLE OF INVENTION:  Method for typing of HLA alleles.
;  FILE REFERENCE:  PCT99.86.HLA
;  CURRENT APPLICATION NUMBER: US/09/673,809
;  CURRENT FILING DATE:  2000-10-20
;  PRIOR APPLICATION NUMBER:  98870088.6
;  PRIOR FILING DATE:  1998-04-20
;  NUMBER OF SEQ ID NOS:  107
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 97
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-673-809-97

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        107 CGGACTGGCGGCGGCG 122
              |||||| |||||| ||
Db         17 CGGACTCGCGGCGTCG 2


RESULT 119
US-09-474-432B-736/c
; Sequence 736, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 736
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-09-474-432B-736

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        662 CGGCTTCACCAGCTTC 677
              ||||| |||||||| |
Db         17 CGGCTCCACCAGCTCC 2


RESULT 120
US-09-474-432B-789/c
; Sequence 789, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 789
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-09-474-432B-789

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        168 GCAGCCGCTCTTCCTT 183
              |||||||||| ||||
Db         16 GCAGCCGCTCCCCCTT 1


RESULT 121
US-09-106-375-21/c
; Sequence 21, Application US/09106375
; Patent No. 6541218
;  GENERAL INFORMATION:
;    APPLICANT:  Schuchman, Edward H.
;    APPLICANT:  Desnick, Robert J.
;    TITLE OF INVENTION:  The Acid Sphingomyelinase Gene and
;    TITLE OF INVENTION:  Diagnosis of Niemann-Pick Disease
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/106,375
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/695,472
;      FILING DATE:  03-MAY-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  6923-014
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 7908864/9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  21:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA
US-09-106-375-21

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        714 ATCAGGTCGCACAGTG 729
              ||||||| |||||| |
Db         17 ATCAGGTGGCACAGAG 2


RESULT 122
US-09-371-772B-470
; Sequence 470, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 470
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-470

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 84;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        566 GAGGGCCTGTGGTGGT 581
              |||||||: :| :||:
Db          1 GAGGGCCUCUGAUGGU 16


RESULT 123
US-09-371-772B-2094
; Sequence 2094, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2094
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2094

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 84;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        580 GTAAAACCAATCCCAG 595
              |:||||  ||:|||||
Db          1 GUAAAAGUAAUCCCAG 16


RESULT 124
US-09-371-772B-2720
; Sequence 2720, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2720
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2720

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 84;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGA 936
              :::||:|  :||||||
Db          1 UUUCCUGUAUGGAGGA 16


RESULT 125
US-09-371-772B-4761
; Sequence 4761, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 4761
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4761

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 84;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        566 GAGGGCCTGTGGTGGT 581
              ||||||| :| :||:
Db          2 GAGGGCCUCUGAUGGU 17


RESULT 126
US-09-371-772B-6336
; Sequence 6336, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6336
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6336

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 84;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        585 ACCAATCCCAGTTAAA 600
              |||||:|||| :: ||
Db          2 ACCAAUCCCAUUUCAA 17


RESULT 127
US-09-371-772B-6337
; Sequence 6337, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6337
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6337

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 84;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        585 ACCAATCCCAGTTAAA 600
              |||||:|||| :: ||
Db          1 ACCAAUCCCAUUUCAA 16


RESULT 128
US-08-325-955-1
; Sequence 1, Application US/08325955
; Patent No. 6610299
;  GENERAL INFORMATION:
;    APPLICANT:  Seeman, Gerhard
;    APPLICANT:  Bosslet, Klaus
;    APPLICANT:  Czech, Joerg
;    APPLICANT:  Kolar, Cenek
;    APPLICANT:  Hoffman, Dieter
;    APPLICANT:  Sedlacek, Hans-Harald
;    TITLE OF INVENTION:  Glycosyl-Etoposide Prodrugs, A Process For
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner
;      STREET:  1300 I Street, N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/325,955
;      FILING DATE:  19-OCT-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ogden, Stasia L.
;      REGISTRATION NUMBER:  36,228
;      REFERENCE/DOCKET NUMBER:  05552.0981-04000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-408-4000
;      TELEFAX:  202-408-4400
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-325-955-1

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         17 GCGGCGGCGGAGGAGC 32
              |||||||||| || ||
Db          1 GCGGCGGCGGCGGTGC 16


RESULT 129
US-09-476-387-735/c
; Sequence 735, Application US/09476387
; Patent No. 6617438
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 735
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-735

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        662 CGGCTTCACCAGCTTC 677
              ||||| ||||||||  |
Db         17 CGGCTCCACCAGCTCC 2


RESULT 130
US-09-476-387-788/c
; Sequence 788, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 788
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-788

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        168 GCAGCCGCTCTTCCTT 183
              ||||||||||  ||||
Db         16 GCAGCCGCTCCCCCTT 1


RESULT 131
US-09-827-998-76
; Sequence 76, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 76
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-76

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 AAACTGAAGGCAACCT 520
              |||||||||| ||| |
Db          2 AAACTGAAGGAAACAT 17


RESULT 132
US-09-827-998-77
; Sequence 77, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 77
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-77

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 AAACTGAAGGCAACCT 520
              |||||||||| ||| |
Db          1 AAACTGAAGGAAACAT 16
```

```
RESULT 133
US-09-827-998-136/c
; Sequence 136, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 136
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-136

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        816 TTCACCAGATGGCTTC 831
              ||| ||||||| ||||
Db         17 TTCTCCAGATGTCTTC 2


RESULT 134
US-09-827-998-137/c
; Sequence 137, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 137
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-137

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        816 TTCACCAGATGGCTTC 831
              ||| ||||||| ||||
Db         16 TTCTCCAGATGTCTTC 1


RESULT 135
US-09-866-108A-1547/c
; Sequence 1547, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1547
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1547

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        629 CAGCTGAGTCTCCAGG 644
              |||||  |||||||||
Db         17 CAGCTCTGTCTCCAGG 2


RESULT 136
US-09-866-108A-1548/c
; Sequence 1548, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1548
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1548

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        629 CAGCTGAGTCTCCAGG 644
              |||||  |||||||||
Db         16 CAGCTCTGTCTCCAGG 1


RESULT 137
US-09-866-108A-6302/c
; Sequence 6302, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6302
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6302

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         26 GAGGAGCCCTCAAGGC 41
              ||||  ||||||  ||||
Db         17 GAGGTGCCCTCCAGGC 2


RESULT 138
US-09-866-108A-6304/c
; Sequence 6304, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6304
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6304

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         25 GGAGGAGCCCTCAAGG 40
              |||||  ||||||  |||
Db         16 GGAGGTGCCCTCCAGG 1


RESULT 139
US-09-866-108A-6376/c
; Sequence 6376, Application US/09866108A
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6376
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6376

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        181 CTTGCCGCCTCACCGC 196
              ||| || |||||||||
Db         17 CTTTCCTCCTCACCGC 2


RESULT 140
US-09-866-108A-6377/c
; Sequence 6377, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6377
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6377

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        181 CTTGCCGCCTCACCGC 196
              ||| || |||||||||
Db         16 CTTTCCTCCTCACCGC 1


RESULT 141
US-09-866-108A-8004/c
; Sequence 8004, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
```

```
; SEQ ID NO 8004
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8004

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        148 GAGCTGGACCAGCTGC 163
              |||||| ||||||||
Db         17 GAGCTGCTCCAGCTGC 2


RESULT 142
US-09-866-108A-8006/c
; Sequence 8006, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8006
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8006

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        147 GGAGCTGGACCAGCTG 162
              ||||||| |||||||
Db         16 GGAGCTGCTCCAGCTG 1


RESULT 143
US-09-866-108A-9603
; Sequence 9603, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9603
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9603

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 TCCTGCAGCGGCCCCC 420
              |||| ||||||||| |
Db          2 TCCTTCAGCGGCCCTC 17


RESULT 144
US-09-866-108A-9604
; Sequence 9604, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
```

```
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9604
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-9604

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        405 TCCTGCAGCGGCCCCC 420
              |||| |||||||||| |
Db          1 TCCTTCAGCGGCCCTC 16


RESULT 145
US-09-866-108A-9943
; Sequence 9943, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9943
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-9943

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        365 CCGAGCCCGGGGAGAA 380
              |||||| ||||||||
Db          2 CCGAGCATGGGGAGAA 17


RESULT 146
US-09-866-108A-9944
; Sequence 9944, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9944
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-9944

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 84;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        365 CCGAGCCCGGGGAGAA 380
              |||||| ||||||||
Db          1 CCGAGCATGGGGAGAA 16


RESULT 147
US-08-465-485A-28/c
```

```
; Sequence 28, Application US/08465485A
; Patent No. 5831066
; GENERAL INFORMATION:
;   APPLICANT:  Reed, John
;   TITLE OF INVENTION:  Regulation of bcl-2 Gene Expression
;   NUMBER OF SEQUENCES:  29
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;     ADDRESSEE:  P.C.
;     STREET:  1755 S. Jefferson Davis Hwy., Suite 400
;     CITY:  Arlington
;     STATE:  Virginia
;     COUNTRY:  U.S.A.
;     ZIP:  22202
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/465,485A
;     FILING DATE:  05-JUN-1995
;     CLASSIFICATION:  514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 08/124,256
;     FILING DATE:  20-SEP-1993
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/840,716
;     FILING DATE:  21-FEB-1992
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/288,692
;     FILING DATE:  22-DEC-1988
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Fortney, Andrew D.
;     REGISTRATION NUMBER:  34,600
;     REFERENCE/DOCKET NUMBER:  3335-070-55 CONT
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (408) 436-2070
;     TELEFAX:  (408) 436-2075
; INFORMATION FOR SEQ ID NO:  28:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  20 base pairs
;     TYPE:  nucleic acid
;     STRANDEDNESS:  single
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  Other nucleic acid;
;     DESCRIPTION:  Synthetic DNA
;   ANTI-SENSE:  YES
;   FEATURE:
;     NAME/KEY:  Modified_base
;     LOCATION:  18..19
;     OTHER INFORMATION:  Last two internucleoside linkages are
;     OTHER INFORMATION:  phosphorothioates
US-08-465-485A-28

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        268 GCGGTGCCGCCGCCCC 283
              ||| |||||||||| |
Db         20 GCGCTGCCGCCGCCGC 5


RESULT 148
US-09-080-285-28/c
; Sequence 28, Application US/09080285
; Patent No. 6040181
; GENERAL INFORMATION:
;   APPLICANT:  Reed, John
;   TITLE OF INVENTION:  Regulation of bcl-2 Gene Expression
;   NUMBER OF SEQUENCES:  29
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;     ADDRESSEE:  P.C.
;     STREET:  1755 S. Jefferson Davis Hwy., Suite 400
;     CITY:  Arlington
;     STATE:  Virginia
;     COUNTRY:  U.S.A.
;     ZIP:  22202
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/09/080,285
;     FILING DATE:
;     CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 08/465,485
;     FILING DATE:  05-JUN-1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 08/124,256
;     FILING DATE:  20-SEP-1993
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/840,716
;     FILING DATE:  21-FEB-1992
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/288,692
;     FILING DATE:  22-DEC-1988
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Fortney, Andrew D.
;     REGISTRATION NUMBER:  34,600
;     REFERENCE/DOCKET NUMBER:  3335-070-55 CONT
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (408) 436-2070
;     TELEFAX:  (408) 436-2075
; INFORMATION FOR SEQ ID NO:  28:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  20 base pairs
;     TYPE:  nucleic acid
;     STRANDEDNESS:  single
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  Other nucleic acid;
;     DESCRIPTION:  Synthetic DNA
;   ANTI-SENSE:  YES
;   FEATURE:
;     NAME/KEY:  Modified_base
;     LOCATION:  18..19
;     OTHER INFORMATION:  Last two internucleoside linkages are
;     OTHER INFORMATION:  phosphorothioates
US-09-080-285-28

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        268 GCGGTGCCGCCGCCCC 283
              ||| |||||||||| |
Db         20 GCGCTGCCGCCGCCGC 5


RESULT 149
US-09-724-426-28/c
; Sequence 28, Application US/09724426
; Patent No. 6414134
; GENERAL INFORMATION:
;  APPLICANT: Reed, John
;  TITLE OF INVENTION: Regulation of BCL-2 Gene Expression
;  FILE REFERENCE: 10412-024
;  CURRENT APPLICATION NUMBER: US/09/724,426
;  CURRENT FILING DATE:  2000-11-28
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-724-426-28

  Query Match             1.3%;  Score 12.8;  DB 1;  Length 20;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        268 GCGGTGCCGCCGCCCC 283
              ||| |||||||||| |
Db         20 GCGCTGCCGCCGCCGC 5


RESULT 150
US-08-914-961-2
; Sequence 2, Application US/08914961
; Patent No. 6018042
;  GENERAL INFORMATION:
;    APPLICANT:  Mett, Helmut
;    APPLICANT:  Haner, Robert
;    APPLICANT:  Dean, Nicholas Mark
;    TITLE OF INVENTION:  Antitumor Antisense Oligonucleotides
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CIBA-GEIGY Corporation
;      STREET:  7 Skyline Drive
;      CITY:  Hawthorne
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10532
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII Editor
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/914,961
;      FILING DATE:  20-AUG-1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/287,753
;      FILING DATE:  09-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Spruill, W. Murray
;      REGISTRATION NUMBER:  32,943
;      REFERENCE/DOCKET NUMBER:  4-20047/P1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919) 541-8615
;      TELEFAX:  (919) 541-8689
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
;    POSITION IN GENOME:
;      MAP POSITION:  -80
;      UNITS:  bp
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..20
;      OTHER INFORMATION:  /note= "All nucleotides are of the
;      OTHER INFORMATION:  phosphorothioate type"
US-08-914-961-2

  Query Match             1.3%;  Score 12.6;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        406 CCTGCAGCGGCCCCCGCCG 424
                || || || ||| ||||||
Db          1 CCCGCCGCTGCCGCCGCCG 19


RESULT 151
US-08-244-188-1/c
; Sequence 1, Application US/08244188
; Patent No. 5597713
;  GENERAL INFORMATION:
;    APPLICANT:  Kato, Seishi
;    APPLICANT:  Sekine, Shingo
;    TITLE OF INVENTION:  Process For Producing cDNAs With
;    TITLE OF INVENTION:  Complete Lengths, Process For Producing Intermediates
;    TITLE OF INVENTION:  Thereof And Process For Producing Vectors Containing
;    TITLE OF INVENTION:  cDNAs With Complete Lengths
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Birch, Stewart, Kolasch & Birch
;      STREET:  8110 Gatehouse Road, Suite 500 East
;      CITY:  Falls Church
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22042
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/244,188
;      FILING DATE:  25-JUL-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy Jr., Gerald M.
;      REGISTRATION NUMBER:  28,977
;      REFERENCE/DOCKET NUMBER:  760-184P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 205-8000
;      TELEFAX:  (703) 205-8050
;      TELEX:  248345
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Chimeric DNA-RNA
;      DESCRIPTION:  oligonucleotide"
;    HYPOTHETICAL:  YES
;    ANTI-SENSE:  NO
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  12..14
;      OTHER INFORMATION:  /note= "GGA at positions 12-14 are
;      OTHER INFORMATION:  ribonucleotides"
US-08-244-188-1

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 TCCTCGACTTCCCC 215
              ||||||| ||||||
Db         14 TCCTCGAATTCCCC 1


RESULT 152
US-08-244-188-2/c
; Sequence 2, Application US/08244188
; Patent No. 5597713
;  GENERAL INFORMATION:
;    APPLICANT:  Kato, Seishi
```

```
;    APPLICANT:  Sekine, Shingo
;    TITLE OF INVENTION:  Process For Producing cDNAs With
;    TITLE OF INVENTION:  Complete Lengths, Process For Producing Intermediates
;    TITLE OF INVENTION:  Thereof And Process For Producing Vectors Containing
;    TITLE OF INVENTION:  cDNAs With Complete Lengths
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Birch, Stewart, Kolasch & Birch
;      STREET:  8110 Gatehouse Road, Suite 500 East
;      CITY:  Falls Church
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22042
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/244,188
;      FILING DATE:  25-JUL-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy Jr., Gerald M.
;      REGISTRATION NUMBER:  28,977
;      REFERENCE/DOCKET NUMBER:  760-184P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 205-8000
;      TELEFAX:  (703) 205-8050
;      TELEX:  248345
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Synthetic DNA
;      DESCRIPTION:  oligonucleotide"
;    HYPOTHETICAL:  YES
;    ANTI-SENSE:  YES
US-08-244-188-2

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 TCCTCGACTTCCCC 215
              ||||||| ||||||
Db         14 TCCTCGAATTCCCC 1


RESULT 153
US-08-393-734-6
; Sequence 6, Application US/08393734
; Patent No. 5652224
;  GENERAL INFORMATION:
;    APPLICANT:  Wilson, James M.
;    APPLICANT:  Kozarsky, Karen F.
;    APPLICANT:  Strauss, Jerome F.
;    TITLE OF INVENTION:  Methods and Compositions for Gene
;    TITLE OF INVENTION:  Therapy for the Treatment of Defects in Lipoprotein
;    TITLE OF INVENTION:  Metabolism
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Howson and Howson
;      STREET:  Spring House Corporate Cntr., PO Box 457
;      CITY:  Spring House
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19477
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/393,734
;      FILING DATE:
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bak, Mary E.
;      REGISTRATION NUMBER:  31,215
;      REFERENCE/DOCKET NUMBER:  UPNH1254USA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-540-9200
;      TELEFAX:  215-540-5818
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-393-734-6

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        726 AGTGAAATCAGAAT 739
              ||||||||| ||||
Db          1 AGTGAAATCTGAAT 14


RESULT 154
US-08-836-022A-6
; Sequence 6, Application US/08836022A
; Patent No. 6001557
;  GENERAL INFORMATION:
;    APPLICANT:  Trustees of the University of Pennsylvania
;    APPLICANT:  Wilson, James M.
;    APPLICANT:  Fisher, Krishna J.
;    APPLICANT:  Chen, Shu-Jen
;    APPLICANT:  Weitzman, Matthew
;    TITLE OF INVENTION:  Improved Adenovirus Virus and
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Howson and Howson
;      STREET:  Spring House Corporate Cntr, P O Box 457
;      CITY:  Spring House
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19477
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/836,022A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/331,381
;      FILING DATE:  28-OCT-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bak, Mary E.
;      REGISTRATION NUMBER:  31,215
;      REFERENCE/DOCKET NUMBER:  GNVPN.008PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-540-9200
;      TELEFAX:  215-540-5818
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
```

```
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA (genomic)
US-08-836-022A-6

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      726 AGTGAAATCAGAAT 739
            ||||||||| ||||
Db        1 AGTGAAATCTGAAT 14


RESULT 155
US-08-894-489-6
; Sequence 6, Application US/08894489
; Patent No. 6174527
;  GENERAL INFORMATION:
;     APPLICANT:  Wilson, James M.
;     APPLICANT:  Kozarsky, Karen F.
;     APPLICANT:  Strauss, Jerome F.
;     TITLE OF INVENTION:  Methods and Compositions for Gene
;     TITLE OF INVENTION:  Therapy for the Treatment of Defects in Lipoprotein
;     TITLE OF INVENTION:  Metabolism
;     NUMBER OF SEQUENCES:  8
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Howson and Howson
;       STREET:  Spring House Corporate Cntr., PO Box 457
;       CITY:  Spring House
;       STATE:  Pennsylvania
;       COUNTRY:  USA
;       ZIP:  19477
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/894,489
;       FILING DATE:
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/393,734
;       FILING DATE:  24-FEB-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Bak, Mary E.
;       REGISTRATION NUMBER:  31,215
;       REFERENCE/DOCKET NUMBER:  GNVPN.009CIP1USA
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  215-540-9200
;       TELEFAX:  215-540-5818
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  14 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  DNA (genomic)
US-08-894-489-6

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      726 AGTGAAATCAGAAT 739
            ||||||||| ||||
Db        1 AGTGAAATCTGAAT 14


RESULT 156
US-09-427-048A-6
; Sequence 6, Application US/09427048A
; Patent No. 6203975
;  GENERAL INFORMATION:
;       APPLICANT: Trustees of the University of Pennsylvania
;                  Wilson, James M.
;                  Fisher, Krishna J.
;                  Chen, Shu-Jen
;                  Weitzman, Matthew
;       TITLE OF INVENTION: Improved Adenovirus Virus and
;                           Methods of Use Thereof
;       NUMBER OF SEQUENCES: 10
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Howson and Howson
;            STREET: Spring House Corporate Cntr, P O Box 457
;            CITY: Spring House
;            STATE: Pennsylvania
;            COUNTRY: USA
;            ZIP: 19477
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/427,048A
;            FILING DATE: 21-Oct-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/836,022
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Bak, Mary E.
;            REGISTRATION NUMBER: 31,215
;            REFERENCE/DOCKET NUMBER: GNVPN.008PCT
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 215-540-9200
;            TELEFAX: 215-540-5818
;  INFORMATION FOR SEQ ID NO: 6:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 14 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: double
;            TOPOLOGY: unknown
;       MOLECULE TYPE: DNA (genomic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-427-048A-6

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      726 AGTGAAATCAGAAT 739
            ||||||||| ||||
Db        1 AGTGAAATCTGAAT 14


RESULT 157
US-08-872-056-8/c
; Sequence 8, Application US/08872056
; Patent No. 6231863
;  GENERAL INFORMATION:
;    APPLICANT:  COLAU, DIDIER
;    APPLICANT:  ROOS, JOEL
;    TITLE OF INVENTION:  RECOMBINANT DNA SEQUENCES, MOLECULES,
;    TITLE OF INVENTION:  VECTORS AND VACCINES FOR FELINE CALICIVIRUS DISEASE AND
;    TITLE OF INVENTION:  METHODS FOR PRODUCING AND USING SAME
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MCDERMOTT, WILL & EMERY
;      STREET:  1850 K STREET, N.W., SUITE 500
;      CITY:  WASHINGTON
;      STATE:  DC
;      COUNTRY:  USA
```

```
;      ZIP:  20006
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/872,056
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GADIANO, WILHLEM F
;      REGISTRATION NUMBER:  37,136
;      REFERENCE/DOCKET NUMBER:  37712-213
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 778-8373
;      TELEFAX:  (202) 778-8335
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-872-056-8

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        572 CTGTGGTGGTAAAA 585
              ||||||||| |||||
Db         14 CTGTGGTGATAAAA 1


RESULT 158
US-09-529-157-8/c
; Sequence 8, Application US/09529157
; Patent No. 6500939
; GENERAL INFORMATION:
;  APPLICANT: Kato, Seishi
;  APPLICANT:  Sekine, Shingo
;  TITLE OF INVENTION: cDNAs Coding For Human Proteins Having Transmembrane
;  TITLE OF INVENTION:  Domains
;  FILE REFERENCE: GIN-6711CPUS
;  CURRENT APPLICATION NUMBER: US/09/529,157
;  CURRENT FILING DATE:  2000-08-21
;  PRIOR APPLICATION NUMBER: PCT/JP98/04447
;  PRIOR FILING DATE: 1998-10-02
;  PRIOR APPLICATION NUMBER: JP 9-276270
;  PRIOR FILING DATE: 1997-10-08
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: chimeric
;   OTHER INFORMATION: DNA-RNA oligonucleotide
US-09-529-157-8

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        202 TCCTCGACTTCCCC 215
              ||||||| ||||||
Db         14 TCCTCGAATTCCCC 1


RESULT 159
US-07-791-213D-42/c
; Sequence 42, Application US/07791213D
; Patent No. 5409895
;  GENERAL INFORMATION:
;    APPLICANT:  MORISHITA, Hideaki
;    APPLICANT:  KANAMORI, Toshinori
;    APPLICANT:  NOBUHARA, Masahiro
;    TITLE OF INVENTION:  POLYPEPTIDE, DNA FRAGMENT ENCODING THE
;    TITLE OF INVENTION:  SAME AND PROCESS FOR PRODUCING THE SAME, AND ENZYME
;    TITLE OF INVENTION:  INHIBITION PROCESS, DRUG COMPOSITION AND METHODS OF
;    TITLE OF INVENTION:  TREATING USING THE SAME
;    NUMBER OF SEQUENCES:  108
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Burns, Doane, Swecker & Mathis
;      STREET:  P.O. Box 1404
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  United States
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/791,213D
;      FILING DATE:  13-NOV-1991
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 2-306745
;      FILING DATE:  13-NOV-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meuth, Donna M
;      REGISTRATION NUMBER:  36,607
;      REFERENCE/DOCKET NUMBER:  029650-032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 836-6620
;      TELEFAX:  (703) 836-2021
;  INFORMATION FOR SEQ ID NO:  42:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-791-213D-42

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGG 26
              |||||||||| |||
Db         15 GCAGGCGGCGACGG 2


RESULT 160
US-08-050-073-201
; Sequence 201, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
```

```
;       STATE:  New Jersey
;       COUNTRY:  U.S.A.
;       ZIP:  07110
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/050,073
;       FILING DATE:
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Petry, Douglas A.
;       REGISTRATION NUMBER:  35,321
;       REFERENCE/DOCKET NUMBER:  8769
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (510) 814-2974
;       TELEFAX:  (510) 814-2977
;   INFORMATION FOR SEQ ID NO:  201:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  genomic DNA
US-08-050-073-201

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GAGGCGGGCAGCGG 92
              ||||||||| ||||
Db          1 GAGGCGGGCCGCGG 14


RESULT 161
US-08-050-073-202/c
; Sequence 202, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2977
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  202:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-202

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GAGGCGGGCAGCGG 92
              ||||||||| ||||
Db         15 GAGGCGGGCCGCGG 2


RESULT 162
US-08-050-073-301
; Sequence 301, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  301:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-301

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GAGGCGGGCAGCGG 92
              ||||||||| ||||
Db          1 GAGGCGGGCCGCGG 14
```

```
RESULT 163
US-08-050-073-302/c
; Sequence 302, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  302:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-302

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          79 GAGGCGGGCAGCGG 92
               ||||||||| ||||
Db          15 GAGGCGGGCCGCGG 2


RESULT 164
US-08-363-240A-148
; Sequence 148, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  148:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-148

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   78.6%;  Pred. No. 67;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         661 GCGGCTTCACCAGC 674
               |||||::| |||||
Db           2 GCGGCUUCCCCAGC 15


RESULT 165
US-08-363-240A-149
; Sequence 149, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  149:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-149

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   78.6%;  Pred. No. 67;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGC 674
              |||||::| |||||
Db          1 GCGGCUUCCCCAGC 14


RESULT 166
US-08-293-150A-42/c
; Sequence 42, Application US/08293150A
; Patent No. 5792629
;  GENERAL INFORMATION:
;    APPLICANT:  MORISHITA, Hideaki
;    APPLICANT:  KANAMORI, Toshinori
;    APPLICANT:  NOBUHARA, Masahiro
;    TITLE OF INVENTION:  POLYPEPTIDE, DNA FRAGMENT ENCODING THE
;    TITLE OF INVENTION:  SAME AND PROCESS FOR PRODUCING THE SAME, AND ENZYME
;    TITLE OF INVENTION:  INHIBITION PROCESS, DRUG COMPOSITION AND METHODS OF
;    TITLE OF INVENTION:  TREATING USING THE SAME
;    NUMBER OF SEQUENCES:  110
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS
;      STREET:  P.O. Box 1404
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  United States
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/293,150A
;      FILING DATE:  19-AUG-1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/791,213
;      FILING DATE:  13-NOV-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 2-306745
;      FILING DATE:  13-NOV-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meuth, Donna M.
;      REGISTRATION NUMBER:  36,607
;      REFERENCE/DOCKET NUMBER:  029650-049
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 836-6620
;      TELEFAX:  (703) 836-2021
;  INFORMATION FOR SEQ ID NO:  42:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-293-150A-42

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 GCAGGCGGCGGCGG 26
              ||||||||| |||
Db         15 GCAGGCGGCGACGG 2


RESULT 167
US-08-292-620A-56/c
; Sequence 56, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  56:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-56

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
```

```
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      280 CCCCACGGAGCCGC 293
            ||||||||||| ||
Db       15 CCCCACGGAGCAGC 2


RESULT 168
US-08-292-620A-597/c
; Sequence 597, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  597:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-597

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      280 CCCCACGGAGCCGC 293
            ||||||||||| ||
Db       15 CCCCACGGAGCAGC 2


RESULT 169
US-08-585-684B-2297/c
; Sequence 2297, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2297:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2297

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      925 CTGATTGGAGGAGA 938
            ||||||||||| |||
Db       15 CTGATTGGAGAAGA 2


RESULT 170
US-09-071-845-56/c
; Sequence 56, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
```

```
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  56:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-56

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        280 CCCCACGGAGCCGC 293
              ||||||||||| ||
Db         15 CCCCACGGAGCAGC 2


RESULT 171
US-09-071-845-597/c
; Sequence 597, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  597:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-597

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        280 CCCCACGGAGCCGC 293
              ||||||||||| ||
Db         15 CCCCACGGAGCAGC 2


RESULT 172
US-09-038-073-2297/c
; Sequence 2297, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2297:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2297

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        925 CTGATTGGAGGAGA 938
              ||||||||||| |||
Db         15 CTGATTGGAGAAGA 2


RESULT 173
US-09-056-995-22
; Sequence 22, Application US/09056995
; Patent No. 6221586
; GENERAL INFORMATION:
;  APPLICANT: Barton, Jacqueline K.
;  APPLICANT: Hill, Michael G.
;  APPLICANT: Kelley, Shana O.
;  TITLE OF INVENTION: ELECTROCHEMICAL SENSORS USING
;  TITLE OF INVENTION: INTERCALATIVE, REDOX-ACTIVE MOIETIES
;  FILE REFERENCE: 21182-701
;  CURRENT APPLICATION NUMBER: US/09/056,995
;  CURRENT FILING DATE: 1998-04-08
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-09-056-995-22

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        384 GGCGCCCGCCGCCG 397
              |||||||| |||||
Db          1 GGCGCCCGGCGCCG 14


RESULT 174
US-09-056-995-23/c
; Sequence 23, Application US/09056995
; Patent No. 6221586
; GENERAL INFORMATION:
;  APPLICANT: Barton, Jacqueline K.
;  APPLICANT: Hill, Michael G.
;  APPLICANT: Kelley, Shana O.
;  TITLE OF INVENTION: ELECTROCHEMICAL SENSORS USING
;  TITLE OF INVENTION: INTERCALATIVE, REDOX-ACTIVE MOIETIES
;  FILE REFERENCE: 21182-701
;  CURRENT APPLICATION NUMBER: US/09/056,995
;  CURRENT FILING DATE: 1998-04-08
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 23
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-09-056-995-23

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        384 GGCGCCCGCCGCCG 397
              |||||||| |||||
Db         15 GGCGCCCGGCGCCG 2


RESULT 175
US-09-180-437-175/c
; Sequence 175, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
;  APPLICANT: FUKUSAKO, Shioji
;  APPLICANT: MORISAWA, Yoshifumi
;  APPLICANT: KUSUYAMA, Takeshi
;  TITLE OF INVENTION: Antisense Compounds to CD14
;  FILE REFERENCE: 1110-209P
;  CURRENT APPLICATION NUMBER: US/09/180,437
;  CURRENT FILING DATE: 1998-11-06
;  EARLIER APPLICATION NUMBER: PCT/JP98/00953
;  EARLIER FILING DATE: 1998-03-09
;  EARLIER APPLICATION NUMBER: 09-053518 JAPAN
;  EARLIER FILING DATE: 1997-03-07
;  NUMBER OF SEQ ID NOS: 289
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 175
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:other nucleic
;   OTHER INFORMATION: acid
US-09-180-437-175

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        116 GGCGGCGGCAGCTG 129
              |||||||||| ||
Db         14 GGCGGCGGCAGGTG 1


RESULT 176
US-09-549-853-38
; Sequence 38, Application US/09549853
; Patent No. 6391558
; GENERAL INFORMATION:
;  APPLICANT: Henkens, Robert W.
;  APPLICANT:  O'Daly, John P.
;  APPLICANT:  Wojciechowski, Marek W.
;  APPLICANT:  Zhang, Honghua W.
;  APPLICANT:  Naser, Najih W.
;  APPLICANT:  Roe, R. M.
;  APPLICANT:  Stewart, Thomas N.
;  APPLICANT:  Thompson, Deborah M.
;  APPLICANT:  Sundseth, Rebecca
;  APPLICANT:  Wegner, Steven E.
;  TITLE OF INVENTION: ELECTROCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES
;  FILE REFERENCE: 4320.001800
;  CURRENT APPLICATION NUMBER: US/09/549,853
```

```
;  CURRENT FILING DATE:  2000-04-14
;  NUMBER OF SEQ ID NOS: 40
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 38
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-549-853-38

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        707 ACTCCCCATCAGGT 720
              ||||||||||| ||
Db          2 ACTCCCCATCATGT 15


RESULT 177
US-09-753-362-14
; Sequence 14, Application US/09753362
; Patent No. 6461820
; GENERAL INFORMATION:
;  APPLICANT: CALIFORNIA INSTITUTE OF TECHNOLOGY
;  APPLICANT:  BARTON, Jacqueline
;  APPLICANT:  HILL, Michael
;  APPLICANT:  KELLEY, Shana
;  TITLE OF INVENTION: ELECTROCHEMICAL SENSOR USING INTERCALATIVE, REDOX-ACTIVE MOIETIES
;  FILE REFERENCE: CIT1310-1
;  CURRENT APPLICATION NUMBER: US/09/753,362
;  CURRENT FILING DATE:  2000-12-29
;  PRIOR APPLICATION NUMBER: US 60/043,146
;  PRIOR FILING DATE: 1997-04-09
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide probe
US-09-753-362-14

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        384 GGCGCCCGCCGCCG 397
              |||||||| |||||
Db          1 GGCGCCCGGCGCCG 14


RESULT 178
US-09-475-947A-322
; Sequence 322, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
;  APPLICANT: Garner, Harold R.
;  APPLICANT:  Wren, Jonathan D.
;  APPLICANT:  Minna, John D.
;  TITLE OF INVENTION: Polymorphic Repeats in Human Genes
;  FILE REFERENCE: UTSD0667
;  CURRENT APPLICATION NUMBER: US/09/475,947A
;  CURRENT FILING DATE:  1999-12-31
;  NUMBER OF SEQ ID NOS: 346
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 322
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: human
US-09-475-947A-322

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCT 128
              ||||||||| ||||
Db          1 CGGCGGCGGAAGCT 14


RESULT 179
US-09-953-242-14
; Sequence 14, Application US/09953242
; Patent No. 6649350
; GENERAL INFORMATION:
;  APPLICANT: CALIFORNIA INSTITUTE OF TECHNOLOGY
;  APPLICANT:  BARTON, Jacqueline K.
;  APPLICANT:  BOON, Elizabeth  M.
;  APPLICANT:  KELLEY, Shana O.
;  APPLICANT:  HILL, Michael  G.
;  TITLE OF INVENTION: ELECTROCHEMICAL SENSOR USING INTERCALATIVE, REDOX-ACTIVE MOIETIES
;  FILE REFERENCE: CIT1310-2
;  CURRENT APPLICATION NUMBER: US/09/953,242
;  CURRENT FILING DATE:  2001-09-13
;  PRIOR APPLICATION NUMBER: US 09/753,362
;  PRIOR FILING DATE: 2000-12-29
;  PRIOR APPLICATION NUMBER: US 09/056,995
;  PRIOR FILING DATE: 1998-04-08
;  PRIOR APPLICATION NUMBER: US 60/043,146
;  PRIOR FILING DATE: 1997-04-09
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide probe
US-09-953-242-14

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 67;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        384 GGCGCCCGCCGCCG 397
              |||||||| |||||
Db          1 GGCGCCCGGCGCCG 14


RESULT 180
US-08-050-073-235/c
; Sequence 235, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  235:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-235

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GAGGCGGGCAGCGG 92
              ||||||||| ||||
Db         14 GAGGCGGGCCGCGG 1


RESULT 181
US-08-050-073-250/c
; Sequence 250, Application US/08050073
; Patent No. 5567809
;  GENERAL INFORMATION:
;    APPLICANT:  Apple, Raymond J.
;    APPLICANT:  Begovich, Ann B.
;    APPLICANT:  Bugawan, Teodorica L.
;    APPLICANT:  Erlich, Henry A.
;    APPLICANT:  Griffith, Robert L.
;    APPLICANT:  Scharf, Stephen J.
;    TITLE OF INVENTION:  Methods and Reagents for HLA DRBeta DNA
;    TITLE OF INVENTION:  Typing
;    NUMBER OF SEQUENCES:  315
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/050,073
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  8769
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  250:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
US-08-050-073-250

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         79 GAGGCGGGCAGCGG 92
              ||||||||| ||||
Db         15 GAGGCGGGCCGCGG 2


RESULT 182
US-08-373-124A-135/c
; Sequence 135, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  135:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-135

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        116 GGCGGCGGCAGCTG 129
              ||| ||||||||||
Db         14 GGCTGCGGCAGCTG 1
```

```
RESULT 183
US-08-435-628-135/c
; Sequence 135, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  135:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-135

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        116 GGCGGCGGCAGCTG 129
              ||| ||||||||||
Db         14 GGCTGCGGCAGCTG 1


RESULT 184
US-09-549-853-34
; Sequence 34, Application US/09549853
; Patent No. 6391558
; GENERAL INFORMATION:
;  APPLICANT: Henkens, Robert W.
;  APPLICANT:  O'Daly, John P.
;  APPLICANT:  Wojciechowski, Marek W.
;  APPLICANT:  Zhang, Honghua W.
;  APPLICANT:  Naser, Najih W.
;  APPLICANT:  Roe, R. M.
;  APPLICANT:  Stewart, Thomas N.
;  APPLICANT:  Thompson, Deborah M.
;  APPLICANT:  Sundseth, Rebecca
;  APPLICANT:  Wegner, Steven E.
;  TITLE OF INVENTION: ELECTROCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES
;  FILE REFERENCE: 4320.001800
;  CURRENT APPLICATION NUMBER: US/09/549,853
;  CURRENT FILING DATE:  2000-04-14
;  NUMBER OF SEQ ID NOS: 40
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-549-853-34

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        707 ACTCCCCATCAGGT 720
              |||||||||| ||
Db          3 ACTCCCCATCATGT 16


RESULT 185
US-09-479-005A-2
; Sequence 2, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-2

  Query Match             1.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 82;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         16 GGCGGCGGCGGAGG 29
              |||||||||| |||
Db          2 GGCGGCGGCGAAGG 15


Search completed: June 28, 2004, 08:14:00
Job time : 3 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: June 28, 2004, 08:16:17 ; Search time 2 Seconds
(without alignments)
2.734 Million cell updates/sec

Title: US-10-069-079-1
Perfect score: 1000
Sequence: 1 ccgagccctgaggcaggcgg.....ctgcagctgtgcacatggaa 1000

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 158 seqs, 2734 residues

Total number of hits satisfying chosen parameters: 316

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 162 summaries

Database : rnpb1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	17.8	1.8	21	1	US-10-000-864-20	Sequence 20, Appl
	2	16.4	1.6	20	1	US-09-756-071B-2	Sequence 2, Appli
	3	16.4	1.6	20	1	US-10-227-738-2	Sequence 2, Appli
c	4	16.2	1.6	21	1	US-10-461-126-1	Sequence 1, Appli
	5	15.8	1.6	19	1	US-09-925-548-3	Sequence 3, Appli
	6	15.8	1.6	19	1	US-10-349-143-5276	Sequence 5276, Ap
	7	15.8	1.6	20	1	US-09-888-326-410	Sequence 410, App
	8	15.8	1.6	20	1	US-09-776-479-243	Sequence 243, App
	9	15.8	1.6	20	1	US-09-776-479-243	Sequence 243, App
	10	15.8	1.6	20	1	US-10-314-578-243	Sequence 243, App
	11	15.8	1.6	20	1	US-10-112-653-235	Sequence 235, App
	12	15.8	1.6	20	1	US-10-017-995-243	Sequence 243, App
	13	15.8	1.6	20	1	US-10-053-645A-28	Sequence 28, Appl
c	14	15.8	1.6	20	1	US-10-349-143-9876	Sequence 9876, Ap
c	15	15.8	1.6	21	1	US-09-828-034-10	Sequence 10, Appl
	16	15.4	1.5	17	1	US-09-780-533A-765	Sequence 765, App
	17	15.4	1.5	17	1	US-09-780-533A-2337	Sequence 2337, Ap
	18	15.4	1.5	17	1	US-09-780-533A-2338	Sequence 2338, Ap
c	19	15.2	1.5	20	1	US-10-388-360-205	Sequence 205, App
c	20	15.2	1.5	20	1	US-10-349-143-6333	Sequence 6333, Ap
	21	15	1.5	17	1	US-09-780-533A-1789	Sequence 1789, Ap
	22	15	1.5	17	1	US-10-238-700-2867	Sequence 2867, Ap
	23	14.8	1.5	18	1	US-09-500-700-68	Sequence 68, Appl
	24	14.8	1.5	18	1	US-10-314-405-45	Sequence 45, Appl
	25	14.8	1.5	19	1	US-10-016-490C-16	Sequence 16, Appl
c	26	14.4	1.4	17	1	US-09-780-533A-440	Sequence 440, App
	27	14.4	1.4	17	1	US-09-780-533A-1790	Sequence 1790, Ap
	28	14.4	1.4	17	1	US-09-780-533A-1791	Sequence 1791, Ap
	29	14.4	1.4	17	1	US-09-827-395A-510	Sequence 510, App
c	30	14.4	1.4	17	1	US-09-740-332-1479	Sequence 1479, Ap
c	31	14.4	1.4	17	1	US-09-817-879-1479	Sequence 1479, Ap
	32	14.4	1.4	17	1	US-10-430-882-510	Sequence 510, App
c	33	14.4	1.4	17	1	US-10-060-895A-752	Sequence 752, App
c	34	14.4	1.4	17	1	US-10-060-895A-753	Sequence 753, App
	35	14.4	1.4	17	1	US-10-230-006-1390	Sequence 1390, Ap
	36	14.4	1.4	17	1	US-10-230-006-2189	Sequence 2189, Ap
	37	14.4	1.4	17	1	US-10-712-672-407	Sequence 407, App
c	38	14.4	1.4	18	1	US-10-349-143-4210	Sequence 4210, Ap
	39	14	1.4	17	1	US-09-927-046-266	Sequence 266, App
	40	14	1.4	17	1	US-09-927-046-854	Sequence 854, App
	41	14	1.4	17	1	US-09-927-046-1188	Sequence 1188, Ap
	42	14	1.4	17	1	US-09-927-046-1189	Sequence 1189, Ap
	43	14	1.4	17	1	US-09-927-046-1361	Sequence 1361, Ap
	44	14	1.4	17	1	US-09-927-046-1734	Sequence 1734, Ap
	45	14	1.4	17	1	US-10-238-700-2866	Sequence 2866, Ap
c	46	14	1.4	18	1	US-09-918-186A-99	Sequence 99, Appl
c	47	14	1.4	18	1	US-10-181-316-99	Sequence 99, Appl
c	48	13.8	1.4	17	1	US-09-866-108-6303	Sequence 6303, Ap
c	49	13.8	1.4	17	1	US-09-866-108-8005	Sequence 8005, Ap
	50	13.8	1.4	17	1	US-09-814-777A-89	Sequence 89, Appl
c	51	13.8	1.4	17	1	US-09-825-805-564	Sequence 564, App
	52	13.8	1.4	17	1	US-09-825-805-580	Sequence 580, App
	53	13.8	1.4	17	1	US-09-961-077-801	Sequence 801, App
	54	13.8	1.4	17	1	US-09-780-533A-815	Sequence 815, App
c	55	13.8	1.4	17	1	US-09-877-478-2237	Sequence 2237, Ap
c	56	13.8	1.4	17	1	US-09-848-754A-1339	Sequence 1339, Ap
c	57	13.8	1.4	17	1	US-09-848-754A-1340	Sequence 1340, Ap
c	58	13.8	1.4	17	1	US-09-848-754A-1341	Sequence 1341, Ap
c	59	13.8	1.4	17	1	US-09-848-754A-2125	Sequence 2125, Ap
c	60	13.8	1.4	17	1	US-09-848-754A-2407	Sequence 2407, Ap
c	61	13.8	1.4	17	1	US-09-827-395A-756	Sequence 756, App
c	62	13.8	1.4	17	1	US-09-827-395A-992	Sequence 992, App
	63	13.8	1.4	17	1	US-09-740-332-1531	Sequence 1531, Ap
	64	13.8	1.4	17	1	US-09-817-879-1531	Sequence 1531, Ap
c	65	13.8	1.4	17	1	US-10-342-902-2237	Sequence 2237, Ap
c	66	13.8	1.4	17	1	US-10-430-882-756	Sequence 756, App
c	67	13.8	1.4	17	1	US-10-430-882-992	Sequence 992, App
c	68	13.8	1.4	17	1	US-10-163-552-7	Sequence 7, Appli
	69	13.8	1.4	17	1	US-10-163-552-49	Sequence 49, Appl
	70	13.8	1.4	17	1	US-10-156-306-3486	Sequence 3486, Ap
	71	13.8	1.4	17	1	US-10-156-306-5929	Sequence 5929, Ap
	72	13.8	1.4	17	1	US-10-156-306-6336	Sequence 6336, Ap
	73	13.8	1.4	17	1	US-10-156-306-6935	Sequence 6935, Ap
	74	13.8	1.4	17	1	US-10-156-306-6936	Sequence 6936, Ap
	75	13.8	1.4	17	1	US-10-156-306-7029	Sequence 7029, Ap
	76	13.8	1.4	17	1	US-10-238-700-6	Sequence 6, Appli
	77	13.8	1.4	17	1	US-10-238-700-11	Sequence 11, Appl
	78	13.8	1.4	17	1	US-10-238-700-2801	Sequence 2801, Ap
c	79	13.8	1.4	17	1	US-10-061-201-808	Sequence 808, App
c	80	13.8	1.4	17	1	US-10-061-201-809	Sequence 809, App
	81	13.8	1.4	17	1	US-10-230-006-2088	Sequence 2088, Ap
	82	13.8	1.4	17	1	US-10-138-674-2075	Sequence 2075, Ap
	83	13.8	1.4	17	1	US-10-287-949A-2075	Sequence 2075, Ap
c	84	13.8	1.4	17	1	US-10-712-672-716	Sequence 716, App
	85	13.8	1.4	17	1	US-10-712-672-948	Sequence 948, App
	86	13.8	1.4	18	1	US-09-878-582-13	Sequence 13, Appl
c	87	13.8	1.4	18	1	US-09-878-582-13	Sequence 13, Appl
	88	13.8	1.4	18	1	US-09-969-373-1628	Sequence 1628, Ap
c	89	13.8	1.4	18	1	US-09-969-373-4477	Sequence 4477, Ap
c	90	13.8	1.4	18	1	US-09-985-637A-12	Sequence 12, Appl
c	91	13.8	1.4	18	1	US-10-244-633-16	Sequence 16, Appl
	92	13.8	1.4	18	1	US-10-388-263-837	Sequence 837, App
c	93	13.8	1.4	18	1	US-10-388-263-837	Sequence 837, App
	94	13.8	1.4	18	1	US-10-336-213B-13	Sequence 13, Appl
c	95	13.8	1.4	18	1	US-10-336-213B-13	Sequence 13, Appl
	96	13.4	1.3	15	1	US-09-504-231A-343	Sequence 343, App
	97	13.4	1.3	15	1	US-09-274-553D-343	Sequence 343, App
	98	13.4	1.3	15	1	US-10-132-002-13	Sequence 13, Appl
c	99	13.4	1.3	16	1	US-10-001-254-46	Sequence 46, Appl
	100	13.4	1.3	16	1	US-10-712-672-1465	Sequence 1465, Ap
	101	13.4	1.3	17	1	US-09-866-108-2497	Sequence 2497, Ap
	102	13.4	1.3	17	1	US-09-866-108-2498	Sequence 2498, Ap
	103	13.4	1.3	17	1	US-09-866-108-2499	Sequence 2499, Ap
	104	13.4	1.3	17	1	US-09-866-108-8123	Sequence 8123, Ap
	105	13.4	1.3	17	1	US-09-866-108-8124	Sequence 8124, Ap
	106	13.4	1.3	17	1	US-09-866-108-8125	Sequence 8125, Ap

c 107	13.4	1.3	17	1	US-09-825-805-311	Sequence 311, App
c 108	13.4	1.3	17	1	US-09-780-533A-441	Sequence 441, App
109	13.4	1.3	17	1	US-09-780-533A-1788	Sequence 1788, Ap
c 110	13.4	1.3	17	1	US-09-780-533A-2248	Sequence 2248, Ap
c 111	13.4	1.3	17	1	US-09-877-478-346	Sequence 346, App
c 112	13.4	1.3	17	1	US-09-877-478-1056	Sequence 1056, Ap
c 113	13.4	1.3	17	1	US-09-848-754A-831	Sequence 831, App
c 114	13.4	1.3	17	1	US-09-848-754A-2408	Sequence 2408, Ap
115	13.4	1.3	17	1	US-09-930-423-480	Sequence 480, App
116	13.4	1.3	17	1	US-09-930-423-1013	Sequence 1013, Ap
117	13.4	1.3	17	1	US-09-827-395A-769	Sequence 769, App
118	13.4	1.3	17	1	US-09-827-395A-770	Sequence 770, App
119	13.4	1.3	17	1	US-09-740-332-3076	Sequence 3076, Ap
120	13.4	1.3	17	1	US-09-745-237A-480	Sequence 480, App
121	13.4	1.3	17	1	US-09-745-237A-1013	Sequence 1013, Ap
122	13.4	1.3	17	1	US-09-817-879-3076	Sequence 3076, Ap
c 123	13.4	1.3	17	1	US-10-342-902-346	Sequence 346, App
c 124	13.4	1.3	17	1	US-10-342-902-1056	Sequence 1056, Ap
125	13.4	1.3	17	1	US-10-430-882-769	Sequence 769, App
126	13.4	1.3	17	1	US-10-430-882-770	Sequence 770, App
c 127	13.4	1.3	17	1	US-10-041-856-45	Sequence 45, Appl
128	13.4	1.3	17	1	US-10-020-141-15	Sequence 15, Appl
c 129	13.4	1.3	17	1	US-10-060-895A-751	Sequence 751, App
c 130	13.4	1.3	17	1	US-10-060-895A-754	Sequence 754, App
c 131	13.4	1.3	17	1	US-10-163-552-8	Sequence 8, Appli
132	13.4	1.3	17	1	US-10-156-306-4923	Sequence 4923, Ap
133	13.4	1.3	17	1	US-10-156-306-5924	Sequence 5924, Ap
134	13.4	1.3	17	1	US-10-153-244-268	Sequence 268, App
135	13.4	1.3	17	1	US-10-297-068-764	Sequence 764, App
c 136	13.4	1.3	17	1	US-10-138-674-5503	Sequence 5503, Ap
c 137	13.4	1.3	17	1	US-10-676-154-630	Sequence 630, App
138	13.4	1.3	17	1	US-10-676-154-661	Sequence 661, App
c 139	13.4	1.3	17	1	US-10-287-949A-5503	Sequence 5503, Ap
140	13	1.3	15	1	US-09-504-231A-716	Sequence 716, App
141	13	1.3	15	1	US-09-504-231A-717	Sequence 717, App
142	13	1.3	15	1	US-09-274-553D-716	Sequence 716, App
143	13	1.3	15	1	US-09-274-553D-717	Sequence 717, App
144	13	1.3	15	1	US-10-113-877-28	Sequence 28, Appl
145	13	1.3	17	1	US-09-866-108-8640	Sequence 8640, Ap
146	13	1.3	17	1	US-09-866-108-8641	Sequence 8641, Ap
147	13	1.3	17	1	US-09-866-108-8642	Sequence 8642, Ap
148	13	1.3	17	1	US-09-866-108-8643	Sequence 8643, Ap
149	13	1.3	17	1	US-09-866-108-8644	Sequence 8644, Ap
c 150	13	1.3	17	1	US-09-877-478-1055	Sequence 1055, Ap
c 151	13	1.3	17	1	US-09-877-478-1514	Sequence 1514, Ap
c 152	13	1.3	17	1	US-09-740-332-1480	Sequence 1480, Ap
c 153	13	1.3	17	1	US-09-817-879-1480	Sequence 1480, Ap
c 154	13	1.3	17	1	US-10-342-902-1055	Sequence 1055, Ap
c 155	13	1.3	17	1	US-10-342-902-1514	Sequence 1514, Ap
156	13	1.3	17	1	US-09-927-046-1290	Sequence 1290, Ap
157	13	1.3	17	1	US-09-927-046-1610	Sequence 1610, Ap
158	13	1.3	17	1	US-09-927-046-2024	Sequence 2024, Ap
159	13	1.3	17	1	US-10-238-700-5	Sequence 5, Appli
160	13	1.3	17	1	US-10-238-700-10	Sequence 10, Appl
161	13	1.3	17	1	US-10-339-782-491	Sequence 491, App
162	12.8	1.3	17	1	US-10-061-201-808	Sequence 808, App

ALIGNMENTS

```
RESULT 1
US-10-000-864-20
; Sequence 20, Application US/10000864
; Publication No. US20020146798A1
; GENERAL INFORMATION:
;  APPLICANT: CADUS PHARMACEUTICAL CORPORATION
;  TITLE OF INVENTION: HUMAN MEKK PROTEIN AND NUCLEIC ACID MOLECULES
;  TITLE OF INVENTION: AND USES THEREFOR
;  FILE REFERENCE: CPI-085CPPC
;  CURRENT APPLICATION NUMBER: US/10/000,864
;  CURRENT FILING DATE: 2001-10-31
;  EARLIER APPLICATION NUMBER: 09/423,890
;  EARLIER FILING DATE: 2000-06-03
;  EARLIER APPLICATION NUMBER: PCT/US99/05556
;  EARLIER FILING DATE: 1999-03-15
;  EARLIER APPLICATION NUMBER: USSN 60/078,153
;  EARLIER FILING DATE: 1998-03-16
;  EARLIER APPLICATION NUMBER: USSN 60/099,165
;  EARLIER FILING DATE: 1998-09-04
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic construct
US-10-000-864-20

  Query Match             1.8%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 7.2;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        527 CAGCCTGGAAGCACGAATGGT 547
              | |||||||||||||| ||||
Db          1 CGGCCTGGAAGCACGAGTGGT 21


RESULT 2
US-09-756-071B-2
; Sequence 2, Application US/09756071B
; Patent No. US20020052307A1
;   GENERAL INFORMATION:
;        APPLICANT: Tryggvason, Karl
;                   Kallunki, Pekka
;                   Pyke, Charles
;        TITLE OF INVENTION: Laminin Chains: Diagnostic Uses
;        NUMBER OF SEQUENCES: 20
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fay Sharpe Fagan Minnich & McKee
;             STREET: 1100 Superior Ave, Suite 700
;             CITY: Cleveland
;             STATE: Ohio
;             COUNTRY: USA
;             ZIP: 44114
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/756,071B
;             FILING DATE: 08-Jan-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 09/663,147
;             FILING DATE: 150-September 2000
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Minnich, Richard, J.
;             REGISTRATION NUMBER: 24,175
;             REFERENCE/DOCKET NUMBER: TRV 20014
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 216-861-5582
;             TELEFAX: 216-241-1666
;   INFORMATION FOR SEQ ID NO: 2:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: other nucleic acid
;             DESCRIPTION: /desc = "OLIGOMER PRIMER"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-756-071B-2
```

```
  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 15;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              |||||||| |||||||||
Db          1 GAATCACTGAGCAGCTGA 18


RESULT 3
US-10-227-738-2
; Sequence 2, Application US/10227738
; Publication No. US20030100529A1
;   GENERAL INFORMATION:
;        APPLICANT: Tryggvason, Karl
;                   Kallunki, Pekka
;                   Pyke, Charles
;        TITLE OF INVENTION: Laminin Chains: Diagnostic and
;                            Therapeutic Use
;        NUMBER OF SEQUENCES: 19
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: McDonnell Boehnen Hulbert & Berghoff
;             STREET: 300 South Wacker Drive
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: USA
;             ZIP: 60606
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/227,738
;             FILING DATE: 26-Aug-2002
;             CLASSIFICATION: 435
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/800,593
;             FILING DATE: 18-FEB-1997
;             APPLICATION NUMBER: US 08/317,450
;             FILING DATE: 04-OCT-1994
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Chao, Mark
;             REGISTRATION NUMBER: 37,293
;             REFERENCE/DOCKET NUMBER: 94,778-B
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312-913-0001
;             TELEFAX: 312-913-0002
;   INFORMATION FOR SEQ ID NO: 2:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: other nucleic acid
;             DESCRIPTION: /desc = "OLIGOMER PRIMER"
;        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-227-738-2

  Query Match             1.6%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 15;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        618 GAATCACTTAGCAGCTGA 635
              |||||||| |||||||||
Db          1 GAATCACTGAGCAGCTGA 18


RESULT 4
US-10-461-126-1/c
; Sequence 1, Application US/10461126
; Publication No. US20040072150A1
; GENERAL INFORMATION:
;  APPLICANT: SHYAMALA, Verikatakrishna
;  TITLE OF INVENTION: IDENTIFICATION OF OLIGONUCLEOTIDES FOR THE CAPTURE, DETECTION AND
;  TITLE OF INVENTION:  QUANTITATION OF HEPATITIS A VIRAL NUCLEIC ACID
;  FILE REFERENCE: 2300-19317  (PP19317.002)
;  CURRENT APPLICATION NUMBER: US/10/461,126
;  CURRENT FILING DATE:  2003-06-12
;  PRIOR APPLICATION NUMBER: 60/388,544
;  PRIOR FILING DATE: 2002-06-12
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Sense Primer- nt538-558
US-10-461-126-1

  Query Match             1.6%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 16;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        937 GACAGCCCAGACAATAAATAC 957
              |||||||| |||||| ||| |
Db         21 GACAGCCCTGACAATCAATCC 1


RESULT 5
US-09-925-548-3
; Sequence 3, Application US/09925548
; Patent No. US20020107216A1
; GENERAL INFORMATION:
;  APPLICANT: Dedhar, Shoukat
;  APPLICANT:  Hannigan, Greg
;  APPLICANT:  Yee, Arthur
;  TITLE OF INVENTION: INTEGRIN-LINKED KINASE AND ITS USES
;  FILE REFERENCE: KINE001CIP4
;  CURRENT APPLICATION NUMBER: US/09/925,548
;  CURRENT FILING DATE:  2001-08-08
;  PRIOR APPLICATION NUMBER: 09/390,425
;  PRIOR FILING DATE: 1999-09-03
;  PRIOR APPLICATION NUMBER: 09/035,706
;  PRIOR FILING DATE: 1998-03-05
;  PRIOR APPLICATION NUMBER: 08/955,841
;  PRIOR FILING DATE: 1997-10-21
;  PRIOR APPLICATION NUMBER: 08/752,345
;  PRIOR FILING DATE: 1996-11-19
;  PRIOR APPLICATION NUMBER: 60/009,074
;  PRIOR FILING DATE: 1995-12-21
;  NUMBER OF SEQ ID NOS: 97
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-925-548-3

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 21;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        694 CCTTCTCCTGGCAACTCCC 712
              |||||||| || |||||||
Db          1 CCTTCTCCGGGGAACTCCC 19


RESULT 6
US-10-349-143-5276
; Sequence 5276, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
```

```
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5276
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-23123 for SEQ 1342,
US-10-349-143-5276

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 21;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       745 GGAGTAAGGAGAAAAAGAG 763
             |||  ||||||||||||||
Db         1 GGAACAAGGAGAAAAAGAG 19


RESULT 7
US-09-888-326-410
; Sequence 410, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 410
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphodiester backbone
US-09-888-326-410

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       113 GGCGGCGGCGGCAGCTGCG 131
             ||||||||||||| || |||
Db         1 GGCGGCGGCGGCGGCGGCG 19


RESULT 8
US-09-776-479-243
; Sequence 243, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       113 GGCGGCGGCGGCAGCTGCG 131
             ||||||||||||| || |||
Db         1 GGCGGCGGCGGCGGCGGCG 19


RESULT 9
US-09-776-479-243
; Sequence 243, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       113 GGCGGCGGCGGCAGCTGCG 131
             ||||||||||||| || |||
Db         1 GGCGGCGGCGGCGGCGGCG 19


RESULT 10
US-10-314-578-243
; Sequence 243, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
```

```
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-243

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 11
US-10-112-653-235
; Sequence 235, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 235
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-235

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 12
US-10-017-995-243
; Sequence 243, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-243

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              ||||||||||||  || |||
Db          1 GGCGGCGGCGGCGGCGGCG 19


RESULT 13
US-10-053-645A-28
; Sequence 28, Application US/10053645A
; Publication No. US20030176376A1
; GENERAL INFORMATION:
;  APPLICANT: Robert E. Klem
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A
;  TITLE OF INVENTION:  CELL-PROLIFERATIVE DISORDER USING CRE DECOY OLIGOMERS, BCL-2
;  TITLE OF INVENTION:  ANTISENSE OLIGOMERS, AND HYBRID OLIGOMERS THEREOF
;  FILE REFERENCE: 10412-022-999
;  CURRENT APPLICATION NUMBER: US/10/053,645A
;  CURRENT FILING DATE:  2002-01-22
;  PRIOR APPLICATION NUMBER: 60/263,244
;  PRIOR FILING DATE: 2001-01-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 28
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Description of artificial sequence: Synthetic Antisense
;   OTHER INFORMATION: Oligionucleotide
US-10-053-645A-28

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCGC 132
              ||||||||||||  || ||||
Db          2 GCGGCGGCGGCGGCAGCGC 20


RESULT 14
US-10-349-143-9876/c
; Sequence 9876, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
```

```
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9876
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: downstream amplification primer 99-7985 for SEQ 2011, in compleme
US-10-349-143-9876

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 20;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        428 GTGAGATGGAGAATAAAGA 446
              ||||||||||| | ||||||
Db         20 GTGAGATGGAAAGTAAAGA 2


RESULT 15
US-09-828-034-10/c
; Sequence 10, Application US/09828034
; Patent No. US20020064771A1
; GENERAL INFORMATION:
;  APPLICANT: Zhong, Weidong
;  APPLICANT:  Hong, Zhi
;  APPLICANT:  Ferrari, Eric
;  TITLE OF INVENTION: HCV REPLICASE COMPLEXES
;  FILE REFERENCE: IN01165
;  CURRENT APPLICATION NUMBER: US/09/828,034
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: U.S. 60/195,852
;  PRIOR FILING DATE: 2000-04-06
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA
US-09-828-034-10

  Query Match             1.6%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 19;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTGCG 131
              |||||||||||| || |||
Db         21 GGCGGCGGCGGCGGCGGCG 3


RESULT 16
US-09-780-533A-765
; Sequence 765, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 765
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-765

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 28;
  Matches   15;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||  |||||:||
Db          1 GCGGCGGCAGCAGCUGC 17


RESULT 17
US-09-780-533A-2337
; Sequence 2337, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2337
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2337

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 28;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCAGC 127
              | ||||||||||||||||
Db          1 CCGGCGGCGGCGGCAGC 17


RESULT 18
US-09-780-533A-2338
; Sequence 2338, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2338
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2338

  Query Match             1.5%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 28;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||||| ||
Db          1 GCGGCGGCGGCAGCAGC 17


RESULT 19
US-10-388-360-205/c
; Sequence 205, Application US/10388360
; Publication No. US20030225528A1
; GENERAL INFORMATION:
;  APPLICANT: GENOMIC HEALTH
;  APPLICANT:  Baker, Joffre B.
;  APPLICANT:  Cronin, Maureen T.
;  APPLICANT:  Kiefer, Michael C.
;  APPLICANT:  Shak, Steve
;  APPLICANT:  Walker, Michael Graham
;  TITLE OF INVENTION: GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES
;  FILE REFERENCE: 39740-0001US
;  CURRENT APPLICATION NUMBER: US/10/388,360
;  CURRENT FILING DATE:  2003-03-12
;  PRIOR APPLICATION NUMBER: US 60/412,049
;  PRIOR FILING DATE: 2002-09-18
;  PRIOR APPLICATION NUMBER: US 60/364,890
;  PRIOR FILING DATE: 2002-03-13
;  NUMBER OF SEQ ID NOS: 384
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 205
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-388-360-205

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGCAACTCCC 712
              ||| |||| ||| |||||||
Db         20 TCCATCTCTTGGAAACTCCC 1


RESULT 20
US-10-349-143-6333/c
; Sequence 6333, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6333
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: upstream amplification primer 99-10776 for SEQ 2399,
US-10-349-143-6333

  Query Match             1.5%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 26;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        550 GAAAGGAGAAATAGGCGAGG 569
              |||| |||||||||| |||
Db         20 GAAATGAGAAATAGGAAAGG 1


RESULT 21
US-09-780-533A-1789
; Sequence 1789, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1789
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1789

  Query Match             1.5%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGC 127
              |||||||||||||||
Db          2 GGCGGCGGCGGCAGC 16


RESULT 22
US-10-238-700-2867
; Sequence 2867, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2867
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-2867

  Query Match             1.5%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 34;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        767 CCCCAGTGCCTTTTC 781
              ||||||:|||::::|
Db          2 CCCCAGUGCCUUUUC 16
```

```
RESULT 23
US-09-500-700-68
; Sequence 68, Application US/09500700
; Publication No. US20030059767A1
; GENERAL INFORMATION:
;  APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
;  APPLICANT:  BARBAS III, Carlos F.
;  APPLICANT:  GOTTESFELD, Joel M.
;  APPLICANT:  WRIGHT, Peter E.
;  TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR
;  FILE REFERENCE: SCRIP1160-4
;  CURRENT APPLICATION NUMBER: US/09/500,700
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: US 08/863,813
;  PRIOR FILING DATE: 1997-05-27
;  PRIOR APPLICATION NUMBER: US 08/676,318
;  PRIOR FILING DATE: 1996-12-30
;  PRIOR APPLICATION NUMBER: PCT/US95/00829
;  PRIOR FILING DATE: 1995-01-18
;  PRIOR APPLICATION NUMBER: US 08/312,604
;  PRIOR FILING DATE: 1994-09-28
;  PRIOR APPLICATION NUMBER: US 08/183,119
;  PRIOR FILING DATE: 1994-01-18
;  NUMBER OF SEQ ID NOS: 127
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: (GCG)6 probe
US-09-500-700-68

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 35;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GCGGCGGCGGCGGCGGCG 18


RESULT 24
US-10-314-405-45
; Sequence 45, Application US/10314405
; Publication No. US20030108940A1
; GENERAL INFORMATION:
;  APPLICANT: Hidetoshi, Inoko
;  APPLICANT:  Gen, Tamiya
;  APPLICANT:  Yasunari, Matsuzaka
;  TITLE OF INVENTION: NOVEL POLYMORPHIC MICROSATELLITE MARKERS IN THE HUMAN MHC CLASS I
;  FILE REFERENCE: 06501-069001
;  CURRENT APPLICATION NUMBER: US/10/314,405
;  CURRENT FILING DATE:  2002-12-06
;  PRIOR APPLICATION NUMBER: US/09/713,616
;  PRIOR FILING DATE: 2000-11-15
;  NUMBER OF SEQ ID NOS: 46
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 45
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-314-405-45

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 35;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 GCGGCGGCGGCGGCGGCG 18


RESULT 25
US-10-016-490C-16
; Sequence 16, Application US/10016490C
; Publication No. US20040072769A1
; GENERAL INFORMATION:
;  APPLICANT: Yin, James Q.
;  TITLE OF INVENTION: Methods for design and selection of short double-stranded
;  TITLE OF INVENTION:  oligonucleotides, and compounds of gene drugs
;  FILE REFERENCE: 01-2793
;  CURRENT APPLICATION NUMBER: US/10/016,490C
;  CURRENT FILING DATE:  2002-11-22
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: The same as those in human.
US-10-016-490C-16

  Query Match             1.5%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 33;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        279 GCCCCACGGAGCCGCCAG 296
              ||||| ||||||||| ||
Db          2 GCCCCCCGGAGCCGCGAG 19


RESULT 26
US-09-780-533A-440/c
; Sequence 440, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 440
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-440

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAAA 616
              ||||||| ||||||||
Db         16 GGAGATGAATCTGAAA 1


RESULT 27
US-09-780-533A-1790
; Sequence 1790, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
```

```
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1790
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1790

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGC 130
              ||||||||||||| ||
Db          1 CGGCGGCGGCAGCAGC 16


RESULT 28
US-09-780-533A-1791
; Sequence 1791, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1791
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1791

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 45;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGC 130
              ||||||| |||||:||
Db          1 CGGCGGCAGCAGCUGC 16


RESULT 29
US-09-827-395A-510
; Sequence 510, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 510
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-510

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         80 AGGCGGGCAGCGGGGG 95
              |||| ||||||||||||
Db          1 AGGCAGGCAGCGGGGG 16


RESULT 30
US-09-740-332-1479/c
; Sequence 1479, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1479
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1479

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAGA 810
              |||||||||||||| ||
Db         16 CACACCACCCCGACGA 1


RESULT 31
US-09-817-879-1479/c
; Sequence 1479, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1479
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1479
```

```
  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAGA 810
              ||||||||||||| ||
Db         16 CACACCACCCCGACGA 1


RESULT 32
US-10-430-882-510
; Sequence 510, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  APPLICANT:  Peter Haeberli
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-H (400/112)
;  CURRENT APPLICATION NUMBER: US/10/430,882
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: 09/827,395
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: PCT/US01/04273
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  PRIOR APPLICATION NUMBER: PCT/US02/10512
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 510
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-430-882-510

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         80 AGGCGGGCAGCGGGGG 95
              |||| ||||||||||
Db          1 AGGCAGGCAGCGGGGG 16


RESULT 33
US-10-060-895A-752/c
; Sequence 752, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  APPLICANT:  Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
;  FILE REFERENCE: PB0158
;  CURRENT APPLICATION NUMBER: US/10/060,895A
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/315,984
;  PRIOR FILING DATE: 2001-08-30
;  NUMBER OF SEQ ID NOS: 1682
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 752
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-895A-752

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              ||||||||| ||||||
Db         17 AGCCCTCAATGCGAGC 2


RESULT 34
US-10-060-895A-753/c
; Sequence 753, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  APPLICANT:  Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
;  FILE REFERENCE: PB0158
;  CURRENT APPLICATION NUMBER: US/10/060,895A
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/315,984
;  PRIOR FILING DATE: 2001-08-30
;  NUMBER OF SEQ ID NOS: 1682
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 753
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-895A-753

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAGC 45
              ||||||||| ||||||
Db         16 AGCCCTCAATGCGAGC 1
```

```
RESULT 35
US-10-230-006-1390
; Sequence 1390, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1390
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-1390

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 45;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        407 CTGCAGCGGCCCCCGC 422
              |:||||||| |||||
Db          1 CUGCAGCGGCACCCGC 16


RESULT 36
US-10-230-006-2189
; Sequence 2189, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2189
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-2189

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 45;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        407 CTGCAGCGGCCCCCGC 422
              |:||||||| |||||
Db          2 CUGCAGCGGCACCCGC 17


RESULT 37
US-10-712-672-407
; Sequence 407, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 407
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-407

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 45;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        388 CCCGCCGCCGAGCCGT 403
              ||||| |||||||||:
Db          1 CCCGCUGCCGAGCCGU 16


RESULT 38
US-10-349-143-4210/c
; Sequence 4210, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4210
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-1394 for SEQ 276,
US-10-349-143-4210

  Query Match             1.4%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 42;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        549 GGAAAGGAGAAATAGG 564
              |||||||||||||| |
Db         17 GGAAAGGAGAAATATG 2


RESULT 39
US-09-927-046-266
; Sequence 266, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
```

```
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 266
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-266

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||:|||:|:||||:
Db          2 GAUGGAUCUGAAAU 15


RESULT 40
US-09-927-046-854
; Sequence 854, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 854
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-854

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 54;
  Matches   10;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        604 GATGGATCTGAAAT 617
              ||:|||:|:||||:
Db          1 GAUGGAUCUGAAAU 14


RESULT 41
US-09-927-046-1188
; Sequence 1188, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1188
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1188

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 54;
  Matches   11;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              |||||:|||||:|:
Db          4 AGAACUGCAGCUGU 17


RESULT 42
US-09-927-046-1189
; Sequence 1189, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1189
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1189

  Query Match             1.4%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 54;
  Matches   11;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTGT 990
              |||||:|||||:|:
Db          1 AGAACUGCAGCUGU 14


RESULT 43
US-09-927-046-1361
; Sequence 1361, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
```

; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1361

Query Match 1.4%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 54;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 977 AGAACTGCAGCTGT 990
||||||:|||||:|:
Db 3 AGAACUGCAGCUGU 16

RESULT 44
US-09-927-046-1734
; Sequence 1734, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1734
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1734

Query Match 1.4%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 604 GATGGATCTGAAAT 617
||:|||:|:||||:
Db 4 GAUGGAUCUGAAAU 17

RESULT 45
US-10-238-700-2866
; Sequence 2866, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2866

Query Match 1.4%; Score 14; DB 1; Length 17;
Best Local Similarity 64.3%; Pred. No. 54;
Matches 9; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 767 CCCCAGTGCCTTTT 780
||||||:|||::::
Db 4 CCCCAGUGCCUUUU 17

RESULT 46
US-09-918-186A-99/c
; Sequence 99, Application US/09918186A
; Patent No. US20020137708A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Eric E. Swayze
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: ISPH-0585
; CURRENT APPLICATION NUMBER: US/09/918,186A
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 09/496,694
; PRIOR FILING DATE: 2000-02-02
; PRIOR APPLICATION NUMBER: 09/286,407
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 09/163,162
; PRIOR FILING DATE: 1998-09-29
; NUMBER OF SEQ ID NOS: 250
; SEQ ID NO 99
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-186A-99

Query Match 1.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 112 TGGCGGCGGCGGCA 125
||||||||||||||
Db 16 TGGCGGCGGCGGCA 3

RESULT 47
US-10-181-316-99/c
; Sequence 99, Application US/10181316
; Publication No. US20030211607A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Eric E. Swayze
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: ISPH-0650
; CURRENT APPLICATION NUMBER: US/10/181,316
; CURRENT FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: PCT/US01/02939
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/496,694
; PRIOR FILING DATE: 2000-02-02
; PRIOR APPLICATION NUMBER: 09/286,407
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 09/163,162
; PRIOR FILING DATE: 1998-09-29
; NUMBER OF SEQ ID NOS: 249
; SEQ ID NO 99
; LENGTH: 18
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-316-99

  Query Match 1.4%; Score 14; DB 1; Length 18;
  Best Local Similarity 100.0%; Pred. No. 51;
  Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 112 TGGCGGCGGCGGCA 125
        ||||||||||||||
Db 16 TGGCGGCGGCGGCA 3

RESULT 48
US-09-866-108-6303/c
; Sequence 6303, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6303
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6303

  Query Match 1.4%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 59;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 25 GGAGGAGCCCTCAAGGC 41
           ||||| |||||| ||||
Db 17 GGAGGTGCCCTCCAGGC 1

RESULT 49
US-09-866-108-8005/c
; Sequence 8005, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8005
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8005

  Query Match 1.4%; Score 13.8; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 59;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 147 GGAGCTGGACCAGCTGC 163
        ||||||| ||||||||
Db 17 GGAGCTGCTCCAGCTGC 1

RESULT 50
US-09-814-777A-89
; Sequence 89, Application US/09814777A
; Patent No. US20020142415A1
; GENERAL INFORMATION:
; APPLICANT: KOOPMAN, Peter Anthony

```
;  APPLICANT:  MUSCAT, George Eugene Orlando
;  TITLE OF INVENTION: NOVEL POLYPEPTIDES AND POLYNUCLEOTIDES AND METHODS OF USING THEM
;  FILE REFERENCE: 21415-0003
;  CURRENT APPLICATION NUMBER: US/09/814,777A
;  CURRENT FILING DATE:  2001-03-23
;  PRIOR APPLICATION NUMBER: AU PQ6457
;  PRIOR FILING DATE: 2000-03-24
;  NUMBER OF SEQ ID NOS: 128
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 89
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: hSOX18 primer E
US-09-814-777A-89

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        387 GCCCGCCGCCGAGCCGT 403
              ||||||||||||  | ||
Db          1 GCCCGCCGCCGATCTGT 17


RESULT 51
US-09-825-805-564/c
; Sequence 564, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 564
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-564

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         51 GCGCGCGGCTGCCGCGG 67
              |||||||||||||  ||
Db         17 GCGCGCGGCTGCCCGGG 1


RESULT 52
US-09-825-805-580
; Sequence 580, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 580
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-580

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        281 CCCACGGAGCCGCCAGC 297
              ||| |||||||||  |||
Db          1 CCCCCGGAGCCGCGAGC 17


RESULT 53
US-09-961-077-801
; Sequence 801, Application US/09961077
; Publication No. US20030014775A1
;   GENERAL INFORMATION:
;        APPLICANT: Zwick, Michael G.
;                   Edington, Brent E.
;                   McSwiggen, James A.
;                   Merlo, Patricia Ann Owens
;                   Guo, Lining
;                   Skokut, Thomas A.
;                   Young, Scott A.
;                   Folkerts, Otto
;                   Merlo, Donald J.
;        TITLE OF INVENTION: COMPOSITION AND METHODS FOR
;                            MODULATION OF GENE EXPRESSION
;                            IN PLANTS
;        NUMBER OF SEQUENCES: 1263
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Lyon & Lyon
;             STREET: 633 West Fifth Street
;                     Suite 4700
;             CITY: Los Angeles
;             STATE: California
;             COUNTRY: U.S.A.
;             ZIP: 90071-2066
```

```
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;                         storage
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: IBM P.C. DOS 5.0
;            SOFTWARE: Word Perfect 5.1
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/961,077
;            FILING DATE: 21-Sep-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/679,645
;            FILING DATE: July 12, 1996
;            APPLICATION NUMBER: 60/001,135
;            FILING DATE: July 13, 1995
;            APPLICATION NUMBER: 08/300,726
;            FILING DATE: September 2, 1994
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Warburg, Richard J.
;            REGISTRATION NUMBER: 32,327
;            REFERENCE/DOCKET NUMBER: 219/247
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (213) 489-1600
;            TELEFAX: (213) 955-0440
;            TELEX: 67-3510
;   INFORMATION FOR SEQ ID NO: 801:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 17 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 801:
US-09-961-077-801

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 59;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        203 CCTCGACTTCCCCGTCG 219
              ||:||| ::|| ||:||
Db          1 CCUCGAGUUCCUCGUCG 17


RESULT 54
US-09-780-533A-815
; Sequence 815, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 815
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-815

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 59;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        388 CCCGCCGCCGAGCCGTC 404
              |||||||||| || |:|
Db          1 CCCGCCGCCGGGCUGUC 17


RESULT 55
US-09-877-478-2237/c
; Sequence 2237, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2237
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-2237

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        474 TGATCGTCCAGAGGAAC 490
              |||| ||||||| ||||
Db         17 TGATAGTCCAGAAGAAC 1


RESULT 56
US-09-848-754A-1339/c
; Sequence 1339, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1339
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1339

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        406 CCTGCAGCGGCCCCCGC 422
              ||||||||| ||| ||||
Db         17 CCTGCAGCAGCCTCCGC 1
```

RESULT 57
US-09-848-754A-1340/c
; Sequence 1340, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1340
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1340

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        403 TCTCCTGCAGCGGCCCC 419
              |||||||||||| ||| |
Db         17 TCTCCTGCAGCAGCCTC 1
```

RESULT 58
US-09-848-754A-1341/c
; Sequence 1341, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1341
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1341

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        400 CCGTCTCCTGCAGCGGC 416
              || |||||||||||  ||
Db         17 CCCTCTCCTGCAGCAGC 1
```

RESULT 59
US-09-848-754A-2125/c
; Sequence 2125, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2125
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2125

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        321 GTCGGTGGCGGCGCCGG 337
              | ||| ||||||||||||
Db         17 GGCGGCGGCGGCGCCGG 1
```

RESULT 60
US-09-848-754A-2407/c
; Sequence 2407, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2407

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        405 TCCTGCAGCGGCCCCCG 421
              ||||||||| ||| |||
Db         17 TCCTGCAGCAGCCTCCG 1
```

RESULT 61
US-09-827-395A-756/c
; Sequence 756, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 756
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-756

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        563 GGCGAGGGCCTGTGGTG 579
              ||||||||||| | |||||
Db         17 GGCGAGGGCCCGAGGTG 1


RESULT 62
US-09-827-395A-992/c
; Sequence 992, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 992
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-992

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        564 GCGAGGGCCTGTGGTGG 580
              ||||||||| | |||||
Db         17 GCGAGGGCCCGAGGTGG 1


RESULT 63
US-09-740-332-1531
; Sequence 1531, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1531
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1531

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        620 ATCACTTAGCAGCTGAG 636
              |:|||: ||| ||:|||
Db          1 AUCACUCAGCUGCUGAG 17


RESULT 64
US-09-817-879-1531
; Sequence 1531, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1531
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1531

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        620 ATCACTTAGCAGCTGAG 636
              |:|||: ||| ||:|||
Db          1 AUCACUCAGCUGCUGAG 17


RESULT 65
US-10-342-902-2237/c
; Sequence 2237, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2237
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-2237

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        474 TGATCGTCCAGAGGAAC 490
              |||| ||||||| ||||
Db         17 TGATAGTCCAGAAGAAC 1
```

RESULT 66
US-10-430-882-756/c
; Sequence 756, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 756
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-756

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 GGCGAGGGCCTGTGGTG 579
|||||||||| | ||||
Db 17 GGCGAGGGCCCGAGGTG 1

RESULT 67
US-10-430-882-992/c
; Sequence 992, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-992

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 564 GCGAGGGCCTGTGGTGG 580
||||||||| | |||||
Db 17 GCGAGGGCCCGAGGTGG 1

RESULT 68
US-10-163-552-7/c
; Sequence 7, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-7

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 51 GCGCGCGGCTGCCGCGG 67
||||||||||||| ||
Db 17 GCGCGCGGCTGCCCGGG 1

RESULT 69
US-10-163-552-49
; Sequence 49, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 49
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-49

Query Match 1.4%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 281 CCCACGGAGCCGCCAGC 297
||| |||||||||| |||
Db 1 CCCCCGGAGCCGCGAGC 17

RESULT 70
US-10-156-306-3486
; Sequence 3486, Application US/10156306
; Publication No. US20030119017A1

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3486
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-3486

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        117 GCGGCGGCAGCTGCGCA 133
              ||||||||  || |||||
Db          1 GCGGCGGCGGCGGCGCA 17


RESULT 71
US-10-156-306-5929
; Sequence 5929, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5929
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5929

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 AACTGAAGGCAACCTGT 522
              |||:||||||  | |:|:
Db          1 AACUGAAGGCCAGCUGU 17


RESULT 72
US-10-156-306-6336
; Sequence 6336, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6336
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6336

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 59;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        147 GGAGCTGGACCAGCTGC 163
              | || :||||||||:||
Db          1 GCAGGUGGACCAGCUGC 17


RESULT 73
US-10-156-306-6935
; Sequence 6935, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6935
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6935

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        145 GTGGAGCTGGACCAGCT 161
              |:| || :|||||||:
Db          1 GUGCAGGUGGACCAGCU 17


RESULT 74
US-10-156-306-6936
; Sequence 6936, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6936
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6936

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 59;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        146 TGGAGCTGGACCAGCTG 162
              :| || :|||||||:|
Db          1 UGCAGGUGGACCAGCUG 17


RESULT 75
US-10-156-306-7029
; Sequence 7029, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7029
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-7029

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 59;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        505 AAACTGAAGGCAACCTG 521
              ||||:|||||| | |:|
Db          1 AAACUGAAGGCCAGCUG 17


RESULT 76
US-10-238-700-6
; Sequence 6, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-6

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||  ||||||  |||
Db          1 CGGCGGAGGCAGCAGCG 17


RESULT 77
US-10-238-700-11
; Sequence 11, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-11

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||||||||  |||
Db          1 CGGCGGCGGCAGUGGCG 17


RESULT 78
US-10-238-700-2801
; Sequence 2801, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2801
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-2801

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        115 CGGCGGCGGCAGCTGCG 131
              ||||||||||| || |||
Db          1 CGGCGGCGGCGGCGGCG 17


RESULT 79
US-10-061-201-808/c
; Sequence 808, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 808
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-808

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||| | |||||||||
Db         17 GCGGCTGGGGCAGCTGC 1


RESULT 80
US-10-061-201-809/c
; Sequence 809, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 809
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-809

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        113 GGCGGCGGCGGCAGCTG 129
              |||||| | |||||||||
Db         17 GGCGGCTGGGGCAGCTG 1


RESULT 81
US-10-230-006-2088
; Sequence 2088, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2088
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-2088

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 59;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         48 CGCGCGCGCGGCTGCCG 64
              |||||||| ||:||||
Db          1 CGCGCGCGGAGCUGCCG 17


RESULT 82
US-10-138-674-2075
; Sequence 2075, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2075
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-2075

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 59;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              :::||:|  :|||||||
Db          1 UUUCCUGUAUGGAGGAG 17


RESULT 83
US-10-287-949A-2075
; Sequence 2075, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
```

```
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2075
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-2075

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 59;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        921 TTTCCTGATTGGAGGAG 937
              :::||:|  :|||||||
Db          1 UUUCCUGUAUGGAGGAG 17


RESULT 84
US-10-712-672-716/c
; Sequence 716, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 716
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-716

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 59;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          4 AGCCCTGAGGCAGGCGG 20
              ||| ||| |||||||||
Db         17 AGCGCTGGGGCAGGCGG 1


RESULT 85
US-10-712-672-948
; Sequence 948, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 948
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-948

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 59;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        153 GGACCAGCTGCCTGAGC 169
              ||||| || |||:||||
Db          1 GGACCCGCCGCCUGAGC 17


RESULT 86
US-09-878-582-13
; Sequence 13, Application US/09878582
; Patent No. US20020058638A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/878,582
;  CURRENT FILING DATE:  2001-06-11
;  PRIOR APPLICATION NUMBER: 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  PRIOR APPLICATION NUMBER: PCT/US99/29594,
;  PRIOR FILING DATE: 1999-12-14
;  NUMBER OF SEQ ID NOS: 51
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-878-582-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 87
US-09-878-582-13/c
; Sequence 13, Application US/09878582
; Patent No. US20020058638A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/878,582
;  CURRENT FILING DATE:  2001-06-11
;  PRIOR APPLICATION NUMBER: 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  PRIOR APPLICATION NUMBER: PCT/US99/29594,
;  PRIOR FILING DATE: 1999-12-14
;  NUMBER OF SEQ ID NOS: 51
; SEQ ID NO 13
;   LENGTH: 18
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-878-582-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              ||||||||||||| || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 88
US-09-969-373-1628
; Sequence 1628, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1628
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-1628

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 TGTATGCCAGCCTGGAA 536
              ||| |||||||||| ||
Db          1 TGTTTGCCAGCCTGTAA 17


RESULT 89
US-09-969-373-4477/c
; Sequence 4477, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4477
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-4477

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        824 ATGGCTTCTCACCATAT 840
              | ||||||| |||||||
Db         17 ACGGCTTCTGACCATAT 1


RESULT 90
US-09-985-637A-12/c
; Sequence 12, Application US/09985637A
; Publication No. US20030119000A1
; GENERAL INFORMATION:
;  APPLICANT: Polansky, Jon
;  TITLE OF INVENTION: METHODS TO SCREEN AND TREAT INDIVIDUALS WITH GLAUCOMA OR THE PROPI
;  TITLE OF INVENTION:  TO DEVELOP GLAUCOMA
;  FILE REFERENCE: 13587.296
;  CURRENT APPLICATION NUMBER: US/09/985,637A
;  CURRENT FILING DATE:  2001-11-05
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer Sequence
US-09-985-637A-12

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2


RESULT 91
US-10-244-633-16/c
; Sequence 16, Application US/10244633
; Publication No. US20030068640A1
; GENERAL INFORMATION:
;  APPLICANT: Nguyen, Thai D.
;  APPLICANT:  Polansky, Jon R.
;  APPLICANT:  Chen, Pu
;  APPLICANT:  Chen, Hua
;  TITLE OF INVENTION: Nucleic Acids, Kits, And Methods For The Diagnosis,
;  TITLE OF INVENTION:  Prognosis And Treatment Of Glaucoma And Related
;  TITLE OF INVENTION:  Disorders
;  FILE REFERENCE: 07425.0057.US01
;  CURRENT APPLICATION NUMBER: US/10/244,633
;  CURRENT FILING DATE:  2002-09-17
;  PRIOR APPLICATION NUMBER: US/09/306,828
;  PRIOR FILING DATE: 1999-05-07
;  PRIOR APPLICATION NUMBER: US 09/227,881
;  PRIOR FILING DATE: 1999-01-11
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: Microsoft Word 97
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-244-633-16

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        831 CTCACCATATAGCCCTG 847
              | ||| ||||||||||||
Db         18 CCCACAATATAGCCCTG 2
```

```
RESULT 92
US-10-388-263-837
; Sequence 837, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 837
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-837

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 93
US-10-388-263-837/c
; Sequence 837, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 837
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-837

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        114 GCGGCGGCGGCAGCTGC 130
              |||||||||||| || |
Db         18 GCGGCGGCGGCACCTCC 2


RESULT 94
US-10-336-213B-13
; Sequence 13, Application US/10336213B
; Publication No. US20040002153A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  APPLICANT:  Tim Vickers
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISIS0004-100
;  CURRENT APPLICATION NUMBER: US/10/336,213B
;  CURRENT FILING DATE:  2003-01-03
;  PRIOR APPLICATION NUMBER: US 60/411,780
;  PRIOR FILING DATE: 2002-09-18
;  PRIOR APPLICATION NUMBER: US 09/878,582
;  PRIOR FILING DATE: 2001-06-11
;  PRIOR APPLICATION NUMBER: US 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: PCT/US99/29594
;  PRIOR FILING DATE: 1999-12-14
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-336-213B-13

  Query Match             1.4%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        267 GGCGGTGCCGCCGCCCC 283
              || |||||||||||| |
Db          2 GGAGGTGCCGCCGCCGC 18


RESULT 95
US-10-336-213B-13/c
; Sequence 13, Application US/10336213B
; Publication No. US20040002153A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  APPLICANT:  Tim Vickers
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISIS0004-100
;  CURRENT APPLICATION NUMBER: US/10/336,213B
;  CURRENT FILING DATE:  2003-01-03
;  PRIOR APPLICATION NUMBER: US 60/411,780
;  PRIOR FILING DATE: 2002-09-18
;  PRIOR APPLICATION NUMBER: US 09/878,582
;  PRIOR FILING DATE: 2001-06-11
;  PRIOR APPLICATION NUMBER: US 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: PCT/US99/29594
;  PRIOR FILING DATE: 1999-12-14
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 88
```

; SEQ ID NO 13
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE: O
; OTHER INFORMATION: Oligonucleotide
US-10-336-213B-13

Query Match 1.4%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 114 GCGGCGGCGGCAGCTGC 130
||||||||||||| || |
Db 18 GCGGCGGCGGCACCTCC 2

RESULT 96
US-09-504-231A-343
; Sequence 343, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: rpi 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 343
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-343

Query Match 1.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 385 GCGCCCGCCGCCGAG 399
|||||| ||||||||
Db 1 GCGCCCUCCGCCGAG 15

RESULT 97
US-09-274-553D-343
; Sequence 343, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: rpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 343
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-343

Query Match 1.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 385 GCGCCCGCCGCCGAG 399
|||||| ||||||||
Db 1 GCGCCCUCCGCCGAG 15

RESULT 98
US-10-132-002-13
; Sequence 13, Application US/10132002
; Publication No. US20030022204A1
; GENERAL INFORMATION:
; APPLICANT: Lansdorp, Peter
; TITLE OF INVENTION: Method for Detecting Multiple Copies of
; a Repeat Sequence in a Nucleic Acid Molecule
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWSON & HOWSON
; STREET: 321 No. US20030022204A1ristown Road
; CITY: Spring House
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/132,002
; FILING DATE: 25-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/730,635
; FILING DATE: 11-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bak, Mary E.
; REGISTRATION NUMBER: 31,215
; REFERENCE/DOCKET NUMBER: B&P7USA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 540-9200
; TELEFAX: (215) 540-5818
; TELEX: N/A
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-10-132-002-13

Query Match 1.3%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        113 GGCGGCGGCGGCAGC 127
              ||||||||||||| ||
Db          1 GGCGGCGGCGGCGGC 15
```

RESULT 99
US-10-001-254-46/c
; Sequence 46, Application US/10001254
; Publication No. US20030049702A1
; GENERAL INFORMATION:
; APPLICANT: Reed, John C.
; APPLICANT: Godzik, Adam
; APPLICANT: Pawlowski, Krzysztof
; APPLICANT: Fiorentino, Loredana
; APPLICANT: Lee, Sug Hyung
; APPLICANT: Roth, Wilfred
; APPLICANT: Stenner-Liewen, Frank
; TITLE OF INVENTION: No. US20030049702A1el Death Domain Proteins
; FILE REFERENCE: P-LJ 5037
; CURRENT APPLICATION NUMBER: US/10/001,254
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/301,889
; PRIOR FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 09/715,893
; PRIOR FILING DATE: 2000-11-17
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic primer
US-10-001-254-46

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 75;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy         14 CAGGCGGCGGCGGAG 28
              ||| ||||||||||||
Db         15 CAGACGGCGGCGGAG 1
```

RESULT 100
US-10-712-672-1465
; Sequence 1465, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1465
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1465

Query Match 1.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 75;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        388 CCCGCCGCCGAGCCG 402
              ||||| |||||||||
Db          2 CCCGCUGCCGAGCCG 16
```

RESULT 101
US-09-866-108-2497
; Sequence 2497, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2497
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2497

Query Match 1.3%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          3 CCTGCACCAGATGGC 17
```

```
RESULT 102
US-09-866-108-2498
; Sequence 2498, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2498
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2498

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          2 CCTGCACCAGATGGC 16


RESULT 103
US-09-866-108-2499
; Sequence 2499, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2499
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2499

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        814 CCTTCACCAGATGGC 828
              ||| ||||||||||||
Db          1 CCTGCACCAGATGGC 15


RESULT 104
US-09-866-108-8123
; Sequence 8123, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
```

```
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8123
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8123

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          3 GCGGCTTCATCAGCT 17


RESULT 105
US-09-866-108-8124
; Sequence 8124, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8124
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8124

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          2 GCGGCTTCATCAGCT 16


RESULT 106
US-09-866-108-8125
; Sequence 8125, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8125
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8125

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        661 GCGGCTTCACCAGCT 675
              ||||||||| |||||
Db          1 GCGGCTTCATCAGCT 15


RESULT 107
US-09-825-805-311/c
; Sequence 311, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 311
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-311

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 108
US-09-780-533A-441/c
; Sequence 441, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 441
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-441

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        601 GGAGATGGATCTGAA 615
              ||||||| |||||||
Db         15 GGAGATGAATCTGAA 1


RESULT 109
US-09-780-533A-1788
; Sequence 1788, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1788
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1788

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        111 CTGGCGGCGGCGGCA 125
              | ||||||||||||||
Db          3 CCGGCGGCGGCGGCA 17


RESULT 110
US-09-780-533A-2248/c
; Sequence 2248, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
```

```
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2248
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2248

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        602 GAGATGGATCTGAAA 616
              ||||||  ||||||||
Db         17 GAGATGAATCTGAAA 3


RESULT 111
US-09-877-478-346/c
; Sequence 346, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 346
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-346

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | |||||||||||||
Db         15 GCGGAGAAGCGGGCG 1


RESULT 112
US-09-877-478-1056/c
; Sequence 1056, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1056
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1056

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | |||||||||||||
Db         16 GCGGAGAAGCGGGCG 2


RESULT 113
US-09-848-754A-831/c
; Sequence 831, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 831
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-831

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        323 CGGTGGCGGCGCCGG 337
              ||| ||||||||||||
Db         16 CGGCGGCGGCGCCGG 2


RESULT 114
```

```
US-09-848-754A-2408/c
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-2408

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        403 TCTCCTGCAGCGGCC 417
              ||||||||||| |||
Db         16 TCTCCTGCAGCAGCC 2


RESULT 115
US-09-930-423-480
; Sequence 480, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-480

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         55 GCGGCTGCCGCGGGA 69
              |||||:||| |||||
Db          1 GCGGCUGCCCCGGGA 15


RESULT 116
US-09-930-423-1013
; Sequence 1013, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1013
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-1013

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         55 GCGGCTGCCGCGGGA 69
              |||||:||| |||||
Db          3 GCGGCUGCCCCGGGA 17


RESULT 117
US-09-827-395A-769
; Sequence 769, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 769
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-769

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         80 AGGCGGGCAGCGGGG 94
              |||| ||||||||||
Db          3 AGGCAGGCAGCGGGG 17


RESULT 118
US-09-827-395A-770
; Sequence 770, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 770
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-770

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
```

```
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         81 GGCGGGCAGCGGGGG 95
              ||| ||||||||||||
Db          1 GGCAGGCAGCGGGGG 15


RESULT 119
US-09-740-332-3076
; Sequence 3076, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3076
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3076

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAG 809
              ||||||||||||| |
Db          3 CACACCACCCCGACG 17


RESULT 120
US-09-745-237A-480
; Sequence 480, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-480

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         55 GCGGCTGCCGCGGGA 69
              |||||:||| |||||
Db          1 GCGGCUGCCCCGGGA 15


RESULT 121
US-09-745-237A-1013
; Sequence 1013, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1013
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-1013

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 70;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         55 GCGGCTGCCGCGGGA 69
              |||||:||| |||||
Db          3 GCGGCUGCCCCGGGA 17


RESULT 122
US-09-817-879-3076
; Sequence 3076, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3076
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3076

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGAAG 809
              |||||||||||| |
Db          3 CACACCACCCCGACG 17


RESULT 123
US-10-342-902-346/c
; Sequence 346, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
```

```
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 346
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-346

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | ||||||||||||||
Db         15 GCGGAGAAGCGGGCG 1


RESULT 124
US-10-342-902-1056/c
; Sequence 1056, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1056
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1056

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        373 GGGGAGAAGCGGGCG 387
              | ||||||||||||||
Db         16 GCGGAGAAGCGGGCG 2


RESULT 125
US-10-430-882-769
; Sequence 769, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  APPLICANT:  Peter Haeberli
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-H (400/112)
;  CURRENT APPLICATION NUMBER: US/10/430,882
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: 09/827,395
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: PCT/US01/04273
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  PRIOR APPLICATION NUMBER: PCT/US02/10512
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 769
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-430-882-769

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         80 AGGCGGGCAGCGGGG 94
              |||| ||||||||||
Db          3 AGGCAGGCAGCGGGG 17


RESULT 126
US-10-430-882-770
; Sequence 770, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  APPLICANT:  Peter Haeberli
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-H (400/112)
;  CURRENT APPLICATION NUMBER: US/10/430,882
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: 09/827,395
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: PCT/US01/04273
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  PRIOR APPLICATION NUMBER: PCT/US02/10512
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 770
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-430-882-770
```

```
  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         81 GGCGGGCAGCGGGGG 95
              ||| ||||||||||||
Db          1 GGCAGGCAGCGGGGG 15


RESULT 127
US-10-041-856-45/c
; Sequence 45, Application US/10041856
; Publication No. US20020169299A1
; GENERAL INFORMATION:
;  APPLICANT: SLAUGENHAUPT, SUSAN
;  APPLICANT:  GUSELLA, JAMES F.
;  TITLE OF INVENTION: GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL
;  TITLE OF INVENTION:  DYSAUTONOMIA
;  FILE REFERENCE: 1829-4004US1
;  CURRENT APPLICATION NUMBER: US/10/041,856
;  CURRENT FILING DATE:  2002-07-08
;  PRIOR APPLICATION NUMBER: 60/260,080
;  PRIOR FILING DATE: 2001-01-06
;  NUMBER OF SEQ ID NOS: 88
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Mus sp.
US-10-041-856-45

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        531 CTGGAAGCACGAATG 545
              ||||||||| |||||
Db         15 CTGGAAGCAAGAATG 1


RESULT 128
US-10-020-141-15
; Sequence 15, Application US/10020141
; Publication No. US20030092013A1
; GENERAL INFORMATION:
;  APPLICANT: McCarthy, Jeanette
;  APPLICANT:  Ableson, Allen
;  TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
;  FILE REFERENCE: MMI-002
;  CURRENT APPLICATION NUMBER: US/10/020,141
;  CURRENT FILING DATE:  2001-12-14
;  PRIOR APPLICATION NUMBER: US 60/313,097
;  PRIOR FILING DATE: 2001-08-16
;  PRIOR APPLICATION NUMBER: US 60/327,485
;  PRIOR FILING DATE: 2001-10-05
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-020-141-15

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 GAGCCCTGAGGCAGG 17
              |||||| ||||||||
Db          3 GAGCCCGGAGGCAGG 17


RESULT 129
US-10-060-895A-751/c
; Sequence 751, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  APPLICANT:  Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
;  FILE REFERENCE: PB0158
;  CURRENT APPLICATION NUMBER: US/10/060,895A
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/315,984
;  PRIOR FILING DATE: 2001-08-30
;  NUMBER OF SEQ ID NOS: 1682
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 751
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-895A-751

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         31 GCCCTCAAGGCGAGC 45
              ||||||| ||||||
Db         17 GCCCTCAATGCGAGC 3


RESULT 130
US-10-060-895A-754/c
; Sequence 754, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  APPLICANT:  Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN UDP-GALNAC:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
;  FILE REFERENCE: PB0158
;  CURRENT APPLICATION NUMBER: US/10/060,895A
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/315,984
;  PRIOR FILING DATE: 2001-08-30
;  NUMBER OF SEQ ID NOS: 1682
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 754
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-060-895A-754

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         30 AGCCCTCAAGGCGAG 44
              ||||||||| |||||
Db         15 AGCCCTCAATGCGAG 1


RESULT 131
US-10-163-552-8/c
; Sequence 8, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-163-552-8

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         49 GCGCGCGCGGCTGCC 63
              | ||||||||||||||
Db         16 GGGCGCGCGGCTGCC 2


RESULT 132
US-10-156-306-4923
; Sequence 4923, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4923
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-156-306-4923

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 70;
  Matches   12;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        149 AGCTGGACCAGCTGC 163
              || :|||||||:||
Db          1 AGGUGGACCAGCUGC 15


RESULT 133
US-10-156-306-5924
; Sequence 5924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5924
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-156-306-5924

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 70;
  Matches   12;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        149 AGCTGGACCAGCTGC 163
              |||:||| ||||:||
Db          2 AGCUGGAGCAGCUGC 16


RESULT 134
US-10-153-244-268
; Sequence 268, Application US/10153244
; Publication No. US20030144191A1
; GENERAL INFORMATION:
;  APPLICANT: Bristol-Myers Squibb Company
;  TITLE OF INVENTION: POLYNUCLEOTIDE ENCODING A NOVEL TRP CHANNEL FAMILY MEMBER, TRP-PLI
;  TITLE OF INVENTION:  SPLICE VARIANTS THEREOF
;  FILE REFERENCE: D0144 NP
;  CURRENT APPLICATION NUMBER: US/10/153,244
;  CURRENT FILING DATE:  2002-05-22
;  PRIOR APPLICATION NUMBER: US 60/292,599
;  PRIOR FILING DATE: 2001-05-22
;  PRIOR APPLICATION NUMBER: US 60/362,944
;  PRIOR FILING DATE: 2002-03-08
;  NUMBER OF SEQ ID NOS: 335
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 268
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-153-244-268

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        246 TGGGACCGGCTTCCA 260
              |||||||| ||||||
Db          3 TGGGACCGCCTTCCA 17


RESULT 135
US-10-297-068-764
; Sequence 764, Application US/10297068
```

```
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 764
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-764

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         78 GGAGGCGGGCAGCGG 92
              ||||||||||| ||||
Db          2 GGAGGCGGGCCGCGG 16


RESULT 136
US-10-138-674-5503/c
; Sequence 5503, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5503
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5503

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGG 458
              ||||||||| |||||
Db         17 AGAAACTCTGAAAGG 3


RESULT 137
US-10-676-154-630/c
; Sequence 630, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 630
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-630

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 70;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| |||||| |||
Db         17 GGGKAGGGGGACCAGCT 1


RESULT 138
US-10-676-154-661
; Sequence 661, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 661
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-661

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 70;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        240 GGGGAGTGGGACCGGCT 256
              |||:|| |||||| |||
Db          1 GGGKAGGGGGACCAGCT 17


RESULT 139
US-10-287-949A-5503/c
; Sequence 5503, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
```

```
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5503
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5503

  Query Match             1.3%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 70;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        444 AGAAACTCTCAAAGG 458
              ||||||||| |||||
Db         17 AGAAACTCTGAAAGG 3


RESULT 140
US-09-504-231A-716
; Sequence 716, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/504,231A
;  CURRENT FILING DATE:  2000-02-15
;  PRIOR APPLICATION NUMBER: 09/274,553
;  PRIOR FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3242
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 716
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-504-231A-716

  Query Match             1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 95;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              :||::|:||:|||
Db          3 UCCUUCUCCUGGC 15


RESULT 141
US-09-504-231A-717
; Sequence 717, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATEI
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/504,231A
;  CURRENT FILING DATE:  2000-02-15
;  PRIOR APPLICATION NUMBER: 09/274,553
;  PRIOR FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3242
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 717
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-504-231A-717

  Query Match             1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 95;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              :||::|:||:|||
Db          1 UCCUUCUCCUGGC 13


RESULT 142
US-09-274-553D-716
; Sequence 716, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATEI
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/274,553D
;  CURRENT FILING DATE:  1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3148
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 716
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-274-553D-716

  Query Match             1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 95;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              :||::|:||:|||
Db          3 UCCUUCUCCUGGC 15


RESULT 143
```

```
US-09-274-553D-717
; Sequence 717, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/274,553D
;  CURRENT FILING DATE:  1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3148
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 717
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-274-553D-717

  Query Match             1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 95;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        693 TCCTTCTCCTGGC 705
              :||::|:||:|||
Db          1 UCCUUCUCCUGGC 13


RESULT 144
US-10-113-877-28
; Sequence 28, Application US/10113877
; Publication No. US20020177218A1
; GENERAL INFORMATION:
;  APPLICANT: Fang, Yu
;  APPLICANT:  Wang, Xiao-Yang
;  APPLICANT:  Turpin, Pierre
;  TITLE OF INVENTION: Methods of detecting multiple DNA
;  TITLE OF INVENTION:  binding protein and DNA interactions in a sample, and
;  TITLE OF INVENTION:  devices, systems and kits for practicing the same.
;  FILE REFERENCE: CLON-071
;  CURRENT APPLICATION NUMBER: US/10/113,877
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: 60/280,658
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 60/314,330
;  PRIOR FILING DATE: 2001-08-20
;  NUMBER OF SEQ ID NOS: 192
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 28
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-113-877-28

  Query Match             1.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 95;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 CGCACAGTGAAAT 733
              |||||||||||||
Db          3 CGCACAGTGAAAT 15


RESULT 145
US-09-866-108-8640
; Sequence 8640, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8640
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8640

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          5 AGAACTGCAGCTG 17


RESULT 146
US-09-866-108-8641
; Sequence 8641, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
```

```
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8641
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8641

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          4 AGAACTGCAGCTG 16


RESULT 147
US-09-866-108-8642
; Sequence 8642, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8642
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8642

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          3 AGAACTGCAGCTG 15


RESULT 148
US-09-866-108-8643
; Sequence 8643, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8643
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8643

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          2 AGAACTGCAGCTG 14


RESULT 149
US-09-866-108-8644
; Sequence 8644, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8644
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8644

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        977 AGAACTGCAGCTG 989
              |||||||||||||
Db          1 AGAACTGCAGCTG 13


RESULT 150
US-09-877-478-1055/c
; Sequence 1055, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1055
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1055

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        375 GGAGAAGCGGGCG 387
              |||||||||||||
Db         17 GGAGAAGCGGGCG 5
```

```
RESULT 151
US-09-877-478-1514/c
; Sequence 1514, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1514
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1514

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        375 GGAGAAGCGGGCG 387
              |||||||||||||
Db         16 GGAGAAGCGGGCG 4


RESULT 152
US-09-740-332-1480/c
; Sequence 1480, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1480
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1480

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGA 807
              |||||||||||||
Db         13 CACACCACCCCGA 1


RESULT 153
US-09-817-879-1480/c
; Sequence 1480, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1480
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1480

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        795 CACACCACCCCGA 807
              |||||||||||||
Db         13 CACACCACCCCGA 1


RESULT 154
US-10-342-902-1055/c
; Sequence 1055, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1055
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1055
```

```
  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        375 GGAGAAGCGGGCG 387
              |||||||||||||
Db         17 GGAGAAGCGGGCG 5


RESULT 155
US-10-342-902-1514/c
; Sequence 1514, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1514
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1514

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 83;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        375 GGAGAAGCGGGCG 387
              |||||||||||||
Db         16 GGAGAAGCGGGCG 4


RESULT 156
US-09-927-046-1290
; Sequence 1290, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1290
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1290

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   69.2%;  Pred. No. 83;
  Matches    9;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        605 ATGGATCTGAAAT 617
              |:|||:|:||||:
Db          1 AUGGAUCUGAAAU 13


RESULT 157
US-09-927-046-1610
; Sequence 1610, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1610
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1610

  Query Match             1.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   76.9%;  Pred. No. 83;
  Matches   10;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        978 GAACTGCAGCTGT 990
              ||||:|||||:|:
Db          1 GAACUGCAGCUGU 13


RESULT 158
US-09-927-046-2024
; Sequence 2024, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2024
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-09-927-046-2024

Query Match 1.3%; Score 13; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 83;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```
Qy        604 GATGGATCTGAAA 616
              ||:|||:|:||||
Db          5 GAUGGAUCUGAAA 17
```

RESULT 159
US-10-238-700-5
; Sequence 5, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-5

Query Match 1.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         17 GCGGCGGCGGAGG 29
              |||||||||||||
Db          3 GCGGCGGCGGAGG 15
```

RESULT 160
US-10-238-700-10
; Sequence 10, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-10

Query Match 1.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        114 GCGGCGGCGGCAG 126
              |||||||||||||
Db          3 GCGGCGGCGGCAG 15
```

RESULT 161
US-10-339-782-491
; Sequence 491, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 491
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-491

Query Match 1.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        776 CTTTTCAGAGTGG 788
              |||||||||||||
Db          4 CTTTTCAGAGTGG 16
```

RESULT 162
US-10-061-201-808
; Sequence 808, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 808
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-808

Query Match 1.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        409 GCAGCGGCCCCCGCCG 424
              ||||| ||||| ||||
Db          1 GCAGCTGCCCCAGCCG 16
```

Search completed: June 28, 2004, 08:16:20
Job time : 3 secs